<SEC-DOCUMENT>0001493152-23-027825.txt : 20230811
<SEC-HEADER>0001493152-23-027825.hdr.sgml : 20230811
<ACCEPTANCE-DATETIME>20230811160547
ACCESSION NUMBER:		0001493152-23-027825
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230811
DATE AS OF CHANGE:		20230811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				911835664
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37603
		FILM NUMBER:		231164024

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:BRTX="http://biorestorative.com/20230630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_BRTX_biorestorative.com_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20230101_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001505497 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityCentralIndexKey">0001505497</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GrantIncome" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GrantIncome" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GrantIncome" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0368" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0406" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0416" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0454" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0464" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0601" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0623" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0643" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-06-30_custom_PatentsAndTrademarksMember" id="xdx2ixbrl0669" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-06-30_custom_LicensesMember" id="xdx2ixbrl0671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2023-06-30_custom_PatentsAndTrademarksMember" id="xdx2ixbrl0685" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xs:nil="true"></ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-06-30_custom_PatentsAndTrademarkMember" id="xdx2ixbrl0697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0790" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0792" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687" id="xdx2ixbrl0810" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687" id="xdx2ixbrl0812" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_custom_SharesIssuedForServicesMember" id="xdx2ixbrl0828" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-06-30_custom_SharesIssuedForServicesMember" id="xdx2ixbrl0844" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="brtx-20230630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-14_custom_JonesTradingInstitutionalServicesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-132023-04-14_custom_JonesTradingInstitutionalServicesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-13</xbrli:startDate>
        <xbrli:endDate>2023-04-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-122023-07-13_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-12</xbrli:startDate>
        <xbrli:endDate>2023-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-13_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PatentsAndTrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_AccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_PatentsAndTrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-08</xbrli:startDate>
        <xbrli:endDate>2022-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-08</xbrli:startDate>
        <xbrli:endDate>2022-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-242022-10-25_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-24</xbrli:startDate>
        <xbrli:endDate>2022-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember37476781">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember37476781">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476781">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember37476781">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_SharesIssuedForServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_SharesIssuedForServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember37476796">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_SharesIssuedForServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_SharesIssuedForServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_MelvilleLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-122023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-12</xbrli:startDate>
        <xbrli:endDate>2023-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90E_edei--DocumentType_c20230101__20230630_zM1SqfU3knsd"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--DocumentQuarterlyReport_c20230101__20230630_zklWWiUoFYVe"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Quarterly Period Ended <span id="xdx_909_edei--DocumentPeriodEndDate_c20230101__20230630_zQ8x8w7TjnQd"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, <span id="xdx_90E_edei--DocumentFiscalYearFocus_c20230101__20230630_z6arlizkj962" title="Document Fiscal Year Focus"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>or</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--DocumentTransitionReport_c20230101__20230630_zNg7VOHPUfQ6"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Transition Period from _________ to _________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
file number: <span style="text-decoration: underline"><span id="xdx_90C_edei--EntityFileNumber_c20230101__20230630_z7eI9QroIGf2"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityFileNumber">001-37603</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityRegistrantName_c20230101__20230630_zqpbVnLWT0Si"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityRegistrantName">BIORESTORATIVE
THERAPIES, INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20230101__20230630_zgfbcmBWmGV1"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20230101__20230630_zrCIyU2P98qk"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityTaxIdentificationNumber">30-1341024</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other Jurisdiction of</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation
                                            or Organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
                                            No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityAddressAddressLine1_c20230101__20230630_z3sGuYodZLM2"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityAddressAddressLine1">40
    Marcus Drive</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCityOrTown_c20230101__20230630_zKFsQEHti247"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityAddressCityOrTown">Melville</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20230101__20230630_zIFQn7SCORgd"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityAddressPostalZipCode_c20230101__20230630_zFbWN5nqgoj3"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityAddressPostalZipCode">11747</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_906_edei--CityAreaCode_c20230101__20230630_zNWAglf5ag2e"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:CityAreaCode">(631)</ix:nonNumeric></span>
<span id="xdx_90F_edei--LocalPhoneNumber_c20230101__20230630_zf2eTeyDBA7b"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:LocalPhoneNumber">760-8100</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 0pt; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%; padding-bottom: 0pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 0pt; width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%; padding-bottom: 0pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 0pt; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20230101__20230630_zREK2LCSHdbb"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20230101__20230630_zOvecvLWDYx8"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:TradingSymbol">BRTX</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--SecurityExchangeName_c20230101__20230630_zRuKaCf6iVxd"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_905_edei--EntityCurrentReportingStatus_c20230101__20230630_z0lzG4HEhB0f"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_904_edei--EntityInteractiveDataCurrent_c20230101__20230630_zVYwZAaVVhx3"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityFilerCategory_c20230101__20230630_zrDThVO2GPo3"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntitySmallBusiness_c20230101__20230630_zLOJf96qsIG"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20230101__20230630_z9XQvX2IWnbg"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_907_edei--EntityShellCompany_c20230101__20230630_zQnQHybgy90g"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by checkmark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. <span id="xdx_90A_edei--EntityBankruptcyProceedingsReportingCurrent_c20230101__20230630_zH6ba6BXnYVc"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleantrue" name="dei:EntityBankruptcyProceedingsReportingCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 8, 2023 there were <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_pid_c20230808_zmdjyFovweq"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667,641</ix:nonFraction></span> shares of the registrant&#8217;s Common Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
10-Q </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.6in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_001"><span style="font-size: 10pt"><b>PART
    I. FINANCIAL INFORMATION</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_002"><span style="font-size: 10pt">Financial
    Statements</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_003"><span style="font-size: 10pt">Condensed
    Consolidated Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_004"><span style="font-size: 10pt">Condensed
    Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2023 and 2022 (unaudited)</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_005"><span style="font-size: 10pt">Condensed
    Consolidated Statements of Changes in Stockholders&#8217; Equity for the Three and Six Months Ended June 30, 2023 and 2022 (unaudited)</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_006"><span style="font-size: 10pt">Condensed
    Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022 (unaudited)</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#f_007"><span style="font-size: 10pt">Notes
    to Condensed Consolidated Financial Statements (unaudited)</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_008"><span style="font-size: 10pt">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_009"><span style="font-size: 10pt">Quantitative
    and Qualitative Disclosures about Market Risk</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_010"><span style="font-size: 10pt">Controls
    and Procedures</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_011"><span style="font-size: 10pt"><b>PART
    II. OTHER INFORMATION</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_012"><span style="font-size: 10pt">Risk
    Factors</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_013"><span style="font-size: 10pt">Unregistered
    Sales of Equity Securities and Use of Proceeds</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_014"><span style="font-size: 10pt">Exhibits</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_015"><span style="font-size: 10pt"><b>SIGNATURES</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I - FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_002"></span>Item
1. Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="f_003"></span>CONDENSED
Consolidated Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_111_z41h2h3deCJ8" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230630_zdvdQNn0qJxc" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20221231_zTfyIbsWyTw9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-size: 11pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_z0jxuCrsagQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zHiWojL7GXr1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Current
    Assets:</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzsph_zD7v6Uvj5ERg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,783,646</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,676,577</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--MarketableSecuritiesCurrent_i02I_maACzsph_zlynvWaxhsyi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Investments held in marketable
    securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,831,719</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,072,831</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzsph_z26GktrLiAGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzsph_zjKO9wJS7zS7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,559</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,082</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrent_i02TI_mtACzsph_maAzhZI_z9mOzYRTI9s6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,043,924</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,128,490</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzhZI_zQlAKyXStT47" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Property and equipment,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,070</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">261,003</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzhZI_zzasu2vVhLnb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Right of use asset</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,738</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maAzhZI_z0BrUlEvmZqb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    assets, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">758,565</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">803,438</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--Assets_i01TI_mtAzhZI_zIImDHc0xhp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,300,297</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,434,691</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z1mkXOyZT3Ob" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES
    AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zJkvCZzr5cvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Current
    Liabilities:</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i02I_maLCzrOD_z28HGWbmdWMg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,048</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,902</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzrOD_zh1yHNPKwVpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses and other
    current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,325</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,072</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzrOD_zy1Zfmz4HTX3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liability, current portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,480</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,328</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzrOD_maLzD8l_zUhyf9eA6qdc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Current Liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,853</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">440,302</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzD8l_zOupQLpA8eE" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liability, net of current portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,580</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,317</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_i01TI_mtLzD8l_maLASEzXVv_ztmjyKjMSjZ3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">896,433</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">602,619</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockholdersEquityAbstract_i01B_zLyDQNTD9jbj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217;
    Equity</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_i02I_maSEz26Y_zctjlXMI5zq9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Preferred stock, $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230630_zKkIUFHVmuO4" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20221231_zEka3oQetAFi" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; Authorized,
    <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20230630_zK9II3ncfyKj" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zkYwd3R405X4" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-size: 11pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_maSEz26Y_zf0PcvrGsfa9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible Preferred
    Stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_ztMUtOQqTSc2" title="Preferred stock, par value"><span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zxnSBaXl3vT9" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zWd7EgCJtmq3" title="Preferred stock, shares authorized"><span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zEuL7unO3njc" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></ix:nonFraction></span></span> designated shares, <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zrEFsbj00wH1" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zGUXp0lViwqj" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zjZfCc8Cygu4" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zkXM1SGKcmA3" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding at June 30, 2023 and December
    31, 2022, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,182</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_maSEz26Y_zpQUBkWkxEn6" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    stock, value</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,182</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_maSEz26Y_zaR05J8Xri4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Common Stock, $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230630_zeZC3aG83qUa" title="Common stock, par value"><span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zAPLeFCps23g" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par
    value; Authorized, <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20230630_zICPXEmmTvOj" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zHRLL7iz94Nc" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20230630_zHuabw8vT7Dd" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20230630_z37RXMp7Pdya" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,982,608</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20221231_zvvb6Fd3LCEd" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zPp1t5wZJo2j" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,677,775</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding at June 30, 2023 and December 31, 2022, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maSEz26Y_zvQCgnxFgQn9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Additional paid in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,695,154</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,457,418</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEz26Y_zpBy8shs85Ve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">161,305,671</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">152,640,897</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquity_i02TI_mtSEz26Y_maLASEzXVv_zzh8kCSAMWz5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Stockholders&#8217; Equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,403,864</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,832,072</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzXVv_z2rT4wrQsUh6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities and Stockholders&#8217; Equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,300,297</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,434,691</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="f_004"></span>CONDENSED
Consolidated STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_113_zXVxDQjC60J6" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20230401__20230630_zE0pwEoDEos3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20220401__20220630_zCulzpfq3wcf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20230101__20230630_zfngKzG2nHmg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20220101__20220630_zlj7foJt0u7b" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">For
    the Three Months Ended,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">For
    the Six Months Ended,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="padding-bottom: 0pt; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzNfg_zjgRTkP4b5N9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 44%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 2%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 1%; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 10%; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 1%; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 2%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 1%; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 10%; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,100</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 1%; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 2%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 1%; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 10%; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,800</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 1%; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 2%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 1%; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 10%; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,100</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 1%; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_z7Qvq8LYCgAj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses:</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzQwd_z6mnbxvrNUsi" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">967,891</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,224</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,479,136</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,850,561</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzQwd_zCLKHJPr1VI2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 0pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,213,160</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,624,504</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,512,313</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,918,960</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01T_mtCzQwd_msCzNfg_zlsD4J9HbUz7" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,181,051</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,699,728</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,991,449</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,769,521</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_iT_mtCzNfg_maCzAjY_zsmQQVEZxyJh" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,116,551</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,628,628</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,895,649</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,682,421</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z5sHhH5zfZb8" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    (income) expense:</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--InterestIncomeExpenseNet_i01N_di_maCziQG_maNIEzzFP_zRGCyHjjhht2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    (income) expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,187</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,613</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,403</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,624</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--GainOnPppLoanForgiveness_i01N_di_maCziQG_maNIEzzFP_zMUX6NAyTkmi" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Gain
    on PPP loan forgiveness</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0205">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0206">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0207">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_ecustom--GrantIncome_i01N_di_maCziQG_maNIEzzFP_z9b2dXupaLKb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Grant
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0210">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0211">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0212">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="BRTX:GrantIncome" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,654</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_i01N_di_maCziQG_maNIEzzFP_zs2X3YBrWqK3" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income, net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,812</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0216">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,472</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01NT_di_maCzAjY_mtNIEzzFP_zfDHV1bQE53l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    other (income) expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,999</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,613</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,875</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,030</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_mtCzAjY_zxVPRghKCC7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,980,552</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,675,241</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,664,774</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,491,391</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    Loss Per Share - Basic and Diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20230401__20230630_zFABhNDKfCc2" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_zE6rAZQom69h" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.77</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20220401__20220630_zsf2OpNlSec6" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20220401__20220630_ztIJQuDLNHC4" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.28</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230630_zqHq3ZX2stah" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_z3PwyZqjCQ25" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.28</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220630_za2vF9MHe5yc" title="Net Loss Per Share - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220630_zLyJ9WoQHsHb" title="Net Loss Per Share - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.65</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Number of Common Shares Outstanding - Basic and Diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230401__20230630_zkb5ZDp9y6Z2" title="Weighted Average Number of Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401__20230630_zQffqpXt8AFi" title="Weighted Average Number of Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,886,309</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220401__20220630_zsW20eze1KJ7" title="Weighted Average Number of Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220401__20220630_zIS9xZDnpK1e" title="Weighted Average Number of Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,638,383</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zC1SyrZsEnid" title="Weighted Average Number of Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_zRsJUy2nFCsl" title="Weighted Average Number of Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,803,323</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: right; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220630_znrEYb7XM4Q1" title="Weighted Average Number of Common Shares Outstanding - Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220630_zMdM4sCKVRe2" title="Weighted Average Number of Common Shares Outstanding - Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,581,110</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="f_005"></span>CONDENSED
Consolidated STATEMENTS of CHANGES IN STOCKHOLDERS&#8217; EQUITY </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_114_zB7obmqw3mB5" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesBConvertiblePreferredStockMember_zNk5EeX6h35a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zULhHPAlJAG1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zuYQdpDMZDna" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zosHExRuY94j" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_zoNJuCWuwZbk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Series B Convertible</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Preferred
    Stock</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Paid-in</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43D_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zA1QELIhgWic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Balance at
    January 1, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zq9SR04pMHHk" title="Beginning balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,182</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJvljS6viaVh" title="Beginning balance, shares" style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,677,775</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,457,418</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">152,640,897</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,832,072</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zSlIkbXWIep" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- restricted share units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2drbuTIBi25" title="restricted stock units, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,840</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,148,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,148,759</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_zXhLPcFaL9Jj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0280">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0281">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,190,428</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,190,428</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zGAsA77HWbpj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0287">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zfTbEcq61P81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,684,222</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,684,222</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43B_c20230401__20230630_eus-gaap--StockholdersEquity_iS_z79Garl9wY52" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of March 31, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_za8tlH4fIL38" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,518,158</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,182</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zv5y2vFqwLTh" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,767,615</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">378</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,796,596</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">158,325,119</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,487,037</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zOOiwTKNmUr1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- restricted share units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze5qTGpiqXpd" title="restricted stock units, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,442</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,135</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,135</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_zhkNq97xMHS" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0317">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321,534</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321,534</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zzB4iWPjk9Zc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0324">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0326">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zHYxVlAaGrhj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn7fz5YflTuc" title="Issuance of common stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">93,551</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">411,701</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">411,710</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zXjnOKBCmwka" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Conversion of Series B preferred
    to common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zdBLaS5Wm8l8" title="Common stock issued in exchange for Series B Preferred Stock, Shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">120,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3Uh4yFOHKj5" title="Conversion of Series B preferred to common stock, Shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,188</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zWgBr23zQFw4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0346">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,980,552</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,980,552</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43A_c20230401__20230630_eus-gaap--StockholdersEquity_iE_zIfI7oxV0Jfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of June 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zmELcQqKC02f" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,982</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTyzEyK7iU32" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,982,608</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,695,154</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">161,305,671</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,403,864</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43B_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zMJSvEa9fgLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Balance at January 1, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z3uwX37jXUTa" title="Beginning balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjqGB21yVS8j" title="Beginning balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,520,391</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,727,292</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">134,146,128</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,596,949</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zYFhwBN1EOG" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- restricted share units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSbqmC4RVe9h" title="restricted stock units, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,828</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,125</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,135</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_zGwiEvpKzTAh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,138,949</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,138,949</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zU7G1df2Sopi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpQcS6mwR7t4" title="- common stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,818</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,819</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zDWbzbh9bKbe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,816,150</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,816,150</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_437_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zuwDGcqzjjme" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    at March 31, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zdGqJbYpW76g" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0400">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z53xwor1cOw4" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,631,719</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,103,184</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">138,962,278</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,156,702</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_433_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zHLACCwJhcud" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Beginning
    balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zlXRqnSKYai" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcClDheOboRg" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,631,719</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,103,184</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">138,962,278</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,156,702</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zZaxS9ZgmOZ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- restricted share units</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHy1KvjPT0B3" title="restricted stock units, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,220</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,190,349</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,190,350</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_z13mtYQep6C2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,865,297</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,865,297</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z7CxDKhwlCk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">- common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0434">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDZrrA4tUM2b" title="- common stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,770</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0435">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,504</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,504</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zxFCVTTzlbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0444">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,675,241</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,675,241</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_43E_c20220401__20220630_eus-gaap--StockholdersEquity_iE_zZcPJDDiUit3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of June 30, 2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zs2gSTpCdg4f" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zntdMBbVNhB8" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,643,709</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,207,334</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">143,637,519</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,585,612</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_438_c20220401__20220630_eus-gaap--StockholdersEquity_iE_zqPGRnDnaajg" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Ending
    balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zemfoBUiC4n6" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTLRprtbyU4l" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,643,709</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,207,334</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">143,637,519</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,585,612</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>BIORESTORATIVE
THERAPIES, INC. AND SUBSIDIARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="f_006"></span>CONDENSED
Consolidated STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_112_zL3pTtntnlLe" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_499_20230101__20230630_zaRoKRM7r5rl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20220101__20220630_zgrs6k7y72u7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zBRmdnZkfb91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cash flows from operating
    activities:</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_i01_maNCPBUzMkp_zSsHuU5o36zj" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net Loss</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,664,774</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,491,391</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zLwEQlIragUf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash used in operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUzMkp_zeNpkycilj57" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation
    and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,877</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,526</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i02N_di_msNCPBUzMkp_zGEofdLpbLCf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Unrealized
    gain on marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,392</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0481">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_maNCPBUzMkp_zkbSR2ZNOjCa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,824,865</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480,055</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--GainOnPppLoanForgiveness_i02N_di_msNCPBUzMkp_zjBakhA1Coib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Gain
    on PPP loan forgiveness</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0486">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="BRTX:GainOnPppLoanForgiveness" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_ecustom--NoncashLeaseExpense_i02_maNCPBUzMkp_zgmRisHdbtWi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Non-cash
    lease expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,022</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BRTX:NoncashLeaseExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,022</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zc9Xynafid6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Changes in operating assets
    and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzMkp_zxNipDNpwFMe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzMkp_zuTya3uH6cSj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    assets and other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,477</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">61,688</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzMkp_z330MRMhzLB2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Accounts
    payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,146</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">327,406</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_i03_maNCPBUzMkp_z9lWR68bFiFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses and other current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,253</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,311</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzMkp_zEUciF4HoNQb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">67,585</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,751</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCzjE7_mtNCPBUzMkp_zyYDDaIDFl56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,479,065</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,845,756</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zY6Z4QE53V3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cash flows from investing
    activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_maNCPBUzoR2_zqbZGCi08rAi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Sale
    of marketable securities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,263,504</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzoR2_znJNflikabl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: 10pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Purchases
    of equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,071</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,247</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_maCCERCzjE7_mtNCPBUzoR2_z3owOBXBIHkb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by (used in) investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,174,433</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">247,247</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zpUpUn6Kx627" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cash flows from financing
    activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_maCzOx0_maNCPBUzJ18_maNCPBUzwBX_zitBGbWnnA5g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    proceeds from issuance of common stock in at-the-market offering</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">411,701</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCCERCzjE7_mtNCPBUzwBX_zfW0Cwwnqui8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">411,701</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzjE7_z0eV2o1MJM63" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease)
    in cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,069</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,093,003</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zrBfnwgWmYR9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents
    - beginning of period</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,676,577</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,026,727</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zDKpS3OjMJi7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents - end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,783,646</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,933,724</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zHns9mg93nMg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Supplemental cash flow information:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--SupplementalCashFlowInformationRelatedText_i01B_z9JobXut4ut3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cash paid for:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
THERAPIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_007"></span>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAwKW7UmS0Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 - <span id="xdx_820_zQd2QG33gsnf">NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2022, the Company reincorporated from Delaware to Nevada. The reincorporation was structured as a statutory merger of BioRestorative
Therapies, Inc., a Delaware corporation, with and into its wholly-owned subsidiary, BioRestorative Therapies, Inc., a Nevada corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern,
which contemplates realization of assets and satisfying liabilities in the normal course of business. For the six months ended June 30,
2023, the Company had a net loss of $<span id="xdx_908_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230630_zKoiWk4KgFD4" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">8.7</ix:nonFraction></span> million (of which, $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20230630_zvOp6hjAWosd" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million was attributable to non-cash stock-based compensation) and negative
cash flows from operations of $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20230630_zScWMEPdCnSa" title="Cash flows from operations"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">3.5</ix:nonFraction></span> million. The Company&#8217;s operating activities consume the majority of its cash resources. The
Company anticipates that it will continue to incur net losses as it executes its development plans throughout 2023 and beyond, as well
as other potential strategic and business development initiatives. In addition, the Company has had and expects to have negative cash
flows from operations, at least into the near future. The Company has previously funded, and plans to continue funding, these losses
primarily through current cash on hand, investments in marketable securities and additional infusions of cash from equity and debt financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 14, 2023, the Company entered into a sales agreement with JonesTrading Institutional Services LLC for an at-the-market (&#8220;ATM&#8221;)
offering of the Company&#8217;s Common Stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230414__dei--LegalEntityAxis__custom--JonesTradingInstitutionalServicesLLCMember_znwIUkHC1pl4" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-04-14_custom_JonesTradingInstitutionalServicesLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, at an aggregate offering price of up to $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230413__20230414__dei--LegalEntityAxis__custom--JonesTradingInstitutionalServicesLLCMember_zXl7Ym7zK01j" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-04-132023-04-14_custom_JonesTradingInstitutionalServicesLLCMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.7</ix:nonFraction></span> million. During
the three months ended June 30, 2023, net proceeds of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230401__20230630_zp4eB2lfLCTa" title="Issuance of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">411,710</ix:nonFraction></span> were received from the issuance of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630_ztCFAExsLfj1" title="Issuance of common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">93,551</ix:nonFraction></span> shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2023, the Company sold an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp0ZL0amDKMj" title="Sale of aggregate shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-122023-07-13_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">685,033</ix:nonFraction></span> shares of Common Stock to several institutional buyers and accredited investors
in a registered direct offering at an offering price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2JsrEU10Mmi" title="Offering price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-07-13_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.03</ix:nonFraction></span> per share. The offering closed on July 13, 2023, with net proceeds of approximately
$<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQh5mOxRcrJ3" title="Net proceeds offering price"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-07-122023-07-13_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million. The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its
lead cell therapy candidate, <i>BRTX-100</i>, pre-clinical research and development with respect to its metabolic <i>ThermoStem Program
</i>and for general corporate purposes and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on cash on hand as of June 30, 2023, the Company believes it has sufficient cash to fund operations for the twelve months subsequent
to the filing date of this Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations.
If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development,
marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial condition
and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;GAAP&#8221;), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying
condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue
as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at <span style="text-decoration: underline">www.biorestorative.com</span>. The information contained in our website is not intended to be incorporated by reference
into this Quarterly Report. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its lead cell therapy
candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal stem cells collected
from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders
or as a complimentary therapeutic to a surgical procedure. BRT is investigating the expansion of the clinic application of <i>BRTX-100
</i>to other indications within the body. BRT is also engaging in research efforts with respect to a platform technology utilizing brown
adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled this initiative
its ThermoStem Program. Further, BRT has licensed a patented curved needle device that is a needle system designed to deliver cells and/or
other therapeutic products or material to the spine and discs or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_801_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zTN69WmswyIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_823_zFIIUySPA5Wa">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRlhrC4DEtT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zA8eCeh1sJN1">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#8217;s condensed consolidated financial statements. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations
of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in
financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules
and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022,
filed with the SEC on March 27, 2023 (the &#8220;Annual Report&#8221;). The summary of significant accounting policies presented below
is designed to assist in understanding the Company&#8217;s condensed consolidated financial statements. Such condensed consolidated financial
statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity and objectivity.
Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected
for the entire year or for any other subsequent interim period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zREhKsxX6Td5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_znlhd3ELGaOi">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts
and transactions have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_zwtoat1ghDr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zMN58ygL53si">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent
liabilities at the date of the condensed consolidated financial statements. The Company bases its estimates and assumptions on historical
experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects
cannot be determined with precision, actual results could differ from these estimates which may cause the Company&#8217;s future results
to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zcSACGDy8Ha2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_z3WbZdua1oW4">Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Deposit Insurance Corporation coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20230630_zNayDp0CxbU5" title="FDIC insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. As of
June 30, 2023, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
royalties related to the Company&#8217;s sublicense comprised all of the Company&#8217;s revenue during the three and six months ended
June 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Summary
of Significant Accounting Policies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting
Standards, in the Annual Report. During the three and six months ended June 30, 2023, the Company did not make any changes to its significant
accounting policies, except as described below with respect to recent accounting pronouncements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_znOeGAyqEkBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zv8XAjWsqIHb">Fair
Value Measurements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
defined in ASC 820, <i>Fair Value Measurements and Disclosures </i>(&#8220;ASC 820&#8221;), fair value is the price that would be received
for an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price).
The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed
    methodologies that result in management&#8217;s best estimate of fair value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_892_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zW4jbsJByhDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zkdefYQKHU2a" style="display: none">SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value measurements at reporting date using:</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Quoted
    prices in active markets for identical liabilities (Level 1)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant
    other observable inputs (Level 2)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant
    unobservable inputs (Level 3)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities
    as of June 30, 2023</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zu4oQGXJlX26" title="Cash and cash equivalents, fair value disclosure" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,831,719</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38Gcg8zLNid" title="Cash and cash equivalents, fair value disclosure" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,831,719</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPFGOiLkX45f" title="Cash and cash equivalents, fair value disclosure" style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqRy9nOQf8h" title="Cash and cash equivalents, fair value disclosure" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities as of
    December 31, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6URVs2noVp9" title="Assets fair value disclosure" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,072,831</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxIcGBmbuG7b" title="Assets fair value disclosure" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,072,831</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze6juTXqxlij" title="Assets fair value disclosure" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJp5ylMONiFj" title="Marketable securities fair value disclosure" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zG5lvpiaknp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvVPxBCuna8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zr12olmF0qe2">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of cash, accounts receivable, and accounts payable approximate their fair values based on the short-term maturity of these
instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zWpy9BeM7Nc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zNIGYNH3Uw17">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year.
All outstanding options and warrants are considered potential Common Stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered Common Stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of Common Stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#8217;s
computation of diluted net loss per common share for the three and six months ended June 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zWDwDFjj1aO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_8BE_zmG1LMRaRtJf" style="display: none">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zoVAZU1l0674" title="Total" style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,466,890</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zdKOjnSs6JIl" title="Total" style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">864,609</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zc0EPtjDys1g" title="Total potentially dilutive shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,072</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zz6X9pJJlLg1" title="Total potentially dilutive shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,739,733</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zi9d04LG8wFc" title="Unvested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zmpUhm1zxDDk" title="Unvested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">214,303</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred
    stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zYSf03qkG40a" title="Convertible notes" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjfyRiVBMauh" title="Convertible notes" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630_fKDIp_zwj5cmepYbYf" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,753,947</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630_fKDIp_zSi4gJoWHmgd" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,818,645</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z5wLvddjCTp3" title="Total" style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,466,890</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zsQQw2lkcHx1" title="Total" style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">864,609</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zZeocQHQDFe4" title="Total potentially dilutive shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,791,072</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoRAybkNxNi5" title="Total potentially dilutive shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,739,733</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zjC70CZjP5p7" title="Unvested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zs5G9aXwP524" title="Unvested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">214,303</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred
    stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zInpt4CcrdUa" title="Convertible notes" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_ConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zY4Dlp2Gxwfl" title="Convertible notes" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630_fKDIp_zAxmQ19gtKFk" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,753,947</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630_fKDIp_zBZIpuo4UaQh" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,818,645</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zjZWA5yxsR65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ0NnOo8kjS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z7grb1Ai6bb5">Recently
Adopted Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses,</i> which requires entities to estimate all expected
credit losses for financial assets measured at amortized cost basis, including trade receivables, held at the reporting date based on
historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted this guidance on January 1,
2023. The adoption of this accounting standard did not have a material impact on the Company&#8217;s condensed consolidated financial
statements.</span></p>

</ix:nonNumeric><p id="xdx_85B_zmb5KKwrIRR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_z3DXiu3SB77f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - <span style="text-transform: uppercase"><span id="xdx_821_zElumeMfieWh">INTANGIBLE ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a license agreement with a stem cell treatment company (the &#8220;SCTC&#8221;) (as amended) (the &#8220;SCTC Agreement&#8221;).
Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from the SCTC
to utilize or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or
spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or
sublicense a certain method for culturing cells. Pursuant to the license agreement with the SCTC, certain performance milestones (or
payouts in lieu of performance milestones) had to be satisfied in order for the Company to maintain its exclusive rights with regard
to the disc/spine technology. The Company did not timely satisfy the third of these performance milestones (which needed to be satisfied
by February 2022). Accordingly, such rights became non-exclusive. However, in November 2022, the Company entered into an amended agreement
under which it paid $<span id="xdx_902_eus-gaap--PaymentsToAcquireIntangibleAssets_c20221101__20221130_zfN1MS780mae" title="Payment to acquire intangible assets"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-11-012022-11-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></span> and issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzGeSwEB3yh1" title="Stock issued new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-012022-11-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,370</ix:nonFraction></span> warrants, with a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221101__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zW5ak0HvlSg3" title="Fair value of warrants"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-11-012022-11-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,030</ix:nonFraction></span>, in exchange for renewed exclusivity. The consideration
transferred to the SCTC in exchange for exclusivity was capitalized to intangible assets on the Company&#8217;s consolidated balance
sheet as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, the Company received authorization from the Food and Drug Administration (the &#8220;FDA&#8221;) to proceed with a Phase
2 clinical trial. In March 2022, the United States Patent and Trademark Office issued a patent relating to the Company&#8217;s BRTX-100
clinical program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEsmIKeehgfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zEJ0LcKDLXHk" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Patents
    and Trademarks</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    Amortization</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zPmzRQOFS9ti" title="Finite Lived Intangible Assets, Gross, beginning balance" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_PatentsAndTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z1wPZDTV3Ii7" title="Finite Lived Intangible Assets, gross, beginning balance" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593,530</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zR0Kbv10m0F6" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">793,768</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20230101__20230630_zh0qufzFys61" title="Finite Lived Intangible Assets, Net, beginning balance" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">803,438</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Amortization expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zm9CaSx6pvKa" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zYD1fTeq1AK6" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zvtZDmGgQd9i" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-06-30_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,873</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20230630_z8wIyterxqFh" title="Finite Lived Intangible Assets, Amortization expense" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,873</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zokTDpGmZh0a" title="Finite Lived Intangible Assets, Gross, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-06-30_custom_PatentsAndTrademarksMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,676</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z8fOX4SaPKl2" title="Finite Lived Intangible Assets, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-06-30_custom_LicensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593,530</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zcMTvQKJmnk8" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-06-30_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">838,641</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20230101__20230630_z34utZSYBoOg" title="Finite Lived Intangible Assets, Net, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">758,565</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining amortization
    period as of June 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zpOAMVBGgBB" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zJZJ9QiTOoY3" title="Finite Lived Intangible Assets, weighted average amortization period"><ix:nonNumeric contextRef="AsOf2023-06-30_custom_LicensesMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">10.75</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zK8LVrSyr5u7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z5pJulk0Orfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
amortization of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zD7VQS2J3io7" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Patents
    and Trademarks</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    Amortization</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCPGaWTdyY6" title="Beginning Balance" style="padding-bottom: 0pt; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_PatentsAndTrademarkMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zE8ZCjlwtaCe" title="Beginning Balance" style="padding-bottom: 0pt; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">790,092</ix:nonFraction></span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zu9jAk4IM1v2" title="Beginning Balance" style="padding-bottom: 0pt; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">793,768</ix:nonFraction></span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Amortization expense</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zfpzkjcjS488" title="Amortization expense" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zNYR99kmrBo" title="Amortization expense" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,873</ix:nonFraction></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zQZSJjW6XJ66" title="Amortization expense" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-06-30_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,873</ix:nonFraction></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 30, 2023</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zIMAWTvQfMM6" title="Beginning Balance" style="padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-06-30_custom_PatentsAndTrademarkMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,676</ix:nonFraction></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBqs1aRGbARb" title="Beginning Balance" style="padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">834,965</ix:nonFraction></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zBEKEeHprqm9" title="Ending Balance" style="padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-06-30_custom_AccumulatedAmortizationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,641</ix:nonFraction></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_z7JoxfcYog0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_808_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zCUPEIRoNF0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 - <span id="xdx_828_zItoCNvh5ZLa">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z9DuZrOyjTga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zHg3RGG5qemd" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20230630_zLROBTFFOyng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20221231_zmNRx7NXLmr8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zAPVwqYApceg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued payroll</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">325,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,250</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zA5adVmI4qOc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued general and
    administrative expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,325</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BRTX:AccruedGeneralAndAdministrativeExpenses" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,822</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zZLVspUdYBX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,325</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,072</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zddjRb6QZT8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zoRQVbwCoSn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
5 - <span id="xdx_827_zEOZJQqo4s7g">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, in connection with the Company&#8217;s public offering, the Company&#8217;s Board of Directors adopted a resolution
allowing for the designation and issuance of <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjtg6zP4wu3" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of the Company&#8217;s Preferred Stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zPcorMWtAGzb" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="USDPShares">.01</ix:nonFraction></span> par value per share, designated
as Series A Preferred Stock (&#8220;Series A&#8221;). The Series A had a liquidation preference of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBWqdUyzvWgg" title="Preferred stock, liquidation preference"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. On September 8,
2022, the Company issued <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDgoLAd9PQUj" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of Series B Preferred Stock (&#8220;Series B&#8221;) to Auctus Fund, LLC (&#8220;Auctus&#8221;)
in exchange for an equal number of shares of the Company&#8217;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#8217;s Board
of Directors cancelled the Series A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 8, 2022, the Company issued <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zIbqBFEI0Wd2" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,543,158</ix:nonFraction></span> shares of Series B to Auctus in exchange for an equal number of shares of the Company&#8217;s
outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of Common Stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is <span id="xdx_901_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7vIuiqhpq9h" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember" name="us-gaap:PreferredStockVotingRights">9.99</ix:nonNumeric></span>% of the then outstanding Common Stock of the Company instead of <span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7bA92hignrj" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember" name="us-gaap:PreferredStockVotingRights">4.99</ix:nonNumeric></span>% as
provided for the Series A. The Company shall, at all times, reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to redemption
by the Company or any Series B holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting
Rights</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7DagVLZRLVh" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the then outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
Conversion - <span id="xdx_90F_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwlfxZg9vp6c" title="Preferred stock conversion term"><ix:nonNumeric contextRef="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember" name="us-gaap:ConvertiblePreferredStockTermsOfConversion">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock</ix:nonNumeric></span>; provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than <span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUl1gl7nslOc" title="Preferred stock voting percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the outstanding
shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic
Conversion &#8211; From time to time, if an event occurs, including adjustment due to merger, consolidation, etc., subdivision or combination
of Common Stock, adjustment due to distribution, purchase rights, and notice of adjustments, which has the effect of reducing a Series
B holder&#8217;s beneficial ownership of shares of Common Stock to less than <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zw67XtWAPFv3" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2023-06-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.5</ix:nonFraction></span>% of the then publicly disclosed outstanding shares of
Common Stock, then, within five (5) business days, the Series B holder shall provide notice to the Company to such effect, which notice
shall state the number of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard
thereto, including the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have
the effect of a notice of conversion with respect to the conversion of such number of shares of Series B as would increase the Series
B holder&#8217;s beneficial ownership of Common Stock to<span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zf3oOpgUB7h4" title="Preferred stock voting percentage"> <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% of the then publicly disclosed outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2023, Auctus converted <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zWtGfk0zZb9c" title="Number of shares converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of Series B into <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20221024__20221025__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJGmPqTA1sdc" title="Number of shares issued in conversion"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2022-10-242022-10-25_custom_AuctusFundLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> shares of Common Stock. As of June 30, 2023, the number of shares
of Series B remaining outstanding after giving effect to such conversion was <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z2eOiDOJAP05" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,398,158</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
and Option Valuation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined
from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument
being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options granted during the three months ended June 30, 2023. The Company granted options for the purchase of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_z3B7ZJCvZfma" title="Number of options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">629,017</ix:nonFraction></span> shares
of Common Stock during the six months ended June 30, 2023. The grant date fair value of options issued during the six months ended June
30, 2023 was $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_c20230101__20230630_zM9otZTzI5s2" title="Grant date fair value of options granted"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,745,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options granted during the three months ended June 30, 2022. The Company granted options for the purchase of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220630_znjJhKiPETHh" title="Number of options, granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares
of Common Stock during the six months ended June 30, 2022. The grant date fair value of options issued during the six months ended June
30, 2022 was $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_c20220101__20220630_zje6NeHpe1Nf" title="Grant date fair value of options granted"><ix:nonFraction name="BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,117</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW0R13kT1jL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted during the six months ended June 30, 2023, the Company used
the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zDq2cHk08Thc" style="display: none">SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the <br />
Six
    Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the <br />
Six
    Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDSkZ37Igyd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.22</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZtgZ8QUyqe1" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.42</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBhSZaQxdAFg" title="Expected term (years)"><ix:nonNumeric contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.50</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5JzdB8fjNlb" title="Expected term (years)"><ix:nonNumeric contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.50</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zby1UAbkAsBb" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">175</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqv9Sd8BWgk9" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">286</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividends</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zu9HApWxUHLg" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNbPFihnX0Jh" title="Expected dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zdLgnTYG7sX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zod8JJGBmmSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity during the six months ended June 30, 2023 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zrv49KVB03V9" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January
    1, 2023</span></td><td style="width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230630_zmqPO3psl6J7" title="Number of options, beginning balance" style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">864,639</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630_zb1G2Hk2oxs9" title="Weighted average exercise price, beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_zpHlNPQJ4TKg" title="Number of options, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">629,017</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230630_z5w0JgAU9F9l" title="Weighted average exercise price, granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.91</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230630_zIPI50soujR" title="Number of options, expired" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230630_zVH5uKxRXHW5" title="Weighted average exercise price, expired" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> <span style="-sec-ix-hidden: xdx2ixbrl0792">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230630_zCG2iBNn9Uic" title="Number of Options Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,766</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230630_zYgN6ZaK0Rwc" title="Weighted Average Exercise Price Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.08</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, June 30, 2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230630_zDrmnGBj3Ef1" title="Number of options, ending" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,466,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630_zGCpZj59PtKd" title="Weighted average exercise price, ending" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.17</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, June 30, 2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630_z8Ycbbk55yaj" title="Number of options, exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,041,062</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630_zSqvYqqK8Ig1" title="Weighted average exercise price, exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.66</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zgnbMQlAn8k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Company&#8217;s 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;), the Company may grant restricted stock units (&#8220;RSUs&#8221;)
to employees, consultants or non-employee directors (&#8220;Eligible Individuals&#8221;). The number, terms and conditions of the RSUs
that are granted to Eligible Individuals are determined on an individual basis by the 2021 Plan administrator. On the distribution date,
the Company shall issue to the Eligible Individual one unrestricted, fully transferable share of the Company&#8217;s Common Stock (or
the fair market value of one such share in cash) for each vested and nonforfeitable RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zhR277GmpHve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s unvested RSUs as of June 30, 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zwEfQhs2PAyi" style="display: none">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 75%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    December 31, 2022</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z51dUu8f06R5" title="Number of shares outstanding beginning" style="padding-bottom: 0pt; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">201,870</ix:nonFraction></span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgLen2L5AgGl" title="Number of shares granted" style="padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztOMKQsc9xX2" title="Number of shares forfeited" style="padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztkwfcWR3sgk" title="Number of shares vested" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">104,043</ix:nonFraction></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    June 30, 2023</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCp5KXNFgd39" title="Number of shares outstanding ending" style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,827</ix:nonFraction></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zvALObrIoyMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"><p id="xdx_89F_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z5AzYWxXfpoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents stock compensation by award type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zdyvbNup9OG8" style="display: none">SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Three Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDfpQS5NlEh" title="Stock-based compensation award" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember37476781" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">321,534</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG5gfN4kthq5" title="Stock-based compensation award" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember37476781" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,865,297</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDCbt1c6FTBi" title="Stock-based compensation award" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476781" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,164,135</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEREzz7ndOCb" title="Stock-based compensation award" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember37476781" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,190,349</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zIZEKXG43Udh" title="Stock-based compensation award" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zWM796kT5zmc" title="Stock-based compensation award" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_custom_SharesIssuedForServicesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,504</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230401__20230630_zEck7EsYqcil" title="Stock-based compensation award" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,485,669</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_zVmnkKQX3n58" title="Stock-based compensation award" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,104,150</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Six Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB9UH8kS7oW1" title="Stock-based compensation award" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,511,962</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOFgeN6j0zrk" title="Stock-based compensation award" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,004,246</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeLbOukUuin3" title="Stock-based compensation award" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,312,885</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbVB9R9W6a64" title="Stock-based compensation award" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember37476796" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,354,474</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zNFeSSDDOuA" title="Stock-based compensation award" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zShdxp6AJlyj" title="Stock-based compensation award" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30_custom_SharesIssuedForServicesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">121,322</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230630_zRFHHQtJjHG3" title="Stock-based compensation award" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,824,847</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220630_z9sj7xmEFZoh" title="Stock-based compensation award" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480,042</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zGgBDZacKlS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation is included in General and administrative expenses on the consolidated statements of operations. As of June 30, 2023,
unrecognized stock based compensation expense is $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20230630_zaXfXzTG0NE3" title="Unrecognized expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,201,875</ix:nonFraction></span> with a weighted average remaining amortization period of <span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230630_zzXeczZvZeW4" title="Weighted average remaining amortization period"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.04</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zlndkIz3u3Ra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
6 - </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_824_zsvL3sbPbRXg">LEASES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a lease for <span id="xdx_908_eus-gaap--AreaOfLand_iI_usqft_c20230630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zzXYDXB53ZZa" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2023-06-30_custom_MelvilleLeaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">6,800</ix:nonFraction></span> square feet of space located in Melville, New York (the &#8220;Melville Lease&#8221;) with respect
to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIVoJ2NitjW1" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-06-30_custom_MelvilleLeaseMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,600</ix:nonFraction></span> and
$<span id="xdx_902_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zaqC6PgIdX0j" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-06-30_custom_MelvilleLeaseMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,260</ix:nonFraction></span>. In June 2019, <span id="xdx_90A_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zWLSS1zQlkkh" title="Lease extension description"><ix:nonNumeric contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember" name="us-gaap:LessorOperatingLeaseOptionToExtend">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zkDAc3ek9uY3" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,748</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zCtVMBWdIMC5" title="Rent expense"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,060</ix:nonFraction></span>.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230630_zHdPrF0PBv24" title="Weighted average incremental borrowing rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zW5SqB6eDYq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zFNMTlnW2HMg" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20230101__20230630_zAJjbLhIF7F9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220101__20220630_zqNvy7oBLJN" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zMljgG65GQGi" style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost (cost resulting
    from lease payments)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,014</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,566</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zEVxoxlUHLL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,014</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,566</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zJOh96MPVHUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease &#8211; operating cash flows
    (fixed payments)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,014</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,566</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFcU1cz1j3j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease &#8211; operating cash flows
    (liability reduction)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BRTX:OperatingLeaseLiabilityReduction" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,585</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="BRTX:OperatingLeaseLiabilityReduction" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,751</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current leases &#8211; right of use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20230630_zxxShXwMOek2" title="Non-current leases - right of use assets" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">183,738</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220630_z2Kh8pieJBnd" title="Non-current leases - right of use assets" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">299,783</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities &#8211; operating lease
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20230630_zLaiciFlln7e" title="Current liabilities - operating lease liabilities" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,480</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220630_zH65EMzxLRQa" title="Current liabilities - operating lease liabilities" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">128,899</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current liabilities &#8211; operating lease
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20230630_zEZAX9TMYJq9" title="Non-current liabilities - operating lease liabilities" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,580</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20220630_zwIinaSkCiz7" title="Non-current liabilities - operating lease liabilities" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">234,060</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zGyTbXHJAoy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3ofkMUnbeXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of June 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z6KIOPVmJpBa" style="display: none">SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fiscal
    Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20230630_zUokooBdJQwi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zI2y2IqCMy29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 78%"><span style="font-family: Times New Roman, Times, Serif">Remainder of 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,014</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zeF8mVF1zE7h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,060</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zERuRTZ5vC1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257,074</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za99u9rqEpjk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Amount representing
    interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,014</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_z3L2pUZXwTNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of net
    future minimum lease payments</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,060</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zg5RXeDPMMX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-transform: uppercase"><b>Note 7
&#8211; </b></span><b><span id="xdx_827_zQN5OASAr6P4">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 13, 2023, the Company
sold an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsjcrJCDwMMi" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-122023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">685,033</ix:nonFraction></span> shares of Common Stock to several institutional buyers and accredited investors in a registered direct offering
at an offering price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMx5DgJZkt91" title="Offering price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.03</ix:nonFraction> </span>per share. The offering closed on July 13, 2023, with net proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH6DD6F5Zq4a" title="Procceds fom offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-07-122023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million. The Company
intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy candidate,
<i>BRTX-100</i>, pre-clinical research and development with respect to its metabolic <i>ThermoStem Program </i>and for general corporate
purposes and working capital.</p>

<p id="xdx_8AD_zQlp4Tjb2c7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Note
Regarding Forward-Looking Statements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q includes a number of forward-looking statements that reflect management&#8217;s current views with respect
to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial
performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;should,&#8221;
&#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221;
&#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements include
statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions
on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of
future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such
forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors,
including the risks set forth in the section entitled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 27, 2023, any of
which may cause our company&#8217;s or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.
These risks and factors include, by way of example and without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financing needed to complete our clinical trials and implement our business plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully develop and commercialize BRTX-100, our lead product candidate for the treatment of chronic lumbar disc disease,
    as well as our metabolic ThermoStem Program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our proprietary rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to achieve and sustain profitability of the existing lines of business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain world-class research and development talent;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain key science, technology and management personnel and to expand our management team;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of estimates regarding expenses, future revenue, capital requirements, profitability, and needs for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from geo-political actions, including war and terrorism or disease outbreaks (such as the recent outbreak
    of COVID-19);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain customers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to navigate through the increasingly complex therapeutic regulatory environment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity or performance. Except as required by applicable law, including the securities laws of the United States, we do not intend
to update any of the forward-looking statements to conform these statements to actual results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Readers
are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the
SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated
events or changes in the future operating results over time, except as required by law. We believe that our assumptions are based upon
reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or
the results of our future activities will not differ materially from our assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221;
and &#8220;our&#8221; refer to BioRestorative Therapies, Inc., a Nevada corporation (&#8220;BRT&#8221;), and its wholly-owned subsidiary,
Stem Pearls, LLC, a New York limited liability company (&#8220;Stem Pearls&#8221;). Unless otherwise specified, all dollar amounts are
expressed in United States dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intellectual
Property</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report includes references to our federally registered trademarks, <i>BioRestorative Therapies and Dragonfly </i>design, <i>BRTX-100,
ThermoStem, </i>and <i>BRTX</i>. The <i>Dragonfly</i> logo is also registered with the U.S. Copyright Office. This report may also include
references to trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks
and trade names referred to in this report appear without the &#174;, <sup>SM</sup> or &#8482; symbols, and copyrighted content appears
without the use of the symbol &#169;, but the absence of use of these symbols does not reflect upon the validity or enforceability of
the intellectual property owned by us or third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
offices are located in Melville, New York where we have established a laboratory facility in order to increase our capabilities for the
further development of possible cellular-based treatments, products and protocols, stem cell-related intellectual property and translational
research applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, our accumulated deficit was $161,305,671. We have historically only generated a modest amount of revenue, and our losses
have principally been operating expenses incurred in research and development, marketing and promotional activities in order to commercialize
our products and services, plus costs associated with meeting the requirements of being a public company. We expect to continue to incur
substantial costs for these activities over at least the next year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells.
We are currently pursuing our <i>Disc/Spine Program</i> with our initial investigational therapeutic product being called <i>BRTX-100</i>.
In March 2022, a United States patent was issued in our <i>Disc/Spine Program</i>. We submitted an IND application to the FDA to obtain
authorization to commence a Phase 2 clinical trial investigating the use of <i>BRTX-100</i>, our lead cell therapy candidate, in the
treatment of chronic lower back pain arising from degenerative disc disease. We have received such authorization from the FDA and have
commenced such clinical trial through the execution of a CRO agreement with Professional Research Consulting, Inc., d/b/a PRC Clinical (&#8220;PRC&#8221;),
the execution of clinical trial site agreements, patient enrollment, the commencement of patient procedures, the purchase of manufacturing
equipment and the expansion of our laboratory to include capabilities for clinical production. We have received a license from the New
York State Department of Health to act as a tissue bank for mesenchymal stem cell processing. In June 2023, we received a unanimous recommendation
from the Data Safety Monitoring Board (&#8220;DSMB&#8221;) to continue our Phase 2 clinical trial without any changes. We have obtained
a license to use technology for investigational adult stem cell treatment of disc and spine conditions, including protruding and bulging
lumbar discs. The technology is an advanced stem cell injection procedure that may offer relief from lower back pain, buttock and leg
pain, and numbness and tingling in the leg and foot. We are investigating the expansion of the clinic application of <i>BRTX-100</i>
to other indications within the body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing our <i>ThermoStem Program</i>. This pre-clinical program involves the use of brown adipose (fat) in connection with
the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
United States patents related to the <i>ThermoStem Program</i> were issued in September 2015, January 2019, March 2020, March 2021, and
July 2021; a notice of allowance was issued in February 2023 by the United States Patent Office for a patent application related to our
<i>ThermoStem</i> Program; Australian patents related to the <i>ThermoStem Program</i> were issued in April 2017, October 2019, and August
2021; Japanese patents related to the <i>ThermoStem Program</i> were issued in December 2017, June 2021, and February 2022; a notice
of allowance was issued in May 2023 by the Japanese Patent Office for a patent application related to our <i>ThermoStem Program</i>;
Israeli patents related to our <i>ThermoStem Program</i> were issued in October 2019, May 2020, and March 2022; European patents related
to the <i>ThermoStem Program </i>were issued in April 2020 and January 2021; and a notice of allowance was issued in February 2023 by
the European Patent Office for a patent application related to our <i>ThermoStem</i> Program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have licensed a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products or
materials to the spine and discs or other potential sites. We anticipate that FDA approval or clearance will be necessary for this device
prior to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
derived all of our revenue pursuant to a license agreement with the SCTC entered into in January 2012, as amended in November 2015 and
November 2022. Pursuant to the license agreement, the SCTC granted to us an exclusive license to use certain intellectual property related
to, among other things, stem cell disc procedures and we have granted to the SCTC a sublicense to use, and the right to sublicense to
third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual
property. In consideration of the sublicenses, the SCTC has agreed to pay us royalties on a per disc procedure basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Results
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Three Months Ended June 30, 2023 to the Three Months Ended June 30, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial results for the three months ended June 30, 2023 are summarized as follows in comparison to the three months ended June 30,
2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Three Months Ended,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(unaudited)</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">967,891</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,075,224</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,213,160</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,624,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,181,051</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,699,728</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,116,551</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,628,628</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    (income) expense:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Interest (income) expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(96,187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,613</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(39,812</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total other (income) expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(135,599</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,613</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,980,552</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,675,241</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended June 30, 2023 and 2022, we generated $64,500 and $71,000, respectively, of royalty revenue in connection with
our sublicense agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development
expenses are expensed as they are incurred. For the three months ended June 30, 2023, research and development expenses decreased by
$107,333, or 10.0%, compared to the three months ended June 30, 2022. The decrease was primarily the result of a difference in the timing
of payments made for PRC service expenses. A milestone payment in the amount of $150,000 was paid on June 30, 2022 compared to the three
months ended June 30, 2023 in which no milestone payment was due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our research and development expenses will increase in subsequent fiscal periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees, as well
as corporate expenses such as legal and professional fees, investor relations and occupancy-related expenses. For the three months ended
June 30, 2023, general and administrative expenses decreased by $1,411,344, or 38.9%, as compared to the three months ended June 30,
2022, primarily driven by a $1,618,481 decrease in stock-based compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
(income) expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended June 30, 2023, interest income was $96,187 compared to interest expense of $46,613 for the three months ended
June 30, 2022. The change was primarily due to our investments in marketable securities during the three months ended June 30, 2023,
which generated interest income. During the three months ended June 30, 2022, we did not have any such investments and only incurred
interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other
income, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended June 30, 2023, Other income, net primarily relates to gains from settlements of certain accrued expenses and realized
and unrealized gain on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Six Months Ended June 30, 2023 to the Six Months Ended June 30, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial results for the six months ended June 30, 2023 are summarized as follows in comparison to the six months ended June 30, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Six Months Ended,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(unaudited)</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,800</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">87,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,479,136</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,850,561</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,512,313</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,918,960</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,991,449</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,769,521</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,895,649</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,682,421</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    (income) expense:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Interest (income) expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(114,403</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,624</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Gain on PPP loan forgiveness</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(250,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Grant income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,654</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(116,472</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total other income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(230,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(191,030</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,664,774</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,491,391</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2023 and 2022, we generated $95,800 and $87,100, respectively, of royalty revenue in connection with our
sublicense agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development
expenses are expensed as they are incurred. For the six months ended June 30, 2023, research and development expenses increased by $628,575,
or 34.0%, compared to the six months ended June 30, 2022. The increase was primarily driven by increased salaries and wages of $836,000,
increased lab site fees of $84,000, and increased consulting fees of 95,000, offset by a decrease in PRC service expenses of $532,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our higher level of research and development expenses will continue in subsequent fiscal periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees, as well
as corporate expenses such as legal and professional fees, investor relations and occupancy-related expenses. For the six months ended
June 30, 2023, general and administrative expenses decreased by $1,406,647, compared to the six months ended June 30, 2022. The decrease
was primarily driven by a $1,655,195 decrease in stock-based compensation, offset by an increase in salaries and wages of $167,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses will increase as we expand our staff, develop our infrastructure and incur additional
costs to support the growth of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
(income) expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2023, interest income was $114,403 compared to interest expense of $75,624 for the six months ended June
30, 2022. The change was primarily due to our investments in marketable securities during the six months ended June 30, 2023, which generated
interest income. During the six months ended June 30, 2022, we did not have any such investments and only incurred interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other
income, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2023, Other income, net primarily relates to gains from settlements of certain accrued expenses and realized
and unrealized gain on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Gain
on PPP loan forgiveness</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the U.S. Small Business Administration&#8217;s Paycheck Protection Program (&#8220;PPP&#8221;), our $250,000 PPP loan was
forgiven during the six months ended June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Grant
income</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
income of $16,654 during the six months ended June 30, 2022 consists of funding received under a $256,000 National Institutes of Health
Small Business Technology Transfer (STTR) Phase 1 grant, which we were awarded in September 2021. There was no grant income during the
six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Capital Resources</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure our liquidity in a number of ways, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash, Cash
    Equivalents, and Investments</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,615,365</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,749,408</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Working Capital</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,231,071</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,688,188</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
capital decreased by $3,457,117 primarily due to the $3,479,065 of cash used to fund our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Availability
of Additional Funds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon our accumulated deficit of $161,305,671 as of June 30, 2023, along with our forecast for continued operating losses and our need
for financing to fund our current and contemplated clinical trials, we will eventually require additional equity and/or debt financing
to continue our operations. However, based on cash on hand as of June 30, 2023 and the recent offerings discussed below, we believe we
have sufficient cash to fund operations for the twelve months subsequent to the filing date of this Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating needs include the planned costs to operate our business, including amounts required to fund our clinical trials, working capital
and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including
our ability to successfully commercialize our products and services, competing technological and market developments, and the need to
enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service
offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to raise sufficient additional capital when we need it or raise capital on favorable terms. Future financing may require
us to pledge certain assets and enter into covenants that could restrict certain business activities or our ability to incur further
indebtedness and may contain other terms that are not favorable to our stockholders or us. If we are unable to obtain adequate funds
on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing
agreements on unattractive terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;At-the-Market&#8221;
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, we entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (the &#8220;Sales Agent&#8221;)
under which we have the ability to issue and sell shares of our Common Stock, from time to time, through the Sales Agent, up to an aggregate
offering price of $4,200,000 in what is commonly referred to as an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;) program. During the
three months ended June 30, 2023, we sold 93,551 shares of our Common Stock under the ATM program with the Sales Agent at a weighted-average
gross price of approximately $5.74 per share and raised approximately $536,600 of gross proceeds. The total commissions and related legal
fees were approximately $125,000, and we received net proceeds of approximately $412,000. As of June 30, 2023, we had remaining capacity
to sell up to an additional $3,663,407 of Common Stock under the ATM program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registered
Direct Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we sold an aggregate of 685,033 shares of our Common Stock in a registered direct offering. We received net proceeds of approximately
$1,831,000 from the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023 and 2022, our sources and uses of cash were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,479,065</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,845,765</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by (used in) investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,174,433</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(247,247</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by
    financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">411,701</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease)
    in cash</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">107,069</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,093,003</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $3,479,065 for the six months ended June 30, 2023, primarily due to cash used to fund the net loss
of $8,664,774, which was partially offset by non-cash expenses of $4,824,865 related primarily to stock-based compensation. Cash flows
were also impacted by routine fluctuations in our operating assets and liabilities. Net cash used in operating activities was $2,845,756
for the six months ended June 30, 2022, primarily due to cash used to fund the net loss of $9,491,391 and a non-cash gain of $250,000
on forgiveness of our PPP loan, which were partially offset by non-cash expenses of $6,480,055 related primarily to stock-based compensation
and $300,032 of cash provided by changes in the levels of operating assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities increased by $3,421,680 for the six months ended June 30, 2023 compared to the six months ended
June 30, 2022, primarily due to a sale of marketable securities, which provided $3,263,504 of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities increased by $411,701 for the six months ended June 30, 2023 compared to the six months ended June
30, 2022, due to the net proceeds from the ATM offerings of the Company&#8217;s Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effects
of Inflation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that inflation had a material impact on our business, revenues or operating results during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Critical
Accounting Policies and Estimates</i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies are more fully described in the notes to our unaudited condensed consolidated financial statements included
herein for the quarter ended June 30, 2023, and in the notes to our audited consolidated financial statements included in our Annual
Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_009"></span>Item
3. Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable. As a smaller reporting company, we are not required to provide the information required by this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_010"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934, as amended (&#8220;the Exchange Act&#8221;), that are designed to ensure that information required to be disclosed in our reports
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and
forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal
financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures,
our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls
and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance
of achieving the desired control objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our principal executive officer and principal financial officer,
we are required to perform an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the
Exchange Act, as of June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has completed such evaluation and has concluded that our disclosure controls and procedures were not effective to provide reasonable
assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is appropriate to allow
timely decisions regarding required disclosures. As a result of the material weakness in internal controls over financial reporting described
below, we concluded that our disclosure controls and procedures as of June 30, 2023 were not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Weaknesses in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed the effectiveness of our internal control over financial reporting as of June 30, 2023 based on the framework established in
Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based
on this assessment, management has determined that our internal control over financial reporting as of June 30, 2023 was not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness, as defined in the standards established by Sarbanes-Oxley, is a deficiency, or a combination of deficiencies, in internal
control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated
financial statements will not be prevented or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ineffectiveness of our internal control over financial reporting was due to the following material weaknesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of adherence to formal policies and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of risk assessment procedures on internal controls to detect financial reporting risks in a timely manner; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of sufficient formal management testing over documented formal procedures and controls, and time to evaluate continuous effectiveness
    of controls to achieve complete and accurate financial reporting and disclosures, including documented controls over the preparation
    and review of journal entries and account reconciliations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Plan to Remediate the Material Weaknesses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weaknesses
are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    management personnel, including our Chief Financial Officer, who is overseeing the financial reporting process and implementation
    of enhanced controls and governance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement
    of external financial consulting firm to continue to enhance financial reporting, financial operations and internal controls; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documentation
    of key procedures and controls using a risk-based approach.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is committed to maintaining a strong internal controls environment and implementing measures designed to help ensure that control deficiencies
contributing to the material weaknesses are remediated as soon as possible. We have documented key procedures and controls using a risk-based
approach and have, therefore, made progress toward remediation. We continue to implement our remediation plan, which includes continued
engagement of an external financial consulting firm to enhance financial reporting and operations as well as design and implementation
of controls. We will consider the material weaknesses remediated after the applicable controls operate for a sufficient period of time,
and Management has concluded, through testing, that the controls are operating effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing
basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than described above, there have been no changes in our internal control over financial reporting that occurred during our second quarter
of 2023 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_012"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in
the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC
on March 27, 2023, in addition to other information contained in that report and in this quarterly report in evaluating the Company and
its business before purchasing shares of our Common Stock. The Company&#8217;s business, operating results and financial condition could
be adversely affected due to any of those risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_013"></span>Item
2. Unregistered Sales of Equity Securities and Use Of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended June 30, 2023, we did not have any unregistered sales of equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_014"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated
    by Reference</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex33-certificatetoaccompanya.jpg" style="-sec-extract: exhibit">Amended and Restated Articles of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/5/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex34-certificateofdesignatio.jpg" style="-sec-extract: exhibit">Certificate of Designations of Preferred Stock (Series B)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/5/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_5.htm" style="-sec-extract: exhibit">Bylaws</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/5/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><a href="ex31-1.htm"><span style="font-size: 10pt">Certification
    of Principal Executive Officer</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><a href="ex31-2.htm"><span style="font-size: 10pt">Certification
    of Principal Financial Officer</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><a href="ex32-1.htm"><span style="font-size: 10pt">Section
    1350 Certification of Principal Executive Officer and Principal Financial Officer</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Date File (embedded within the Inline XBRL document)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Filed
    herewith.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>**</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
    accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
    THERAPIES, INC.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lance Alstodt</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President, and Chairman of the Board</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert E. Kristal</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Kristal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 25; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Lance Alstodt, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of BioRestorative Therapies, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Lance Alstodt</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 11, 2023</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance Alstodt</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Robert Kristal, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of BioRestorative Therapies, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Robert Kristal</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 11, 2023</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Kristal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AND PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to 18 U.S.C. &sect; 1350,
the undersigned officers of BioRestorative Therapies, Inc. (the &ldquo;Company&rdquo;) hereby certify that the Company&rsquo;s Quarterly
Report on Form 10-Q for the period ended June 30, 2023 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a)
or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 50%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Lance Alstodt</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 11, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance Alstodt</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Robert Kristal</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Kristal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The foregoing certification is
being furnished solely pursuant to 18 U.S.C. &sect; 1350 and is not being filed as part of the Report or as a separate disclosure document.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>brtx-20230630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaOK6bP9z5Z8OekhvWBzbYmqTyMmRru7SSNBbIl20fYL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:BRTX="http://biorestorative.com/20230630" elementFormDefault="qualified" targetNamespace="http://biorestorative.com/20230630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://biorestorative.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness" id="NatureOfOrganizationLiquidityAndBusiness">
          <link:definition>00000007 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>00000009 - Disclosure - INTANGIBLE ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
          <link:definition>00000010 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/Leases" id="Leases">
          <link:definition>00000012 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000013 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000014 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000015 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>00000016 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
          <link:definition>00000017 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>00000018 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000019 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" id="NatureOfOrganizationLiquidityAndBusinessDetailsNarrative">
          <link:definition>00000020 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" id="ScheduleOfFairValueRecurringBasisDetails">
          <link:definition>00000021 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" id="ScheduleOfWeightedAverageDilutiveCommonSharesDetails">
          <link:definition>00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000023 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>00000024 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails" id="ScheduleOfIntangibleAssetsAmortizationExpensesDetails">
          <link:definition>00000025 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>00000026 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:definition>00000027 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails" id="ScheduleOfStockOptionsGrantedAssumptionsDetails">
          <link:definition>00000028 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>00000029 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" id="ScheduleOfUnvestedRestrictedStockUnitsDetails">
          <link:definition>00000030 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" id="ScheduleOfStockCompensationByAwardTypeDetails">
          <link:definition>00000031 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000032 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" id="ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails">
          <link:definition>00000033 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" id="ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails">
          <link:definition>00000034 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000035 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="BRTX_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_JonesTradingInstitutionalServicesLLCMember" name="JonesTradingInstitutionalServicesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PatentsAndTrademarksMember" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_LicensesMember" name="LicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccumulatedAmortizationMember" name="AccumulatedAmortizationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_PatentsAndTrademarkMember" name="PatentsAndTrademarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_BeneficialOwnershipMember" name="BeneficialOwnershipMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AuctusFundLLCMember" name="AuctusFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SharesIssuedForServicesMember" name="SharesIssuedForServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_MelvilleLeaseMember" name="MelvilleLeaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_GainOnPppLoanForgiveness" name="GainOnPppLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_GrantIncome" name="GrantIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_AccruedGeneralAndAdministrativeExpenses" name="AccruedGeneralAndAdministrativeExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_OperatingLeaseLiabilityReduction" name="OperatingLeaseLiabilityReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BRTX_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>brtx-20230630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheets" xlink:href="brtx-20230630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:href="brtx-20230630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfOperations" xlink:href="brtx-20230630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="brtx-20230630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlows" xlink:href="brtx-20230630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness" xlink:href="brtx-20230630.xsd#NatureOfOrganizationLiquidityAndBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssets" xlink:href="brtx-20230630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="brtx-20230630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquity" xlink:href="brtx-20230630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/Leases" xlink:href="brtx-20230630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEvents" xlink:href="brtx-20230630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsTables" xlink:href="brtx-20230630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="brtx-20230630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityTables" xlink:href="brtx-20230630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesTables" xlink:href="brtx-20230630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" xlink:href="brtx-20230630.xsd#NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:href="brtx-20230630.xsd#ScheduleOfFairValueRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="brtx-20230630.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfIntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:href="brtx-20230630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails" xlink:href="brtx-20230630.xsd#ScheduleOfStockOptionsGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="brtx-20230630.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:href="brtx-20230630.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:href="brtx-20230630.xsd#ScheduleOfStockCompensationByAwardTypeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:href="brtx-20230630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:href="brtx-20230630.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:href="brtx-20230630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:href="brtx-20230630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="loc_BRTXGainOnPppLoanForgiveness" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_BRTXGainOnPppLoanForgiveness" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_GrantIncome" xlink:label="loc_BRTXGrantIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_BRTXGrantIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="loc_BRTXGainOnPppLoanForgiveness" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BRTXGainOnPppLoanForgiveness" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_NoncashLeaseExpense" xlink:label="loc_BRTXNoncashLeaseExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BRTXNoncashLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness" xlink:title="00000007 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="00000009 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000010 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="00000012 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="00000013 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000014 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000015 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="00000016 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000017 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityTables" xlink:title="00000018 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="00000019 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" xlink:title="00000020 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="00000021 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000023 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000024 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails" xlink:title="00000025 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000026 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_BRTXAccruedGeneralAndAdministrativeExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:to="loc_BRTXAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000032 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="00000035 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>brtx-20230630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheets" xlink:href="brtx-20230630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:href="brtx-20230630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfOperations" xlink:href="brtx-20230630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="brtx-20230630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlows" xlink:href="brtx-20230630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness" xlink:href="brtx-20230630.xsd#NatureOfOrganizationLiquidityAndBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssets" xlink:href="brtx-20230630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="brtx-20230630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquity" xlink:href="brtx-20230630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/Leases" xlink:href="brtx-20230630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEvents" xlink:href="brtx-20230630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsTables" xlink:href="brtx-20230630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="brtx-20230630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityTables" xlink:href="brtx-20230630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesTables" xlink:href="brtx-20230630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" xlink:href="brtx-20230630.xsd#NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:href="brtx-20230630.xsd#ScheduleOfFairValueRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="brtx-20230630.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfIntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:href="brtx-20230630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails" xlink:href="brtx-20230630.xsd#ScheduleOfStockOptionsGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="brtx-20230630.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:href="brtx-20230630.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:href="brtx-20230630.xsd#ScheduleOfStockCompensationByAwardTypeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:href="brtx-20230630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:href="brtx-20230630.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:href="brtx-20230630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:href="brtx-20230630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssetsCurrentAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_50" xlink:to="loc_us-gaapAssetsCurrent_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_50" xlink:to="loc_us-gaapAssets_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccountsPayableCurrent_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_50" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilities_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquityAbstract_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapPreferredStockValue_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapCommonStockValue_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapAdditionalPaidInCapital_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_50" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_50" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness" xlink:title="00000007 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="00000009 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000010 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="00000012 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="00000013 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000014 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000015 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="00000016 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000017 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityTables" xlink:title="00000018 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="00000019 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" xlink:title="00000020 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_JonesTradingInstitutionalServicesLLCMember" xlink:label="loc_BRTXJonesTradingInstitutionalServicesLLCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXJonesTradingInstitutionalServicesLLCMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="00000021 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_210" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000023 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000024 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="loc_BRTXPatentsAndTrademarksMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarksMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_LicensesMember" xlink:label="loc_BRTXLicensesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXLicensesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_130" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails" xlink:title="00000025 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="loc_BRTXPatentsAndTrademarkMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarkMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000026 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SharesIssuedForServicesMember" xlink:label="loc_BRTXSharesIssuedForServicesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_BRTXSharesIssuedForServicesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000032 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_BeneficialOwnershipMember" xlink:label="loc_BRTXBeneficialOwnershipMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BRTXBeneficialOwnershipMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="00000035 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_MelvilleLeaseMember" xlink:label="loc_BRTXMelvilleLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_BRTXMelvilleLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLessorOperatingLeaseOptionToExtend_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseOptionToExtend_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_30" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>brtx-20230630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SeriesBConvertiblePreferredStockMember" xlink:to="BRTX_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_JonesTradingInstitutionalServicesLLCMember" xlink:label="BRTX_JonesTradingInstitutionalServicesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_JonesTradingInstitutionalServicesLLCMember" xlink:to="BRTX_JonesTradingInstitutionalServicesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_JonesTradingInstitutionalServicesLLCMember_lbl" xml:lang="en-US">Jones Trading Institutional Services L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="BRTX_PatentsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarksMember" xlink:to="BRTX_PatentsAndTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PatentsAndTrademarksMember_lbl" xml:lang="en-US">Patents and Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_LicensesMember" xlink:label="BRTX_LicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LicensesMember" xlink:to="BRTX_LicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_LicensesMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="BRTX_AccumulatedAmortizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccumulatedAmortizationMember" xlink:to="BRTX_AccumulatedAmortizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccumulatedAmortizationMember_lbl" xml:lang="en-US">Accumulated Amortization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="BRTX_PatentsAndTrademarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarkMember" xlink:to="BRTX_PatentsAndTrademarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_PatentsAndTrademarkMember_lbl" xml:lang="en-US">Patents and Trademark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_BeneficialOwnershipMember" xlink:label="BRTX_BeneficialOwnershipMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BeneficialOwnershipMember" xlink:to="BRTX_BeneficialOwnershipMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_BeneficialOwnershipMember_lbl" xml:lang="en-US">Beneficial Ownership [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AuctusFundLLCMember" xlink:label="BRTX_AuctusFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AuctusFundLLCMember" xlink:to="BRTX_AuctusFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AuctusFundLLCMember_lbl" xml:lang="en-US">Auctus Fund LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SharesIssuedForServicesMember" xlink:label="BRTX_SharesIssuedForServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedForServicesMember" xlink:to="BRTX_SharesIssuedForServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_SharesIssuedForServicesMember_lbl" xml:lang="en-US">Shares Issued for Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_MelvilleLeaseMember" xlink:label="BRTX_MelvilleLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MelvilleLeaseMember" xlink:to="BRTX_MelvilleLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_MelvilleLeaseMember_lbl" xml:lang="en-US">Melville Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Investments held in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.0001 par value; Authorized, 75,000,000 shares; 3,982,608 and 3,677,775 issued and outstanding at June 30, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (income) expense:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest (income) expense</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="BRTX_GainOnPppLoanForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnPppLoanForgiveness" xlink:to="BRTX_GainOnPppLoanForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_GainOnPppLoanForgiveness_lbl" xml:lang="en-US">Gain on PPP loan forgiveness</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_GrantIncome" xlink:label="BRTX_GrantIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="BRTX_GrantIncome_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (income) expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Share - Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding - Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">- restricted share units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">- options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">- common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of Series B preferred to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of Series B preferred to common stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">- common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_NoncashLeaseExpense" xlink:label="BRTX_NoncashLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashLeaseExpense" xlink:to="BRTX_NoncashLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_NoncashLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid assets and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds from issuance of common stock in at-the-market offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents - beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents - end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationRelatedText" xlink:to="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationRelatedText_lbl" xml:lang="en-US">Cash paid for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="BRTX_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Net proceeds offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Marketable securities fair value disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">FDIC insured limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite Lived Intangible Assets, gross, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Accumulated amortization, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Net, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Accumulated amortization, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite Lived Intangible Assets, Net, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite Lived Intangible Assets, weighted average amortization period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payment to acquire intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued new issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:to="BRTX_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Accrued general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of options, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation award</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidation preference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xml:lang="en-US">Preferred stock voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock voting percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Preferred stock conversion term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Number of shares issued in conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average remaining amortization period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="BRTX_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Net Lease Cost And Other Supplemental Lease Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost (cost resulting from lease payments)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Net lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease &#8211; operating cash flows (fixed payments)</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_OperatingLeaseLiabilityReduction" xlink:label="BRTX_OperatingLeaseLiabilityReduction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OperatingLeaseLiabilityReduction" xlink:to="BRTX_OperatingLeaseLiabilityReduction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_OperatingLeaseLiabilityReduction_lbl" xml:lang="en-US">Operating lease &#8211; operating cash flows (liability reduction)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Non-current leases - right of use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current liabilities - operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Non-current liabilities - operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_DisclosureLeasesAbstract" xlink:to="BRTX_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="BRTX_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Future Minimum Payments Under Non-cancelable Leases For Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Amount representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of net future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseOptionToExtend" xlink:to="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease extension description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_3_lbl" xml:lang="en-US">Procceds fom offering</link:label>
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesAConvertiblePreferredStockMember" xlink:label="BRTX_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SeriesAConvertiblePreferredStockMember" xlink:to="BRTX_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnPppLoanForgiveness" xlink:to="BRTX_GainOnPppLoanForgiveness_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_GainOnPppLoanForgiveness_doc" xml:lang="en-US">Gain on PPP loan forgiveness.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_GrantIncome_doc" xml:lang="en-US">Grant Income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_NoncashLeaseExpense" xlink:to="BRTX_NoncashLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_NoncashLeaseExpense_doc" xml:lang="en-US">Noncash Lease Expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarksMember" xlink:to="BRTX_PatentsAndTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PatentsAndTrademarksMember_doc" xml:lang="en-US">Patents and Trademarks [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_LicensesMember" xlink:to="BRTX_LicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_LicensesMember_doc" xml:lang="en-US">License [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccumulatedAmortizationMember" xlink:to="BRTX_AccumulatedAmortizationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AccumulatedAmortizationMember_doc" xml:lang="en-US">Accumulated Amortization [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_PatentsAndTrademarkMember" xlink:to="BRTX_PatentsAndTrademarkMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_PatentsAndTrademarkMember_doc" xml:lang="en-US">Patents and Trademark [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:to="BRTX_AccruedGeneralAndAdministrativeExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AccruedGeneralAndAdministrativeExpenses_doc" xml:lang="en-US">Accrued general and administrative expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_BeneficialOwnershipMember" xlink:to="BRTX_BeneficialOwnershipMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_BeneficialOwnershipMember_doc" xml:lang="en-US">Beneficial Ownership [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_AuctusFundLLCMember" xlink:to="BRTX_AuctusFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_AuctusFundLLCMember_doc" xml:lang="en-US">Auctus Fund LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_SharesIssuedForServicesMember" xlink:to="BRTX_SharesIssuedForServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_SharesIssuedForServicesMember_doc" xml:lang="en-US">Shares Issued for Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_MelvilleLeaseMember" xlink:to="BRTX_MelvilleLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_MelvilleLeaseMember_doc" xml:lang="en-US">Melville Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_OperatingLeaseLiabilityReduction" xlink:to="BRTX_OperatingLeaseLiabilityReduction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_OperatingLeaseLiabilityReduction_doc" xml:lang="en-US">Operating lease liability reduction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" xlink:to="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments options grants in period grant date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_2_lbl" xml:lang="en-US">License [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GainOnPppLoanForgiveness" xlink:to="BRTX_GainOnPppLoanForgiveness_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_GainOnPppLoanForgiveness_3_lbl" xml:lang="en-US">GainOnPppLoanForgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BRTX_GrantIncome" xlink:to="BRTX_GrantIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="BRTX_GrantIncome_3_lbl" xml:lang="en-US">GrantIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Marketable Security, Unrealized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_3_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share Price</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>brtx-20230630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheets" xlink:href="brtx-20230630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:href="brtx-20230630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfOperations" xlink:href="brtx-20230630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="brtx-20230630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StatementsOfCashFlows" xlink:href="brtx-20230630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness" xlink:href="brtx-20230630.xsd#NatureOfOrganizationLiquidityAndBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssets" xlink:href="brtx-20230630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="brtx-20230630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquity" xlink:href="brtx-20230630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/Leases" xlink:href="brtx-20230630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEvents" xlink:href="brtx-20230630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsTables" xlink:href="brtx-20230630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="brtx-20230630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityTables" xlink:href="brtx-20230630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesTables" xlink:href="brtx-20230630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" xlink:href="brtx-20230630.xsd#NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:href="brtx-20230630.xsd#ScheduleOfFairValueRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="brtx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="brtx-20230630.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfIntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:href="brtx-20230630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails" xlink:href="brtx-20230630.xsd#ScheduleOfStockOptionsGrantedAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="brtx-20230630.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:href="brtx-20230630.xsd#ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:href="brtx-20230630.xsd#ScheduleOfStockCompensationByAwardTypeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:href="brtx-20230630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:href="brtx-20230630.xsd#ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:href="brtx-20230630.xsd#ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:href="brtx-20230630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:href="brtx-20230630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="loc_BRTXGainOnPppLoanForgiveness" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_BRTXGainOnPppLoanForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_GrantIncome" xlink:label="loc_BRTXGrantIncome" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_BRTXGrantIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_GainOnPppLoanForgiveness" xlink:label="loc_BRTXGainOnPppLoanForgiveness" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_BRTXGainOnPppLoanForgiveness" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_NoncashLeaseExpense" xlink:label="loc_BRTXNoncashLeaseExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_BRTXNoncashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationRelatedText" xlink:label="loc_us-gaapSupplementalCashFlowInformationRelatedText" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationRelatedText" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness" xlink:title="00000007 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssets" xlink:title="00000009 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000010 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Leases" xlink:title="00000012 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEvents" xlink:title="00000013 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000014 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000015 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsTables" xlink:title="00000016 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000017 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityTables" xlink:title="00000018 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesTables" xlink:title="00000019 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative" xlink:title="00000020 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_JonesTradingInstitutionalServicesLLCMember" xlink:label="loc_BRTXJonesTradingInstitutionalServicesLLCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXJonesTradingInstitutionalServicesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails" xlink:title="00000021 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails" xlink:title="00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000023 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000024 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_PatentsAndTrademarksMember" xlink:label="loc_BRTXPatentsAndTrademarksMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_LicensesMember" xlink:label="loc_BRTXLicensesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails" xlink:title="00000025 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_PatentsAndTrademarkMember" xlink:label="loc_BRTXPatentsAndTrademarkMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXPatentsAndTrademarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AccumulatedAmortizationMember" xlink:label="loc_BRTXAccumulatedAmortizationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_BRTXAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000026 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AccruedGeneralAndAdministrativeExpenses" xlink:label="loc_BRTXAccruedGeneralAndAdministrativeExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_BRTXAccruedGeneralAndAdministrativeExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SharesIssuedForServicesMember" xlink:label="loc_BRTXSharesIssuedForServicesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_BRTXSharesIssuedForServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000032 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_SeriesBConvertiblePreferredStockMember" xlink:label="loc_BRTXSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_BRTXSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_BeneficialOwnershipMember" xlink:label="loc_BRTXBeneficialOwnershipMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_BRTXBeneficialOwnershipMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_AuctusFundLLCMember" xlink:label="loc_BRTXAuctusFundLLCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_BRTXAuctusFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaapConvertiblePreferredStockTermsOfConversion" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockTermsOfConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_BRTXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_OperatingLeaseLiabilityReduction" xlink:label="loc_BRTXOperatingLeaseLiabilityReduction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_BRTXOperatingLeaseLiabilityReduction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/LeasesDetailsNarrative" xlink:title="00000035 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_DisclosureLeasesAbstract" xlink:label="loc_BRTXDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_BRTXDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="brtx-20230630.xsd#BRTX_MelvilleLeaseMember" xlink:label="loc_BRTXMelvilleLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_BRTXMelvilleLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLessorOperatingLeaseOptionToExtend" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLessorOperatingLeaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex33-certificatetoaccompanya.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex33-certificatetoaccompanya.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" SD"?8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMXVDU*4L51RH)P0,X'H*]C^'?@^\\7>!--UR_P#''C*.ZNO-WI!JQ"#;*Z#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_M:OH"@#Q_]H[_DGFG_ /85C_\ 14M>0?!+_DKVA?\ ;Q_Z3R5Z_P#M'?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD2<':QP><''!Z5Z_/XL^)+6\JV_PSCCG*$1O)KD#JK8X)48)&>V1GU%>B44
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MK,-U:/&PAN((8WW!E,;,\BNN1U95. >,GBN@HH ^0/\ A27Q#_Z%[_R=M_\
MXY7T?\/[SQ4=#MM.\5Z'/:WUK$(S>FZBF2X"X"EB)&?S",YR"#@G(SM'844
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@I>]24+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M [2"#6QX8\,7'CR\A\:^-8()X9HLZ1HS8E@M8'&0[@\/(PP>1QP2 0JQ^H4
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M\I,#)P.-S$;CU[#)"B@#TS6OCIK_ (HU2'0_ .DR0SW+A(IIT62=S\IX3E$
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M\6Z1HWB:>QN+?6\Q65U8VLD)CG5E&R1&=\JV] &!X.<C'S  [BBO-_B3XO\
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M"JO+RN>B(.['!_(DD $@ V**X/6-:\9:5X5U+Q%?R>'])2VMS/'82QR7+9"
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M_#_C'PYX&\+Z1X72VU6XU>&T4C3;;3+KSKAR297C$J+E=WF-SC@' XQ0!8\
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MWJ5!.*V/"7B3QOK'C'4K/7O"T>C:3;6ZM&Y<R,93MPHE!V2#&\G:OR\ G/4
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M8PW'AC1[01Q/9V\S_9XX]JQQ,46/&!C'[MQ@=-O;BNK_ &<?^2>:A_V%9/\
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M!>V\EO(T9 8*ZE21D$9P?0UGZIXKTW2O$&E:"QDGU34G/DVT.TLD8!+2ON(
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M['@ *">2>@ Y/M713I*W/4=D<U;$*/NPU8+;ZEXIUZ?4;@)+J,YWR%2$2,9
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MKLL19'QR49^=O1D*Y!!Q<AT;Q3?_ &<ZUXC@@A\HBXM='M##YC';D&:1G?:
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M[:=HYNY^&=W:_$&Y\7>&_$$>D3W:!;JV?3DGCEY4O_$I <HI./FSN.[G@ ]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>7_%;Q1J<OA>^T'PYH
M6N7M]>;[6>:+2YO+ACSA_F:/#[AE05R,$MN&!GU"B@#Y$\ Z!KWAKQOIFLZM
MX*\07-G:.[M''I3NV[8P0@, ,ABK9SQC(Y%>M^)_BIXLELYK;PQ\/O$<4TD6
M$O+VP<&%R>2(@K!L#H2W4\@@8/L%% 'RYX7^ 'BC4=40>((X]*T]'4RD3I)+
M(O.1&$+ '@#+8QNR V"*]_UK58/!/AJ&#3M&U+4#;VXALK&QMI9BP0*JJS@,
M$ !'+') . Q&*Z2B@#POX9W>LWWQ!U'7O''AW64U2X2.+3;F32Y_(M%)8-&O
M!$8(8?,>P?+?,=WNE%% '@_QNU'5O%VG:;HV@>'-<N[6.4W5Q.VD7$>' *HJ
M[E!Z,Y/R]UP>HKG/@Q8ZSX.\:S7NM>&O$$%I/926_G+I4[A&+(X+!5)Q\A'
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MLOX5\0"!WV6L;Z?-^[A7A!C! ./F(!QN9B.M?7=% 'A_PS\57G@WP7!HU_\
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M+S9V&E:0+V74(_ML<FO0H)098@RAL'Y4R3\P)0?=!4C KC[VZNKJ<O>R227
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MRKK8_!NG0JJ)<7FT#[I9/_B:GGF_AC]X<U-:MGDOB_Q-;^)]2^VP1"VC<EC
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M54CS(LT445F:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV- &I15.VU;3;VWMKBTU"TG@NG*6\D4RLLS ,2$(.&(".2!_=/H:N4 %%%%
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M?;.>H/\ CZT@.<;2>N1FE'; Z#'X5LH1BK)&#G*6K%]/K2@4#UIP].U)L$A
M*7;3@*<%J7)&BB,VT!3GCK4NVE"X-1S(?*021I)&T4B*\<B_,K+E2*YS5?!.
MG:FRLH2(+G;$85>)2<<[.,'CKGN?6NIV#&.U(RY !Y [5+49JS147*.J/"]:
M^'EYH[A([G,)(Q+,3Y8SG@R8&#D=,=^O-6KOXC33^$W\/RZ':0D(82)(CE4
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MC'3O4]LT<.DB4+=C29GV.N0SPR]<AN%Y"@= <,1];/AY$D\%Z^LW$:LK(?\
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MR8((B4E2Q]P!EF537\*^&H?#&ERVZW$EU=W5P]Y?73@*;BX?&]]HX0'  4<
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MS?P?YOB'XJ^+O$LGGBUT_;H5F'V ?(0TX(')PX# D]']L+Z10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY6.,%CCK/BQ-KMGX&FU#0=7@TN:QE6ZGFF<+YD: D1KE3EF?RP%. WW3P2"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1&K,2!DDD# !+8R,XQD9S6I10!3TF2^FT:QEU2&.#4'MXVNHHSE4E*C>HY/
M;(ZGZFKE%% 'D]SX1\4^#/B+J7BGPG80:MINK?\ 'WI1O# XD.6,@9SM.'!(
M/)'F,H4#YJ[2'Q%K%\A%GX1U*"3>R!]2G@@B!5B#N*/(^#@[2$8-D'[IW5TE
M% 'F_P 1/".NZIX+TVWTU8-:U*QU5-1DAO2!'<<R%HPK-CRP9,!&;A%V[B0,
MT_'>C>-/'GP\N;>71X]+NPZ21:;!J*RO.PD Q*^%C"!=S[06R=ARI3:WJE%
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M+:SX9\+VMA?V?]EM'++-=IYJ2O>2L2%.06"1J@CZ89F7^$*?,](HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHBY+8VJ,;F&<'%<?I_P<U'PSKE_?>#_&<^BVMW@?9'L5N0J]0"7?#8.<$C<
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MLRH&#AC,JY!E8\J<DG)(P![Y7D^G_!S4?#.N7]]X/\9SZ+:W>!]D>Q6Y"KU
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M%RY!&5VY- '44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN?!<&H>(+R>YU.]EDEE,A0HH!\M/*V +Y91%<%<AMY8$[J["@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG>+(S-)=7*[L[8IQ$ /QS@>U>DGH<DM'<M3VD]]=RRZA(LBF(1DKPQ^8$$X
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MF<,K!R^2 L?Q)MO^$P^(OA3P.ZSFP7=JNH@1;D:-=RH"P(9<[9$)R /-4\G
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M$>>PV)(T? .!P".W?OG/>L_3YFBU.U>)F#&XB4G'4%P".1Z$_G1>O/<:S?L
MTCFX9&.,!5#$#GIP *IR]VYTSK3Q&'7)O<AN);F>X^T-</YV,>;G+GZMU-=S
MX M=2UW5C+<7US)I]HP\V*65V64D-@=<<$ D'UK,L_#NAR,INO$IAZ[E6R;(
M].<D?I7>V.J^&M!TG[!H]Y&RR<NTC-DM@#<<^H'; J5*VK9K@\+74^:IHB_J
M=W]KNCM+>2 ,#^OZUPWB^1C=VT6>%C+?F?\ ZU=''J%C+PEY;M])!_C6%XKM
MC-'#=I\RQJ58@@C&1C^=<MVY:GMM)*QRW\ZCFN/LB"Y/2,Y ]SQG\C4E5=1C
M\S3Y5[' _45=KHA'-6LVI174FGV%Q<J#,UN(XF8*Q)"XVCKG X[X%4EN&LY%
MGB)5X^05/3/''YUU'A7Q=)X0\0ZK.MJMPEQ<D,K/M"@.3G@$Y_3KP>V%XCOQ
MJE]-<*J*A"JOEA@.,=B2?6O53<L._-'$[1J?,Z[0]$LKX^(3>7BVJ65Z41V&
M?E+$ #+#TQ^-7XM+\,0Q2227T]RL6 PCC'/4\8E]C5.VDMMFO6D\ZPO?%98R
MQX9@S,!GH,G Y]:SK2[@L8KF&:U:9Y5,>Y9P O49& <]?6O3PG-.BFFSS<0X
MPF[I'1&703:V,NDVDT<L>I1>9)*,%EZ$?>;U'Y56\2N'TV,]=EW+CVWLQ_I6
M5975O%9QP#<UPTZN3G 4!AVQST]>_M5S67+V5PO99H"/^!1N37+BH>SKQF]]
MATI<]-I'>?!6XC'AJ]LP&#I>NQXXQLC_ ,:]-KRKX,C%OJ8_Z>&_]%PUZK7+
M65JDEYGKT7>G'T"BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** (YH(;E D\4<J!U<*ZA@&5@RGGN
M& (/8@&I*** "BBB@ HHHH **** "BBB@ HHHH **** (X8(;9"D$4<2%V<J
MBA069BS'CN6))/<DFI*** "N7\8^+;SPM_9WV/PUJNM_:92)OL$)?R(UQN8X
M!RW(VJ< X/S#'/444 8=GI37^J0:[J]M&MY CI8VYVL;)'QNRPR#*P W$$A0
M-JY&YY-#58+ZZTNX@TR]CL;R1-L5R\'G"(_WMF0"<9QDXSC((X-RB@#+\.:!
M8^%O#]GHNFK(+2U0JGF-N9B269B?4L2>,#G@ <5J444 %1S00W*!)XHY4#JX
M5U# ,K!E//<, 0>Q -244 %1QP0PO,\44:/,^^5E4 NVT+EO4[549/8 =JDH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *^:?%I ^)'B/\ Z[K_ .@U]+5\U^-(GA^)?B)7&,RQO^!0$?H:Z,,K
MSMY,Y<9_".A\6D?8M0'_ $\QG/\ P!*PF\6:]&1'%JES D:[%B5N% Z#'MTK
M6\3.);6^7/!5)?\ QY5I7\8V]J(#9:? T@B42R2B3EN^,/C]*WRYWIN/+>QY
M^(^*[E8S$\6^*G7$.JW,C9X 0,?RQ65J;22V6NR2<2&\WR#_ &C(,_K7::_X
MZ\0:=JT]E:RV\44>W;^ZR>5!/7/K7&WLC7&E^([AQAI'MY^/]N9L_P J>.C^
M[4N6VWYFN$E[_+S7-7P1K_AK2]+U :KHR2R%%#.T@D,S?.1B-\ 8'''K[US>
MEL&UJ?$HES$OSA0N[YT[#CVJWX5\&WWBQKM+,(K0P^8K2.%4MG '0GG^AYJM
M8VPLO$5S:+,LH$*?,F=K'S(SW /3VKCQ=O9Z>1VT6^8Z3K[>U.T[5X=/U2*=
MHI9HTSEH@"I)4\9]>:JWLIA@*J!\[>7S[YKS_5[YK^\;.?*4#8I &/\ ))K@
MA#F.S9)GT1I>KVNK0N\!9&0\QR8#CC/0$^_Y&K_;/:O$/ >JSKK%JCL&,<L<
M:G;R%;Y2/RKV\$=>QK&I#E9:9/:SM;7<<N6P&&<'J/\ .:W]3M(-9T.>WDB2
M1)X&"AAG!*D?GS7&IJ43ZS/I:I*9X8TD=L#: V['?/\ ">U=#I>I?9LPSD^4
M/NX'3GG^=:49V?*R9QZGC5QXL\*6[.)O!TB.J!ROVEL@9QT-,/B[P<CLJ^$6
M&&D4XNVZH,G_ .M7>>._AK-KU^VJZ1*JW#A!)'))A6P",C*GG&WOC@UY?;>%
M=4OOM"Q*"UK(894+J"C#J#V/X9%7*+1TKZAI>GKZ&FWB3POJ%O/#:>&&@F*#
M;*UP3L++\IQWQ5&;3Y/L9E"HVX!@J\MS[8J(^$=81PK11['(7F0?,/2KRZ9X
MI2(6PEA"*OEA<IPH&,9QZ4DKG'B,%A:U2\8M(=IELET!"--=I4QO8R.O'K@"
MLO6]?N]!\6JR27,+1PC<5E)<9S_$><<CO4M]X0U>Y=)+A8S*0!N$@&0  /TQ
M5";P1J9MFE14#(<,6D&!^7/<4E&T[W,8X2$8<O+KW('\:ZC//YCWET7D!29F
M?=N5LA@0?8M],U?@<2#>.C*",]<$"H#X#U>01QQ"/S6&"&D&"1Z<=*V+/PMK
MR-;VJV\!E=O(7]X,;E0L1U]%)JY--71P8S SG%<B([,,U_:[ "$N82Q!Y_U@
M_P *O<"[O2%QFYESQU^=NM;.K6.GZ7<65G8JVY;B(RNQ)+'S%&?3L>@%8R6-
MWJNK7%A9*IDDN93*2<83S"">?]X4;TSJPF&5&"74>2/[P/O297VJHUK);3/:
MWD82YC^^H.>H!'(XZ$4ODI_=_6IY+CGBN5V:+:N4.4;:?]DXJ5[VX>(Q/<RM
M&>JM(2/RK/\ *3^[^M'E)Z?K1[,7UQ+H6\C_ .O4-WC[*^3@<?SHA)5BF>,9
M'T[U#J@8Z9-@9)( 'OD?TJ&N4Z83YTFAG@[0-/\ $7BC4;?4)X[>))MX=V(#
MG?CR^HY;/U^7I6-XPL;73M9N8;.>&:$!"#%C:"0,C@GZUFS@G6;LIRYNW\O/
MKNXJ&^E>5)'D)+D GI[#M7J4_=P]_(YIV=7YG4ZCC[:> -J 'ZY-5PCE=VUM
MN,@XX_"MJQ-I%J&LZC<AI&L+QE@BYVN^X@;L8. 2IZCOUZ5JI\3-?C4(D5AY
M X"&-N!Z?>S^M>G@I3C0BHJYY6)A"55N;L<E;\W4)QC+ ?K6UJ__ !Z70QC]
MY:_^B7JU?#3M6>UU6RC>"9[J.">$DX//WADGML'7UXJ+74V6$I'\5S&O_?*N
M*PQTN>K!=1T(\L7V.Q^#7_'OJ?\ U\-_Z!#7JM>4?!<AK74R/^?EO_0(:]7K
MBK_Q)>I[%#^''T"BBBLC4**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KB_%&M>+_P#A);;1/"%AILKI;BXO[G4RPBA5
MRXB V.'))BD!PI_AZ<UVE1QP0PO,\44:/,^^5E4 NVT+EO4[549/8 =J /([
M?QC\2[OQS=^$8/\ A#7U*TM!=3MLNQ&@)7"Y)R6PZG@8P>N<BNH\)ZMXXN/%
MNIZ3XHMM#CM[.TBF233_ #<RF5F"D;F/RCRY0<@'(&,@YKG_ ()_;-8_X2CQ
ME>>>G]N:A^YAFRVR./=MVR'[ZCS#&,  >5CV'H&MZQI?A73I]2NDVM/*H$5O
M%NFO)R J(BCEY"%51[+R0!D &Q7+^/=;O_#7A>[URSO;&WCLXF=TN[.2?SG)
M C0%)%V98@9(;[P/ !SA^+/%WB;PGX3'B;4%T:V >$'1F5I)268!HUN!(%+[
M=S9$1 P?O ;CG_%^YN]:TOPWX0MH[NUN/$=ZBSKY*2F*%-K2;]K'E69&.TXP
MC?-CJ =IX'OM4U3P7I>I:S) ]]>Q?:F\A<(J2$O&H'^RC*O.>G4]3T%9>OZ_
M8^&]+:_OVD(+B*&"%=\MQ*W"Q1IU9V/0?4G !(X_Q9XN\3>$_"8\3:@NC6P#
MP@Z,RM)*2S -&MP) I?;N;(B(&#]X#<0#T2BO-_&'C?Q!X:\4>&+9(;'[!K4
MN);>>W;[3;(@C,BADE*R2?.VU54Y("J')&8_%_COQ-X)%CKFK:=IO]@W-Z+=
M[*(LU[$C1[E8ON\LOE7RH&!@ .V=P .X\0W-S8Z-/?6]_:6*6J-//-=6CW"B
M)5);"(Z'/&>IZ$8.>,?X<ZOK7B'P=;ZWKOEI<:@[316\=N8E@BX50,DE@VTR
M;B>?,XX K+^,EY<1_#^32[$3F_UJ[@TVU$+A-SNV2K,2,*RJRG_>P>":Y_QG
MXWUCP!X-T:X\,6MC<:#!Y>G17.H%WDN=L?RR(J%1Y>(S\Y/SGE5V[68 ]@HK
M'\3^)]+\(Z'-J^KS^5;Q\*J\O*YZ(@[L<'\B20 2,/5=5\9:=X:N/$,L6C6X
MM;?[7/I#I)(ZH@W2)]I5PN_:&P1$0#@<@;B =I17+WGBSSO (\7:(D%U:I:-
M?/!,^TO&J$M'O7<$D4CGAAE2O&=R\W#X[\377PR.M6^G::=:@LFO[O>6%K!%
M@R(ORL6:5X=K!-PVA@6*Y56 /3**XOPAXY74OAA:^+_$4MI8H4E>X>,,L:A9
M608!)))V@8Y))P.H%5]6\2^)K?P=?>*&CTW1+>WMY)HK'4X&EGD SY>]EE01
M._RCR\.5)'))V@ [RBLOPWJ[>(/#6FZP]G)9F]MTG\AW5RH89'*\$$<CH<$9
M .0)-<UFS\/:'>ZO?OLM;2)I7P0"V.BKD@%B< #/)(% !J>I_8?*M[>'[3J%
MQD6]L&V[L8W.S8.R-<C<V#C( #,RJW'^)_$'C'3OLND>$]/@U_5TWR:A<3IY
M4$ X(C'S*H8^8"J%RX106W;M]5_A/9ZIJMG=>./$9WZMK.!;J4VBVM%)V(@(
MRJL<MP2&&QB222?2* /%V\9?&*#6-,TR\\.>'+6XU*5HK<2S9SM4L[86<MM5
M022 >PZD ]AXT\3>*;6\@TSP1HL&K7Z[GO7G)$-LH"[4+%D7S&WAMN[<%&=N
M&!JQX4\_Q#JUQXQN?DM9XC::1#^]4K:B0DS,K8&Z8JC?=X1(^3S784 >+MXR
M^,4&L:9IEYX<\.6MQJ4K16XEFSG:I9VPLY;:J@DD ]AU(!]4\1ZTOA[P_>:H
MT$EP\* 16\88M/*Q"QQC:"<L[*N<'&:P_"GG^(=6N/&-S\EK/$;32(?WJE;4
M2$F9E; W3%4;[O")'R>:D\>^$M2\8Z7:V%AX@DT9(KA;AY(86=W9.4 (D7 #
M?-WY52,;>0#E])UWXRS:S8Q:IX3T:#3WN(UNI8Y5+)$6&]A^_/(7)Z'Z&N\\
M17UQI=G:ZA%)MM[>[B-XA48:!SY;LS'[BQ[Q*6](B"0"2.#^&/BOQ'_PDNJ>
M _%ACGU/2;=7BNX_F,T8(Y=\_,2LD14[0<9W?-76?$>^M]/^&OB.:ZD\N-M/
MFA!VDY>13&@X]691[9YXH ZBBL?PG?7&I^#=#O[R3S+JZT^WFF?:!N=HU+'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/YA <,I\MOF.<_,,X['UJX4B:WXB09X VCCFH_*B6(#RH]V<9VCKS@UFE9-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3PH\Q>O 'HEKX<TBS\07VO06,:ZI?(B7%R269E4  #)PHPJY"XS@9S@57O\
MP?H&I^);/Q#?:;'/JED@2WF=V(0 L1\F=I(+$@D9!P1T& #SOQC_ ,33]HGP
M5I-Y^]L;:T>]BB^[MF'FMNR,$\PQ'!./EZ<G/0?&#69;+P6VC6#YU?7I4TZS
MA!3+[R ^=YX4J2I;L77IG(ZS5_#VF:Z]I+?P2&>T=GMYX)Y()8BR[6VR1LK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]$\W^R=*L;#SL>9]DMTBWXSC.T#.,GKZFM"O.W^+EM#<6D%QX.\76KWEPEK
M;K3TA5Y7.%0,\@&3]>QKT2@ HHHH **** "BBL>3Q#;Q?VA<LN-*TZ*1[J^R
M2H=.61% )?: VXCHP"C<P<( ;%%>/_\ #1W@_P#Z!NN?]^(?_CM=QX=\>:7X
MC\)77B>.WOK+3+;S2[WD.TLD:Y9U"EMRCD<=U88XH ZBBO'_ /AH[P?_ - W
M7/\ OQ#_ /':] \'>+K/QMH?]KV%G?6UJ96B3[9$$,FW&67#$%<DC.>JL.U
M&Y!!#:V\5O;Q1PP1($CCC4*J*!@  <  <8J2O._%OQG\,^#O$$NBWL&I7%W"
MBM+]EA4JA8;@I+,N3M(/&1R.<Y ZSPMXDL_%WARTURPCGCM;K?L2=0'&UV0Y
M )'53WH V**S]$U/^V-'@O6A\B9MT<\&[=Y,R,4DCW8&[:ZLNX<'&1P16A0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA"PR03^)K1O-/L(1)%=&>YB3!5L9V@C(.-IQQ5,:3I,@/DP7,DO\,26C$O\
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M/4@>U>K",:---/0X)R=26J+>D2R6]G=74:AC<!K%<]EQF0_49CQ]3P>UA5
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MD?9TXTWON_4]?"KFDZGR1;'6G4@ZTM8'8@HHHH **** "BBB@ HHHH ****
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M !R20!DFO)_&@F\3_$CP9X<U62.(3W#:C)IKH9%AAB5F19,'9(\FR16^\$P
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M5@1Q6?XBN$\5>+;7P9'%YMC:^5J.LN0KQE%;,-LP*M\SN$<@[<HIP3N..XH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&E
MHQ0 Q@&7:0"/0U\^>,O#I\(^*L6KJL%WNN[81C:(2'.5 S_""F.WMQ7T+BN-
M^(WA#_A+- 'D[EOK$O<6NQ03(X4XCR<8#';SGL*UHSY)79C6I>T@UU/.F6/6
M[ F)4M[.XEP@(SY,RC)& .A12<CC+=.]<Y97MQHVK12*[K);3@LBN0"5/(XX
M/3%)H&HPEWCO@R6DH*S(<G81@@XQU^5>W0UL:W8R74)N/+"SVZ;7 QF= >)1
MW.?G)//2NC#U/JU;V<]82V/+JQ=2',M)1,W5=>U#5[J>2:ZN&CDD+^4TI95'
M. !T& << 5F%G0AHG\N1#O1L9*,.0:/Y5JZ9X?U#5XU>PA,W[S8RJRY0<98@
MG.!D<]/>O9G&FJ?++X3@C*<I\RW,*_M1>I+>VX+3Q)OOHSP/NY,@R<'=@L0
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M'4FI\<5A4FYR<F>I""@E% *6BBH+"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,_$/PSU
M[Q+XJTCQ!>^*[19]*='MK>+3'$&Y7WY*FX)R2 "01D*/2O2(!,MO$MQ)').$
M D>-"BLV.2%)) SVR<>IJ2B@"GJVFPZSHU]I=PTBP7MO);R-&0&"NI4D9!&<
M'T-<?X7^'^IZ-I::1K'BV[UC2(46.*Q-K'$A09^21OF=T^Z-NX# VD,IVUWE
M% 'F^B?#36?#7A>#2M$\7_8;J&5F^TQ::A21&)+;XV8AY"=@\PGY5C55"Y<M
MJ>+?AS8^*?!TNAM=21W#W"W?]H2KYDC3C@R. 5#$IE .%4$!0 J@=I10!EZ)
MI#:7;[[N\DU#4Y4075]*BHTQ4< *O"(,G"#@;B>69F.I110!Y_\ "G1/^$<M
M?%.DK;_9X8/$$_D1;]^V%HHFCYR<_(5/)SZ\YKJ/$VB/XBT<Z7]K^SVLTL?V
MP!6W30!@7B#*ZE=X&TGGY2PQSQ<@TV&VU2\OXFD5[M(Q+&" A9-PWXQ]\J54
MD]1&@_AJY0 5C^)M$?Q%HYTO[7]GM9I8_M@"MNF@# O$&5U*[P-I//REACGC
M8HH *Y/Q7X8U_6M4T^_T3QA=Z&;5'5H%MEGBE+<;F0D G&?O;@." IR3UE%
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M]DEWI\4TYW$[W#/&#ST^5%''IZYKU_X'>(;C7_AK;)=+^\TV4V ?(^=$52G
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M>G_%KP'#XP?PZ8=.DDNSJ<5O<W4&%>*S*NTA+'C P"-P."<#EL$^!&B3:/\
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M%P)))&2257;)!(?@=,C)Y[0Z7<ZBNG7DM[<WG]N3:RGDVCLV1'YL>Y5!Y\L
MOT., ^]<_%X_\5:/=&UOX[=63 *01J2!P>I;T-;4?Q;(3;+9W ]WC3^CUSRI
M5T[NFS=8BD]I(NZ+=WES>W]O<ZE=K<#50IA\\YC3S)1@#J%QM]NGM61X"UO4
MI;[29-0OKS[,WFJ]S<7#/%*V)"$(/1NAY)X7IR"+G_"V+8'>T6"1C+1'^C4O
M_"VX-W[N!F)](N3^;5%JCTY&7[2&[9O:?YS^(=<3Q!;R!2X%B6C9P8@TF"G!
M^;ID#_9XZ5D:SH&J:GX5UC0K>RF\V:^^T6=R1@F,E6!YQM(&Y,$@X'3M6?=?
M%FX9"+:TN$;& 3''CV_CK-;7_'&N*98+>R-LW(9PH;_T+%7&CB-E!D?6*/\
M,=WIVBIX>O+^,:E ;2^NOMTRN@#I)NW$##=/E4=/_K07_C+P]I&^+[7%>.LK
M2A)GWM$V2V54+G@MCCVKS+7M)\0V]LIUK<UO*"0,QXQQ_=YZD5B6D21/%'&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!&689(Z$TK5?$R>-9-"U:+3;BS6R:[6^LD:,Y+(J(\;.QC.1,022' XP4<4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[4KM(O.N')W22.!N=N2>3DGDU]SV%C;Z9IUM86<?EVMK$D,*;B=J* %&3R<
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MY8;).HX#<'DU]!P00VMO%;V\4<,$2!(XXU"JB@8  '  '&*^+/B+XAM_%7Q
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M@5$ZMTHPT1VTL/&'O/5@!2T45BCH"BBB@ HHHH **** "BBB@ HHHH ****
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MG))/))).2: +E>-_%\S7/Q&^'5KIT<=UJ$-ZT_V;>00HDA(9]H8JG[M\MM.
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M'-/1+&V\Y@^^9%+RA,X;AV1C[Q\$X-=1X>^'GACPI>&ZT.QGLI&^^$OIRDF
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!Y_;?!3P#;Z<MF^A^?]PO-+<2>8[*",[@PQG<20N%)QQP,
M9]]\!?!UQ+(;*35=+AEB$4T%G=Y24!@WS>8')Y"G&<?*IQD9KU"B@#A_#'PD
M\'>%98;FUTS[5?0\K=WK>:X.[<& X16! PRJ",=>3GN*** "N'\3_"3P=XJE
MFN;K3/LM]-RUW9-Y3D[MQ8CE&8DG+,I)SUX&.XHH \KTW]GWP18W#2W U+4$
M*%1%=7(50<CYAY:H<\8ZXY/'3'IEC86>F6<=G86D%I:QYV0P1B-%R23A1P,D
MD_C5BB@ K#\2^#] \86\$&O:;'>) Y>(EV1D)&#AE(.#QD9P<#T%;E% 'D\/
M[/\ X;M[.YLX=<\1QVMUM^T0I=QA)=IRNY1'AL'D9Z5VF@> /"GA=UET?0[2
M"=7+K.P,LJ$KM.V1R6 QQ@'')]37244 %%%% '%ZE\*/!VLW"W&J:==WTZH$
M62ZU.ZE8+DG +2$XR2<>YJO!\&? 5K<17%OHDD,\3AXY([^Y5D8'(((DR"#S
MFN\HH KV-E%I]G':PO.\:9P9YWF<Y)/+N2QZ]SQTZ58HHH YO7_ ?A[Q2[-K
M5M=W:%P_DMJ%PL2L%V@K&KA%.,\@#J?4UA_\*2^'G_0O?^3MQ_\ '*] HH R
M]$\/Z?X>M_L^G?:U@V(BQS7LTZQJHPH02.P0 '&%QT'H*U*** "N7\0_#SPQ
MXKO!=:Y8SWLB_<#WTX2/( .U X5<[1G &<9/-=110!S_ (;\%:#X1\P:':SV
MD<F2T/VR:2,DXRVQW*[OE W8S@8SBMB^LHM0LY+69YTC?&3!.\+C!!X="&'3
ML>>G2K%% '!S_!GP%=7$MQ<:))-/*Y>222_N69V)R229,DD\YK0T7X;>%O#K
MS/H]E=V)G0I+Y&HW*AQM9>1YF"0&;!ZJ3D8/-=910!P]]\(?!&IWDEY?Z3/=
MW4F-\T^HW,CM@ #+&3)P !^%=1HVBV6@:<EAIRSI:I@(DUS)-L   53(S%5
M PHX'I6A10 5GZAH>EZK>6%W?V$%S<:?*9K621,F)\8R/T/U53U4$:%% $<\
M*W-O+ YD"2(48QR,C $8X92"I]P01VKB[[X0^"-3O)+R_P!)GN[J3&^:?4;F
M1VP !EC)DX  _"NXHH \_P#^%)?#S_H7O_)VX_\ CE7--^$O@/2KAI[?PU:.
M[(4(NF>X7&0>%D9@#QUQGKZFNTHH C@@AM;>*WMXHX8(D"1QQJ%5% P  .
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MY%:>.UL+-@#F28&1@02-NW>..,YQUXKVVPT72M('_$OTVSM" 1F"!8^"<D<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>(?=@B+<A >2<#>Q+$#A5U+Z^M].LY+JZD\N%, D*6))("JJC)9B2 % ))(
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M/]W." :T/AUX>N/"OP_T?1[QLW4,1>88'R.[-(R<$@[2Q7(/.,]Z .HHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.Q\/-X=^&NE3ZG<1Q/;6LVGQ@V=K)L#;GN'_ ';-A]V,L688;!:MCX:^"/\
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M**^7/C/\3YO$NJ3>'M'NXSH-LX#R0,2+R08))/=%;@ 9!(W9/RX /:[[XP>
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ML>+J:*>&1]Q^9$*%1CIP9'_/V% 'H_\ PNWX>?\ 0P_^25Q_\;H_X7;\//\
MH8?_ "2N/_C=<_\ LX_\D\U#_L*R?^BHJ[SQ+X>\.>-$N=!U:VCGN(;=9 X3
M$MLLK,%>-R."6A/ Z[?F!!P0#4T36].\1Z/!JVDW'VBQGW>7+L9-VUBIX8 C
MD$<BM"N/^%VC7GA[X>Z?I%^FRZM);F)\ @-BXDPRY )4C!!QR"#784 >?_\
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M+[+8WWVM)XHD;RXYA#(P.22%W!B @  $9QWP >P4444 %%%% !1110 4444
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M.60 *JLS-MSLV26O@%H_%FOZK=:Q)=V&M/"]Q8O;JI81*56-G!PT6&.5V@L
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M*JC).2=2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .#^,\\UM\)->>"62)RD2%D8J2K3(K#
MCL5)!'<$BOG3X/V-OJ'Q7T"&ZC\R-97F W$8>.-Y$/'HRJ??'/%?4?C_ $!O
M%'@/6='B61IY[<M B,JEY4(>-<MP 650<XX)Y'6ODSP-?7'AOXE:+-/)]@DM
M]02&Z-PH3RD9O+E#[ON_*6!SC'L10!]KUS_CO_DGGB7_ +!5U_Z*:N@KD_B=
MJ4.E?#+Q%<3K(R/9/;@( 3NE'E*>2.-S@GVSUZ4 ?'FA:G_8GB'3-6\GSOL-
MW%<^5NV[]CAMN<'&<8S@U]G^._\ DGGB7_L%77_HIJ^6/A'X>N/$/Q*TE(&V
M1V$JW\[X!VI$P(X)&<MM7C.-V<$ U]3^._\ DGGB7_L%77_HIJ /E#X6ZK_8
MGQ'TG4?L%]?^3YW^C6$/FS/F%U^5<C.,Y/L#7I_B7XJWGB3Q]X;\-0Z/?:1:
MQ:W92W"WN8YY?G0JKQCA5R=V"6SA&XQBN ^"7_)7M"_[>/\ TGDKZ7\9^&$\
M0+HMU'!YE]I6JVMW"PV@A!*GF@D_P[,L0",E%ZXP0#J*^?\ ]IK_ )E;_M[_
M /:-?0%?/_[37_,K?]O?_M&@"A\(_'O_  B'P\U5?^$;US4MEW-<_:+2UW6R
M8BC^627/R8VY)P< @\UU_P &?%EYXU\4>,M:O$\KS?L:0P!RZPQJ)@J@G\2<
M8!8L<#.*/V<?^2>:A_V%9/\ T5%7<:'X831?'/B35+:#R[75HK65B-H4SJ9A
M)A1R,@QL2>K.QR>< %CQW_R3SQ+_ -@JZ_\ 135\@>!/^2A^&O\ L*VO_HU:
M^O\ QW_R3SQ+_P!@JZ_]%-7R!X$_Y*'X:_["MK_Z-6@#['\67UQIG@W7+^SD
M\NZM=/N)H7V@[76-BIP>#@@=:^+/#6FPZSXJTC2[AI%@O;V&WD:,@,%=PI(R
M",X/H:^W]6TV'6=&OM+N&D6"]MY+>1HR P5U*DC((S@^AKX8GAOM"UF6!S):
MZA87!1C')\T4J-CAE/4,.H/;B@#[SHJO87UOJ>G6U_9R>9:W4230OM(W(P!4
MX/(R".M6* (S!"UPEPT49G1&1)"HW*K$%@#U )521WVCTKP/]IK_ )E;_M[_
M /:->^&>%;A+=I8Q.Z,Z1EAN95(#$#J0"R@GMN'K7@?[37_,K?\ ;W_[1H Y
MSX)^*YO"]OXC:W\.ZSK,\Z0&--.MC(J,HEP)&'* EN#@]#QQ7=_ _P 0W'BO
MQ1XYURZ79)=RVKA,@^6@$H1,@#.U0HSCG&3S6/\ LR_\S3_VZ?\ M:O5/#_A
M=M#\>>*M5BCC6SUA+29-B*@651*L@P#DDG:Y8@9,AZD$T =916''XEAG\:S>
M&K>WDE>VLOM5U<J04@9F CB;'1V7<V#C@ C.3C<H ^9/VD)YF\=:9;M+(8$T
MQ72,L=JLTL@8@= 2%4$]]H]*[/\ 9NL;>/P;JU^L>+J;4/)D?<?F1(T*C'3@
MR/\ G["L?]H_PQ<2RZ9XGMH)Y88XC:7;C!2$!LQDCJ,EW!/3A1P2,R?LTZJS
M6^OZ/)<Q[$>*Z@MSM#98,LCCN1\L0/8<=,\@'OE?/_[37_,K?]O?_M&OH"OG
M3]I;4H9=9T#2U63S[>WEN'8@;2LC*J@<YSF)L\=QU[ $?[->I^5XAUS2?)S]
MIM$N?-W?=\I]NW&.<^=G.>-O?/%_]IK_ )E;_M[_ /:-;'[.?AZXT_POJ.N3
MMB/5)52!,#E(BX+Y![LS#! QLSR"*Q_VFO\ F5O^WO\ ]HT 4/A'X]_X1#X>
M:JO_  C>N:ELNYKG[1:6NZV3$4?RR2Y^3&W).#@$'FNO^#/BR\\:^*/&6M7B
M>5YOV-(8 Y=88U$P503^)., L6.!G%'[./\ R3S4/^PK)_Z*BKN-#\,)HOCG
MQ)JEM!Y=KJT5K*Q&T*9U,PDPHY&08V)/5G8Y/. #J**** "OD#XV_P#)7M=_
M[=__ $GCKZ_KY ^-O_)7M=_[=_\ TGCH ]_^"7_)(="_[>/_ $HDKT"O/_@E
M_P DAT+_ +>/_2B2O0* /F#]H[_DH>G_ /8*C_\ 1LM;'P4\:?\ ".>#;RS_
M .$9\1ZIOU!Y?.TRP\^-<QQC:6W##<9QZ$>M8_[1W_)0]/\ ^P5'_P"C9:[_
M /9Q_P"2>:A_V%9/_145 &?\4O'_ /;?PXU;3O\ A$O%=AYWD_Z3?Z;Y4*8F
M1OF;<<9Q@>Y%>8?!+_DKVA?]O'_I/)7O_P ;?^20Z[_V[_\ I1'7@'P2_P"2
MO:%_V\?^D\E 'T_X[_Y)YXE_[!5U_P"BFKXX\)W7V'QEH=Y]GGN/(U"WE\FW
M3?))MD4[47NQQ@#N:^Q_'?\ R3SQ+_V"KK_T4U?('@3_ )*'X:_["MK_ .C5
MH ]<\7_$*^\3?$;P;HK:'J6CV<&L6MT(]1B\N6X)D55?81E0I\T##$'//(P/
MH.N3\<>%V\0GP_=V\<9N])UBUO 2B[C$) )5#$C:-OSGKGRP,$XQH>+?$L/A
M3P_+J3V\EW.76&ULXB!)<S.<)&@ZDD\G )P"0#C% &Y1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!CV/BSPWJ=Y'9V'B#2KNZ
MDSLA@O8Y'; ).%!R< $_A6I//#:V\MQ<2QPP1(7DDD8*J*!DDD\  <YKP?XH
MP3:?\09/'6D12$>''L$U$1*8?.9RY8&7^(^6UNA #?+,,\ BO<(-5L;G1HM8
M2YC&GR6XNEN)/D41%=V\[L;1MYYQCO0!3L?%GAO4[R.SL/$&E7=U)G9#!>QR
M.V 2<*#DX )_"MBN/^'&EV\'APZX+*"WOM?E?5+EHW+DB9VDC4L0,[4=1@ #
M.XCJ2=R;Q+H-MJ@TN?6]-BU NJ"T>Z192S8VC83G)R,#'.10!J453U+5M-T:
MW6XU34+2Q@9PBR74RQ*6P3@%B!G )Q[&H_[=T?\ L?\ M?\ M6Q_LS_G]^T)
MY/WMOW\[?O<=>O% &A5>^O[/3+.2\O[N"TM8\;YIY!&BY( RQX&20/QKE_&/
MQ)\/^#]#^WRWD%Y<31++9VD$RE[@-G8PQG$9P?GZ<<9. =@Z_9V_A*;7C>0:
MC:VMH]Q+/88*2^6I+^6-Q'56 !8XZ$]Z )-*\2:+KEQ<0:3JEI?O;(CS&UE$
MBH'+!<LN1GY&XSD<9ZC.I7F?PLN[;0_AO#KGB+48[*XUR]FOKB6_=(%>61C@
MKD* &1 X'?)(XQCTB">&ZMXKBWECF@E0/')&P974C(((X((YS0!)7/\ _"=^
M#_\ H:]#_P#!C#_\5705XGX=TJQ\3_M&^*=8-M'>6>E)&B2/P(KM5CC'RG!)
M!CFP<$ J".=IH ]H@GANK>*XMY8YH)4#QR1L&5U(R""."".<U)15>^O[/3+.
M2\O[N"TM8\;YIY!&BY( RQX&20/QH L45EVWB70;VXMK>TUO39Y[I"]O'%=(
MS3*"P)0 Y8 HX)']T^AJ34]=T?1/*_M;5;&P\[/E_:[A(M^,9QN(SC(Z>HH
MT**KV=_9ZA$9;*[@N8QMR\,@<#<H=>1ZJRL/4,#T-6* .?\ ^$[\'_\ 0UZ'
M_P"#&'_XJM2;5M-MM+&J3ZA:1:>45Q=O,JQ%6QM.\G&#D8.><BO(_$=A9O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?\
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M%%9L<D*22!GMDX]30!7U;4H=&T:^U2X61H+*WDN)%C +%44L0,D#.!ZBO/\
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MG(&YNASY*#@XKI-#_MNX^(NJ:MJ?A:>TM9[2"SL;IWMF>*-/,>02;96(W.X
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M,WB:Y>^+]?&S7=0B$*VD<Q>*PMQ@B%3G#-D!F8<;L[0!DMV% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(C8)!PPX.""/PH L445S_P#PG?@__H:]#_\ !C#_ /%4 =!17/\ _"=^#_\
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MZ'_X,8?_ (JK%CXL\-ZG>1V=AX@TJ[NI,[(8+V.1VP"3A0<G !/X4 ;%%%%
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MXQ(C8@D(RIX." ?PKZ'^-O\ R2'7?^W?_P!*(Z\ ^"7_ "5[0O\ MX_])Y*
M/H_6?A;X*UO3GLY?#UC:YR5FL85MY$;! (9 ,XSG#97(&0<5\J:=JNM?#CQK
M</87,:W^G7$EK-MRT4P5MK(PX+(2OL>A&" 1]KSSPVMO+<7$L<,$2%Y))&"J
MB@9))/  '.:^'-=NO^$C\9:G>:=;SO\ VEJ$LMO#LS(WF2$JNT9RW(&!GF@#
M[/\ "OB&W\5^%].URU79'=Q!RF2?+<'#ID@9VL&&<<XR.*\S_:0@A;P+IEPT
M49G34U1)"HW*K12%@#U )521WVCTKO/AUX>N/"OP_P!'T>\;-U#$7F&!\CNS
M2,G!(.TL5R#SC/>N'_:._P"2>:?_ -A6/_T5+0!XQ\(+"SU/XI:-9W]I!=VL
MGG[X9XQ(C8@D(RIX." ?PKZ?O/ O@=XA:W'AO0XOM>Z% MI%$[DJ20C !@VT
M,?E.1M)[5\T?!+_DKVA?]O'_ *3R5[WK?BZQO?BMX0\.:?>VET\5Q=W%XL3;
MVA=+>5%4D' /S294\C:.G< XNS^'=OX#^/?AF73IMVF:E]L>WA<DO 4@;<A)
M^\OSC!SGL>FYNL^->B3>(]!\/:-!Y@>\UV"(ND9D,:F.7<^T=0JY8\C@'D5Z
M)<6-O=SVDT\>^2TE,T!W$;'*-&3QU^5V'/KZXJ22"&9X7EBC=X7WQ,R@E&VE
M<KZ':S#([$CO0!R>C?"WP5HFG)9Q>'K&ZQ@M-?0K<2.V "2S@XSC.%PN2< 9
MKY,\:00VOCKQ#;V\4<,$6IW*1QQJ%5%$K   <  <8K[CKX@\=_\ )0_$O_85
MNO\ T:U 'T_X3\"^$]3^'FAF\\-Z5))=:5;F:;[(@D8M$NYMX&X,<D[@<YYS
MFN?\'>!;?P-\<+V'3A/_ &9>Z))/;^8I(C/GQAH@Y^]MX/J ZYSU/H'@3_DG
MGAK_ +!5K_Z*6MPP0M<)<-%&9T1D20J-RJQ!8 ]0"54D=]H]* )***X?XGWU
MPVAV?ANPDV7WB*[73MR*'>*!LF:41_Q*J9!Z8WYR,"@#Q33?B?,WQZ;7VNXW
MTNZN#IP9V,<:V98*C?/DH 0LI^[D[NFXU]1U\,>*O#UQX4\4:CH=TV^2TE*!
M\ >8A&4? )QN4J<9XS@\U]7_  D\3OXJ^'6GW5S/YU];9M+ICNR73H6+9W,4
M*,3DY+'IT !W%>-_M(00MX%TRX:*,SIJ:HDA4;E5HI"P!Z@$JI([[1Z5[)7C
M_P"T=_R3S3_^PK'_ .BI: /-/@%I.FZSXZOK?5-/M+Z!=,D=8[J%95#>;$,@
M,",X)&?<U[7XP^$?A;Q#H=Q!8Z-8Z?J21/\ 9)[5!;A9#@C>$&&7( .02 3C
M!.:\@_9Q_P"2AZA_V"I/_1L5?1^N:S9^'M#O=7OWV6MI$TKX(!;'15R0"Q.
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M@73)'6.ZA650WFQ#(# C."1GW-=7^TU_S*W_ &]_^T:P/V<?^2AZA_V"I/\
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M20,*,DD@#)H Y/0M:?Q[XY\6Z;<75]!I6ARQ6T%O;3M:L\N9%DD=XV#GYD(
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M?) X+;F)..I)KS?X B;4[?Q5XJN)(Q/JVIXD@C0A4909"022<$SXQVV]3G@
M]DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:QD\=/F1ASZ>F*]KT;QS8^,?C&VFZ;+'=:9I&F32),!E7N3)&C.AS@A4)4,
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MOB&W\5^%].URU79'=Q!RF2?+<'#ID@9VL&&<<XR.*\W_ &CO^2>:?_V%8_\
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M4_MNQ&/GM(R)E^Z.8LDGDG[I;A23BO6_AKXVAF\7^*_"%]<1I<6^L7DM@K$
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M&W\5^%].URU79'=Q!RF2?+<'#ID@9VL&&<<XR.*V* //_C;_ ,DAUW_MW_\
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M5/P+\-EU*U\2ZQXNTJ.,^)KC[1_9SEA+;1>:90K2+M8$L4)48^XN><JOKE%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Y_JOPGL=;\0V6OZCXBUR;4['R_L\^;9=
MFQRZ_*( IPQ)Y!KO((VAMXHGFDG=$"M+(%#.0/O': ,GKP /0"I** *]_8V^
MIZ=<V%Y'YEK=1/#,FXC<C AAD<C()Z5R?A?X9Z1X61(H=1UF_MXG5X+6^O2\
M$+!BV5B4*A.XALL#AE##!&:[2B@#@[;X5:;8^'[;2+/7?$%J+5SY%U;W:QSQ
MQL69H@RH!L9FW-QEBJ9)"*!L:_X&T7Q%X3;PY=1216>\2+)$094<-N+AW#'>
MQ+;F.2V]LG))KI** ,_1M'M]#TY+2W>>9N#+<W,IEFG? &^1SRS8 'L
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MV@DX S6QH^C6>AV;V]HGS2RO<7$S !YYG.7D?  +$^@ '     T** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUCX@?VS_ &M;6,/V'R/+^R(ZYW^9G.YF_N#ICO0!ZA1110!\@?&W_DKVN_\
M;O\ ^D\=>E_ +Q+H.C>!;ZWU36]-L9VU.1UCNKI(F*^5$,@,0<9!&?8UYI\;
M?^2O:[_V[_\ I/'7?_!3P/X:\7?#R\.N:1!=R1ZJX6;+1R "*/"[T(;;\Q.W
M.,G.,T ;"_$C3O&GQJ\)Z=H<T\FFV7VJ1YCN1)Y&MWQA" ?D (#'GYFP,<M[
M17@]G\.[?P'\>_#,NG3;M,U+[8]O"Y)> I VY"3]Y?G&#G/8]-S>\4 ?,GQG
MOM9\'>-8;+1?$OB""TGLH[CR6U6=PC%G0A2S$X^0'DGDGM@#J_V>-=UC6_\
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M[2=0OM4OKNT:&-K^[DEALLNA-PP;(^4 @9[L.&SM;T_]H[_DGFG_ /85C_\
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MJI)V[B..@\W_ &FO^96_[>__ &C0!@?LX_\ )0]0_P"P5)_Z-BKWOQSXSL?
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MOXI^,?CF#1M8UF^CTRXW/=060*PQ0H2X&P?+][:H=]Q!*YW8 K8^)\VLZ/\
M![P7X:U^UV:D)97<^8A\M(,QQI\F0<I*G.?X><DG%?\ 9Q_Y*'J'_8*D_P#1
ML5 &Y\2/ NK^!/ -Y!H6KW=]X7F2.*\L]0E#M:L)@ZR0X"@ L0I '\62&ZIP
M?P2_Y*]H7_;Q_P"D\E>__&W_ ))#KO\ V[_^E$=> ?!+_DKVA?\ ;Q_Z3R4
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MSYN5.5!!'0@9!&09/'7P?U3QYKAO[_QAY5O'E;6T33\I;H>P_>\L<#+=\=@
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M?%*FF\J?^_N"",@@\$$@Y!H U/VCO^2>:?\ ]A6/_P!%2UP'[./_ "4/4/\
ML%2?^C8J];\>_#O6O'UE:V%YXFM+6S@=9O*@TLDO*$VEBS3$XR7P!C ;!+$
MUA^#O@MJG@?7/[6TGQ= TS1-#)'/I6Y)$.#@XF!'(4\$=/3((!S_ .TU_P R
MM_V]_P#M&C]F7_F:?^W3_P!K5V'Q ^%.J?$'48)K[Q1!;6MIO%K;PZ9G8&()
M+,9<LV H)X'R\ 9-1^ ?A'J7P_UF2]LO%,=Q!<(L=S;2V#!74,#D8FP' R Q
M!QN/!S0!S?[1_AAY[/3/$]M!N^SYM+MQN)"$YC)'W0H8N">.74<\8K_LR_\
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MFC7/RC<@8.<9R<+TZ<\=/X(^ 5CX>U2RUC6-4DOKRU>.>*"!/+BCE7GDY+.
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M'N3(D;EU5O);(#$ D9[X&?05R?@#X*:7X)UA-9GU*?4M2AWB!]GDQQAEVD[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OG_P"*?_)PO@K_ +<?_2MZ^@*^?_BG_P G"^"O^W'_ -*WH ^@
M*PY/#4,_C6'Q+<7$DKVUE]EM;9@"D#,Q,DJYZ.R[5R,< @YR,;E% !7SQX2\
M/7&A_M.:A8Z6V+&#SKBX2$"%$@EC#JFP'E5>2)0!_=!P,<>[ZYK-GX>T.]U>
M_?9:VD32O@@%L=%7) +$X &>20*\_P#@[X8N+>SU'QEJ\$":MXCE-VHBP1%
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M6V8 I S,3)*N>CLNU<C' (.<C&Y16?KFLV?A[0[W5[]]EK:1-*^" 6QT5<D
ML3@ 9Y) H \(\)>'KC0_VG-0L=+;%C!YUQ<)"!"B02QAU38#RJO)$H _N@X&
M..G_ &B=;^P^!K328[C9-J5V-\6S/F0QC<W..,.8CU!/TS6A\'?#%Q;V>H^,
MM7@@35O$<INU$6"(H'/F +U*[BQ8C<> F<$&N/\ VFO^96_[>_\ VC0!ZI\,
M=-ATKX9>';>!I&1[)+@ER"=TH\UAP!QN<@>V.O6O*_VB/^)1XA\)Z_8_NM33
MS=L_WL>2\;Q_*<KPSL>G.><\5[!X$_Y)YX:_[!5K_P"BEKQ_]IK_ )E;_M[_
M /:- 'KFIV</C_P&D,%W=V%IJ]O!*9$P)1"Q5V3@X!9,H>H^8\,.#T$$$-K;
MQ6]O%'#!$@2..-0JHH&  !P !QBL/P)_R3SPU_V"K7_T4M=!0!X7^TGHD+Z-
MHVO+Y:SPW!LWQ&-TBNI=<MUPIC; Y^^>G?U2PTW5+CX>6VEWEY/::O)I26\U
MUYGF213F(*S[@WS,&R<AN2.O>O/]>L4^)GQAL]-6.";0O"GSW[EE;S9Y.?*Q
M\P9<QJK @8VR@G.VO8* ,_0]&L_#VAV6D6";+6TB6),@ MCJS8 !8G))QR23
M7G?Q_P!$AU'X;OJ+>6L^EW$<J,8PS,KL(V0-U4$NK'KG8..X]4KR/XFPMX^\
M8Z-\/K(QF*W<:GJTPD4-!$/D"J<G#E7/RE3]^,],F@#J/A+#?0?"OP^FHF0S
MFW+KODWGRF=FBYR>/+*8'88'&,5VE1P00VMO%;V\4<,$2!(XXU"JB@8  '
M'&*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOG_XI_\ )PO@K_MQ_P#2MZ]XOKB6TLY)X;*>]D7&(("@=\D#@NRKQUY(Z>O%
M>%^,_#?CWQ#\4M.\4VGA*3['ICVYMX);RVCDD6-_,(<B5@"6+@$=L<9S0![Y
M4<\\-K;RW%Q+'#!$A>221@JHH&223P !SFJ^FWL]];M+<:9=Z>X<J(KIHF8C
M ^8>6[C'..N>#QTSYO\ %F'X@Z];OH'A;1I!IDB8N[W[7"C7 (YC4%P53LQ(
M!;I]W.X N6(M_BW>1ZE=0;O".FW9-E;S0D'49T!'G/N'^I7<RJ@^\=V_ILKT
M2>>&UMY;BXECA@B0O))(P544#)))X  YS7@$$'[0-K;Q6]O%'#!$@2..-=/5
M44#   X  XQ5_1] ^*_B3Q!IMCX\61_#:7 N+J-6M LAC!9%=8^70N%!4@CO
MP0" #N/BK/-=>'[+PQ9RR1WGB&]BL0T+$R10YW32[!RZ!5PPR!A^3CKW$$$-
MK;Q6]O%'#!$@2..-0JHH&  !P !QBN+^P7FM?&'[=<VDZ:9H&G^7:/-&462Z
MG^^\3#B11&-C9/RMT'>NXH **\G\?ZK\5M$\4/J/AVP@O_#T,2;;:*%96=B-
MIWJ")2P8Y^3Y=H7/\5:'_"2?$K7=.\C3_!,&AS7468M0O]321;?(SEH0F_=C
M@ CAB-PP"* .+^#&@+8_%SQK+9+'%I^FO-8I$68L TYV 9SD!82"2<].O.-3
M]H_1OM?A+3-71)WDL+LQ-L&42.5>6;CCYDC .0/FQR2*](\'>%+?P?H?V"*Y
MGO+B:5KF\NYV)>XG;&^0Y)QG X]N23DG4U72K'7-+N-,U.VCN;.X39+$_1A_
M,$'!!'((!&"* ,?X?3PW/PY\-O!+'*@TRW0LC!@&6,*PX[A@01V((KR/]I'_
M $S4?"NG6O[^^;[1BVB^:0[S$J?*.?F*L!ZD''2NL\&67C#X;6KZ!?Z3)K^A
MQOFPN]+,8EC+RD;)(W93@EMY;)"9.6*\I)X>\%Z[KOCX^-_&]I8PR0Q>5IFE
MHPE-IM<E69A\K,.2#\W+Y^0J  #8\9W/_"%?"J2QTMIY+I+2+2M.59=L\DC
M1(4*C+2 9?"C)VG&.HZ3PWHD/ASPUINC0>64L[=(BZ1B,2,!\S[1T+-ECR>2
M>37-^)K"\U_XB^&-.-I.=(TS?JUU*\96%YE^2!5D'_+16+,4) *G)STKN* (
MYYX;6WEN+B6.&")"\DDC!510,DDG@ #G->=V(M_BW>1ZE=0;O".FW9-E;S0D
M'49T!'G/N'^I7<RJ@^\=V_ILJG\68?B#KUN^@>%M&D&F2)B[O?M<*-< CF-0
M7!5.S$@%NGW<[N0@@_:!M;>*WMXHX8(D"1QQKIZJB@8  '  '&* /?YYX;6W
MEN+B6.&")"\DDC!510,DDG@ #G->-_M'Z-]K\):9JZ).\EA=F)M@RB1RKRS<
M<?,D8!R!\V.215/1] ^*_B3Q!IMCX\61_#:7 N+J-6M LAC!9%=8^70N%!4@
MCOP0"/:-5TJQUS2[C3-3MH[FSN$V2Q/T8?S!!P01R" 1@B@#'^'T\-S\.?#;
MP2QRH-,MT+(P8!EC"L..X8$$=B"*\C_:1_TS4?"NG6O[^^;[1BVB^:0[S$J?
M*.?F*L!ZD''2NL\&67C#X;6KZ!?Z3)K^AQOFPN]+,8EC+RD;)(W93@EMY;)"
M9.6*\I)X>\%Z[KOCX^-_&]I8PR0Q>5IFEHPE-IM<E69A\K,.2#\W+Y^0J  #
MT32=-AT;1K'2[=I&@LK>.WC:0@L510H)P ,X'H*Y?Q+XMF?Q!!X-\-S1GQ!=
M(7GN3&9(]-AQDRN!P7(P$0X!++N(! ;<\3WVLZ?H<TOA_2/[4U,_)!"TJ1HI
M/\;EF7Y1Z Y/ XR6'A&GZ)\=M+O+^\M+?9=:A*)KJ9WL7>1@, %F)(4#@*/E
M7L!0![OX8\,:7X1T.'2-(@\JWCY9FY>5SU=SW8X'Y     :D<\,SS)%+&[PO
MLE56!*-M#8;T.UE.#V(/>O _^,A_\_V?7J'AC2;WP?\ #J&.'39]1ULQ?:;J
M!IXQ+<7<GS2;Y20IPQQN))VJ/O$#(!)XO\9KH-Q8Z+IL<=YXDU1Q'96C;BJ
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MM+Z!7*-):S+*H; ."5)&<$''N* +E%%8_B'Q5H7A2S%UKFIP64;?<#DEY,$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>!_M&^%[&.RT_Q1!''%>/<"SN=J<S@H61F.<941D=,D,.<*!7OE8?C'0%\4
M^#M5T5EC+W5NRQ>8S*JRCYHV)7G <*>_3H>E 'S9\ ]9L](^)2Q7C^7_ &A:
M/9PN2 HD+(Z@DD==A48R2S*,<U]/ZYHUGXAT.]TB_3?:W<31/@ E<]&7((#
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M.2.,]@!@  #F]?,WB?XLZ)H*1QRZ7H2#5[]@YXN#N6W0[1E74_.%+ ,K$D'
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M;=:;JE[=W<#I-)J,%ZQS;%20"B$CRR)&52JC&&^[\H*@'%_&W_DKVN_]N_\
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M)M_#FDZ]=QZG':I/]DU4?+)<*1%E9$R2'0@?-D[@RG[P:@#T/]G'_DGFH?\
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M5:_^BEKPS]H:SUJTU33Y[[7I+NPOGE-OIZ1&**V$6T XWD.Y$IRY /7&!@
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M%)52FTDD8):9,=NN2._JFA:9_8GA[3-)\[SOL-I%;>;MV[]B!=V,G&<9QDT
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M*741-U' D*$^P/!Z'SOX.WUQIGP*\67]G)Y=U:RWDT+[0=KK;1E3@\'! ZT
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MW-NUG%&T@0NTHV?+ZE5+/@=0IZ=0 5_A!XKF\6_#ZTN+LR->63FRN)'R?-9
MI#Y)))*LA).,MNXQBM3Q_P"(;CP]X7=].7?J]_*EAIJ9 W7,IPG+ J,<M\V
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MX8,I[_P7X>N/''B&U^)?B-K&17B*:5IT($JVJ*^4=I <-(#YF00<,V?E*A5
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MH>"N0&-?8=A?6^IZ=;7]G)YEK=1)-"^TC<C %3@\C((ZT 6*\+_:6TV:71M
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M\_85[Q7D_P ?O##ZUX&CU2V@\RZTF7S6(W%A PQ)A1P<$(Q)Z*C'(YR <O\
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MUJV/VD;ZWC\&Z38-)BZFU#SHTVGYD2-PQSTX,B?G[&L?]F7_ )FG_MT_]K4
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MA6U_]&K7T_\ &W_DD.N_]N__ *41T >0?LX_\E#U#_L%2?\ HV*N_P#VCO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7<USMVX\O!$6W.>?]5G/'WL=LGT35=5L=#TNXU/4[F.VL[=-\LK]%'\R2<
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M3RZ9;/))(Q9G8Q*223R23SFO-];^$&M:3XQ_X2'X<:K::,\R.)[>;(C0GJ$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M] HH X/2_@]X+T^X6\N-.DU6_P![O)=:G,T[3,Q.2ZGY&/S==O8'KS7>444
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MDF%/&1RC''RY92<8'88KZ5\&O >DO;RIH4=S/"FWS+N5YA(=N"S(QV$GK]W
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MFO)ER "<N2>BC\JP_%OPK\*>,[B6\U&RDBU"1%0WMK(4DPIXR.48X^7+*3C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7G_ ,;?^20Z[_V[_P#I1'7H
M%>?_ !M_Y)#KO_;O_P"E$= '@'P2_P"2O:%_V\?^D\E?7<\\-K;RW%Q+'#!$
MA>221@JHH&223P !SFOC3X6ZWIWASXCZ3JVK7'V>Q@\[S)=C/MW0NHX4$GD@
M<"O2/C!\8-&U_P .-X<\.-]MAO-CW5V\;QB,*X8(H8 EB5!)(P!P,D_* =O?
M?#_2]!^+/A3Q%HUK!90SRSVMS;0C8F_[+*49$ PO",&P1_"<9+&I/B_\-M2^
M(-OI+:7>6D$]B\H9+K<JNKA>0R@D$%!QCG)Y&.?3*^?_ (\SZGX5U'2+S1?$
M&N6?]H_:#/"FIS>6&4H054M\O^L(P/E  P!SD ],^&'@>;P#X5?2[B^CNYY[
M@W4C1QE51F1%*#)RP!3[V!G/05\Z?&W_ )*]KO\ V[_^D\=>U_ +5M2UGP+?
M7&J:A=WTZZG(BR74S2L%\J(X!8DXR2<>YKQ3XV_\E>UW_MW_ /2>.@#Z?\"?
M\D\\-?\ 8*M?_12UX_KO[/VL:WXYU/4?[:L8=,OKN6Y\S8[3)O)?;Y?"G#';
MG>..?]FO6/"5E%J'PQ\.VLSSI&^E6F3!.\+C$:'AT(8=.QYZ=*^7/$OBGQ5H
MWBK5]+M_%OB!H+*]FMXVDU*4L51RH)P0,X'H* /LNBN;\?1%O NM7"7%W;SV
MEE/<PR6MS) RR)$Q4DHP)&>=IR#QD<5\T> ?''C:7QOID-OJNI:K/,[Q1VMY
M>S/ 69&4/(H))1"=YXZ(>1U !]=T5\N?&+X>ZUX?M[?Q'JWBB37'N;@VSM-"
M8VB)#.H0;F 3A^!M"\8'/'I?P&\97GB;PO>:=J4T]S?:9*,W,S%VECD+,NYF
M8DL"KCL H3KS0!ZQ17@?QQ^)^I:;JG_"*Z#=R6CQ(DM[=0,R2AC\RQJW&T;=
MK$J3G<!D88'4\%_"#2=3\#6NLZG+._B;4HC?1ZJ+J4O;R2#=$X 9<LN58YR2
MV[G&* /:**^0/!>M>)/%7BBUT6\\?ZYIGVK*0SF[DD4R8RJD&5<;N0,9)8J,
M<Y'UGI-G-IVC6-E<7<EY/;V\<4ES)G=,RJ 7.23DD9ZGKU- %RO-_CK8V]W\
M*-2FGCWR6DL$T!W$;',BQD\=?E=ASZ^N*](KS_XV_P#)(==_[=__ $HCH ^4
M+ZQU3PSKDEK=1SV&IV,H) ;:\3C!5E8?@0P//!!KZO\ A9\2+/QSH<=O--LU
MVTB47D+X!EQ@&9<  J3U 'RDXZ;2</XS_#"'Q+I<WB'1[20Z];("\<"@F\C&
M 01W=5Y!&20-N#\N/G3PQXGU3PCKD.KZ1/Y5Q'PRMRDJ'JCCNIP/R!!! ( /
MJ/XXP0S?"35WEBC=X7@>)F4$HWG(N5]#M9AD=B1WKT"""&UMXK>WBCA@B0)'
M'&H544#   X  XQ7D_C_ ,46/C']GS4M8L)(R)4MA-$K[C!+YT6Z-N <@GK@
M9&"."*]<H **^4/BEX@U_P .?$?5M)TGQ'KEO8P>3Y<7]J3OMW0HQY9R3R2>
M37O^F:=/XG^%FC12ZG?6]]/I4$BWT-S*DBS- ,2,4=2^"VXJQP3UH ["BOCS
MP7XT\577CKP];W'B769H)=3MDDCDOY65U,J@@@M@@CC%?3_CZ(MX%UJX2XN[
M>>TLI[F&2UN9(&61(F*DE&!(SSM.0>,CB@#I**^,-"\<>.)/$.F1V>OZK>W3
M7<0AM;B_E,<SEQM1P7 *DX!R1P>M=A\8/AWJF@:=%XEU?Q9/KEU<78ML36WE
M[ PDD^7YV"J"#A0 !NXQ0!]/T5\X?##QAXU\:6=YX+CUSR)#$UQ_;$^Z6Y@A
MR R)R-S%G3#%@5&[!)V[>+^(/AO4OAMXU@6#Q#=W6H3V_P!L.H(&@E#.TBM\
MP<DD[3DYYW&@#[#KY ^-O_)7M=_[=_\ TGCKZ3^&FOWWBCX>:1K&IM&UY.DB
MRNB[0Y21DW8Z D*"<8&2< #BOFSXV_\ )7M=_P"W?_TGCH ^G_ G_)//#7_8
M*M?_ $4M=!7B^F?"ZX\<_#S1I/$'B.^C8Z? ;&TLF M+=!$!$SQL,R28)+-D
M?>*@@ &O-/A_\0=:^'/BK^Q=7GD.DQW!M+VTED+K:$.0SQ[=V"K%B0N0W/?!
M !]9T5C^*O$-OX4\+ZCKETN^.TB+A,D>8Y.$3(!QN8J,XXSD\5XA\/HKSXU:
MYJ=YXSU&>YTW3?+:/2H6,,!:3S-I^4@_( P!Y8Y&6P"" ?0]%?.%QXLO/@Q\
M4+S184OI_";;'CL9W+>7&XW%H"W]UVD'HV"&.X;AZW\4M/O;GP'JE[I=_=V.
MH6%NUQ%-!>2P *I#R A" Q**P&X'!/;)- ':45\@>"?B%XLM_%]B6UC5=4DD
M\R&WL[B\>2.6>2-DA#AG V^8R$\C &>HJYXJ\#?$_P#X36)[Z+4M5U(NCV^H
MVA=XD)8L-LF (@K$\':%ZC P2 ?6=%<7\5[_ %K3/AOJUUH)D6[1%WRQ,1)%
M$6&]TPIY"YR?EVC+9!49\0_9]U/6D\>#3;22232WMY9;R!I3LC&% E5-P&_<
M(US@G#'Z@ ^HZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!*\C:%..02>0&VE3U&N:S9^'M#O=7OWV6MI$TKX(!;'15R0"Q. !GDD"N?\
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MC!@&6%%8<=PP(([$$4 ?4?@3_DGGAK_L%6O_ **6OD#QW_R4/Q+_ -A6Z_\
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M5AF)XE"$$ DY) *CJ0Z\9(%<?\>/B'?:"B>%=-2-3J-D[7DTD>XB)V*!4.<
MD+(&RIX(P0>1GP3?L]VUQ%.@C+QN'421WSJ2#GE6!##V((/>@#A/@QX-O/$?
MCFPU%H9TTS39?M4ER%(1I(RK+&&VE2VXH2O!V[O:OK>N3\)>,/!&JV\6G^&-
M2TU$5V2&QB06[9QO;9$P4D<DD@8Z^AKK* "O/_C;_P DAUW_ +=__2B.O0*\
MO^/>LV>G_#.YTZ9_]*U*6.*WC!&3L=9&8@G.T!<$C."R^M 'J%?/GQS^&$WV
MB;Q?H5I&8"F[4K>%2&#9),^.A!&-V ,8W'.6(]WTK5;'7-+M]3TRYCN;.X3?
M%*G1A_,$'((/(((."*L3P0W5O+;W$4<T$J%)(Y%#*ZD8((/!!'&* /A2QUF\
MT_3-4TZ%_P#1=2B2*XC).#LD616 !QN!7 )S@,WK7W?7R1\7OAO_ ,(-KB7.
MFPSG0KSF%W^802<YA+9R< 9!;!(X^8JQKZWH ^0/C;_R5[7?^W?_ -)XZ^G_
M  )_R3SPU_V"K7_T4M?.'Q[T:\T_XF7.HS)_HNI11RV\@!P=B+&RDD8W KD@
M9P&7UKT?P]\7-.7P#H6B>&[6?4_%7V2&QATYH64+(B;3([_=\L;2W#9QC.WY
MBH!X1X$_Y*'X:_["MK_Z-6OK_P =_P#)//$O_8*NO_135\>>"YX;7QUX>N+B
M6.&"+4[9Y))&"JBB5222>  .<U]A^._^2>>)?^P5=?\ HIJ /D#P)_R4/PU_
MV%;7_P!&K7O_ .T=_P D\T__ +"L?_HJ6O / G_)0_#7_85M?_1JU[W^TA/"
MO@73+=I8Q.^IJZ1EAN95BD#$#J0"R@GMN'K0!PG[./\ R4/4/^P5)_Z-BH_:
M._Y*'I__ &"H_P#T;+1^SC_R4/4/^P5)_P"C8JC_ &BIX9OB-:I%+&[PZ9$D
MJJP)1O,D;#>AVLIP>Q![T >Q_!+_ ))#H7_;Q_Z425X!\;?^2O:[_P!N_P#Z
M3QU[O\"KZWN_A1IL,$F^2TEGAG&TC8YD:0#GK\KJ>/7US7AGQG@FN?C%KR01
M22N$B<JBEB%6V1F/'8*"2>P!- 'TWX$_Y)YX:_[!5K_Z*6OD#QW_ ,E#\2_]
MA6Z_]&M7U7X!\2:*_P +=%OSJEI':6=E!:W,TLHC6&5$5&1RV-IW8QGKD$9!
M!/SQX-\.3?%'XI7-X]C(FERWLE]?X)98HV=G$18%3EC\@(YZL!\IH ]'^+T^
MI0_ ?PREY+=I=S/9I>K,S!W;[.[,),\D[U!(/< ]17*? O2/$6J?V]_8'BC^
MP_+^S^=_H$=SYV?,V_?(VXPW3KN]J]O^)WA'_A-/ U[IL2[KZ+_2;+G'[Y <
M+]X#Y@63).!NSVKY@\ >*[CX=^.4OKJVG$:;[6_M=H6383\RX8<,K*K8XR5P
M2 30![/XD^!VL^+M1CO]<\=_:[J.(0J_]D)'A 20,)(!U8_G7>>);.;3OA'J
M]E<7<EY/;Z%-%)<R9W3,L!!<Y).21GJ>O4USY^+%CXIMTTGP0EW>:]>V[%"\
M/EQZ>< &2=F!&%W9PH<,5V_Q#.Q\3;]M#^$VN2.9+Q_L7V1GD959S+B+>=J@
M9^?=@  XP,=@#YT^"7_)7M"_[>/_ $GDKZ_KX\^#$\-M\6]!>>6.)"\J!G8*
M"S0NJCGN6( '<D"OL.@ JO:V%G8^?]CM(+?SY6GF\F,)YDC?>=L=6.!DGDUQ
M_P 6O$.L^&/A_=:GH:[;I)8D:XRA^SH6 +[7!#Y.$QC^//:O(/@EXV\67_Q
MBTNZU*^U.PN8I#<B[D>?R BDJX8D[/FVKZ'< 1G;@ ^EZ*** "BBB@ HHHH
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MR!E@Q[X^7^$8RIP_C1I-QI?C?POX\,,]QIFGRP1WHAC!,(CF\Q3R?XMS*,X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,>^\)^&]3O)+R_\/Z5=W4F-\T]E'([8  RQ&3@ #\*K_\ "">#_P#H5-#_
M /!=#_\ $UT%% &/8^$_#>F7D=Y8>']*M+J/.R:"RCC=<@@X8#(R"1^-;%%%
M &/K'A3P_P"()4EU?1;&]F38%EF@5G 5MP7=C.W.<KG!R0002#H6-A9Z99QV
M=A:06EK'G9#!&(T7)).%' R23^-6** *>I:3INLVZV^J:?:7T"N'6.ZA650V
M",@,",X)&?<UE_\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_ /H5-#_\
M%T/_ ,36I-I.FW.EC2Y]/M)=/"*@M'A5H@JXVC81C P,#'&!5RB@#G_^$$\'
M_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** *<.DZ;;:6=+@T^TBT
M\HR&T2%5B*MG<-@&,')R,<Y-9?\ P@G@_P#Z%30__!=#_P#$UT%% '/_ /""
M>#_^A4T/_P %T/\ \36IINDZ;HUNUOI>GVEC SEVCM85B4M@#)"@#. !GV%7
M** "N3D^&/@B75(=1;PQIHGB38J+"%B(Y^]$/D8_,>2I/3T&.LHH C@@AM;>
M*WMXHX8(D"1QQJ%5% P  .  .,5)110 5GZ9H6CZ)YO]DZ58V'G8\S[);I%O
MQG&=H&<9/7U-:%% !1110!GVNA:/8ZC/J-GI5C;WT^[SKF&W1))-QW-N8#)R
M0"<]36A110!EZWX;T7Q';^1K.EVE\@1T0S1!FC###;&ZH3@<J0>!Z57T#P=X
M<\+(JZ+H]I:.$*><J;I64MN(:1LNPSC@D]!Z"MRB@ KF[+P#X7L=4DU1=)CN
M-0D>-S=WTCW<H9/N%7E9BI''((Z#T&.DHH *CG@ANK>6WN(HYH)4*21R*&5U
M(P00>"".,5)10!S_ /P@G@__ *%30_\ P70__$T?\()X/_Z%30__  70_P#Q
M-=!10!3TW2=-T:W:WTO3[2Q@9R[1VL*Q*6P!DA0!G  S["KE%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117'^)_'Z^$;.:^U
M3PUK@L(I?*-W"MO(AR<*V!-N53Q@L!U ."<4 =A17D]C^T!X;U.\CL[#0_$=
MW=29V0P6D<CM@$G"B3)P 3^%;'_"T_\ J0O'/_@G_P#LZ /0**\W\+?&OPWX
MN\1VFAV%EJL=U=;]CSQ1A!M1G.2)">BGM6A\1_B59_#NSLVFT^>]NKW?]GC1
MPB?(4W;F.2.'XPISC''6@#N**YOP-XSL?'7AJ/6+&.2$AS#<0/R890 2N<88
M88$$=01D Y Y?7_C9HWA;5&TW6M \06EV$#[&A@8,IZ%664AAU&03R".H- '
MIE%8_A;Q)9^+O#EIKEA'/':W6_8DZ@.-KLAR 2.JGO7G>I_'W1=+\:R:%/I=
MVMG;W#VUW?,XS$ZLRDK& 2R9 .<@X)^4D $ ]<HHHH **** "BBB@ HHHH *
M**X/QK\6=!\!ZS#I>J6FI33RVZW"M:QHRA2S+@[G4YRA[>E '>45YO??&*ST
MRSDO+_P;XRM+6/&^:?3!&BY( RQ? R2!^-9]C^T!X;U.\CL[#0_$=W=29V0P
M6D<CM@$G"B3)P 3^% 'K%%>9ZE\:=-T:W6XU3PEXNL8&<(LEUIRQ*6P3@%G
MS@$X]C7:>%O$EGXN\.6FN6$<\=K=;]B3J XVNR'(!(ZJ>] &Q1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI?:$2PM8C;I'&!&"KD,3+D-SNXZX !P/9_ G_)//#7_8*M?_ $4M '04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_P ;?^20Z[_V[_\
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MOM\9R!Y;@I&W;)W!D[\;.G)H ^AZQ[[Q9X;TR\DL[_Q!I5I=1XWPSWL<;KD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M._$/QQ\%:!>"U2ZGU23^,Z:JRHG (^<LJMG/\).,$'!KTBOF#]H[_DH>G_\
M8*C_ /1LM 'L?C/XN>&?!&J)IE^;NZO"F^2*R17,(.-N_<R@$@Y Y..3@$9L
M>$/BEX9\9V]]+9W$EF]DAEGBO]L3+$!S+PQ&P="<\=\9&>HTW2K'2+=H+"VC
M@1W,DA7EI7( +NQY=S@99B2>Y-?,GA&PLY?V@M2T)[2 Z3<ZA>02V?ECRVCB
M=ID3;V4/#&<#@A<'()! /3[[]H;P5:7DD$,6JWL:XQ/!;J$?(!X#NK<=.0.G
MIS7H'ACQ/I?B[0X=7TB?S;>3AE;AXG'5''9AD?F""003G^.K"S7X8^(+,6D
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MUB)()L,$;RF+CS,,2/E!^ZQ&5&:L>"/B5X?\>_:8]*>>&ZM^7M;M520IQ\X
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MY44<>GKFO2_B_P"*YO"7P^N[BT,BWEZXLK>1,CRF<,2^0000JN01G#;>,9H
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MM1T.PL;^"YNK'[2+I(7W>26* *Q' ;*-E>HQR!D9 .O_ &<?^2>:A_V%9/\
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M,N7#%A@E@I*C/;?[U[_X\\*0^,_!U_HSB,3NF^UD?'[N9>4.<$@9^4D#.UF
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\DDD@'D?[37_ #*W_;W_ .T:](L+&XU/X%6UA9Q^9=77AI(84W ;G:V 49/
MR2.M<O\ %/X=^,/B'J-GY#:'9V-AYH@WW4S22;R,LV(L+PB_*,X.?F/&.\\$
M6&O:1X:LM)UV+30]C;QV\4UC.[B55&T%E=%VD*%Z$Y.3\O H \G_ &<O%%C'
M9:AX7GDCBO'N#>6VY^9P4"NJC&,J(P>N2&/&%)KWRO"_B#\$=2O?$LWB3P?>
M1PW$CM=RV\LS(XN =VZ%\<%FYPQ4*>AP<+0T#X7_ !/UIUC\4>*-2L=+D<Q7
M=NVJO-++%MY"@%DPV=OS'CD[3P" >QV_BRSN/"^I>)%3S-,L_M+QO XD:>.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5&3V ':I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFB-)&LH99E(P70'Y@ W!'.W<OS'->@3SPVMO+<7$L<,$2%Y))&"JB@9))/
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M%W%'NVI*N,XR.A4JW4XW8R2#764 %%1SSPVMO+<7$L<,$2%Y))&"JB@9))/
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M>'7=9DM((+!YDCCCD\QKC*% PQPJ$.3S\WRX*C.1[Y0 4444 %%%% !1110
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M8C<> F<$&H_CEX&OO%OAJTOM*BDN+_2W=Q;H>98G W[1C+."B$#(R-P&20*
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M.7>C&]GLH[O8DLT!P_EAU+J/]Y0R\Y'S<@C@^;Z#8I\1?C#>>,&C@ET+0/\
MB7V#AE;[1.G._'S J#(S*P*]8B.0U>P4 1P00VMO%;V\4<,$2!(XXU"JB@8
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M$MS(!\J;?+P",[O-4[B<5[_\//$Z>+O VF:IY_G71B$5X3M#"=1A\JO"Y/S
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MM>P5Y/\ &C1/$_C#2;;0]#\.3W$<%VMR]X]U!&C8C("JI?<?OG)(7&WC(.0
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MOQ#T3Q#IFK?\(QYWV&[BN?*^WVZ[]CAMN=YQG&,X- 'M_P ;?^20Z[_V[_\
MI1'7D'[./_)0]0_[!4G_ *-BKU?XF1>(_%/@2?1-)\*7S7%]Y9D:>ZM8Q $E
MW8.)3N8[%X'&'SG(*UP'PJ\$^-_ 7BV34[_PI/<6LUH]LX@O;;>F65@P!D /
M* 8R.N>V" 9_[2-C<1^,M)OVCQ:S:?Y,;[A\SI(Y88Z\"1/S]C77_!+3/!_B
M/X?Q17.A:5=:G8RR17;W-I"\C;F+HV2"Q7:=H)QRC =*[3XF> 8?'_AH6:RQ
MV^H6SF6SN'0$!L8*,<9"-QG'<*<';@^">'?#_P 5OA[XAC72=%ODFN_+$D:Q
MK/;2KOX$C*2B\@\EE90Q.0#F@#Z/'A/P?IDL-X/#^AVDD<J>5,+*&,K(6 3:
MV.&+%0,<Y(QS6Y//#:V\MQ<2QPP1(7DDD8*J*!DDD\  <YKS_P .:%XO\0:S
M9ZYX^BTV&.Q0M8Z3:[F6.XW$>?)\S*7"C"\L!NR-K YV/B7H%]XH^'FKZ/IB
MQM>3I&T2.VT.4D5]N>@)"D#.!DC) YH L>&O'WA?Q?<3V^A:M'=3P('DC,;Q
MMM)QD!U!(S@$C.,C/45TE?-GP?\ AMXKTSXAVVL:GI4EC9Z<\\<KW!"EW\MD
MP@ZL,N#N'RD X8G@_2= !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3R3R:Y?7M)FU7QYX3T:#3Y(M!T=&U.8B$QV_F(/+MTC=1PZ,2VS(&WUZ5WE
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M>5SU=SW8X'Y      &7\2=;FT/P'J4UGYC:A<H+.RCAD*2O-*=B^7CDNN2X
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MW"R?VA*GVG4))65Y)+F3YI"[C[Y#':#DG"CDXS724 %>?_&W_DD.N_\ ;O\
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M2Q\)^&],O([RP\/Z5:74>=DT%E'&ZY!!PP&1D$C\:V* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ***\W^*$OB/PQX0U'Q%I'BN^BDMY4?[--:VLD
M>QY FQ?W088W@@DMPN#DG( /2**^4-"^+7Q#UOQ#IFD_\)/Y/VZ[BMO-^P6[
M;-[A=V-@SC.<9%>W_P#")?$/_HI__E M_P#&@#T"BOG^X\0_%CPMX^\.:3XD
MUF"6QU+4(85D@A@*3IOC$@'R!UP' Y"^WK7<?&[Q/JGA?P")M(G^SW%Y=K:-
M.OWXT9'8E#_"WR 9[9.,'! !Z117A_P!\8>)?$$NJZ?JUS/J%C:1(\=U/*K/
M"[,WR$D;WW#<<DG;Y>.XH^,WBCQ?X$U'39M(\3S_ &74?./V>:SMV\DH5.%;
MR\E<.  <D;>2<\ 'N%%>;_!3Q3K/B[P;>7^N7GVNZCU!X5?RDCP@CC(&$ '5
MC^=</\?O&WB#1_$.G:)I6I3V%K]D6[=[21HI)'9W3!<'.T!>@QR23G P ?0%
M%</\)?$.L^)_A_:ZGKB[KIY946XR@^T(&(#[4 "8.4QC^#/>NXH **** "BB
MB@ HHHH ***IZE93WUNL5OJ=WI[APQEM5B9B,'Y3YB.,<YZ9X'/7(!<HKYD\
M??$CQ[X0\;ZGH5OXIDN(+9T,<DEC;!MKHK@'$>"0&QGC.,X&<5V_A"+XD^+_
M  1:^(+?X@1V\]RDICM9-(@*[D=D ,@&0"5Z[3C/0XH ]DHKYLTWXW>-/"GB
M!M(\96<=T(+@K=AH5CN$4@?<*$(1T89!W _>P01]#Z5JMCKFEV^IZ9<QW-G<
M)OBE3HP_F"#D$'D$$'!% %RBBB@ HHHH **** "BBB@ HHHH **\_P#&WQ$?
M2-<L/"GAN&"_\37TJ)Y<H9H;1#R7EV?-]W)P.BY8\8#=9H6EW>E63I?ZQ=ZK
M=RN));BX5$&[8JD(B !$^7.WGEB22230!J4444 %%>7^)_$/B7X9ZM-JMTL^
MO>$;N7+ E1/ICO)DC=CYXSN(4-TPJ97 W^B:5JMCKFEV^IZ9<QW-G<)OBE3H
MP_F"#D$'D$$'!% %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N/UGXI^"= U%[#4=?@2Z3(=(8Y)MA!(
M*L8U8*P(.5/(]*X_XZ^(M1CL])\'Z)+B_P!<E\N5(YE5VC)"+&0>BR,V-V0/
MD8<@FO2-&\+Z/H7AY-#L[&#[#Y0BF1HD_P!(^0(S2@ !V8 ;B1S0!H6-_9ZG
M9QWEA=P7=K)G9-!()$;!(.&'!P01^%6*\#T:];X3_&F7PM#%=GPWK;Q&TMS,
MK^6\I55D&><!P\9!()4 G<57/OE !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,@R23N&"%/RDC<,D9?[0GB>XT?PE9:19SSP3:K*XE:/ #P(OSH3U&2Z=.H#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M< CD!26VXSD;L4 ?1]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5P?Q,\;S>&M+&EZ$LEUXIOT/V&T@@,[JH^]*
M4'8*&QD')'0@-CI/$.A2Z_9BU37-5TN/^,Z;(D3OR"/G*,RXQ_"1G)!R*CT/
MP?H'ARXN;K2]-CBN[EV>:ZD=I9Y"Q!;,CDN02H.,XSSUH Y?X3?#F'P/X?2X
MO;:,>(+M/]+DWA_+7.1$IQ@ #!;&<MW("X]$HHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?*\B9+1JP\R,-U7(P?0E%!QU&QK.M66@:<]_J+3I:IDN\-M)-L !)9A&K%5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M->__  2_Y)#H7_;Q_P"E$E?*FDO#HWBJQ?6;*1H+*]C-Y:21 L51QO0HV!G
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MW?[0UC<7?PUCF@CWQVFH133G<!L0J\8//7YG4<>OIFN7_9E_YFG_ +=/_:U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO<MMSO&<9QG KZOHH \[UV?QCJ7PMDTM/#=W-X@O++['<M-+:K'N**LLGRS
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "L_4]"T?6_*_M;2K&_\ )SY?VNW279G&<;@<9P.GH*T** *]
MC86>F6<=G86D%I:QYV0P1B-%R23A1P,DD_C5BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBL_4]1NK#ROLVC7VI;\[OLCP+Y>,8SYLB=<]L]#G'&0
M#0HKQ_\ X:.\'_\ 0-US_OQ#_P#':W(/BW#=6\5Q;^"/&LT$J!XY(])#*ZD9
M!!#X((YS0!Z)17D]]^T!X;TR\DL[_0_$=I=1XWPSVD<;KD C*F3(R"#^->L4
M %%%% !1110 45&9X5N$MVEC$[HSI&6&YE4@,0.I +*">VX>M5]6U*'1M&OM
M4N%D:"RMY+B18P"Q5%+$#) S@>HH N45Y?X&^->E^-/%$NA_V;/822;C8N[^
M9YX4$D, /W;;1G&6'!&<XW>H4 %%1B>%KA[=98S.B*[QAAN56)"DCJ 2K 'O
MM/I4E !1110 4444 %%8?B'Q%)X>MY[M]$U*\L[>W:XFN;5H-L:J"6!#RJQ(
M SP#U&,GBO._^&CO!_\ T#=<_P"_$/\ \=H ]@HK#TW7[S4;=ISX8UFT3[.9
MXQ=&W5I#@$1A1,2KG/1PH&#DBN/U_P"-FC>%M4;3=:T#Q!:780/L:&!@RGH5
M992&'49!/((Z@T >F45Y?IGQQT?6_-_LGPQXKO\ R<>9]DL$EV9SC.V0XS@]
M?0U8TSXX>#K[49;"^>^T:ZCE$)34[?R_G)(()4L$VD<[]N,^QP >D45'!/#=
M6\5Q;RQS02H'CDC8,KJ1D$$<$$<YJ2@ HHHH **** "BBN#\2_%&W\(6\%QK
MOACQ!:P3N4CD"6TB[@,X)28@'&2 <9P<=#0!WE%>;V/QBL]3LX[RP\&^,KNU
MDSLF@TP2(V"0<,'P<$$?A4D_Q;AM;>6XN/!'C6&")"\DDFDA510,DDE\  <Y
MH ]$HK'\+>)+/Q=X<M-<L(YX[6ZW[$G4!QM=D.0"1U4]ZY_Q[\4M"\ XMKQ9
M[K4Y(O-ALX4(RIW!69S\JKN0@XRPSG:: .XHKQ/1/VD-%N[CRM9T6[TY&=%2
M6&47"@$_,S\*0!P?E#$\\<<^T03PW5O%<6\L<T$J!XY(V#*ZD9!!'!!'.: )
M**Y_Q7XQTOP?9V\M_P"?/<74HAM;*T3S)[AR0,(F1G&1GGN!U(!PX?&OBUG-
MU/\ #C4DTG8THE2^@:Z\O:2O^CD@[SQE-V021R1@@'>45C^&/$^E^+M#AU?2
M)_-MY.&5N'B<=4<=F&1^8()!!-S5=5L=#TNXU/4[F.VL[=-\LK]%'\R2<  <
MDD 9)H N45X?=?M*:.FHP)9^'[Z6Q.WSIIIDCD3GYMJ#<&P,$99<GCCK7JGA
M3Q;I'C/1AJFC3220!_+D62,HT<FU6*'/!(##D$CT)H W**CGGAM;>6XN)8X8
M(D+R22,%5% R22>  .<UXOK?[2&BVEQY6C:+=ZBBNZO+-*+=2 ?E9.&)!Y/S
M!2...> #VRBN7\%^/]"\>6<\^CR3B2WV_:()XBCQ;BP7)&5.=A/RD^^#Q744
M %%<?XD^(FEZ'K$>@6<,^K>(IL"'3+0?-DJ64R.?EC7@$DDD*0V,<U7TOXA2
MIKEIH?BO09_#NI7VXV7F7"3P7&,#8)5X$A)/RD?W><LH(!W%%%<?XA^(-GH^
MN#P_IVFWVMZZT7F?8[%01#G 3SG)Q&I+#YN=H.2,$9 .PHKS^7XBZMH5FU]X
MP\%WVCV'FQQ?:[:[BO4CW$@M($(9%''(#9SCK@'O()X;JWBN+>6.:"5 \<D;
M!E=2,@@C@@CG- $E%5[^^M],TZYO[R3R[6UB>:9]I.U%!+' Y. #TKR?_AH[
MP?\ ] W7/^_$/_QV@#V"BN7\$>.K#Q[IUS?Z997T%K!+Y)>[6-=[X!( 5V/
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MY'0@'I%%9^A6MY8^'M,L]1N/M%]!:117$V\OYDBH S;CR<D$Y/)K0H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#X@\=_\E#\2_P#85NO_ $:U?7_@3_DGGAK_ +!5K_Z*6OD#QW_R4/Q+
M_P!A6Z_]&M7K&N_%;^S?A!IWA^+P]JL%U>:5'8K<ZA;^5!)'Y(222([LR<$8
MZ#Y@3Z$ ]#^(&@V/Q&^%O]HV]I(UW]B&HZ:QAW3J2@?RP%/)=1M(R1D@X)45
MZ)7/^!/^2>>&O^P5:_\ HI:W)X(;JWEM[B*.:"5"DD<BAE=2,$$'@@CC% $E
M4]2U;3=&MUN-4U"TL8&<(LEU,L2EL$X!8@9P"<>QKXH\:00VOCKQ#;V\4<,$
M6IW*1QQJ%5%$K   <  <8KV?XK?#IAX,U#QEK^L7=YXBB2(-'"RK:1!I57RX
MT*[@BAS@ELDY8\DB@#WB">&ZMXKBWECF@E0/')&P974C(((X((YS67XG\3Z7
MX1T.;5]7G\JWCX55Y>5ST1!W8X/Y$D@ D>"?LWZK?+XJU/1Q<R?V>]DUT;<\
MKYJO&H<>AVL0<=>,YP,=_P#'?P]IE[X!O]=N())-0L$B2UD,\FV(/,@;";MF
M2#@G&>!Z# !R_P *?&=]XZ^,^J:O?1QP@:.\-O G(AB$T9"YQECEB23U). !
M@#W#5M-AUG1K[2[AI%@O;>2WD:,@,%=2I(R",X/H:^5/@IX6T;Q=XRO+#7+/
M[7:QZ>\RIYKQX<21@'*$'HQ_.O=_&7@?PU:?"K4]/BTB#[/IFGW4UEO+.]N^
M#+E78EAEP">><8.1Q0!E_#_X)V/@GQ!_;5QJLFI7<2%;7$'DK$6!5F(W-N)4
MX'89/!.".L\=>.M+\!Z&;^_/FW$F5M;1&P]PX[#T49&6[9[D@'YH^"7_ "5[
M0O\ MX_])Y*]+_:*\/:9%H-KXA6"0ZI+>Q6K3-/(P$7ER'8J%MJC*@\ <Y/<
MY +'P(U^^\4^(/&FM:DT9N[I[-G\M=JJ )550/0* .<GCDD\U[97S!\"_!/A
MWQC_ &]_;^G_ &S[+]G\G]])'MW>9N^XPSG:O7TKO_C!\--+N/ +7VBZ=!;W
MVC1(X=%^>6VC0(R,Y8;MJ*K MN/[O ^]0![!17R9\"'TW_A9MO;ZA91W3SV\
M@M"\2N(9D(E#\_=(6-@".<D>YKV/XV:'I>J^'+*)[" ZWJ&H6VG:?>LF#$[N
M3AW'S>7M\SC#<L#C/( /4**R_#WA[3?#&C0:7I=M'#!$BAF5%5I6"A=[[0 S
MD*,G'-:E !7P!7W_ %\ 4 ??]?,'[1W_ "4/3_\ L%1_^C9:^GZ^8/VCO^2A
MZ?\ ]@J/_P!&RT ;_P"S+_S-/_;I_P"UJZSXY^"8?$/@Z;6K:WC_ +4TI/-\
MP !I+<9,B$D@8 )<9R?E( ^8UR?[,O\ S-/_ &Z?^UJ]TU;38=9T:^TNX:18
M+VWDMY&C(#!74J2,@C.#Z&@#Y<^"?CJX\,^+8-'F,\VF:M*D'D(PQ%.S*J2@
M'_ODX(R#GG:!7U?7P!7W/87UQXC\&VU_9R?V==:EIZ30OM$WV9Y(P5.#@/M)
M'7&<4 7(]6TV;5)M+BU"T?4(4WRVBS*947CEDSD#YEY([CUJY7QAH?@GQC#X
M^LM(M--GL];MY5N(VGCPD(1_]<205,89?O#(;H-Q(!^SZ "BBB@ KQ_]H[_D
MGFG_ /85C_\ 14M>P5X_^T=_R3S3_P#L*Q_^BI: .@^"7_)(="_[>/\ THDK
MT"O#_A;X_P#[$^'&DZ=_PB7BN_\ )\[_ $FPTWS87S,[?*VX9QG!]P:N>(_B
M3J6JZOX>TB+PAK.FZ?>:Q8K+>ZM;-"=RSJ^Q%Y&?D4Y+= PV]Z /3/#&C?V!
MHITX)!'&MW=2Q1P#")')/)(B@8&,*ZC X&..*P_!O@R&QN+GQ+K-A&?$NHW$
MES*\LHN&LU8L$AC<@8"QD*=O7D9*A0.THH \O^,GP_TO7_"6I:W#:P0:S81-
M=?:E&PS(BC>LA ._Y%^7/0@#(!.:_P"SS?7%W\-9(9Y-\=IJ$L, V@;$*I(1
MQU^9V//KZ8KH/BWK#Z5\.M0AMD\V^U/&FVL B9S*\WRE5"_Q;-Y'N!UZ&Q\,
M?"/_  A?@:RTV5=M]+_I-[SG]\X&5^\1\H"ID'!VY[T >;^/M3L]*_:.\,WF
MMPP"PBM(E1V8,%W-,JR/N ";9&SG)P$#9SP/>*\_^*?P[TOQKH<EW+-!8:G8
MQ,\-_*=J*@RQ24_\\^IS_#R1_$&\0\,?%/7=)LX?!VJZO]ETA9?L\NI6JB>Y
MM8<X*PR*VTJ,$!@&*@Y7.%% '=_!Z>[NOBYX]N+*6.;19;B5Y)(V1E>0SL82
M#U(*^:<CCU[5ZYK/AVSU^\L3JD4%W86OF2?8IX0Z/,0%20Y_NJ91M((/F9ZJ
M*C\(Z!HOAOPU:6&@+&; H)5G5@YN"P!\UG'#%ACD<8P!@  ;E %/5=*L=<TN
MXTS4[:.YL[A-DL3]&'\P0<$$<@@$8(KPC]FFROOM&OWXED33RD4)C,/RS2Y8
M@A^Q12<J/^>H)Z"NG^*7Q,U71M+U33]'\-ZRH"-;RZS-;R0P0%L+NC;&6.68
M!LJ P4C<#4GP+\4^']2\+IH.F6/V"_L(EDNT9E/VEV)#3*<[FZ+G(&W<JC(
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M$#.T\#%<G\8?B3?^%=.N-+TS2+[S+F(PMJS))%# [C@1N -\FW<>&&T@=2&
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M92<YX!X/2@"OJ7Q TVTUE=)TZQU+7;P.$N%TB%9EM&+%0)G+!8R2&X)XVDG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2_]@JZ_]%-7S)\)O$\/@/QU=/JFG:E-/+;O8+:6L :<3&5/E*,5.<H1CKG
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MPL4D4TLGF3%",Q398$H-@#!B  O. ./M.@ HHHH *\?_ &CO^2>:?_V%8_\
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M+%9W<$*A[<+G8HQC,8R?DZ<\8."//_B#H>J>$?BOI_Q(T^PGO]-X.HK$GFO
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MI516&Q9EG7S%1>JK@H<=/F(' P/6_BUILVJ_"OQ!;P-&KI;BX)<D#;$ZRL.
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MMN[8OS8VIG(4''B%K\=,^*)_$&J^'/M]VFZ/3T^W;(["$CD(OEG,C?Q2'DC
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M_BS7M#U31-&ATJWAO(O)6\GO7W[&QY@,7D,.1N7AN^>#Q0!\H>!/^2A^&O\
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M" PP,'GH03]IUS?CGP98^.O#4FCWTDD)#B:WG3DPR@$!L9PPPQ!!Z@G!!P0
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MNS6\D<%^]N(8T(9@MQ(J1%LX .)$+ 9Q\P!; )\_\<_ ?1?$+R7^@O'H]^4
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M 4453U*34HK=6TNTM+F?> R75RT"A<'D,L;DG..,=SSQR ?-G@W_ ).AN?\
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M<?/O'7YD7CN/5]5N/B1XC2XT6UT6T\-1N^R36?[2%R?*W8;R4558.0<@MMP
M?NM@@ X/X(_\3[XI^,/%%K\EC)YN(Y>)/W\_F)P,C@1MGGJ1C-'[37_,K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7A_[0.N>+-%_L@Z5?SV.D2[@\UF[QR&<9^5W'12IRJ@\D.2#M&/<** /(_#
MNOWWQ1M_"J6[7:V.F/%>:[=LOD^==Q &.%,?*X+CS&7& I3E6P*]<HHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *IZEJVFZ-;K<:IJ%I8P,X19+J98E+8)P"Q
MS@$X]C5RB@#YH^&?BK0K3XX>)-5NM3@MK#4?MGV:XG)C1]TZR+DMC;E5)^;'
MIU(%?2<$\-U;Q7%O+'-!*@>.2-@RNI&001P01SFI** "BBB@ HHHH **** "
MBBB@##\1'Q'*D5EX>CM(7N$82ZE<OD6F&096+!\QRK.0"54%.3S@V- T"Q\-
MZ6MA8+(07,LT\S;Y;B5N6ED?JSL>I^@&  !J44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<WXC\6R>&K>\O+CPYK-S86B!Y+JT$#KMP,D*90^!GD[>,$]!FNDKG_'?_)//
M$O\ V"KK_P!%-0!R>@?&S1O%.J+INBZ!X@N[LH7V+# H51U+,TH"CH,DCD@=
M2*](@D::WBE>&2!W0,T4A4LA(^Z=I(R.G!(]":\#_9E_YFG_ +=/_:U?0% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %<_P"._P#DGGB7_L%77_HIJZ"N?\=_\D\\2_\ 8*NO_134 >/_ +,O_,T_
M]NG_ +6KU#XB:?>R^$M9O[7Q!JNG?9=/EF6&R>.,,\:LX)?89!D@ [7&0,=S
MGR_]F7_F:?\ MT_]K5[!X[_Y)YXE_P"P5=?^BFH \ ^!>DZ[K7]O6>EZW_9%
MBWV?[=-#$&N9%_> )&QXCR"YW\LI"8[U)\4_A9IOPZT;3=>T'5-2$XO5B_?.
MI96VLZNC(%*D%#Z]1R,<[?[,O_,T_P#;I_[6KH/VCO\ DGFG_P#85C_]%2T
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M 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ K/U/3KJ_P#*^S:S?:;LSN^R) WF9QC/FQOTQVQU.<\8T**
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MH **** "BBB@ HHHH **** "N;^(,$-S\.?$B3Q1RH-,N'"NH8!EC+*>>X8
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M&G/#IVKSZ7=<E+B&*.7!P0 RR*05R02!@G'44 :%%?*&N?%3XG^'M<O=(O\
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M)JL%]=:7<0:9>QV-Y(FV*Y>#SA$?[VS(!.,XR<9QD$<'XD\5Q7EOXMU:UO\
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MKO\ V[_^E$=8?QG^&$/B72YO$.CVDAUZV0%XX%!-Y&, @CNZKR",D@;<'Y<
M'KE>=_'&"&;X2:N\L4;O"\#Q,R@E&\Y%ROH=K,,CL2.]<G\$?BE_:D5IX-U=
M<7D,7EZ?.B<2QHN?+8#HRJIPW0@<_,,MV'QM_P"20Z[_ -N__I1'0!N?#Z"&
MV^'/AM((HXD.F6[E44*"S1AF/'<L22>Y)-=)7/\ @3_DGGAK_L%6O_HI:YOQ
M+XWU*Z\;P>!/"BQIJC(7O]0N(&DCL8BFX%5'#/AE()^3)53G<=H!Z)17G_B'
MP[\0(=#$OA_QO/<:G#%F2&ZL+4)<OQPA$8\O^+ 8MU )'+57^$_Q0_X6!9W5
MM?P06NKVF'=(6PDT9)PR*26&. W4#*G/S8 !Z117A_Q=\?\ CWPC_9B0#2M+
MCO-Y5K20W<A,>-P)EC50I\Q> I.5/.#BM2SU?XH>,_"NE3:!'::(!;PO+J6I
M%3)?L4PQ2(1L(TW!CD@;@4*X&10!ZY17B?@+QWXPM?BI=>"?&EU'>3NC+"\,
M,8".J>8&#(%^1H\GD$YV\+\U>J>)_$^E^$=#FU?5Y_*MX^%5>7E<]$0=V.#^
M1)( ) !L45Y_9Z7X^UZS.K2^+?[!:]B66#2XM+CE%ED@A9&D 9VV9##"X<G'
M P>/\-_$SQ+H?Q0D\$>,+B"]C>[-O%?>0L<F7 ,)VQY7:^5X(R#)RV%Q0![A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q!X[_P"2
MA^)?^PK=?^C6KU3Q'X2\>7OP<TRZC\3QW^AQ:9#>3::;=+=HHEC5E4,O^M"K
MDG<1]P$ MC'E?CO_ )*'XE_["MU_Z-:OK_P)_P D\\-?]@JU_P#12T '@3_D
MGGAK_L%6O_HI:Z"L_0M,_L3P]IFD^=YWV&TBMO-V[=^Q N[&3C.,XR:P_ 7B
M>;Q=9:OJNR1=/.IR1:<S(5$ENB(H=<JI(9Q(>>025S\M 'S9\;?^2O:[_P!N
M_P#Z3QU]%_#3P]ING_"W1[)+:.6"^LDN+I945O.:9 SA^,,,-M&<_* #G%?.
MGQM_Y*]KO_;O_P"D\=?3_@3_ ))YX:_[!5K_ .BEH ^1/A]/-;?$;PV\$LD3
MG4[="R,5)5I K#CL5)!'<$BOKOQW_P D\\2_]@JZ_P#135\@>!/^2A^&O^PK
M:_\ HU:^O_'?_)//$O\ V"KK_P!%-0!\P?!+_DKVA?\ ;Q_Z3R5]?U\@?!+_
M )*]H7_;Q_Z3R5]?T ?$'@3_ )*'X:_["MK_ .C5KZ_\=_\ )//$O_8*NO\
MT4U?('@3_DH?AK_L*VO_ *-6OK_QW_R3SQ+_ -@JZ_\ 134 ?,'P2_Y*]H7_
M &\?^D\E?7<\$-U;RV]Q%'-!*A22.10RNI&""#P01QBOD3X)?\E>T+_MX_\
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MCW!O+;<_,X*!751C&5$8/7)#'C"DU[Q//#:V\MQ<2QPP1(7DDD8*J*!DDD\
M <YH YOX=6.LZ9\/]'L-?C\O4K6(PNFY#M1681C*<'"!/Z\YKJ*R_#VM+XAT
M2'58H)(8+AY#!O# R1!V6.3# $!U"N 1T8=>M:E !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'?\ )0]/_P"P5'_Z-EKO_P!G'_DGFH?]A63_ -%14 > >._^2A^)?^PK=?\
MHUJ^WZ^(/'?_ "4/Q+_V%;K_ -&M7VW!/#=6\5Q;RQS02H'CDC8,KJ1D$$<$
M$<YH DHHHH ^(/'?_)0_$O\ V%;K_P!&M7U_X$_Y)YX:_P"P5:_^BEKX\\:3
MPW7CKQ#<6\L<T$NIW+QR1L&5U,K$$$<$$<YKZ[\"W]FOPQ\/WANX!:PZ5!YL
MQD&R/9& ^YN@VE6!STP<]* .7^/VI_8/A?/;>3YG]H7<-MNW8\O!,N[&.?\
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MC<!._E"('E!QY8+E>"I=.O- %/\ ::_YE;_M[_\ :->P>!/^2>>&O^P5:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<9/S.[?Q&MRN'^+=]X@TWX=:A=^')/*N(\&XD16,J0'AVCQT89!+'[JAB""
M: .HUS1K/Q#H=[I%^F^UNXFB? !*YZ,N00&!P0<<$ UY7^SKH#:?X.OM:E61
M7U2X"QY92K1194, .0=[2@Y_NCCN><^'WQ \0>(/ VH>$[2ZOK[Q5/*4M+J<
ML5M[9P-\KS [AY?SX)R=SQA0W0>]Z3IL.C:-8Z7;M(T%E;QV\;2$%BJ*%!.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF/.Y>"."1SWE &?K.BV6OZ<]AJ*SO:OD.D-S)#O!!!5C&REE()RIX/I7'_\
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M;(HDZ*/YDDY))Y)))R36/XE\ ^%_%]Q!<:[I,=U/ A2.02/&VTG."48$C.2
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M,;W=R^^5TGEC#-W.U& R>I..3DGDFNP@@AM;>*WMXHX8(D"1QQJ%5% P  .
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLM 'T/167X<U^Q\4^'[/6M-:0VETA9/,7:RD$JRD>H8$<9''!(YK4H ****
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M $5+0!3_ &;--AB\*ZSJBM)Y]Q>BW=21M"QH&4CC.<RMGGL.G?VRO'_V<?\
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M&,(.WK7D?Q3_ .3A?!7_ &X_^E;T >^3SPVMO+<7$L<,$2%Y))&"JB@9))/
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M +6KZ H *\?_ &CO^2>:?_V%8_\ T5+7L%>/_M'?\D\T_P#["L?_ **EH ]
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MQ7CGPD@AM?C[XPM[>*.&")+U(XXU"JBBZ0  #@ #C%>Q^._^2>>)?^P5=?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KG_''AO\ X2[P7JFAB3RY+J+]TY; $BD.
MFXX/R[E7.!G&<<UT%% 'SA\!/%W]@:Y?>#]8;[(MU+NMTG&PI=#"-&05SN8
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M_%7P>UKQ=XEBUZ^\9QV]Y B);_9-,,8@"$L-I\XMG<2V22<GC@   ]<KY_\
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M7@/69M4TOQ1:33RV[6[+=:4S*%+*V1MG4YR@[^M>N4 %>/\ [1W_ "3S3_\
ML*Q_^BI:]@KR_P ;_"_Q!X]^S1ZKXQ@AM;?E+6TTMDC+\_.09R2V#CD\#. ,
MG(!UGP^GAN?ASX;>"6.5!IENA9&# ,L85AQW# @CL017B'Q)\+WWPL\;VGCC
MPU':0Z?+<8C@"?+!*R$/&4)Y1U#D%<;<D#;A2?7_  )X.UKP5I=MH[>(+2_T
MN!W98VTTQRJ&R=JN)2,;B6Y4GDC/3'2:YHUGXAT.]TB_3?:W<31/@ E<]&7(
M(# X(.." : *?A'Q18^,?#5IK%A)&1*@$T2ON,$N!NC;@'()ZX&1@C@BO%/C
M[]LT'XA^&/%$'D/Y<2^1&^3^\@E\P[@,?*?,7H<\'IQ73^$_@SKO@K46O-%\
M=>5YNT3POI8>.95.0&4R_49&& )P1DUZ)K_A>Q\6>&FT?7XX[@.@+2PIY924
M#_61Y+%""3@$G@D'<"<@$GACQ/I?B[0X=7TB?S;>3AE;AXG'5''9AD?F""00
M33NO%<)\;V/A;3C'<7@1[G4@,'[+;A#M).1\[2-%A<$[220 0:\4NOV:]834
M8$L_$%C+8G;YTTT+QR)S\VU!N#8&",LN3QQUKV?P+X%TOP'H8L+ >;<28:ZN
MW7#W#CN?11DX7MGN220#G_C/%I>I>%[#0KQ?,U+5-0B@TQ1/Y?ESD[?-;@DQ
MJ&(;"G[X'!(8:&C>%?&.B>'DT:#QE8RQQ1"&WGFT7,D"! JA<3!3MQD;E;GK
MD<5S_P 7?#=GXVUSPWX<BDG75V\Z59(V!BM+?Y/,EF7!8YV!$&5!8G+<8/-Q
M_L_:]H:37?ASQO)!J!38-L+VH=2P)#2([$#C.,') ^H /5/ O@72_ >ABPL!
MYMQ)AKJ[=</<..Y]%&3A>V>Y))L>._\ DGGB7_L%77_HIJ\8U#1OBQ\-],N/
M%%UXN@O[6T\L36TUY-<B16D1<;9$P,DC)!5@,X->S^,-#U3Q'H=QI.GZO!IL
M-W$\-S(]GY[LC8!"_.H7(W Y!^]Q@C- 'G_[./\ R3S4/^PK)_Z*BKT2YO--
MU;7KWPMJ-I:7"+907GDW&V03*TDBG]VPY"-&ASSRZ].,\?\ #[X7:E\/+B[:
MR\16EU!>O$;E)M-8,50MPC";"DASR0W;CUT/%'@'5]8\:VWBC1?%<FB7<%D+
M/:MF)PZ[G8[MS@$?,."#@J#UQ@ \P^+GP;TCPYX?G\2>'I)+:"W=!<64LA==
MK%4!C8Y;.XY(8G.XX(P ?6_A9K-YK_PST34;]_,NFB:)Y"22_ENT89B226(0
M$GN2:Q]2\)^./&FCS:-XKU70[#39)8GE31[>622=%;<4+RG$?(4@A6Y'ID-Z
M!86-OIFG6UA9Q^7:VL20PIN)VHH 49/)P .M '@_[,O_ #-/_;I_[6JQ^T?:
M_;M#T'5[:X@DM;6[GLY-CY/F-C@8X^4P.#SD'C'7&I'\!%T[Q+-J.@^+=2T>
MSE?!M[56658B06C$P<'&1P2IQ@9W$9/IG_"*Z%_PB_\ PC7]F0?V-Y7D_9,'
M;MSG.>N[/S;L[MWS9SS0!E_#[QS8^.O#4-]!+&+^)%2_MP-IAEQS@$D["02I
MR<CCJ"!8\0^*X=*UG2-!LS'/K6I7">7;<'9;ALS2MR, 1K)M[EAP&P<>,:W^
MS9J27&[0=<M)H&=SLOU:)HUS\HW(&#G&<G"].G/'J?P[^&6E_#ZSE,4GVW4Y
M\B:^>/82F<A%7)VKP">3D\D\*  <O^T=_P D\T__ +"L?_HJ6O0/ G_)//#7
M_8*M?_12US_Q$^'NJ?$"**RD\106.F0RB:.W33O,<OMVY9S*,XR^,!?O<YP#
M6IX&\+ZUX2TN/2K[Q%'J]A A6W#V1CEB'&%W^8P*  X!7(R #@ 4 >;_ +2V
MFS2Z-H&J*T?D6]Q+;NI)W%I%5E(XQC$39Y[CKV](^'WCFQ\=>&H;Z"6,7\2*
ME_;@;3#+CG ))V$@E3DY''4$#H-5TJQUS2[C3-3MH[FSN$V2Q/T8?S!!P01R
M" 1@BO -;_9LU)+C=H.N6DT#.YV7ZM$T:Y^4;D#!SC.3A>G3G@ ]G\0^*X=*
MUG2-!LS'/K6I7">7;<'9;ALS2MR, 1K)M[EAP&P<>*?M!_VCI'Q#T#7[;]UL
MM$^RS_*V)H96<_*<]-Z'D8.>_->K_#OX9:7\/K.4Q2?;=3GR)KYX]A*9R$5<
MG:O )Y.3R3PH&QXQ\':7XXT/^R=6\]85E6:.2!]KQN,C(R"#P6'(/7UP0 :F
ME:K8ZYI=OJ>F7,=S9W";XI4Z,/Y@@Y!!Y!!!P17A?Q3_ .3A?!7_ &X_^E;U
MJ>&OA3X_\(7\]EH7C:TM=%G</)(;7S)-P3J(7!4'. 2'&0 3T JYK7P+BU3Q
M;::M;^(+ZTCMXK?S+AY7GO+B9&.Z0RLW[MMHC (! (X4 #(![!16?HVD1:)I
MR6<5U?76,%IKZZ>XD=L $EG)QG&<+A<DX S6A0!C^*O$-OX4\+ZCKETN^.TB
M+A,D>8Y.$3(!QN8J,XXSD\5C_#'P\_A[P-9)=-.^I7_^GW[W 82-/* 6WAB2
M& VJ>F2N2 2:Q_'OPWUWQ]BVO/%D%KID<OFPV<.E X8;@K,YEW,VUR#C"G&=
MHKM-$M=:M+?RM9U6TU%U1%26&R-NQ('S,_[Q@2>#\H4#GCG@ U*^4/&,,OPJ
M^-O]I:9;>7:K*M];0@H \,@(DC7 (1<^:@XR  ?0GZOKQ_QC\%M4\<:Y_:VK
M>+H%F6)88XX-*VI&@R<#,Q)Y+'DGKZ8  /8*\?\ '>@V?C/XM:1IVD7OV#Q#
MI5H+ZXU#(F2&-'!BC\G^*3>X;DJ K9._( [3P-X7UKPEI<>E7WB*/5["!"MN
M'LC'+$.,+O\ ,8%  < KD9 !P *\S\3?#6S^)GQ,UZXTW4)[*.S\N*]O)$$\
M4MP$4>5"J[<;%7YRSDAF V@<T =YKW@GQ'XI\/QZ%K/BJT:P9XC=O:Z3Y4]R
MJ$$@L96522 <J@P0.,9![#2M*L=#TNWTS3+:.VL[=-D42=%'\R2<DD\DDDY)
MKP\_!#QMH-NEOX6\=R1P.[/-&99K-0V  0(RX8D#!)QT'7MJ>$8_B!X)\=Z%
MH'B77X-6L-:^U$*9I)WC:*(/D.ZAAT4 9*\MP#S0!QEKKZ_#3]H;7)]5:,V=
MW<3+<R1*SF.*<B9& X.03'NX/&[ )Q7TO!/#=6\5Q;RQS02H'CDC8,KJ1D$$
M<$$<YKB_B)\,M+^(-G$99/L6IP8$-\D>\A,Y*,N1N7DD<C!Y!Y8'RS3?V;-2
M.LLNJ:Y:+I:.2KVJL9Y5##@JP"H2N><O@XX:@#V?PUXKA\4ZIJ[:88Y]'L7C
MMH[Q,8FN!N,H4YY15,6&P 26P6&#7D?_ #=Y_G_GPKW"QTFWT70X]+T2&"RA
M@B,=LIC+I&><%AD%N3D_,"W/.3FO-_\ A4FN_P#"P/\ A-/^$R@_M;S?,Q_9
M \O;MV;-OF_=V?+UW8YSGF@#UBOG_P#9E_YFG_MT_P#:U>P:IIGB34-#-C#K
MMC:74L4L5Q=Q:?("-W"M$!.#&R@]26R<'CI7'_#_ .%.J?#[49YK'Q1!<VMW
ML%U;S:9C>%)(*L)<JV"P!Y'S<@X% ''_ +37_,K?]O?_ +1KWR2>&%X4EEC1
MYGV1*S %VVEL+ZG:K' [ GM7'_$;X<V/Q#TNV@GNI+.\M'+6URJ[P@;&]63(
M# A1W!! YQD&OX&^&J^%'CN=3UJ[UV\MD,-C)=;@EE$5 *Q(68*2  2#T
M&<@'>4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!XGXXT'QOX4^)%WX]\)VD>J1
M7ENL-S;"$R,@"QIM* AV!*HX*<C!R !\US_A;_C#_HDVN?G-_P#&*]@HH \[
MMK?Q7X_2U'B'1[30O#N^*XFT^5Q<75VR,)$5\J%2(G;N4C?E"IP&X]$HHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY
M\T.'XA_!N_N=*M?#LGB+0;BX::-[2)BSG8!N!0,8R?DR'4CY"%/5C]!T4 >1
MP?%GQE<W$4"?"?60\CA%,DLB*"3CEFA 4>Y( [UUF@Z-KNHZY%XD\6)8PW5O
M$\6G:?:@2"S63:79Y",M-@!"5PN%.,[SCL** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_DD.N_\ ;O\ ^E$= '/_ +./_)/-0_["LG_HJ*O8*\?_ &<?^2>:A_V%9/\
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MJZSVDLF[:DJYQG!Z%2R]#C=G!(%>7_ O7)O#.MZG\/M=M9+/4'N&G@1HR29
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M*\@\&_\ )T-S_P!A74O_ $&:OI^@#G_"?@O0O!6G-9Z+:>5YNTSS.Q>29E&
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M0?#^;P)X:F.H>7_:VH.LMR$8D1*H^2/.<$KEB2.[$9( ) ,/]H[_ ))YI_\
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M,,,,.1AE#D?*217V'7E_Q^_L[_A5\_VW_CX^UP_8?O?Z[)STX_U?F_>X_'%
M'<>%?$-OXK\+Z=KEJNR.[B#E,D^6X.'3) SM8,,XYQD<5\\?M'?\E#T__L%1
M_P#HV6O6_@EHM]HWPRL1?SR.;QVO(8F.1!$X&U5Y(P0-_;!D.1G->2?M'?\
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MC  4(!WKUB>"&ZMY;>XBCF@E0I)'(H974C!!!X((XQ7QQ]@U_P $>/-6\+6
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MCJ&2.X7!V2;3P2 SKWP=X!/- 'U_XT@FNO OB&WMXI)IY=,N4CCC4LSL8F
M Y))XQ7SY^SC_P E#U#_ +!4G_HV*OI^OE3Q'I5S\%OBS::M9VT=SIY=[BS1
MMZKY3;D:'<<_.JMC.6ZHQ'.V@#ZKHK/T;7-+\0Z<E_I%_!>VK8&^%\[20#M8
M=5;!&5.",\BM"@ HKFX=?;6?%ATW2&D:STMV_M*\55:)I=I5;4$\EP6$C%?N
M[%4\N0+'B7QAH'@^W@GU[4H[-)W*1 HSLY R<*H)P.,G&!D>HH W**C@GANK
M>*XMY8YH)4#QR1L&5U(R""."".<U)0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA<,<D;0 1SGN** "N'\6?#.U\:[8]9\0ZY):QRM+%:Q/!''&3["++8' +$D
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M>@44 <'H'PGT70?%B^)FU+6=3U14*K-J-T)2"5V;LA02=N5&21@]. 1WE%%
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MG88 .YE.?E /444 %%%% '!^)?A=;^+[>"WUWQ/X@NH('+QQA[:-=Q&,D)"
M3C(!.<9..IJ3PG\,[7P5NCT;Q#KD=K)*LLMK*\$D<A'L8LKD<$J02 .>!CN*
M* "N'\8_"?PMXVO/MU_!/;7YVA[NSD"/(J@@!@05/4<XW?*HS@8KN** /(X/
M@WKUK<116_Q-\00Z7$X6.UC=U9(0>$#"3:"%XSLQ_L]J[#0/A[I&A:HNK2W.
MI:OJR(8XK_5KHW$L49_@3H%'WN0,_.PS@XKK** *>I64]];K%;ZG=Z>X<,9;
M58F8C!^4^8CC'.>F>!SUSYOJOP&\/:YJEQJ>IZWX@N;RX??+*\\.6/\ WZP
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M6XN0FYR''W3&Q=2@)(\P;CD GU#7=+N]8LDM+76+O2T9SY\MHJ>:\91EVJS
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M%E;QV\;2$%BJ*%!. !G ]!5RBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "2'0O\ MX_]*)* .DG\:>%;6XEM[CQ+HT,\3E)(Y+^)61@<$$%L@@\8J/\
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M'&H544#   X  XQ7S!\;_AS#X6U2+7='MHX-'OGV/$CC$-P=S$*N.$91D 9
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M!F&_<5!(SM!P,G% &I_PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\
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M>V275QLX#RF212^.@)"C..IR3R23]3P00VMO%;V\4<,$2!(XXU"JB@8  '
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M )./,^R7"2[,YQG:3C.#U]#4FJZ58ZYI=QIFIVT=S9W";)8GZ,/Y@@X((Y!
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MQ*6P3@%B!G )Q[&L/P+XZTOQYH8O[ ^5<1X6ZM';+V[GL?53@X;OCL00.HH
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MPL^)%GXYT..WFFV:[:1*+R%\ RXP#,N  5)Z@#Y2<=-I/H% '/\ _"=^#_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>#_'NS?Q+XM\(>&--._4Y?.)0HQ")(R!78@'Y1Y<A.,X"DD5[!XG
M\3Z7X1T.;5]7G\JWCX55Y>5ST1!W8X/Y$D@ D<O\/O#%Q_:.H>.==@G@U_6L
M_P"BRX'V.VR/+BP,9;:D>2P!X (!W9 .XL+&WTS3K:PLX_+M;6)(84W$[44
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MK_%GC:X^)7BA?A]X0U*"VL9=PU#4S(!YR*/G2(9!=<9SM^_SR$#,W(?M'?\
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M !4NO$EW?21:M"C6VC:9,-ICMU3YI"P&'=M\AV9)4%OO  K[97S!\7/ MO\
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M*\_^%G_,Z_\ 8UWW_LE 'C'A/Q#X@^"_CEM!UU=NE3RK]J0EFCV$X%S$0,G
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M01R" 1@BNH^'^E+HOP^T"P6VDM72RC>6&3<&65QODR&Y!WLW';IQTK#\)?\
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MAS3H_"]Y;7SWVI:J/)DA1#&OF".-=Q+ CD'. >* /H^BBB@ HHHH ^8/!O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=N=PPW4#<>D\2>"M!\7>6-<M9[N./!6'[9-'&",X;8CA=WS$;L9P<9Q7/_\
M"DOAY_T+W_D[<?\ QR@#T"BJ>FZ9!I5NT%O)=NC.7)NKN6X;. .&D9B!QTSC
MKZFKE 'RAX>\"W$?QM/@^03G3+34/M4T4JB9)((@7B:51\OS(P7)''FD8YVU
M]7UEP>'M-MO$MYX@BMHUU"[MX[>60(H)5"QSG&<G*@Y/(C3^[6I0!\L6_P /
M[^T^-=WX1@M=FD7<HDG3$AC?3A*LP7S"-P^XJ;@?OC;NZFOJ>L_^Q-._X2'^
MW_L__$S^R?8O/WM_J=^_;MSM^]SG&?>M"@ HHHH \?\ VCO^2>:?_P!A6/\
M]%2UT'P2_P"20Z%_V\?^E$E:&I_##PGK?E?VM:7U_P"3GR_M>JW<NS.,XW2G
M&<#IZ"K&C?#WPYX>V#2(+ZRC643>3#JET(V<8Y9/,VMT .0<@8/% '44444
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M,VH7$T:(,8"I([*N, # X''2@#0O[ZWTS3KF_O)/+M;6)YIGVD[44$L<#DX
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M+]R-V55(0?PK\@..V3C P!EZW\-O"WB.X\_6;*[OG#NZ";4;EEC+'+;%\S"
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M3M10 HR>3@ =:S]!\+:-X:^V'2;/R9+V7SKF9Y7EDF?U9W)8]2>O4D]2<[%
M$<\\-K;RW%Q+'#!$A>221@JHH&223P !SFO*_@T+CQ%>>)/'NH0;+C5[OR;9
M7A&8X(Q@!9,#<O*H< 9,.3D]/2-<TE->T.]TF6YGMX;R)H9)(-N_8W# ;E8<
MC(Z=^,'!J/PYH%CX6\/V>BZ:L@M+5"J>8VYF))9F)]2Q)XP.> !Q0!J5S_\
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MBU2'4-'NM9T2>)-JG3KTJ03D%MSAF!(.#@@8[=<@'8>*/%VB^#M+>_UB]CA
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M]I_M&Y\SS,[M^[S,[L\YZYKL+&RBT^SCM87G>-,X,\[S.<DGEW)8]>YXZ=*
M+%?*EA?K\(_CK>0YCCTM;@P3(C,X2TEVNG)4L2@,;'')*$9.<GZCOK*+4+.2
MUF>=(WQDP3O"XP0>'0AAT['GITKBY_@SX"NKB6XN-$DFGE<O)))?W+,[$Y))
M,F22><T =Y16/X>\+Z3X5LS9Z/#/!:GI"]W+*B<D_*KL0N2Q)VXSWS6Q0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O/_\ A=OP\_Z&'_R2N/\
MXW7H%<G\.O"-MX/\':?9K91P:@]NC7TFU#(\IRS*SJ/F"L[*O)P.YZT 9?\
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ME_AYXAN/%?@FSURZ79)=RW#A,@^6@GD")D 9VJ%&<<XR>:ZB@ HHHH ****
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M"^-?^W[_ -*TKZ H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\2P^+_#%KKMO;R6\%R\HCCD(+;4D9 3C@$A<XYQG&3C-<W\;?^20Z[_V[_\
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MB'1I_,+V>NSQ!WC,9D41Q;7VGH&7##D\$<F@#TRBBB@ HHHH **** "BBB@
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M8((/!!'&*\?\%>!E\#_'/4H+.*1=)O-'DGLRQ9MH\V$-'N(Y*MVR3M9,DDT
M>R4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8?C#
MQ+#X/\)W^O3V\EPEHBD0H0"[,P11D]!N89/.!G@]*W*CG@ANK>6WN(HYH)4*
M21R*&5U(P00>"".,4 <O\//'$/C_ ,--JT5C)9/'</;RPM(' 8!6RK8&1M9>
MH'.1VR>LJGINDZ;HUNUOI>GVEC SEVCM85B4M@#)"@#. !GV%7* "BBB@#R?
MQ/\ '[PMHLLUMI<4^LW4? :$B. L&PP\P\G !(*JRG(P><CUBOF#]H[_ )*'
MI_\ V"H__1LM?3] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:XO)&4.$C):"0* "<>4GN<DX[8^BZ^8/VCO^2AZ?_P!@J/\ ]&RT ?3]%%%
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MXVG>9,Y&!@YXP*[2@ KS_P"*?_,E?]C78_\ L]>@5Y_\4_\ F2O^QKL?_9Z
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M$[^"%!![3X)?\DAT+_MX_P#2B2CXV_\ )(==_P"W?_THCH^"7_)(="_[>/\
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M6\[16MGAEW)Y)D7S(@OH0S@-N )R<O\ YN\_S_SX5] 4 >=Z[XCU+Q!\09/
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M$<\&V=Y_PDWB/5-^H)%Y.IW_ )\:YCD.X+M&&XQGT)]:[?P)X _XI[PUJ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=;?5-/M+Z!7#K'=0K*H;!&0&!&<$C/N:L000VMO%;V\4<,$2!(XXU"JB@8
M'  '&* /F3X.^+M.^'/B'Q%I/BAOL._;&\N&EV30NRF/$:MG.]CNSCY.^:]7
M^(LUQXJ^"&L7EG:X6:(74(\P?/;),LBR\XQNB42;3R,[>HKM)O#6@W.J#5)]
M$TV74 ZN+M[5&E#+C:=Y&<C P<\8%:E '@_PE^)^C:9\/[7P]*<Z[#++#8V7
MS_Z8[L7C&_85CW.^SYCQC)X-5/CK>WVA_$OPGKLD4D^GVB1S00F;"O+%-OD
M'.TE3$"V.>.N,#V_3?#6@Z-<-<:7HFFV,[(4:2UM4B8KD'!*@'&0#CV%6-2T
MG3=9MUM]4T^TOH%<.L=U"LJAL$9 8$9P2,^YH XO_A;_ (=U'_1O"\5]XAU-
MN$L[2UD3&> \CR*JI'N*@MSC<#BO*/V?O$VG:'>:W8W!GEO]0\@65I!"SO.R
M"4L 0-J]1RY51U) !(^A],T+1]$\W^R=*L;#SL>9]DMTBWXSC.T#.,GKZFBU
MT+1['49]1L]*L;>^GW>=<PVZ)))N.YMS 9.2 3GJ: /"/CKX8U31O%MIX\T>
M#;"ODF>X3YS%<QMA'96R I C4=LK@C+#=T>B?M#^')O#_GZU;7=OJD*()+:W
MBWK.Q."8B3@ #YB'(QG +8R?8)X(;JWEM[B*.:"5"DD<BAE=2,$$'@@CC%<O
M'\,?!$6J3:BOAC33/*FQD:$-$!Q]V(_(I^4<A0>OJ<@&?X*O-7\7:S-XPU"T
MDT_2S;M;:+:28$CPNRM)-(,9RYCCVX.  >#D.WEGQEUFSTSXX>'M1D?SH],B
MM);F.$AG7;.\A7&>&*D$ X^\.QKZ/KG_ /A!/!__ $*FA_\ @NA_^)H Z"OG
MCX47]G)^T!XKECNX'CN_MOV9UD!$V;A7&P_Q?*"W'8$]*]O_ .$3\-_V=_9W
M_"/Z5]A\WS_LWV*/R_,QMW[<8W8XSUQ5?_A!/!__ $*FA_\ @NA_^)H \<^.
MWA>^T;Q+8>/M&CD4J\9NI53>()XROE2-DD8("KC;M!09R7K7TK]I#06TNW.L
M:5J2:ALQ.+2-&BW>JEG!P>N#TSC)QD^R?8+/^SO[.^R0?8?*\C[-Y8\OR\;=
MFWIMQQCIBN7_ .%5^!O[8_M3_A&;'[1_<VGR?N[?]3GR^G^SUYZ\T 9_@[Q!
M<?$'7/\ A(X]/GL_#UC$T.G"Z0;[F=\"2; 8A=@4Q@@'/F2?-]Y1Y)X^T?5_
MAA\68_&=G!)-IMS>M<QR;@=S/DS0L=N$)#2!>#\IR"2IQ]+P00VMO%;V\4<,
M$2!(XXU"JB@8  '  '&*COK"SU.SDL[^T@N[63&^&>,2(V"",J>#@@'\* ./
ML_B]X&N]#.K'7H+>-=HDMY@1.C'''E#+-C< 2H9>#S@&O&/A[XPT[1_CAKVH
MZE!?6T>J2W4$<36S--')).'5'C7+;OEVX4$[B!TR1[OX>^'7A'PK>&\T?1((
M+H])G9Y73@CY6<DKD,0=N,]\UH:5X5T+1-1O=1T[3((;Z^EDFN+G!:1V<AF&
MXY(4D [1A<]J -2"9;FWBG02!)$#J)(V1@",\JP!4^Q ([U)110!\R>/M'U?
MX8?%F/QG9P23:;<WK7,<FX'<SY,T+';A"0T@7@_*<@DJ<>QV?Q>\#7>AG5CK
MT%O&NT26\P(G1CCCRAEFQN )4,O!YP#787UA9ZG9R6=_:07=K)C?#/&)$;!!
M&5/!P0#^%<_X>^'7A'PK>&\T?1((+H])G9Y73@CY6<DKD,0=N,]\T >$?#WQ
MAIVC_'#7M1U*"^MH]4ENH(XFMF::.22<.J/&N6W?+MPH)W$#IDCK_CWX/?7M
M#L?%^F6T\DUI%LND,3*_V8Y<.R,05V$G(VY^<EL!*]8TKPKH6B:C>ZCIVF00
MWU]+)-<7."TCLY#,-QR0I(!VC"Y[5L4 </\ #'Q[9^-/"]D9;V!M;BBVWMMO
M DW(0IDVX'RME6R!M!;;G(KA_B;IG_"U?'.E^&=!FW?V-YIU6^V[H;7S"F$S
MGYI/W;?*._&1M?;Z1J?PY\':QJ,5_?>';&2ZCE,Q=8_+\QR029 N!)DC^//4
M^ISN:;I.FZ-;M;Z7I]I8P,Y=H[6%8E+8 R0H S@ 9]A0!R?Q,\%_\)1\.I]&
MTNT@%U:^7+I\(;RD1DXVKC@90NH!^7D=,9'D'PM^+G_"$P-X6\46L\=C;RLD
M4BPXDM&+_.LB\$J"6;NP.1AL@+]+US>O^ /"GBAVEUC0[2>=G#M.H,4KD+M&
MZ1"&(QQ@G' ]!0!P\_CUOBE<2^%?"%I=C3Y',6KZK.BHL=H3AA%G=\\B[@NY
M01_=ZLG4?%K39M5^%?B"W@:-72W%P2Y(&V)UE8< \[4('OCIUKJ--TG3=&MV
MM]+T^TL8&<NT=K"L2EL 9(4 9P ,^PJY0!X/\)?BOX5T'X?VNCZY?_8;JSEE
M11Y,LOFHS&0/\B$#ERN,_P .>]<Q\=->O/$G]@ZBME]FT1_M TV24%9KI?W>
MZ8J?NQM\NP'YB 6. P%>YR?#'P1+JD.HMX8TT3Q)L5%A"Q$<_>B'R,?F/)4G
MIZ#&IK/A70O$-Y8W6L:9!?26/F?9Q."R+O #90_*W0?>!QC(P: (]%\7Z'K^
MES:II]W(=/A0N]W/;RP1;1NR0\BJ& VMD@G&.<5\\?LZSPP_$:Z266-'FTR5
M(E9@"[>9&V%]3M5C@=@3VKZ7U+2=-UFW6WU33[2^@5PZQW4*RJ&P1D!@1G!(
MS[FLO_A!/!__ $*FA_\ @NA_^)H YOXXSPP_"35TEEC1YG@2)68 NWG(V%]3
MM5C@=@3VKG_V;YX6\"ZG;K+&9TU-G>,,-RJT484D=0"58 ]]I]*]0U+PUH.L
MW"W&J:)IM].J!%DNK5)6"Y)P"P)QDDX]S4=CX3\-Z9>1WEAX?TJTNH\[)H+*
M.-UR"#A@,C()'XT >*?M,SPM<>&K=98S.B7+O&&&Y58Q!21U )5@#WVGTKT?
M2-%L?&?P1TO1WGC:"ZT>"'S4.X1RHBX/RD9*2+RN1RI![UT$_@OPK=7$MQ<>
M&M&FGE<O)))81,SL3DDDKDDGG-7-,T+1]$\W^R=*L;#SL>9]DMTBWXSC.T#.
M,GKZF@#YH^'WQ!U'X3:QJ'ASQ'IL_P!A\TO/ BKYT$VT ,I) =6 7OC&&4]0
MWH__  ONPUK_ (EOA70-5O==N?W=G#<1QK&7/=RLA(4#+'IP.2H^8>B:_P"#
MO#GBE&76M'M+MR@3SF3;*JAMP"R+AU&<\ CJ?4T:!X.\.>%D5=%T>TM'"%/.
M5-TK*6W$-(V789QP2>@]!0!C^);.'P[\'-7LKB[C8PZ/-%)<R83SYFC(+G)/
MSR2-GJ26?J2:XO\ 9NOK>3P;JU@LF;J'4/.D3:?E1XT"G/3DQO\ E[BO6-3T
M+1];\K^UM*L;_P G/E_:[=)=F<9QN!QG Z>@JG!X+\*VMQ%<6_AK1H9XG#QR
M1V$2LC Y!!"Y!!YS0!YO^TA/"O@73+=I8Q.^IJZ1EAN95BD#$#J0"R@GMN'K
M7H'P^GAN?ASX;>"6.5!IENA9&# ,L85AQW# @CL015B?P7X5NKB6XN/#6C33
MRN7DDDL(F9V)R225R23SFK&F^&M!T:X:XTO1--L9V0HTEK:I$Q7(."5 .,@'
M'L* /GS1/$-O\/?V@O$DVOK]GM;N6Z1Y<E_*25Q/&^$#%MP"#';?SC!%>C^.
M[BW^(7P>UZ^TZ*![.'_2;"[F!_>I#M:2105W1MQ-$ 1SC.=K5WFI>&M!UFX6
MXU31--OIU0(LEU:I*P7). 6!.,DG'N:U* /*_P!GW4IK[X9"WE6,)87LMO$5
M!R5(67+<]=TC#C' 'U/JE>/^%-*O/A9\1;C1I3GPKX@E)TZ;<=EO<#)6%MS?
M*Q7*YY,FV/'1@/8* .#^%7C>Q\6>#M.A:^C?6+:W$5W;R3[YR8\*93G!8-E6
MW<C+8R2#7!^-/#&ES_'?PT?#4'F:M]KCOM9@@^Y"B2(PE?LK,-Q(SS\IQEP6
M],U+X8^"-5MU@N/#&FHBN'!M81;MG!'+1[21STSCIZ"MC1/#>B^'+?R-&TNT
ML4*(CF&(*T@487>W5R,GEB3R?6@#4KYT^*NFP^,_CUHOAZW:20BW@M[P1D(T
M:[GE<@L,$B)MW?TY/%?0=_?6^F:=<W]Y)Y=K:Q/-,^TG:B@EC@<G !Z5Y7\+
M/#UWKOB#4OB9KUM)#>:D[#3K:5$/E6Y"A7!P#G: @.%)4$_,'!H ]<HHHH *
M^8++P=K>F?%K6O NG>?9Z1JW,[0O*%6PWB0,K$<L%!AW,&7<[J2=Q-?3]4QI
M5BNLOK MH_[0>W6U-P>6\I6+!!Z#<Q)QUXSG P 8?Q#\,)XN\#:GI?D>==&(
MRV8&T,)U&4PS<+D_*3Q\K,,C->5_L]:;=ZHDNL:BTDUII"-8Z4K%"D+2,9)R
MJXR'^9!NXR'*Y(&![Y5/3M*L=)2X2PMHX!<7$EU-MZR2NVYG8]22?R  &  *
M )+^QM]3TZYL+R/S+6ZB>&9-Q&Y&!##(Y&03TKY<T#7-7^!OQ!O],U"UDGTV
M=PLX,85KB$%O+GC.2,X+?+G'+*<$97ZKK+UOPWHOB.W\C6=+M+Y CHAFB#-&
M&&&V-U0G Y4@\#TH \S_ .&B/#=Q^XT[1-<NKZ3Y+>#R8QYLAX5<AV/)P. 3
MST/2O0/#-O<:/X7%WK\L$-_-YE]J4I(5(W8EBI8LV5C7;&"6/RQKV  CT#P!
MX4\+NLNCZ':03JY=9V!EE0E=IVR.2P&., XY/J:V-2TG3=9MUM]4T^TOH%<.
ML=U"LJAL$9 8$9P2,^YH ^?/V;M9L[37-:TB9]EU?Q12V^2 '\K?N49.2V'R
M  >%8\8KZ/KG_P#A!/!__0J:'_X+H?\ XFMR""&UMXK>WBCA@B0)''&H544#
M   X  XQ0!\N:LFJ? [XJRWVG6>_2;G=]G20?)/;,59H@Y+$,AP,YS\JL00V
M#Z/_ ,-'>#_^@;KG_?B'_P".UZIJ6DZ;K-NMOJFGVE] KAUCNH5E4-@C(# C
M."1GW-<_HGPR\%^'KC[1IWA^T6?>CK)-NG:-E.5*&0L4()SE<=!Z"@"3P0FJ
M76G7.NZY9_8]2U67SOLC#Y[2!0%BA))R< %R,+AI7^52374444 %?,GA_P 0
MPZM^T_\ VI-<V@@>]N+>&:-QY<BK"\,1!)()8!.AY+<=0*^C]2TG3=9MUM]4
MT^TOH%<.L=U"LJAL$9 8$9P2,^YK+_X03P?_ -"IH?\ X+H?_B: .@KY8\&7
M]FW[2KW@NX#:S:K?>5,)!LDWB4)M;H=Q90,=<C'6OI./PUH,.ES:7%HFFII\
MS[Y;1;5!$[<<LF,$_*O)'8>E4_\ A!/!_P#T*FA_^"Z'_P")H C^(,\-M\.?
M$CSRQQ(=,N$#.P4%FC*J.>Y8@ =R0*\@_9FGA6X\2V[2QB=TMG2,L-S*IE#$
M#J0"R@GMN'K7M]YX:T'4+>UM[W1--N8+1-EM'-:HZPK@#" C"C"@8'H/2J\'
M@OPK:W$5Q;^&M&AGB</')'81*R,#D$$+D$'G- 'E_P"T'X)FU72[7Q1I]O)+
M<6"&*\5 6/V?E@_7@(Q;. 3AR2<+5/PQ^T981:'#%XGL+Z74X_D>:RBC*3 =
M'(++M8]P!CC(QG:/>*X^Z^%?@:\U&"^E\,V*S0[=JPJ8HS@Y&Z-"$;D\[@<C
M@Y'% &'X<\9-\4/$%G)I>FW=MX;TMS<7,]Y&O^DW(!$<( <C"[A+GYB&1.%.
MTG@/CAX4U?0_&,/C[21(T!>!Y9AA_LUQ'A4)4C 0A4P3D;L@XRH/T'8V%GIE
MG'9V%I!:6L>=D,$8C1<DDX4<#))/XU)/!#=6\MO<11S02H4DCD4,KJ1@@@\$
M$<8H X/P]\9/!VMZ&;^YU2#3+B&+S+FTNGPZ'G(3C][]TXV9/(R 3BO')O&^
MD6W[10\63K=Q:277#O 5<QM:B-9=AYV'(<<9*D'&>*]WTWX9>"])UEM6LO#]
MI'>%RZLVYUC;<&RB,2J$$#!4#'08%:D/A70H/$=SXA33(#J]QMWW;@NXVIL&
MW.=GR\';C/?- &A8WL6H6<=U"DZ1OG G@>%Q@D<HX##IW'/7I5BBB@"O?V-O
MJ>G7-A>1^9:W43PS)N(W(P(89'(R">E?.'PL\-^)(O'-YX0NY)X=,TG4(M0O
M]C2*C20D^4%R-I61BCX8 LL0((VBOI>J=KI5C97]]?V]M''=W[H]U,/O2E$"
M+D^@4<#IR3U)) .#^-WAA/$'PZN[J.#S+[2O]+A8;00@_P!:"3_#LRQ (R47
MKC!R_@/IMW<>&G\2ZJTDUW<(EA922%"([. !55 !E 7#[A_$4#$9Y/KE4]*T
MJQT/2[?3-,MH[:SMTV11)T4?S))R23R223DF@"Y7RQXSO[-?VE4O#=P"UAU6
MQ\V8R#9'L$0?<W0;2K YZ8.>E?4<\$-U;RV]Q%'-!*A22.10RNI&""#P01QB
ML/\ X03P?_T*FA_^"Z'_ .)H L>++&XU/P;KEA9Q^9=76GW$,*;@-SM&P49/
M R2.M>$?!'XE>'?"?A[4M)U^[^Q9NQ<PR^7))YNY K+A%.-OEJ<D\[O:OH>Q
ML+/3+..SL+2"TM8\[(8(Q&BY))PHX&22?QJG#X:T&VU0ZI!HFFQ:@79S=I:H
MLI9L[CO SDY.3GG)H X?XQ7K-\%+Y]0BCL;RZ2U!M6F5BLOFQNT:L.'("MR.
MH4GI1\!M2AOOA79V\2R!["XFMY2P&"Q<RY7GIMD4<XY!^I[C4O#6@ZS<+<:I
MHFFWTZH$62ZM4E8+DG + G&23CW-1V/A/PWIEY'>6'A_2K2ZCSLF@LHXW7((
M.& R,@D?C0!XI^TS/"UQX:MUEC,Z)<N\88;E5C$%)'4 E6 /?:?2O?X)X;JW
MBN+>6.:"5 \<D;!E=2,@@C@@CG-8?_"">#_^A4T/_P %T/\ \36AIFA:/HGF
M_P!DZ58V'G8\S[);I%OQG&=H&<9/7U- &A7D_P"T-8W%W\-8YH(]\=IJ$4TY
MW ;$*O&#SU^9U''KZ9KUBHYX(;JWEM[B*.:"5"DD<BAE=2,$$'@@CC% 'E?P
MX^)^C:AX7\.>'[4^9KZQ0VAL/G&$C(5Y/,*;.(E:7;GG&T'-<I^TS/"UQX:M
MUEC,Z)<N\88;E5C$%)'4 E6 /?:?2O<],T+1]$\W^R=*L;#SL>9]DMTBWXSC
M.T#.,GKZFJ<_@OPK=7$MQ<>&M&FGE<O)))81,SL3DDDKDDGG- &AI.I0ZSHU
MCJENLBP7MO'<1K( &"NH8 X)&<'U->"?;[/_ (:V\_[7!Y/F^1YGF#;YGV/R
M]F?[V_Y<==W'6O;X?"?ANWL[FSA\/Z5':W6W[1"EE&$EVG*[E PV#R,]*K_\
M()X/_P"A4T/_ ,%T/_Q- ')_&WP3-XM\'+=:?;R3ZII;F6".,%FEC; D0#(&
M<!6Z$G9@#YJX#X??'JVT+PU#H_B2RNYS9(L-I/91H2T0& K@LHRH  (ZCJ,@
MEOH.QL+/3+..SL+2"TM8\[(8(Q&BY))PHX&22?QKF];^&7@OQ#<?:-1\/VC3
M[W=I(=T#2,QRQ<QE2Y)&<MGJ?4T <G8?$1/BEJ-MH7A[2KZ/31*DVL7=[$NQ
M8%(80X5R&\TKL()^Z6^5AG;ZQ5/3=)TW1K=K?2]/M+&!G+M':PK$I; &2% &
M< #/L*N4 %>9_&35;'2K?PA/>W,<*0^([6Z<'EO*C#%W"CDA<C. >H]17IE<
M_P#\()X/_P"A4T/_ ,%T/_Q- &Y!/#=6\5Q;RQS02H'CDC8,KJ1D$$<$$<YH
MG@ANK>6WN(HYH)4*21R*&5U(P00>"".,53TS0M'T3S?[)TJQL/.QYGV2W2+?
MC.,[0,XR>OJ:T* /EC4OAW<?#[XO^%HA-]HTR\U6W>RF8C>0LR;D<#^)=R\@
M8.01CE1]'^*O#UOXK\+ZCH=TVR.[B*!\$^6X.4? (SM8*<9YQ@\5<U'2K'5D
MMTO[:.<6]Q'=0[NL<J-N5U/4$'\P2#D$BKE 'RQ\/OB#J/PFUC4/#GB/39_L
M/FEYX$5?.@FV@!E)(#JP"]\8PRGJ&]'_ .%]V&M?\2WPKH&JWNNW/[NSAN(X
MUC+GNY60D*!ECTX')4?,/1-?\'>'/%*,NM:/:7;E GG,FV55#;@%D7#J,YX!
M'4^IHT#P=X<\+(JZ+H]I:.$*><J;I64MN(:1LNPSC@D]!Z"@"YH>F?V-H=EI
MQF\^2")5EG*[3/)U>1AD_,[%F))))8DDGFO._CUX777/ 9U6*.1KS1W\Y-B,
MY:)B%D& <  ;7+$' C/0$FO5*CG@ANK>6WN(HYH)4*21R*&5U(P00>"".,4
M>=_!VUUBY\//XFUZXGDOM5B@BB25W.VW@0I&V'Y#.3)(2"0V\,,9-=IXEAOK
MGPKJ\&EF0:A)93):F.38PE*$)ALC:=V.<C%7+"QM],TZVL+./R[6UB2&%-Q.
MU% "C)Y. !UJQ0!\X?!'XE>'?"?A[4M)U^[^Q9NQ<PR^7))YNY K+A%.-OEJ
M<D\[O:L_XZ>*/^$I_L&YMM*OK;3$^T"UO+N/ROMF?+)>-#\WE[=A#'&[>1@;
M37T'/X+\*W5Q+<7'AK1IIY7+R226$3,[$Y))*Y))YS6AJ6DZ;K-NMOJFGVE]
M KAUCNH5E4-@C(# C."1GW- ')ZNVG?%?X?ZM8Z/+.UI=1 6U[)&T,<DR-N
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M^IJZ1EAN95BD#$#J0"R@GMN'K7:?"W6;/6_AKH4MF^?LUI'9S(2-R21*$8$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)]+\(Z'-J^KS^5;Q\*J\O*YZ(@[L<'\B20 2 #8HK@Y_&'C1=&EU:W^'TDD
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M-Q(L>KD*&= Q RI.,GU-<G^TU_S*W_;W_P"T:]@\"?\ )//#7_8*M?\ T4M
M'G?A7PYXOT'XEWFA:IXPUF]L[C1VN+2]+LV&$T08!)O,0..0?O?*X/!;CE-$
MTK^Q/VI8-.^WWU_Y.[_2;^;S9GS9%OF; SC.![ 5]%F"%KA+AHHS.B,B2%1N
M56(+ 'J 2JDCOM'I7@$\\-K^UI+<7$L<,$2%Y))&"JBC3\DDG@ #G- 'T'17
MD>O_ !MN=,1K[3_ ^LW>BA PU.Y5[:)PS85E)C8;&!4@D@G=C []QX&\9V/C
MKPU'K%C')"0YAN('Y,,H )7.,,,,"".H(R <@ '245S_ (K\8Z7X/L[>6_\
M/GN+J40VME:)YD]PY(&$3(SC(SSW ZD \OJWCWQMHFARZO??#G;;P;C.L>LQ
MR/$@V_.0L9RO)Z9QM8D 8) /2**YOP9XYT7QUI;WVCRR Q/LFMYP%EA/.-P!
M(P0,@@D'D=00.DH *\K^.7CF^\)>&K2QTJ62WO\ 5'=!<(.8HD W[3G*N2Z
M'!P-Q&" :],OYKBWTZYFL[7[7=1Q.\-OY@C\UP"53<>%R<#)Z9KY0^->HZSJ
M?C*SFUS0?[%NET]$6W^V)<[D\R0A]R# R21CV]Z /;_%WP;\-:UX7:QT?2['
M3=2@B"V=TJ,N""O$A4Y?(7;N;<1N)&3UX31_@1K_ (AL--G\8:[):/9H+6.R
M2-9I$ME<D)YH; /S-CAPH*^FT>M^&]<\5:GJ,D.N>#O[%M5B+K<?VG%<[GR
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MN* .7U/X00ZK\5$\:SZS(J)<07 LDMP#NB10H\PL>-R GY>F1QUKTRO-]/\
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M3(SC(SSW ZD \WK?CGQIH'A_^V;SX?QM B.]S'#K"R26RJ<9<"+!!'S94M@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@@Y!!Y!!!P17@GQ]^V:#\0_#'BB#R'\N)?(C?)_>02^8=P&/E/F+T.>#TXH
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M9)=RV$TYW$[W$YC!YZ?*BCCT]<U]#U\__%/_ ).%\%?]N/\ Z5O7T!0!\_\
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M_8*M?_12U3DL/#GQ'TFXCU?3+2[%G>W-FRE]TD+13%>'7#1E@B,0".& .1U
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MBBB@#Y__ &FO^96_[>__ &C7L'@3_DGGAK_L%6O_ **6O'_VFO\ F5O^WO\
M]HU[!X$_Y)YX:_[!5K_Z*6@#H*^=-4TJQUK]JUK#4K:.ZM'='>&3E6*68=<C
MN-RC@\'H<CBOHNOG_P#YN\_S_P ^% 'NFK:;#K.C7VEW#2+!>V\EO(T9 8*Z
ME21D$9P?0UX?^S-/,UOXEMVED,"/;.D98[59A*&('0$A5!/?:/2O?*^?_P!F
M7_F:?^W3_P!K4 :E_J>I:G^TI]EC^R2/HED186UQ?-;)(TD2ES]R3<^V5N%5
M<B-23\O/I$\GBJZMY;>X\.^'YH)4*21R:O*RNI&""#:X((XQ7B'Q"U*;P'^T
M1;^))ECF@E2&XV("S"$Q^1(,$J-^$<CG'W<]Q7T/I6JV.N:7;ZGIES'<V=PF
M^*5.C#^8(.00>000<$4 >5_"7X6^)/ /B&]O-2U"QEL;FT,1AM)I&S('4JQ5
MD4<#>,]1N/J:]@KF[#Q7#J_C6\T/3#'<6^F6Y_M&X7!$5PS*(X@<\G:LQ;@@
M$*,@Y%=)0 5\P?M'?\E#T_\ [!4?_HV6OI^OF#]H[_DH>G_]@J/_ -&RT ?3
M]?/_ ,4_^3A?!7_;C_Z5O7T!7S_\4_\ DX7P5_VX_P#I6] 'T!7S_P#"S_DX
M7QK_ -OW_I6E?0%?/_PL_P"3A?&O_;]_Z5I0![!X[_Y)YXE_[!5U_P"BFKS_
M /9Q_P"2>:A_V%9/_145>@>._P#DGGB7_L%77_HIJ\__ &<?^2>:A_V%9/\
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M#<1AXU,B'CT95/OCGBO)_A9_R<+XU_[?O_2M*]@\=_\ )//$O_8*NO\ T4U
M'!_LZSS3?#FZ2661TAU.5(E9B0B^7&V%]!N9C@=R3WKG]$F;QS^TO?7%\(Q!
MX?29+>!XUD!$+^4.<#!\R0R@G)!P!T!&Y^SC_P D\U#_ +"LG_HJ*N$T756\
M%?M):HVJW,>GVEW>W*7#R;2IBFS)%EN=H+&(YXQWP,T ?3=?/'P=L;?3/CKX
MLL+./R[6UBO(84W$[46YC"C)Y. !UKZ'KY_^%G_)POC7_M^_]*TH ^@****
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M[LS;^8LTFLN&+.Q=P0ML0I#,PVY.W&"21FMCXM:;-JOPK\06\#1JZ6XN"7)
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M7?AOIUNU]'/?Z<GV:XC "M$H9A$",#CRPH#=\'DD&L/]H[_DGFG_ /85C_\
M14M 'H'@3_DGGAK_ +!5K_Z*6N@KG_ G_)//#7_8*M?_ $4M=!0!S_CO_DGG
MB7_L%77_ **:O/\ ]G'_ ))YJ'_85D_]%15Z!X[_ .2>>)?^P5=?^BFKS_\
M9Q_Y)YJ'_85D_P#145 &'\=9YM>\=>$_!BRR6T%P\;O*&+*6FE\I28^ 2@5B
M#G^,CCO[Y7SA^T':WB>(= \6Z=<;K&6T2*WO+5R=DB.TBL'' R'!4@Y.UCVK
MW_0]9L_$.AV6KV#[[6[B65,D$KGJK8) 8'((SP010!X!\?=,_P"$<\<Z+XKT
MV;R;Z[_>'Y=VV:W*;9/F)!X*#;C'R9YR:^@])U*'6=&L=4MUD6"]MX[B-9
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M9@U!+-+M5^0S!KAT.XC!SM 7.<X ]!7M?@3_ ))YX:_[!5K_ .BEKQ_XI_\
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M7T?10!R_@7P+I?@/0Q86 \VXDPUU=NN'N''<^BC)PO;/<DD]1110 5XN_P
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M8348$L_$%C+8G;YTTT+QR)S\VU!N#8&",LN3QQUKZ/HH Y?P+X%TOP'H8L+
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MY]E]G\J0O\J1Y 9EVELYW$;5R1GYMSXG>,]?\&Z))?Z/H$=W!&BM-?7$ZB*
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MIM+NX?!]RDDD/VFQ\I8X=N8G60\L['9D!F!WL0, %0#V2BBB@ HHHH ****
M"BBB@ HKQ_XI_$WQ=X1BDBLO#/V*UFE:"WU:XE28/A3R(U)"-GYEWDY"G*]0
MOI'A.^N-3\&Z'?WDGF75UI]O-,^T#<[1J6.!P,DGI0!L4444 %%%% !1110
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M .E;U[AJ>NZ/HGE?VMJMC8>=GR_M=PD6_&,XW$9QD=/45X1\8OMG_"]?"?\
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M2[/0= ED&N:L^Q?(&Z6.+[OR@'<'9B%4@'H^,, :[#POX(T7POX:31[>QM)
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M'7?^W?\ ]*(Z #X)?\DAT+_MX_\ 2B2NXOK^STRSDO+^[@M+6/&^:>01HN2
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M*H^YRQ49(3;E=W/L?@OX3Z7X(\6ZGK>G7D[0W47DV]HXXMT+*S L22_*C'3
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_&T)L)<@]=FX#KG'- 'C?_-WG^?^?"O0/C#X.3Q=X&N#'Y$=_IV;JWFF=8U
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MUUHFLZ)KEE=3:AYL3RZ7/Y;AT1/OA2%P4Y+8 !!SUP 6/VCO^2>:?_V%8_\
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MJM_?WODE%L[&65$590Y+.%VC[A&,EN5XP<T 6/@E_P DAT+_ +>/_2B2N?\
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M027\-W#%);-C=<2JX,.U!AI&."I );:%P,*2.XO_ (AM_P (O<WNG>'/$?\
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MRCFNXY;1WTNX^=W&Q]SA2JJ-D?+8QDDG'0 S_P!IK_F5O^WO_P!HU] 5\_\
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M2.OH<>">!I-?T?XS:EXAN?#&N6VD:I+=^;)-I,[/''(QD3Y44_-N5 >HY/U
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M#[#A0J02(/W>/E.U>-IVC.TL!UKQ#P=XT\2_!R\_L+QAI-]_8TNYH4 5S$^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A^B^/].L/C7XF
M;QC)]@NTVZ;IDSQ,D<=N)2=K>F_,<F]N,9.57 /J'_"=^#_^AKT/_P &,/\
M\51XD\#^&O%WEG7-(@NY(\!9LM'( ,X7>A#;?F)VYQDYQFN?_P"%)?#S_H7O
M_)VX_P#CE %?7-4TOX@>(]!T?0+W[;_9&JPZI?7=LGF00)&C%%,F0K,[,% 4
MMC#D_=(KTBJ]C86>F6<=G86D%I:QYV0P1B-%R23A1P,DD_C5B@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQOXI>*ET;XF^$+77H9!X
M7@<7[2)$Q)N5+JK;AR1&2C%5YPQR&RHKV2L_6=#TOQ#ISV&KV$%[:MD[)DSM
M)!&Y3U5L$X88(SP: ,N#X@^#;FWBG3Q5HP21 ZB2]C1@",\JQ!4^Q ([UA^,
M?&WA_4_#U]X?T?4H-7U?5[2:TL[33I%G9G9-N6*G:BC=N)8CY58C.*/^%)?#
MS_H7O_)VX_\ CE=1X>\*Z%X4LS:Z'ID%E&WWR@)>3!)&YSEFQN.,DXS@<4 6
M-"TS^Q/#VF:3YWG?8;2*V\W;MW[$"[L9.,XSC)K0HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOF4EG+8('##'!% &Y5>_OK?3-.N;^\D\NUM8GFF?:3M102QP.3@ ]*L5Y/\
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M\97WPXTFYTGQW_9=B_G>79_V1#/Y>)G!^=CDY()YZ9QVK/\ VFO^96_[>_\
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M#%YOE))AOE7*\H#@'VYKO/BIXH\7^%?#5YJ6C6&FBTC=$:\>X9Y8U<;=WE%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB\DS*, LQ_$X&%!)P!DT 7/$>OV/A;P_>:UJ32"TM4#/Y:[F8DA54#U+$#G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#A_BCI-U/X+U?5-+U&^LM3L[3S8Y8=0GA0
M)&=[_(C;2Q0. 2O<<C (X_X=^#[SQ=X$TW7+_P <>,H[JZ\W>D&K$(-LKH,
MJ3T4=Z](\=_\D\\2_P#8*NO_ $4U<G\)-6TW1O@QH%QJFH6EC SSHLEU,L2E
MO/E. 6(&< G'L: .3;Q_XE^&/Q M_#?B[5_[5T)XHBM_):J)A$590X"-DX<$
M-OW,0A(&3S[Q7SAXHT__ (7)\9EM]&'FZ+IL45M>:A%)\AC#,SLK%<;B695
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!S_CO_DGGB7_L%77_ **:O,_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4452U:?3
M[;2KJ356@%AY;"?[0 8RA&"&!X((XQWH \@T#5;%?VI/$2?:8V-U9?98=GS!
MI4CA9TR,@$"*3.<8*D=>*]LKP.\^)GPDMKTP0>";6ZB!P9X]*MU4^X#8/\J]
MKT+7+#Q'I$&J:;-YMK,,J2,$>H([$4 :-%%% !1110 4444 %%%% !1110 4
M444 %<OX_P#&/_""^%WUK^S)]0VRI%Y<3;57<?O.V#M7C&<'+%1WR.HJ.>"&
MZMY;>XBCF@E0I)'(H974C!!!X((XQ0!Y?H7B<?%?Q9I5YI^G7<'AO0W>ZFDO
MH(R+B\*E8D4 G!179]P)Y(R =IKU2HX((;6WBM[>*.&") D<<:A510,  #@
M#C%24 <WXNMM7UK2[OP_IEK'&E_;F&?4;EAY443Y20*BG>\H4D@$*G/+\;3N
M6%C;Z9IUM86<?EVMK$D,*;B=J* %&3R< #K5BB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >2_'CPW>:OX9MM3L5=Y=.<NX3J$/4CZ8%<U\-OC
MC%!;1:1XKE?Y %BOB"<CT?O^/YU[\R*ZE64,I&"".#7C7C3X!V&L7,U_H-W]
MAN)#N-NZCRB?; R* /5['6]+U.W6>RU"VGB;HT<H-%_KFE:7 9[[4;6WB'5I
M)0!7RA?_  C\>:+,QBTR>4#_ ):6C[N/PJK:?#'QUJ\X!T:]R3CS+CY1^9H
M]-^)OQLT^YTNXT7PR[3M.I2:\P0JKW"^I/KTK@?@I9?;?B;8L1GR%>7],?UJ
MEXS^&NH>!M*LKG5+RW-S=.56WB))4 <DGIZ?G74?L\V9F\:W5R&8"&V.0,8.
M2!0!]&77A[1;Z^2]N])LI[I/NS2P*S#\2*T0 H    Z 4M% %74--LM6LY+/
M4+6*YMY!AHY5# _G7S1\2/A[>_#O6X?$'AYI4T_S T;J<FW?^Z?:OJ&J6K:7
M:ZUI=QIU[&'MYT*,"/7N/>@#F/AMX[M_''AU+@XCOX $N8O1O[P]C7:5\K:8
MU_\ !_XK"WNI)5TZ23:[<$2P,>&Z=1UX]*^IHI$FB22-@R. RD=P: 'T5GZS
MK-CH&ES:CJ,ZPVT*Y9CW]AZFOG37?V@?$,^M&31HXK;3T.%BEC#LX]2>WX4
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MX>T>VTRPCV00(%' RWN<=S0!;M;:&RM8K:WC6.&)0B(HP% X %3444 %%%%
M!7S9\:O$T_BGQ=;>$]+4RK;RA"$.=\QXQ^'3\Z]T\::^GAKPEJ&ILV'BB(C]
MW/ _6O#O@+H,NL^*K[Q+>EI#!G:[@'=(_4].N/YT >T^ O"<'@[PM;:;& 9L
M;YW'\3GK_A^%=/110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC->CWO[1VB1(19Z1>3/C@NP45VFO_"?PAXCO&N[S33'</RSV[F/<?4XK$C^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %(PRI'J,4M% 'RMX:\1K\.?B_J;:I&ZVSS2P3$#E5+9#@=QT_ U[;K7Q@\&
M:/IZW*ZK'>R.NY(;7YF/U_N_CS4GC?X6:!XW87%R);6_48%S!C)'HP/!'ZUP
MME^S;IT=P&OO$-S/"#]R*W6,X],DM_*@#SCQ/XO\2_%C7XK&RM9/(W8@LXLD
M+_M,?YD\5[U\,?AO;^!M+,D^R;5IP/.F ^Z/[J^U=%X:\':%X2M/L^CV$<&?
MOR'YI'^K'DUNT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45R?CS4
MO$VA^'[_ %K06TV9+*W\Y[2ZM69G"G+L)!*H "9.-I)VGGD </X*\:_$WQYH
MTVJ:7!X1A@BN&MV6Z2Y5BP56R-K,,8<=_6@#V2BO*]<^(GB_P#;VT_C#P[IM
MW9SW"QF_TB[953<"=GE2#<S@(S9R%.0,@YKTC2M5L=<TNWU/3+F.YL[A-\4J
M=&'\P0<@@\@@@X(H N445P?Q0^(R_#S2[":*UCN[R\N J0.S*#$N#(V0",X*
MJ,]W!P0I! .\HJ.">&ZMXKBWECF@E0/')&P974C(((X((YS1.)FMY5MY(XYR
MA$;R(756QP2H()&>V1GU% $E%>)^*?B1X^\.?$&T\)K;^'YWO7@6TNI+:6-9
M!*0@8J)F*@/N7U^7..16YK/B/XH>$].?6=6TCPYJFFV^3<PZ4\Z3*F#\^7R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+/G!<L>W7H.E %CX"^*%USP&-*EDD:\T=_)?>[.6B8EHSDC  &Y H)P(QT!
MKU2OESP-J"^!_C=''%I&I6.FZNYM8+?4+5HIXXIG'EX#.>%D55W$G*JQQG@?
M4= 'S_\ %/\ Y.%\%?\ ;C_Z5O7NFJZK8Z'I=QJ>IW,=M9VZ;Y97Z*/YDDX
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M.'Z%2R]#C=G!(%7/V>?$G]I^"[C0WCVR:1+\KA<!HY2SC)SRP829X QMZG-
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MG^'Y2&Y[$'I7N?B/0+'Q3X?O-%U)9#:72!7\MMK*00RL#ZA@#SD<<@CBJ?\
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M<Y &<UQ?PDGAU[2]6\8O+&^H:Y>LT\:L";:.+*0P-C@E4YW;5)#C.>#72?\
M"">#_P#H5-#_ /!=#_\ $U<TWPUH.C7#7&EZ)IMC.R%&DM;5(F*Y!P2H!QD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5Y^FE_$[4+.UU*;Q+I6EWPB#OI$6FB2!G!)"22EV?D85BG3G;G&2?#7XE?\
M";_;M.U'3_[,UO3MHN+9G^__  LRJ<,N'!!4YVY7YB30!L?$+Q9_PA7@N^UF
M-()+I-L=M#,^T22,0![M@98J.2%/(ZCB_P#A5VD>-OAS;:E=K)/XFU*R6^_M
M.>8AS<2QHP#;1CRAA4"[<*N=H!))S_VBH]2'A"UDEN[1M/.IQ"*!;9EE5O)D
MY:3S"&'WN @ZCGCGN/A]!KR^$/#<D^I::^G_ -F6Y$":>ZR[?)&T>89B,CC)
MV<X/ SP :'@32=>T/PG;:?XCU./4=0C=R;A7=R5+$@,[G+D9ZX&!@8XR>?\
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MLN [+&9-SC."'0;AM"X/!49^4 ]<HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,B#RQZ'D;&V\_P#"+5O$%GX<TKPG-X4U6PFMI9&FO[VV9(! 7:0D;MI,A+;
MHSC._D K6'H%_P")O 'Q2\6RW'@[6;_2=5O9)C-8VC2L!O=XF0CY&!$F",@C
M/4%2I ,SQW::C9_'GP:NJ:I_:-T\MI(9%MUA1%-X^U$49(4#'WF9CR2>PZ_]
MH[_DGFG_ /85C_\ 14M<QX\TWQK<?$[PUXJU'PM.]K;_ &:3[/I(:\>)8Y/,
M=)&  \S+'L%.0 3@FM?XNMK_ (E\ V&F2:#?/KJ:@MS<6MC93S10QE)=J^<$
MV.RJZ!BIQNW8XZ 'J'@3_DGGAK_L%6O_ **6H_'GA2'QGX.O]&<1B=TWVLCX
M_=S+RAS@D#/RD@9VLP'6J_PYU W/@K2;*:PU*QN["R@MYX;ZSD@(95V94L &
M!VD_*3@$9P3BNLH \?\ AM\0OLGPJU0:NFS4O"L30303GR2ZJ"(4)*@*Q*F+
M'+93)Y;%=YX$T2[T/PG;0ZGY;:M<N]YJ$BQHA>XE8N^[9P2N0F1P0HQ@8 \O
MF\!*O[2 %G=R06<]NNN742.REBLP^3G=O!G1'(.  3C!45[I0 5X7\<KR&#Q
MUX%.K6D8T6"X,LT\F)%D7S8_-0Q@$X554]]V_ '!KW2O._B_\/YO'?AJ$Z?Y
M?]K:>[2VP=B!*K#YX\YP"V%()[J!D D@ ]$KY_M?]!_:VG@L_P#1X9]WG1P_
M(LFZS\QMP'7+@,<]6YZUWGAKXCRMX:MD\0Z)X@@\01V[&2T&DS,]V8PH:2/:
M@7#%EX.T*6P>,$G@?PO?2^,=9\?ZO')9W>K)Y-KI[)M:&V&P(91DXE*QIE0<
M+SGDX4 P_P!H[_DGFG_]A6/_ -%2UZ!X$_Y)YX:_[!5K_P"BEKSOX]&]US0;
M30=(T76;^[BO5N)7M].E>)%$;#&_;AB?,'W<XVMG!&#VGP[U83^$M&TN;3M5
MLKZST^**:*]T^:$ QJJ'#LNPY(R &S@]!@@ '853DU*&+6;;2V63S[BWFN$8
M ;0L;1JP/.<YE7''8].]RO-_B%)XEM_'/A"[\+V']H75O%>R7%H;A85E@)@5
M@26 ZLI'7#!3@XH N>.?A-X<\</)>3I)9:LR!1>VYY;"D+O0\.!D>C84#< *
M\D^&]]X@^&/Q0B\'ZW)Y%AJ$NQT*L\<CL"(I8B/[S!5)QTR& *_+ZW)\7_"5
MBD*ZU)J6B7<B;_L>HZ;.DH7<0#A5((.TX()_/('/Z%H.K^./BE'XWU_09-+T
MO3[?RM,MKL 3R,KMM>2,Y*D%G;^'!\O:6P6(!S?[37_,K?\ ;W_[1KWR>>&U
MMY;BXECA@B0O))(P544#)))X  YS7D_Q]\(WWB/PUIU_I=E=WMYI]PRF"W7>
M?*D #-L W,0R1].@+$C'(W/[7UWQUX-UZ!/#5]I/F:5+;I!J"".2>Z>,C:A)
M&(UX&Y@-Q?\ AV$$ K^']4N/$6G3Q?#W2;'0-":5U.JSV87SGPREX+=<!L%8
M_GD([@J2I X3X21M#\??&$3S23NB7JM+(%#.1=)\QV@#)Z\ #T K3^%7B3Q9
MHGARW\*W'@753<12D6=Q-"]M!L=R[F:1U.S;EB"H;=PN,\G$\(Z7XZ\-?%?Q
M!=R^&9)]3U))XHKE8W&GK++*DGF-+_SR"AC@'>>%P&/ !;_::_YE;_M[_P#:
M->P>._\ DGGB7_L%77_HIJX/X^^$;[Q'X:TZ_P!+LKN]O-/N&4P6Z[SY4@ 9
MM@&YB&2/IT!8D8Y'6:#J]YXZTZ\@U7PU?:3IDEI]GN8-00QR3R.,.J$$,(U7
MC<0"Q?C;L((!R_P@\-6&H?"W1KJ:XU5)'\_(@U:ZA08GD'")(%'3L.>O6NDE
M^&W@JVUF#7KNRD.H1W$+QWEWJ-P[&4,JQY+R'<=VQ0#G/ ]J\<T^7QK\"=<O
MXI-.GU;PTV)'D166!\_*D@?#"*3.%*G.>G/R-7I_AC4O%/CO7(;_ %O0)] T
M+3OG2QN23)=W7\+,&0$QH#N' ^<*<L5^4 ](HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+_&/QHL_
M!7C3^PK_ $*^>U6)9'O$8 MN!(\M#@.N<*6W#D,,?+SZA5>:PL[B\MKR:T@D
MNK7=]GF>,%XMPPVUCRN1P<=: .7\!V^L7,6I>(_$%C]AU+5Y4:.T,KN;:U1<
M11L&X5LF1R !S(<@'Y5["BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS?XM7?B?PYX7NO$>@>(9[?
MR)8O-M988'C6-B$^3,18MO*GYFQC=["O2*\_^-O_ "2'7?\ MW_]*(Z .;\(
M1?$GQ?X(M?$%O\0([>>Y24QVLFD0%=R.R &0#(!*]=IQGH<58\*_%S4I/'DO
M@SQ?IMI9Z@+AX([JV9HXF8 ;!MDY(?!*MGYMR +SFMSX)?\ )(="_P"WC_TH
MDKS#Q9,GB+]IK2;?2;6!I+*[M4GDAD7]\8CYLCL>/F104())_=8ZX  /H^BN
M/\8?$"S\*ZMI&BQV_P!LU?5I4BMH/.$:)ND5 TK<LJG<<$(V=C#M7-^)?'WC
M+P#<0:CXGT?1KG0;JX,"_P!EW$AGMR3N7<9  YV!^BJ"5Y*\ @'JE%5_M]G_
M &=_:/VN#[#Y7G_:?,'E^7C=OW=-N.<],5P^B^-]8\=Q:M/X1M;&WL+*4PV^
MH:D7<7<@4';Y*E6C7YE.\DG!'R$DA0#T"BO+X/C'Y>N:CH-_X/UQM7L975X-
M+B^UAHQ@"0$A&VG((.W&"ISSBNTU'Q58Z3X:M]:OX;N 7"1^39-%_I4DKC*P
M+'U,I/&WL0<D $T ;E%>9Z_XJ^(WAVR;Q!=>&M&FT>- ]QI]M=2/=P*4Y+2;
M=A"MU*JV![ N.H\#>,['QUX:CUBQCDA(<PW$#\F&4 $KG&&&&!!'4$9 .0 #
MI*IZE/?06Z_V=91W=P[A0LL_DQH,$EG;#$#C VJQR1P!EA<HH \G\%>.?%.N
M?%_6_#^MQ06=KI]I+LLX8SC<LR!9-[ ,V4?@_*I!!VC->L5X_P"'O^3H?%G_
M &"H_P#T&UKV"@ HHK'\3^)]+\(Z'-J^KS^5;Q\*J\O*YZ(@[L<'\B20 2 #
M8HKSO5?$'Q&T>RN-?N="\/G2;:W^T3::E[(;M%"98>;M\LE3EC@'(! R<$]9
MX8\3Z7XNT.'5](G\VWDX96X>)QU1QV89'Y@@D$$@'+^.?$EY)XHT/P)H]U]E
MOM8W27=VK%9+>U4$MY1VD"1@D@5N=I7H,AAGW7A;QCX;\?:1?^&]6U75=$N9
M3'J5IJ=]YR6L1=<E-[ACA2=N,L-G)8,17-Z[/KQ_:-\,22Z;IJZ@-,<10+J#
MM$R[;CEI/)!4_>X"'H.>>/:--DU*6W9M4M+2VGWD*EK<M.I7 Y+-&A!SGC'8
M<\\ %RL_4[G5(?*32M.@NY&R7:YNO(C0#'&0CL6.> %Q@-D@X#:%% 'E?P@\
M;^(_&6J>)U\0+' ]D]NB6:0>4+=CY@<8.7SE!D,3@YQCI7JE>/\ P@_Y*'\3
MO^PJ/_1MQ7L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF-T(&X%0ZY5BW<9)PU 'OE%>?_%KQIK'@3P]9:MI*6,OFW8MI(KN%WSN1F#
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MF!)R"MSP)\4KS4/'-[X'UY8);ZUEGMX-0A0Q_:FA.#NC&0K$+(Y(8+Q@#ID
M]8HKQ?XJ_%?Q)X"\6QZ986^E7%K-:)<H9X)-Z99E*DB0 \H3G ZX[9.7\2/'
M?Q(\&WNB:A/=:;9P7Z._]EPPB41E'!,<DC#+':Z LA49#8 P&8 ]\HK/T+4_
M[;\/:9JWD^3]NM(KGRMV[9O0-MS@9QG&<"M"@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*]/U71M-T75-<UF]TG3GB:&SD-NBXC4JJEDB5R-I(^]GGKGF@#B_AY:WEO\
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MKFLPB[0+,KFW<,0K!&YBR"I<D=B<9!'%5_"GP>T;P9K(U31M8UF.<IY<BR/
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MXSM)!&"!@@@@\'J 1A^&/A!X?\+WD,T-YJM[#!+]HAM+VX5X(Y\8$PC55'F
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR%89Z=, =!I'A[3-">[EL()!/=NKW$\\\D\LI5=J[I)&9B !@#.!SCJ:U**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ>QN1)#'\K"!,<&20'G)(5#EE.],]9!!#:V\5O;Q1PP1($CCC4*J*!@  <
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MVXX&17M%>/\ P@_Y*'\3O^PJ/_1MQ7L% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2\C"HYCC$0(W L-S8/R[3AAA_$/X>W'B6ST.X\.W<&F:GH,HDT]70"!1E."
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex34-certificateofdesignatio.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex34-certificateofdesignatio.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" SD"?8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMXVDU*4L51RH)P0,X'H*]C^'?@^\\7>!--UR_P#''C*.ZNO-WI!JQ"#;*Z#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_M:OH"@#Q_]H[_DGFG_ /85C_\ 14M>0?!+_DKVA?\ ;Q_Z3R5Z_P#M'?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7B?Q0^'GB;QG\2[2\T)X[-++3(6%]-(T2K*)I2%1E!.\<-P..
M,D9&?;** /+]/\:^.?#N++QCX-OM1QN2+4-!C%QYVW:,O&#\N[YFR=O4 (,'
M&/XNG\<_%+3FT/1O#,^B:)+*!<7>LD0R2;0KJ#'@LJ[QU4-D@<J PKVBB@#F
M_ W@RQ\"^&H]'L9))B7,UQ._!FE( +8SA1A0 !T &23DGI*** /%_BUIGC?Q
MYIUEI.D^$)X+&&47,DMW>6PD:0!E"@+*0% 8G).22.F/FXSP#\-_'OA#QOIF
MNW'A:2X@MG<21QWUL&VNC(2,R8) ;..,XQD9S7TW10!3TV]GOK=I;C3+O3W#
ME1%=-$S$8'S#RW<8YQUSP>.F>?\ '.I>+;;2Y+7PAH4EYJ$J +>/- D4&<@G
M:[@LXP,#;M^8$DX*GK** /&_A-IWC'P'HUUI&J>#+N:"6X>Z6XM;^U9@Q5%V
M%&D48PA.[=Z#'>O9*** /%_B[X?\1^/].TR'3/!=]'=6DKN;B[O;5-J, "@5
M9F#;B%.3C&P8SN-<1X+^'WQ/\%>*+76K/PYYOE92: ZA"BS1L,,I(D^A&<@,
M%.#C%?3]% %>QN);NSCGFLI[*1LY@G*%TP2.2C,O/7@GKZ\53UO4M0TZWW:=
MH5WJT[(Y5(9H8E5@/E#M(ZD D]5#8P>.F=2B@#Y,U;X2?$G6=9OM4N/#D:SW
MMQ)<2+'>0!0SL6(&9"<9/J:]K^%\7B/PQX0T[P[J_A2^BDMY73[3#=6LD>QY
M"^]OWH88WD$ -PN1DG ](HH *\?^+6F>+/'?AZRTG2?"%]%Y5V+F26[O+1,;
M490H"RMG.\G)(Q@=<\>P44 ?+G@_X;_$GP?XLL->@\+1W#VCL3"]]  ZLI1A
MD2<':QP><''!Z5Z_/XL^)+6\JV_PSCCG*$1O)KD#JK8X)48)&>V1GU%>B44
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MK,-U:/&PAN((8WW!E,;,\BNN1U95. >,GBN@HH ^0/\ A27Q#_Z%[_R=M_\
MXY7T?\/[SQ4=#MM.\5Z'/:WUK$(S>FZBF2X"X"EB)&?S",YR"#@G(SM'844
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@I>]24+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M [2"#6QX8\,7'CR\A\:^-8()X9HLZ1HS8E@M8'&0[@\/(PP>1QP2 0JQ^H4
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M\I,#)P.-S$;CU[#)"B@#TS6OCIK_ (HU2'0_ .DR0SW+A(IIT62=S\IX3E$
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M\6Z1HWB:>QN+?6\Q65U8VLD)CG5E&R1&=\JV] &!X.<C'S  [BBO-_B3XO\
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M"JO+RN>B(.['!_(DD $@ V**X/6-:\9:5X5U+Q%?R>'])2VMS/'82QR7+9"
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M_#_C'PYX&\+Z1X72VU6XU>&T4C3;;3+KSKAR297C$J+E=WF-SC@' XQ0!8\
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MWJ5!.*V/"7B3QOK'C'4K/7O"T>C:3;6ZM&Y<R,93MPHE!V2#&\G:OR\ G/4
M[RO*_C7?:Y9:7I5MX?UV[M=0U2]BLHK*"6*(RYW'>KX$BG=Y:DAPN" 1SSTF
MG^*;SQ=>7Z>%9;%--L91 ^JW*&=)Y@,M''$KH2H#*?,+8/158?,.#@FUKQ/^
MT#8:5K8TV5/"]O+<,(HR(Y2X!21%8$J_[RWRI8A3&2I]0#UB<S:!X5E:WCN]
M4GT^R)C21R\]TT:< L 278CKCDGI67X UKQ!K_A=+[Q+HW]E7YE=!#M9-Z \
M/L8ED[C!/.W=T85S_P 5?&GB3P+I,>KV":5):R7:6J03PR2.V8V<N6#J%Y4K
MMP>F=W.T=IJ4^I6.C+.DNFF>% ]U/=,T$ 55+.1]XJ"1C))V!BQW[=K &I17
MF?@SX@^(]>\'66HW6BVEQJFI7KQ6-M;2^3&;=,!YY"Q=D16W@G!.2@ ^<$V/
MAKXUU[Q1K/B?2]>@TV.?1;A+?=8(X5VW2JQ^=B2,QC' ZT >B45Y_%X\O_$G
MCF^\,>%K>"./2\_;]4O89)(T<$J8DC4KEMV,$N,A), @ G/\4>/_ !3X(\0Z
M;I-YI%CKO]K[8[&6T8V/[[?M:,AWES]Z([B5'S'KS@ ]0HKC];\9:CX<^'$_
MB?5M ^SWT&WS--^V*^W=,(Q^]52#P0W ]JIZGK7C+2?"::Q%)X?UJ>X2"."W
MM(Y(4,LS*D;+*TC"1-SKP1'N!SN7&" =Y1110!X_\9?$OB?PI>:1_P (YK=\
M+K5)7CCL%LH)D^4(/D)3?N+,/E.[.XX*X /20>%OB##<12O\28YT1PS12:#"
M%< _=.UP<'IP0?0BN;UC_BL/VB=+TE_FL?#-I]MDBE^7,QVL&0KRW+VYPQ ^
M1N/[WL% 'G?ACXAZE)XQ?P9XNTJ/3]<V,]M/:EFM[Q1N;*9Y4;5R"2<E6!VL
M-M>B5\__ !3_ .3A?!7_ &X_^E;UZ9\2/$6O>$_#%YKNEC33!9I&6CNHGD:9
MGD"8&UE"!00<_-NR1A<98 /AYXF\3>)K?4Y_$7AN314BN-MH)%9&=",[2K\D
MKQ\^ &W< ;37:5P\NM^,+GX:V.O:3#I5QJ<NGB_DB:"8J^5#B&.-6+%MI(W%
MCEE V_/E+GPW\5S>,_!%GK-V;07CO(EQ':YVQLKD $$D@[=C8)_B!Z$4 =97
M%^/?$WB;P_<:)!X:\-R:R]Y<%;DA6VQ("HVEAPA;=P['"[3D'M'X7\4^(-6\
M4>,]&O[&QCDT:6,6**S)YJ2"1HS(^7QE5C.0O&3QGBL_0?&/B2[^+FI^#;^3
M2I+73K07+SP6<D;RY6,A0#*P7!E'/.=O;.0 >D45Q>M>*]27X@V7@[2SIMK/
M/9?;FO+[=)N4%U\J.)2A9\J&SO&%#''%7-,U;Q WC*70M0MK&6UMM/%U+J%M
MN3S'DD*Q+Y3,2G$<V?F?.U3E<[: +GC#5M2T/PG?ZCH^F2:EJ$2*(+5$9R[,
MP7.U1DA<[B!U"GD=1)X5U#5-5\+Z=?:UIW]G:E-$&GM<_<.>#@\KD8;:>5S@
M\@UQ?C?QEXJ\,^*O#NF6YT;R-=O6M8Q);2R-;J'C0.6$BAR1)NV[5Q]W+?>/
M6>,?&.E^!]#_ +6U;SVA:588XX$W/(YR<#) ' 8\D=/7 (!T%%<O_P 5Q=Z=
M]KBDT/3KIXMZZ=<6TMQY3XX1YTE4'GJ5CXS@;L9)X.\:6_CCPE_;.DP;;A=T
M4EK.Y41SA0=A<*<KRIW '@],Y4 '445YGI'Q!UI_&/BBPU*WTVXTG0;=0T^F
MY:6>Y;:$B4,_+NPD41@$JX";B>6CM_'GBR/XKZ-X6U?2]*LK74[0W7E0R/--
M"!'(=K2?*I;?&<X4C!X)ZT >H4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 445'//#:V\MQ<2QPP1(7DDD8*J*!DDD\  <YH ^
M6/C_ *W-J/Q(?3F\Q8-+MXXD4R%E9G42,X7HI(=5/7.P<]AU?P]\&_$*U^'5
MC>^%O$\&F_VA*UR]A>V*@*#E1()"KL=RI&0-H&&SGU\4GDOO%GBJ65(8VU#5
MKTLL49VJ997^Z-QX&YL<GZFON.PL;?3-.MK"SC\NUM8DAA3<3M10 HR>3@ =
M: /E#PM<>&O#GBV]M/B9H%]<ZF+L/)<SS-((GW Y>,8\Q6R7+$ON&W"G))^K
M[#['_9UM_9WD?8?*3[/]GQY?EX&W9CC;C&,<8KY ^,%];ZA\5]?FM9/,C65(
M2=I&'CC2-QSZ,K#WQQQ7T'\#C,?A)I ECC5 \XB*N6++YS\L,#:=VX8&> #G
MG  /1*XOQ?XJOK?6;'PEX=AD?7M102-<>5OCT^VW;6N&!P&(P=JYP2.>JJUS
MQOXIN/#>G6T.E6/]HZ[J,OV?3[(,!O?!)=AD'RT RQ'3(R5!W#E],^$5P/-U
M+5?&GB--=OL2:A-IEZ((Y'&< #9G:H.T9[= H^4 &?\ $_1M"\#? N[T+3T\
MB.>6"*(L"SW$WF*[,[ ?>*QL<G ^4 8&!7 ?LX_\E#U#_L%2?^C8JV/C7X+_
M .$<\&V=Y_PDWB/5-^H)%Y.IW_GQKF.0[@NT8;C&?0GUK+_9OA9O'6IS@Q[$
MTQD(,BALM+&1A<Y(^4Y(&!QG&1D ^FZ\#_:3U]1;Z-X<C:,NSF^G4JVY0 4C
M(/3!S+D<GY1T[^^5\>?&/7V\0?$W56W2>18O]AA5U52HC)#CCJ#)YA!/.".G
M0 &A\.;_ ,3>$/"?B#QIH]CHTMG \5K++?*S2Y+#*1;""!F2,MD@'"XR0:CM
M]1U3XV_$"ST_7-4^P-)$ZVB6UMYD,)5=[#87!&X*26RQR%'3&WV_X?>$_P#B
MQMOHK/!;S:OI\SR3PIN_X^%8JS#C<P1D!_W<9P :^7-)O)O#7BJQO;BTD\_3
M+V.62VDS&VZ-P2AR,J<KCIQZ4 ?8?@[X?^'_  /9^5I-KNN&W"2]G"M/("0=
MI< 87A?E  XSC.2>HJ.">&ZMXKBWECF@E0/')&P974C(((X((YS7%_%[6?[$
M^%^M2J\ FN8A9QI,?O\ FD(P49&6"%V'^[G! - 'RAKFIWGB[Q;>ZB(9Y+K4
MKMFB@#&9QN;"1J<9; VJ !V  [5[GXM\#?%#3O!TNE:7XHCU;18+)86LXK1;
M>X>->/+0*I+#:!GY\L,K@YPWFGP6T3^V_BAI>^W\ZWL=U[+\^W9L'R-U!.)#
M'P,^XQFOK>_OK?3-.N;^\D\NUM8GFF?:3M102QP.3@ ]* /GCX,:M\.CJ-A8
MWFB?9O$?W8;V]E\Z.:3*LI3.%CDW9"@+D!0-Y9N?H^O@"OON S-;Q-<1QQSE
M 9$C<NJMCD!B 2,]\#/H* )*\WU&Z_X69XAOO"T5O.OA;3)=FK7>S;]LN(W!
M%JA."J@C<S+R=H *A@S6/&.LZ[K6N?\ "$^$W^S731++JFK@@C3X6SA5 .?.
M8 D#@X((ZETKV/P=L],LX[.P\9>,K2UCSLA@U,1HN22<*$P,DD_C0!YY^TA-
M8PW'AC1[01Q/9V\S_9XX]JQQ,46/&!C'[MQ@=-O;BNK_ &<?^2>:A_V%9/\
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M!>V\EO(T9 8*ZE21D$9P?0UGZIXKTW2O$&E:"QDGU34G/DVT.TLD8!+2ON(
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M['@ *">2>@ Y/M713I*W/4=D<U;$*/NPU8+;ZEXIUZ?4;@)+J,YWR%2$2,9
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MKLL19'QR49^=O1D*Y!!Q<AT;Q3?_ &<ZUXC@@A\HBXM='M##YC';D&:1G?:
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M[:=HYNY^&=W:_$&Y\7>&_$$>D3W:!;JV?3DGCEY4O_$I <HI./FSN.[G@ ]
MFGAMD#SRQQ(75 SL%!9F"J.>Y8@ =R0*\;^*D3^*_BKX-\%.O^@G-]<J\[*D
MZ9;<I"CA@D,@!S_RTQ\O)KTBQ\/7CZG'J6O:K_:-U;RF2RC@A-M!;9C,;8C#
ML78AF^9V;&[Y0O.:_BCP7;^(-1TW6;6?^S]=TR57MKY4+90'+12*&4O&P+#&
MX8W'!P6! .@O[ZWTS3KF_O)/+M;6)YIGVD[44$L<#DX /2O(_@P)K7P_XH\?
MZW)';P:O<27CK&A*I'$9&=Q@LV-SN-I&?D[Y%=AK7@K4O%B0V?B;7HYM)C<2
M266FVC6@N6#*5$KM+(2@P?E7;R0<Y48V/$?A]M7\'7GA_3;J/2DGMQ:I)';J
MZQ1<!D"9 P4RO&,9R.E 'F_P2T*;4DU#QUJ<4:7&J7L\T,<>=ARV#)@LV"K&
M5%X# /)DL'&-SXX^(;C0/AK<I:K^\U*46!?(^1'5B_!!SE49>V-V0<BNT\-Z
M)#X<\-:;HT'EE+.W2(ND8C$C ?,^T="S98\GDGDUC_$/P/#X_P##2Z3+?263
MQW"7$4RQAP& 9<,N1D;6;H1S@]L$ N6%M9^!/ UM:[?-ATRT2/%O$$>YD  ^
M1,\R2.>%SDL^,DFN+^"CMK5OXE\83O)]HUK4V_=-<K-Y448_=IQR"/,9<-CY
M50@ $9W+;P'J,WAF\TO7_$\^LW4EI+:6EU-;*@M5>(QE]@.9),$Y=F+8) (W
M/ND\"> 6\(:7;65[K$FK"R=S8AK=84M@^2Q5022Y+/\ .Q) 8JNT%MP!R_C:
M>;Q-\:?"'ABTED$&E.-5O&B8R*K*=RK(@X4X0 ,3_P MQQS\W0?&/7U\/_#+
M56W1^??)]AA5U9@QD!#CCH1'YA!/&0.O0QR_#6X?XF7_ (NA\1SVL-_$L%S9
MP6X5WB"(I43;LIDQJ=R@,.@(/-7/%WP^A\4W'AM%O([32]&N!*^FBV#P7*J4
MVH5W!0 JLHX. YX[$ K^#-"A^&_PY>[OXI#<6]E]JO8X\,T>R,LT2$L> WF-
MC=M+R.PVAL#/^!]DS>")O$%U+'/J&NWL]Y<3"%4;(<IM)'4;E=AT WD =SUG
MC;PQ_P )CX0OM ^V?8_M7E_O_*\S;MD5_NY&<[<=>]<^/L'PG\%PZEXAU.?5
MIK*)+&"411QOY60%BACW #@!F.2S;,DD*H4 Y/X?Z/=_"WQCXAT>;2M2U"VU
M!XFL)K%4GQ$OF[/.P5,18L$#,%0LKG(52PU$\$Z[XO\ BK:^,/$>GP:7INEX
MCLK%IA)/+Y9+1NYC8J/G<MPQ^X%((.XQW'P_\?V6J:KKWASQ3:6.H:Q<+)=V
MER/M"(J[MH6=H\D+G 7RUP#C)V@G0\/>./%]OX\A\+>-=#M+9[])&T^\T_=Y
M4GEABV2S'(*KGLRY7*_-D '8>(--TCQ98:EX5U!I&$EO').D9*LBL[>6X;&,
M[HF..?N\C!Y\W^&VI:OHGBJ[^&?BE8[F"S3[1I-S=@!I8XW!C" DAA@;UP24
M\MA_#A>P7P=K5CXWUKQ'I/B"T@35DA6:SNM-,R@Q(%5@RRH<\-[?,<@X!&AI
M'A>:V\2W?B/5[^._U::W6SB:"W,$4%N#NV*F]B27RQ9F)Z 8 Y .DJ.>>&UM
MY;BXECA@B0O))(P544#)))X  YS4E<WXNT+6O$>EW>EV&M6FG6=W;F"8M8&>
M7#9#;6\U5 *G;]TD<D'., 'G_P "H(=7N/%GC-HHXY]3U.1$B*AF@7/FL!)P
M2"95!&!_JP?I[!//#:V\MQ<2QPP1(7DDD8*J*!DDD\  <YKA_"7@SQ-X.\/Q
M:+9>)]-N+2%V:+[5H[%D#'<5!6X7(W$GG)Y/., !^'5WK5ND'C+Q7J6NP([$
MVD2)8V\JD# D2+YG(90P);@@<=<@'G_AJ";XJ_&F?Q9)%(WAW17"64A4A9&C
M.8@#\K9+,9B"#C(5N"*Z#XUSS:U<>&O ME+(L^L7JO<M"Q=HX5.,O$.63+%\
MD@?N3Z9'K$$$-K;Q6]O%'#!$@2..-0JHH&  !P !QBN'\2_#N[USX@Z7XMLO
M$4FF3V-N+?9':)*S+F3<0SDJ"5D(Y5L=>: .\KQ/X(WDV@?#35UDM)'U)=8F
M@@L'S')-<"&/$7(RIRIR2,* S-@*2/9+&QM].LX[6UC\N%,D L6)))+,S')9
MB226)))))))KG_#'@72_#.K:QJ\0\_4]5NYIYKEUP41Y"XB7T49&?[Q&3T4*
M 7-#TY?#VC7-UJ5S&+NX=K[4[AYV,0E*C>5+_=B15"J#C"(N><D\'\$_MFL?
M\)1XRO//3^W-0_<PS9;9''NV[9#]]1YAC&  /*Q[#TC7=,_MOP]J>D^=Y/VZ
MTEMO-V[MF]"N[&1G&<XR*XO0OA<VE>"KKP[>Z])J -O<6]C(UJL:68F5@S*@
M;+/EW^9FR 2J[0S;@#/^)'AJ;Q%I>G>/_!UQ=_V]8V\<UFUN#FYMV^;;L;'.
MUV.,98%D*MD8ZCX>>)8?&?A.U\1-;VD.H3IY%X("&*M&S84GJ!\Q<*<X$G?.
M37TKPSXOT?PU;Z);>*]-*6UO]GAN7T5C*B@84_Z_82HP!E3G SGG/0>'- L?
M"WA^ST735D%I:H53S&W,Q)+,Q/J6)/&!SP .* /-X9YO%?[1I>"63^S_  O9
M,A9&,L3S2*58<<1O^\((Y)\@CM\M/4HG\7_M*VEA.O\ H/AJT6Y,3SMAWPKK
M(J@<-OEBR.XBY)^[72:)\+FTKQ5K^ISZ])<Z9K5P]Q=:8MJJ+(2[,JN^XED&
M]@5&T/G#97*G8U?P2MQXLM/%6C7<>F:U$C0W$C0M)%>1%<!945T+%3M(.[^$
M9!PNT T/&.OKX6\':KK3-&'M;=FB\Q696E/RQJ0O."Y4=NO4=:XOX.Z9_P (
M;\)3J6K3>5#<^9JLGR[O*A*+@_*3NRB!^!GYL8R*W+_P)-XEU2SNO%NJQZE:
M6+B2WTVUM3;VK2?-EY59Y#(>1@;@  1@AF!V/&&@3>*?"=_HD&HR:>]XBH;E
M%+%5W L,!ER&4%2,]&/7I0!YO\$M"FU)-0\=:G%&EQJE[/-#''G8<M@R8+-@
MJQE1> P#R9+!QBYX2E3Q7\<O%>MR-OCT*)-+M(IH%W1DLP=E8'CYDEP>I67'
M XKT3PWHD/ASPUINC0>64L[=(BZ1B,2,!\S[1T+-ECR>2>37'^ ?A<W@RWDM
M+O7I-4L?M"W<-I]E6&-)P /,;YF+D;4*@G:I7=@L%*@'HE%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[E!Z,Y/R]UP>HKG/@Q8ZSX.\:S7NM>&O$$%I/926_G+I4[A&+(X+!5)Q\A'
M/)';)'TW10!R?B[QE+H-E=Q:;HNLZGJBH5ACMM+FEB#E"59GP%*9V@[6)YQC
M@X^4)_!?C:ZN);BX\->()IY7+R226$S,[$Y))*Y))YS7VW10!EZ)KL&N6_FP
MVFI6KJB-)%?V,MNR%A]WYU 8C!!VE@/7D9^9/BC\._$$'Q%U>;2]"U6]L;R7
M[7'/#;M,"9/F<90<8<N #S@#KD$_5]% 'F_PT\5W2^$K#2-<\/ZYIU]IUH(B
MSZ3/Y4J1JVW:0&^;8BY!QECA0<XKA/C5J?B'QD]GH^A>&/$$NEVK^?).VES*
M)Y2N%VAD# *"PYQDL>. 3]!T4 ?-GP@EU+P#<:M<:OX&\3SSW21)!):Z2S,B
M@L7!+;2 24.!UVC/05I^.O$GCWXB69\,Z1X%U73K&>4F26\A*&=$.Y 6=52+
ME02-QR< 'J&^@** / _AA\#K[3=9M=>\5>7$]JXFMK&*7<PE5CM:1EXP,!@%
M)SD9(P5/>?$CQGK>B:=+8>%M!U74-7D^3[1%ITLD-L" =^[;MD;G@#(!!W=-
MK>@44 >7_!6(67AR6WO]&U6R\0SRR3ZC<W]E,ANCO)5O-<8;AP-N0<[SCDL?
M2+Z]BT^SDNIDG>-,9$$#S.<D#A$!8]>PXZ]*L44 ?+'Q8M?$_C;QS-?V/A37
M#86\2VMJYTN9&D1226(([LS8Z?+MR <UW_P-GNO#7AG4-(UK1-<LK@W;W:-)
MI<Y1T\I<@$*?F'EG@XSN4+DG%>T44 >#_&77=?\ %>G0:#X=\-^(Y+$2^;=S
MMI<\:SX **H(!*@EB0RCYE4CIFN<^#%CK/@[QK->ZUX:\006D]E);^<NE3N$
M8LC@L%4G'R$< \D=LD?3=% '+^.-&_X3#X=:IIUNDYDN[3S;>,CR7:1<21JP
M<#;EE4$-@C)Z'I\T>!](\8>$?&FEZX?"&N21VLO[U!ILQ)C8%'VC ^;:S8R<
M9QGBOK^B@#@]?^(EQ:^&FNM#\,>(+W5I$ BLYM(N4$3$9S(VS!"]PK')P <'
M<.7^#)O4O]7O/%.BZS%XHU&X).H7FG2JLD.P$('V[8P"IX^4'Y ,X 'LE% $
M<\RVUO+.XD*1H781QL[$ 9X502Q]@"3VKYT^-<FO^-M<T^#1O#&N3:;I\3;9
MSI,Z&223!? 9<[0%0#(!SNZC!KZ/HH ^?_@-!J?A74=7L]:\/ZY9_P!H_9Q!
M,^F3>6&4N"&8+\O^L!R?E !R1QGZ HHH CGF6VMY9W$A2-"[".-G8@#/"J"6
M/L 2>U>%_&77=?\ %>G0:#X=\-^(Y+$2^;=SMI<\:SX **H(!*@EB0RCYE4C
MIFO>** /F#X.Z5J?A3QR=1U_PKKD=N;22**?^R)I/(D)4[L!"PRH9<J"?FQT
M)->I_&"^EU/X>7.CZ9I.LWUYJ*021);Z;,P1/,5\N=N%.$(VGY@2,J!R/3**
M /CCPKHOCCPIXHT[7+7PEKCR6DH<I_9\H\Q",.F2AQN4L,XXSD<UZO\ &M=8
M\7^ =/U/2;*^CTVRE:?4;.[LW@GC;8-K[74$J@9PQ4E?FSR%)7W"B@#YT_9R
MTK6H=>U#4VMKN+19[(H)6RL4THD&W;GAR LHR,[<D'&>?HNBB@ K/US1K/Q#
MH=[I%^F^UNXFB? !*YZ,N00&!P0<<$ UH44 ?*&K?"SQ[\/]<@U/1(I[[R9<
MVUYIB&1P?FP'BP6&5'S##)\VW)SBN_\ #O[1=G?>7:ZMX=OOMS^7'&-,Q/Y\
MAX.$8J5R<84%CSC/'/N%% 'F=A)XO^)">3KFC2>&?#+H/M%L9F-W?89@8B<*
M8HC@;OE#$< D.2.TU/5K+PQIT4::=?2QI$1;VNF:?)-P@&$ C4JG8#<5'O@'
M&Q10!\B>/-/\;>,_&-_K+^%?$ @=]EK&^GS?NX5X08P0#CYB <;F8CK7I?PS
M\57G@WP7!HU_\/O%8NHI9'>:STHL)]QR&;.T[@,+WX1>>P]PHH \3\0_%7Q]
M<V\]OX?^'6LV;EV6.[NK.65@F" PC" *_P!T\E@,$8;K4?P7\+Z[=>*-:\8^
M+[&^34VQ%;R7\01F9A^\958!EPH15(PNUF4=,#W"B@ KYP^('P4UW2]<N?$'
M@\>=:^:;I+:V(BGM6Y<^6!@%5(&T+\W( 4XR?H^B@#RO1/CAH:V_V3QA!=^'
M]:@1!<V\UI*59B,Y0 %@,;6PP&-P +8S7E'Q#&O?%'QJNJ>'M U*ZTG8EE8W
M:V;JDRJS9=G/R@;V?DE< #(!!KZKHH X/X6>')O!/PWAM]2L9+:_WS7-['&3
M.S-N(! 0MD^6J#:O7'3)->=_$/Q'XG\6^(;33(_"/B,^#[>[C:[CCTZ9)-01
M7!8G@$+@':N1SAC@X"_0%% %/2I;2;2[=K"WDM[14V10O;/;E%7Y0/+=5*@8
MX&!QC'&*Q_%WBB7P_I=W]@TS4M0U3[.7M8;;3IIT9SD+N=!M !Y(W X''49Z
M2B@#X@_X03QA_P!"IKG_ (+IO_B:^S]&U>+6].2\BM;ZUS@-#?6KV\B-@$@J
MX&<9QE<KD'!.*T** .?\=_\ )//$O_8*NO\ T4U>?_!3X8_\(WIP\0:Y8^7K
M=QG[.DIRUK"0/X<?+(W.>I"X'RDL*]@HH **** /G#XUZ;X@\8?$ VFBZ3JM
M[:Z5:"*0I"S0K*5,S[2.-Q1HQCAF(  /RYZ_0_C'>:/H=DOC[PYKFGW1E6W?
M4#IY2"3/1VS@AL!B54'[I('.T>P44 ?.'CSQ]JGQ:LX/#_@S0M5DL1+&]Y(T
M>"7)(1'V,46/(W9<\E0>-F3W_P (?A;_ ,(/9OJNIMOUV[B\N1$?*6T9(;RQ
MCAFR 2W3C"\9+>H44 >/_%CQ7JVK^%YM"\+^'_$<\EYM%Q=#2;B)%BR=R D*
MVXX4'Y2I5F&<]/*/AUX<UO0/B!H^J:UX1UQ["WE)D/\ 94LFPE6"OMV_PL5;
MCD;<@$XKZWHH XOQQKD<_P /M22STW6;N?4K*XM[:"'2YS)N8&/+J4!C +9^
M;&0"5W5\N6'A+QQIFHVU_9^&-<CNK65)H7_LV4[74@J<%<'! ZU]KT4 <?8_
M$"&?0X[V[\/>([6^\HO)IXT>Y=PXS\BN(]AR1P21U&=O('SIX\T_QMXS\8W^
MLOX5\0"!WV6L;Z?-^[A7A!C! ./F(!QN9B.M?7=% 'A_PS\57G@WP7!HU_\
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M+S9V&E:0+V74(_ML<FO0H)098@RAL'Y4R3\P)0?=!4C KC[VZNKJ<O>R227
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MRKK8_!NG0JJ)<7FT#[I9/_B:GGF_AC]X<U-:MGDOB_Q-;^)]2^VP1"VC<EC
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M54CS(LT445F:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV- &I15.VU;3;VWMKBTU"TG@NG*6\D4RLLS ,2$(.&(".2!_=/H:N4 %%%%
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M?;.>H/\ CZT@.<;2>N1FE'; Z#'X5LH1BK)&#G*6K%]/K2@4#UIP].U)L$A
M*7;3@*<%J7)&BB,VT!3GCK4NVE"X-1S(?*021I)&T4B*\<B_,K+E2*YS5?!.
MG:FRLH2(+G;$85>)2<<[.,'CKGN?6NIV#&.U(RY !Y [5+49JS147*.J/"]:
M^'EYH[A([G,)(Q+,3Y8SG@R8&#D=,=^O-6KOXC33^$W\/RZ':0D(82)(CE4
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MC'3O4]LT<.DB4+=C29GV.N0SPR]<AN%Y"@= <,1];/AY$D\%Z^LW$:LK(?\
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MR8((B4E2Q]P!EF537\*^&H?#&ERVZW$EU=W5P]Y?73@*;BX?&]]HX0'  4<
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MS?P?YOB'XJ^+O$LGGBUT_;H5F'V ?(0TX(')PX# D]']L+Z10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7)_$O7[[PO\/-7UC3&C6\@2-8G==P0O(J;L="0&)&<C
M(&01Q765E^(] L?%/A^\T74ED-I=(%?RVVLI!#*P/J& /.1QR".* .#^&G@+
MPM<^"[#6+ZRL=<U+4XA<W=[=H+@M(Q9BOSE@&4L48C!)7)YZ5T^'D6B_%#PU
M!IE[.?#T,5S?#1[J=Y8;>2(*@>(,3\Q>X5N>00Q!Y '*:!K^M?!#Q*OACQ.T
MEUX7N7+6=ZBDB($\N@Y.,GYX^2"=RYS\_O</V.\^SZC!Y$^Z(^1<IALQOM8[
M6'\+;5/'!P/04 6**\_\0^,=4O\ QH/ _A+R(]32+SM1U"Z3<EE$0,%$R/,D
M^=".J\@'.6*<_P#$S6->\!?V3<:1XFU74M7U&[2%-/N[>&2.>),D@+'"N&+2
M(ORD,P8==HV@'L%%<WXS\9V/@W2TGGCDNK^Y?R;#3X.9;J4X 50 3C)&3@XR
M."2 <,Z+XEU'PS-J?BO6=5@NUB>X.E>'&6$1$1$*B, 9)),Y;!?87P,%1R >
M@45Q_P -M2\2ZKX7>Z\46<]K=&[E%NMS&J3-!D;3( JC<#N7.Q,A0<<Y/%Q>
M+/$FC_%37;"_UK4K_P .Z);Q2/$-.ADEN99DC6*$-'&N':27Y>F=F#QD@ ]D
MHKS/1;;XH77Q(M=1UJ2TM/#IMY)'L;>976+<N%A;Y=SRAE1B_P!W[VU@&VFY
MXA\8ZI?^-!X'\)>1'J:1>=J.H72;DLHB!@HF1YDGSH1U7D YRQ0 ] HKQ_XF
M:QKW@+^R;C2/$VJZEJ^HW:0II]W;PR1SQ)DD!8X5PQ:1%^4AF##KM&WT#QOY
ML?@W5;J*^OK/[+:37#&QD2.215C8E [H^S/]Y1N! (- %B'7TN?%MSH-M!YO
MV.T6>[N!*N(7=L1Q%<[MS*KL>F %Z[AC8KQ_X#Z#>IX7/B2YU6=I-4NY9I(@
M(V^T $IF5VC\PL'#L,/CD'J6!Z#Q#XQU2_\ &@\#^$O(CU-(O.U'4+I-R641
M P43(\R3YT(ZKR <Y8H >@45Y'\3M2\0_#KPU)JVG>)]2O);ZX6VVWL=NPAD
M(5A(FV( #9"Z%,8)DW<$'=Z)H=KJ*^$K*WU&XGAU62T4W4P=9'CN&7,A7.Y>
M')P,%!@ #: * -BBO%_#'C7Q5!XA\4C4;J^UJULM0?2-)L5LXD:[N=[D9F1%
M"[$B+.3P%;=V /0>$=/^)R>+=;N/$VHV)L7M/+LQ" \ E+;D*1C:^U 75MQ5
MF^7EL!@ >D45XWIVK^--!^.&E>&-=\0QZS9WEE*\;"V6#"E6;)1,#>&@(!);
MY6.,%CCK/BQ-KMGX&FU#0=7@TN:QE6ZGFF<+YD: D1KE3EF?RP%. WW3P2"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#\5W^
MOZ=HQE\-Z+'JVH.^Q8I+A85C!5OWAW$;@&"C:""<]16Y10!Y7'K'Q)L-+FAT
MSX<QK?2OYDEY>ZS!,99#@,\BKLR2HP "H4!0 %4+76>*?"UQXF^'5WX<NK[S
MKZ:T1#=E1$)9TVLKL #M4NH) !P"0*ZBB@#SNS3Q:? NE>%K/0[O2[P64-C<
M:I<7$!CM56+:\L8BE+L_'R#"\D$D &N@@TMO!'@B+3O"^DR:D]D@6"TDNEB:
M8L^78R,, _,S=,=@!P*Z2B@#RNSUCXDV=O=3#X<QRZO<I^\O)=9@*[@#L4(,
M$1*2<(&[DEBS,Y] \.#5QX?LVUZ2-M4D0RW*QH%6)F);RQ@D$("$SDYVYSS6
MI10!3U*]GL;=9;?3+O4'+A3%:M$K 8/S'S'08XQUSR..N.;^'5OJUGH,\6N:
M'_9FIS7<]Y=.C1&.>265WRI1V8[5V+\^#@  G%=A10!YO\6?!UQXH_X1R:T^
MW;H-0%K=&S<*R6EQB.9NF3@!1W&UFR",X[3Q'=:O9^'[R?0=/CU#5%0"VMI)
M1&K,2!DDD# !+8R,XQD9S6I10!3TF2^FT:QEU2&.#4'MXVNHHSE4E*C>HY/
M;(ZGZFKE%% 'D]SX1\4^#/B+J7BGPG80:MINK?\ 'WI1O# XD.6,@9SM.'!(
M/)'F,H4#YJ[2'Q%K%\A%GX1U*"3>R!]2G@@B!5B#N*/(^#@[2$8-D'[IW5TE
M% 'F_P 1/".NZIX+TVWTU8-:U*QU5-1DAO2!'<<R%HPK-CRP9,!&;A%V[B0,
MT_'>C>-/'GP\N;>71X]+NPZ21:;!J*RO.PD Q*^%C"!=S[06R=ARI3:WJE%
M'!ZOI&OQ_"&]T32;".6\:R6QL[2:1=Z0%5B(D?<$,NS>Q*X4'"C>!N;H/!V@
M+X6\':5HJK&'M;=5E\MF96E/S2,"W."Y8]NO0=*W** .375?%-CXGUJ*X\/W
M>H:.7A;39;22V5@/+'FJV^5#C>,CC/+<XVXS_A[X/;P]JGB/5_[-CTB#5[A&
M@TM75S;I'N&YF4E07+,VQ20@( )Z#O** /+_ (=Z#K?PWTG4M#ET.^U:-M0>
MX@O+*2V5)(S'&!E9)E96^4Y&"!V)'-;'ACPC>/XHNO&GB58&UFZB2.ULU)D7
M2XP"#&CEB&8@C<RJ!N+XX8Y[BB@#S_P?X6U2#XB^+O%>MV<$$U[*MKIYCER3
M;)@;BH) W!(CSSE6X4'F.R\/:_'\9=;\0/!)]CFM[>UM+F:=7B2 !&F18PV\
M.77"_=4;I&.XX5O1** "O-]/_P"$NLOB!X@\0)HD][HE]*EDELTZ)=QK K*)
M8UD8)Y+2&3@L&.\.!C[WI%% 'E_C3P]KWQ,O-,T2ZT:?1?#T$OVN[N[F:%YY
M'4,HCC6-W R&/S-]<?+A[GCKP[J^L>//"&HVVBQZAI^E//,Y^V"(K,P7RRX.
M"$5T1B5WG ;Y#@!O1** /-_'WA'7?%7_  BNC2K!J&F)J!N]8N9"(,*O1$56
MW!2KR* -S#"9?JQ](HHH \CTG0/&'@7XC>(;_3M"CUW1==N!<R2PW,<$L!,C
MM@+(P#%0[\=&^4[EY%>D::=7N;AKO4(X[*#85ALD<2-R0=\KXP' ^78A*CYC
MN?*[=2B@#Q_X?:)XR^&L^H: WAS^V=$DNS<1:A9W4,<G* ?ZN1QG.U!C(VG=
MRXQ7IEF-:%O=7-X+3[6Z8@L8IB8(RH.,RE [%B>6VX P I(+/J44 >;_  E\
M+:SX9\+VMA?V?]EM'++-=IYJ2O>2L2%.06"1J@CZ89F7^$*?,](HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHBY+8VJ,;F&<'%<?I_P<U'PSKE_?>#_&<^BVMW@?9'L5N0J]0"7?#8.<$C<
M<9.23W&E^%DM[RTU/5[Z?6=9MHFBCO+E501!@-_EQ( B9(/."^#M+$8% 'E^
ML:G_ &U^U'HNE7,.^UTJ(K''(V]#(;=YO,"D85LE!GK^[4YZ8]PKS_Q=\+TU
M_P 46GBC2-:GT/7;?8/M$,"R(X4,,LOREF((4DL057:016I!X9U^ZN(D\0^)
MX]1TQ;<136,&G+;K=.#]^5MS$@_Q(NU6Z$;2RL =!/JMC;:-+K#W,9T^.W-T
MUQ'\ZF(+NWC;G<-O/&<]J\?^!FE7.L7&L^-M3MHXGOKV62 )O"N[$EW"MD87
M<Z(RG(\R96)XQZIXJT:X\0^%]1T>UU#[!)>Q&$W'DB7:C'#C:2,Y7<O48SD<
MBCPKX>M_"GA?3M#M6WQVD00O@CS')R[X).-S%CC/&<#B@"QKNI_V)X>U/5O)
M\[[#:2W/E;MN_8A;;G!QG&,X->)_ [3=>U'PKKNJ:=K-I:7E]>M%<75U9/=3
MLRH&#AC,JY!E8\J<DG)(P![Y7D^G_!S4?#.N7]]X/\9SZ+:W>!]D>Q6Y"KU
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M%RY!&5VY- '44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN?!<&H>(+R>YU.]EDEE,A0HH!\M/*V +Y91%<%<AMY8$[J["@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG>+(S-)=7*[L[8IQ$ /QS@>U>DGH<DM'<M3VD]]=RRZA(LBF(1DKPQ^8$$X
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MF<,K!R^2 L?Q)MO^$P^(OA3P.ZSFP7=JNH@1;D:-=RH"P(9<[9$)R /-4\G
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M$>>PV)(T? .!P".W?OG/>L_3YFBU.U>)F#&XB4G'4%P".1Z$_G1>O/<:S?L
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MFA!VDY>13&@X]691[9YXH ZBBL?PG?7&I^#=#O[R3S+JZT^WFF?:!N=HU+'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/YA <,I\MOF.<_,,X['UJX4B:WXB09X VCCFH_*B6(#RH]V<9VCKS@UFE9-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3PH\Q>O 'HEKX<TBS\07VO06,:ZI?(B7%R269E4  #)PHPJY"XS@9S@57O\
MP?H&I^);/Q#?:;'/JED@2WF=V(0 L1\F=I(+$@D9!P1T& #SOQC_ ,33]HGP
M5I-Y^]L;:T>]BB^[MF'FMNR,$\PQ'!./EZ<G/0?&#69;+P6VC6#YU?7I4TZS
MA!3+[R ^=YX4J2I;L77IG(ZS5_#VF:Z]I+?P2&>T=GMYX)Y()8BR[6VR1LK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]$\W^R=*L;#SL>9]DMTBWXSC.T#.,GKZFM"O.W^+EM#<6D%QX.\76KWEPEK
M;K3TA5Y7.%0,\@&3]>QKT2@ HHHH **** "BBL>3Q#;Q?VA<LN-*TZ*1[J^R
M2H=.61% )?: VXCHP"C<P<( ;%%>/_\ #1W@_P#Z!NN?]^(?_CM=QX=\>:7X
MC\)77B>.WOK+3+;S2[WD.TLD:Y9U"EMRCD<=U88XH ZBBO'_ /AH[P?_ - W
M7/\ OQ#_ /':] \'>+K/QMH?]KV%G?6UJ96B3[9$$,FW&67#$%<DC.>JL.U
M&Y!!#:V\5O;Q1PP1($CCC4*J*!@  <  <8J2O._%OQG\,^#O$$NBWL&I7%W"
MBM+]EA4JA8;@I+,N3M(/&1R.<Y ZSPMXDL_%WARTURPCGCM;K?L2=0'&UV0Y
M )'53WH V**S]$U/^V-'@O6A\B9MT<\&[=Y,R,4DCW8&[:ZLNX<'&1P16A0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA"PR03^)K1O-/L(1)%=&>YB3!5L9V@C(.-IQQ5,:3I,@/DP7,DO\,26C$O\
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M/4@>U>K",:---/0X)R=26J+>D2R6]G=74:AC<!K%<]EQF0_49CQ]3P>UA5
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MD?9TXTWON_4]?"KFDZGR1;'6G4@ZTM8'8@HHHH **** "BBB@ HHHH ****
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M !R20!DFO)_&@F\3_$CP9X<U62.(3W#:C)IKH9%AAB5F19,'9(\FR16^\$P
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M5@1Q6?XBN$\5>+;7P9'%YMC:^5J.LN0KQE%;,-LP*M\SN$<@[<HIP3N..XH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG.!D<]/>O9G&FJ?++X3@C*<I\RW,*_M1>I+>VX+3Q)OOHSP/NY,@R<'=@L0
M""V,'K6/<S^6 S[F;H.<^^.:ZB[@GTS5'B25EGM9<':V Q!Y1L'E<C!&><5A
M:QI"7-N+O3T:,<>=9KAI(.2-P P2I^7D+C+XSD&O"K1EA'9:Q>S/:P\U7WTD
MMRUH&G:F]W:W/VB.W@GD0"%G(,X.-H^4$#[PP3@KG(Y%=\;M]+M3)?C_ $=2
MX616+;=A(93QDXZ9YSMSWK/2*X6X6&"U,Y\Z8<_O=D04;$P/^6;?,H7H,M[U
MT7AK26U[5;:WDCD6VLT>2X 3"1R%TV1C/' \P8&=NW!Q7F54I/GZGI1T5BAI
MFL6&KZK;6-O,6>5P,-$3D=3UXX /4UWDTTUBT-O:H BJ$?8%7G PWX<\=.>M
M8=_X:N_#5]#=:? U[IZ.LDD13(0 @,0 >PRV,=0:W-.N[/6+T[)(PZ!6*;AO
M3..-A^9?QZX!KR<4W=7-(HD?24^TI>%XT@0851G*]1P>O4G\S2Z9K>AZV7MK
M1_.\O]VW[MD'((QR!Z5F^+/"%YX@OHIH]1ECAVA&MV&Z,$;CNQN SR!4UAI=
MOH,+:9IQ-PDO^N$A&6<#'&,8Z<YSBHI4J52&LM?R&[F-KELL&KW2@+Y#@*@'
M8*H!!J9[/['JUHD;F+SU2567.8PQ(Q[XQ6T+"*20B:U9RNW,9=9$C(']T#BN
M0UGPY>:IJ,UU<M.Q#,%*W2*H!). #D@<\"O1I\JC9,S9Z!%I-PR!O[1G<$9!
MRW/_ (]6?J]M?6$7G1ZE<;. $"@\_4MFN 7PA*G"RW2?[M[&*NV?AZ=6(<7<
MXZD+J,88?C@\5T:,1?\ -N9UDO)-TK0#"@8RSG@8S@?*<'GK5O\ X2"[M]#2
M.:S>>4N=L1=%9UR<DD< 9![YXZ8YJE+X=0BTMO((MAF20O*A(9@ PZ>BCG'Y
MU9M+X:->.!8P2;%\N,,0^$&%'W>A^7)]R>*7P@*=;M9T3S_"EP650H/VM.GM
M\W ]J@%]'/,1::'=V[YX(N5_^+JZWC2<MN2W(0?P?9I>1]:JS>.4F#)/X<:;
M&<-Y#\^_*&E=,"^+7Q*D!DWO& ?]7/<\_7Y=PK#?6+U8'FNMB(N.0%;.>G&/
M7%9@UF34KEX]+TJXGE/2)591P!GYBN!QS76:7X(#AK[79@CGY8XV5=J;ACC)
M."2P'O@"LY2UM$=NK.(\0ZE=ZC9OF>VLU$2N$:W5L#?C><+@\G;M.1T;J*\_
MN1?:!J$$MQ(?-D?S$N(9FRY!Y.< @_7UKT2&SU*WF@L+V>YAU"*,B6/)=HP6
M+"14!R<@A-P)')'J!E:UIZWOARX6*QB6[:" ^7%MRLY?YQMZASP&/7 &>E=5
M&7L];ZD3CS[G/ZKXFU7Q!]FM;RZ>X162.VB?!*,5"CYB ><<Y/UZ9JP+:.RM
M7LMBO<E_](NXR0"N 1$,X.,A'SQSD>Y;80?V-:!(I0]_-$8KG<O_ !Z#T0@_
M?]P3M*X(STO:-I3ZI?II]JJI*RDHJX&<<D<D <9->GAJ3Q#]I45H+\3R\15]
ME[E-WDRD!A=N!Z<#&*V]$\3:EHM]%,MS/)%$K V_FD)@Y[<CJ<]*J:AHU_I"
M1?VC;-;2R9*1/C<5&.<9XZXY]/:J<4$D\BQ0QM(YZ(HR3WZ5[;]FX7>QY"4X
MRTW+^G6\U_<BYN6>6UMSYDQ=L_+R<=<\XQ6EJ]\+2U*P2,CW"CY!D>5!M^5?
MQ4H3CTYR:MQ)#I-BS17*-';XDE!X$TPQA.O(5@I[_>ZCK7/VVG7_ (R\2+9V
ML;L;B4/=O$?]1"6 8C)[!N![5X//]8JNK)>['8].,'%*G'=[G:?"+PU+=7__
M  E<^PVP22"U1C\V[Y07P.!U=>>?PKV2H;2SMK&V2WM8(X($SMCB0*HR<G '
M'4FI\<5A4FYR<F>I""@E% *6BBH+"BBB@ HHHH **** "BBB@ HHHH ****
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M8HH *Y/Q7X8U_6M4T^_T3QA=Z&;5'5H%MEGBE+<;F0D G&?O;@." IR3UE%
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M]DEWI\4TYW$[W#/&#ST^5%''IZYKU_X'>(;C7_AK;)=+^\TV4V ?(^=$52G
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M>G_%KP'#XP?PZ8=.DDNSJ<5O<W4&%>*S*NTA+'C P"-P."<#EL$^!&B3:/\
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M%P)))&2257;)!(?@=,C)Y[0Z7<ZBNG7DM[<WG]N3:RGDVCLV1'YL>Y5!Y\L
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M%FX9"+:TN$;& 3''CV_CK-;7_'&N*98+>R-LW(9PH;_T+%7&CB-E!D?6*/\
M,=WIVBIX>O+^,:E ;2^NOMTRN@#I)NW$##=/E4=/_K07_C+P]I&^+[7%>.LK
M2A)GWM$V2V54+G@MCCVKS+7M)\0V]LIUK<UO*"0,QXQQ_=YZD5B6D21/%'&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!&689(Z$TK5?$R>-9-"U:+3;BS6R:[6^LD:,Y+(J(\;.QC.1,022' XP4<4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[4KM(O.N')W22.!N=N2>3DGDU]SV%C;Z9IUM86<?EVMK$D,*;B=J* %&3R<
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MY8;).HX#<'DU]!P00VMO%;V\4<,$2!(XXU"JB@8  '  '&*^+/B+XAM_%7Q
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M@5$ZMTHPT1VTL/&'O/5@!2T45BCH"BBB@ HHHH **** "BBB@ HHHH ****
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MG))/))).2: +E>-_%\S7/Q&^'5KIT<=UJ$-ZT_V;>00HDA(9]H8JG[M\MM.
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M'-/1+&V\Y@^^9%+RA,X;AV1C[Q\$X-=1X>^'GACPI>&ZT.QGLI&^^$OIRDF
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW4F-\T^HW,CM@ #+&3)P !^%=1HVBV6@:<EAIRSI:I@(DUS)-L   53(S%5
M PHX'I6A10 5GZAH>EZK>6%W?V$%S<:?*9K621,F)\8R/T/U53U4$:%% $<\
M*W-O+ YD"2(48QR,C $8X92"I]P01VKB[[X0^"-3O)+R_P!)GN[J3&^:?4;F
M1VP !EC)DX  _"NXHH \_P#^%)?#S_H7O_)VX_\ CE7--^$O@/2KAI[?PU:.
M[(4(NF>X7&0>%D9@#QUQGKZFNTHH C@@AM;>*WMXHX8(D"1QQJ%5% P  .
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MY%:>.UL+-@#F28&1@02-NW>..,YQUXKVVPT72M('_$OTVSM" 1F"!8^"<D<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>(?=@B+<A >2<#>Q+$#A5U+Z^M].LY+JZD\N%, D*6))("JJC)9B2 % ))(
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M/]W." :T/AUX>N/"OP_T?1[QLW4,1>88'R.[-(R<$@[2Q7(/.,]Z .HHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\C^-7Q U+P^EGX8\/>9_;&J)EI(58RQ1LVU1& .7=@P!!RNTX&2I':?#_P '
M6_@?PE;:3%\UPV)KR0.6$DY4!RN0,+P .!P!GG)/DFHPKJW[65O:WYDG@MWC
M>%&D;$92U\U=O/ $GS8Z$DYSDU]!T %9>D:)#H]UJ\T'EA-1O?MAC2,($8Q1
MHW3J2T9<GC)8_4ZE1SSPVMO+<7$L<,$2%Y))&"JB@9))/  '.: /)YH)O%?[
M1H2>*3^S_"]DKA74RQ/-(H93SQ&_[P$'DGR >WR]19_%?P7J'B6#0;/68YKN
M9WC1PC"(R*0 @<@!BV3M(R#CKDJ#YA\*M+N_&B:]/=I=VUIK=ZUWJLUI*BPS
M1AFVVBX)D0LTDC/SD1J@Z2AJU[W2K'Q%^TEIMA;VT<5IX:TR)Y(3^[4%,O%Y
M87LK30\' ^5AR, @'KFLZU9:!ISW^HM.EJF2[PVTDVP $EF$:L54 '+'@>M8
M_A;5_"WBF\O=?\/VL$TG%O-J8M1$\K8!,99@)#M C)R-O*X)((!\1M9_L#X=
M:]J(>>.1;1HHI(#ATDD_=HP.1C#.IR.1CCFLOX.: OA_X9:4NV/S[Y/MTS(S
M,&,@!0\]"(_+! XR#UZD [2^O[/3+.2\O[N"TM8\;YIY!&BY( RQX&20/QKE
M[CXF>'+6SCOYO[5CTQXO-_M!])NE@4$J$RQC_BW<$9''49&?.]3\1:5XX^+T
MEAK]_:6/A?PV[JUIJ-S'&EY=JS)NVE@2,YQG<,)@@>816YXPN=4^*>G0^'/#
M5C?6VBW$L4M[K5[;>3#)!C>ODHX#R98 Y 7E5&=KYH ] U/Q+9:;IT5ZD-]J
M$<\1EMQIEG)=><  1AHP5&[(P6(!SUP#CR?X2^()_&7Q%UWQ;J5O?0R7$2V-
MBD<4LMM%&/G=#)M*JPV1GDJ"9&(&6 '>>,)X? _PAOTM9;L)8:8ME;3(P\U6
M*B&-\C&"&922,="0.U4_@MHG]B?"_2]]OY-Q?;KV7Y]V_>?D;J0,QB/@8]QG
M- 'H%%%4]6U*'1M&OM4N%D:"RMY+B18P"Q5%+$#) S@>HH \?LT7QQ^TE=7F
MR.73_#-OY*O]F9E:5<C:Q;@.)9)&4X_Y9<#^*O;*\C^ >FW;^']7\5:BTC7F
MNWK2,Y*;9%0M\X51\I,CR@CC[HP .OKE 'SQXXOK?X=_M!:=K-G)]FM=0BBF
MU%=I\O9([1RG:F">$$G.<N,\]*^AZ^?/&,$/CS]HO2=-L(H[N#2TA34#(HDA
M*Q2-+(#C<,8<1X8#YSM..M='\9?%$LFHZ9X"M;[^R_[5VRW^HRRI''':DLK+
MEB,YVL2,KD*%&[>10!W#?$#09/,_LYK[5EBE2)Y-*L)KJ-2=I/[R-2AVJP8@
M,3C(P3Q6AH_BG1O$&AOK.D7GVVQ3>&:&)V<%>2OEXW[L8(7&3D8!R,\?<^*+
M.Q\/-X=^&NE3ZG<1Q/;6LVGQ@V=K)L#;GN'_ ';-A]V,L688;!:MCX:^"/\
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M**^7/C/\3YO$NJ3>'M'NXSH-LX#R0,2+R08))/=%;@ 9!(W9/RX /:[[XP>
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ML>+J:*>&1]Q^9$*%1CIP9'_/V% 'H_\ PNWX>?\ 0P_^25Q_\;H_X7;\//\
MH8?_ "2N/_C=<_\ LX_\D\U#_L*R?^BHJ[SQ+X>\.>-$N=!U:VCGN(;=9 X3
M$MLLK,%>-R."6A/ Z[?F!!P0#4T36].\1Z/!JVDW'VBQGW>7+L9-VUBIX8 C
MD$<BM"N/^%VC7GA[X>Z?I%^FRZM);F)\ @-BXDPRY )4C!!QR"#784 >?_\
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M+[+8WWVM)XHD;RXYA#(P.22%W!B @  $9QWP >P4444 %%%% !1110 4444
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M.60 *JLS-MSLV26O@%H_%FOZK=:Q)=V&M/"]Q8O;JI81*56-G!PT6&.5V@L
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M*JC).2=2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS3*"P)0 Y8 HX)']T^AJ34]=T?1/*_M;5;&P\[/E_:[A(M^,9QN(SC(Z>HH
MT**KV=_9ZA$9;*[@N8QMR\,@<#<H=>1ZJRL/4,#T-6* .?\ ^$[\'_\ 0UZ'
M_P"#&'_XJM2;5M-MM+&J3ZA:1:>45Q=O,JQ%6QM.\G&#D8.><BO(_$=A9O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?\
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M%%9L<D*22!GMDX]30!7U;4H=&T:^U2X61H+*WDN)%C +%44L0,D#.!ZBO/\
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MG(&YNASY*#@XKI-#_MNX^(NJ:MJ?A:>TM9[2"SL;IWMF>*-/,>02;96(W.X
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M,WB:Y>^+]?&S7=0B$*VD<Q>*PMQ@B%3G#-D!F8<;L[0!DMV% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(C8)!PPX.""/PH L445S_P#PG?@__H:]#_\ !C#_ /%4 =!17/\ _"=^#_\
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MZ'_X,8?_ (JK%CXL\-ZG>1V=AX@TJ[NI,[(8+V.1VP"3A0<G !/X4 ;%%%%
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MXQ(C8@D(RIX." ?PKZ'^-O\ R2'7?^W?_P!*(Z\ ^"7_ "5[0O\ MX_])Y*
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M!.:\@_9Q_P"2AZA_V"I/_1L5?1^N:S9^'M#O=7OWV6MI$TKX(!;'15R0"Q.
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M@73)'6.ZA650WFQ#(# C."1GW-=7^TU_S*W_ &]_^T:P/V<?^2AZA_V"I/\
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M20,*,DD@#)H Y/0M:?Q[XY\6Z;<75]!I6ARQ6T%O;3M:L\N9%DD=XV#GYD(
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M?) X+;F)..I)KS?X B;4[?Q5XJN)(Q/JVIXD@C0A4909"022<$SXQVV]3G@
M]DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:QD\=/F1ASZ>F*]KT;QS8^,?C&VFZ;+'=:9I&F32),!E7N3)&C.AS@A4)4,
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MOB&W\5^%].URU79'=Q!RF2?+<'#ID@9VL&&<<XR.*\W_ &CO^2>:?_V%8_\
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M4_MNQ&/GM(R)E^Z.8LDGDG[I;A23BO6_AKXVAF\7^*_"%]<1I<6^L7DM@K$
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M&W\5^%].URU79'=Q!RF2?+<'#ID@9VL&&<<XR.*V* //_C;_ ,DAUW_MW_\
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M5/P+\-EU*U\2ZQXNTJ.,^)KC[1_9SEA+;1>:90K2+M8$L4)48^XN><JOKE%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ+;F.2V]LG))KI** ,_1M'M]#TY+2W>>9N#+<W,IEFG? &^1SRS8 'L
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MV@DX S6QH^C6>AV;V]HGS2RO<7$S !YYG.7D?  +$^@ '     T** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUCX@?VS_ &M;6,/V'R/+^R(ZYW^9G.YF_N#ICO0!ZA1110!\@?&W_DKVN_\
M;O\ ^D\=>E_ +Q+H.C>!;ZWU36]-L9VU.1UCNKI(F*^5$,@,0<9!&?8UYI\;
M?^2O:[_V[_\ I/'7?_!3P/X:\7?#R\.N:1!=R1ZJX6;+1R "*/"[T(;;\Q.W
M.,G.,T ;"_$C3O&GQJ\)Z=H<T\FFV7VJ1YCN1)Y&MWQA" ?D (#'GYFP,<M[
M17@]G\.[?P'\>_#,NG3;M,U+[8]O"Y)> I VY"3]Y?G&#G/8]-S>\4 ?,GQG
MOM9\'>-8;+1?$OB""TGLH[CR6U6=PC%G0A2S$X^0'DGDGM@#J_V>-=UC6_\
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M[2=0OM4OKNT:&-K^[DEALLNA-PP;(^4 @9[L.&SM;T_]H[_DGFG_ /85C_\
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MJI)V[B..@\W_ &FO^96_[>__ &C0!@?LX_\ )0]0_P"P5)_Z-BKWOQSXSL?
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MOXI^,?CF#1M8UF^CTRXW/=060*PQ0H2X&P?+][:H=]Q!*YW8 K8^)\VLZ/\
M![P7X:U^UV:D)97<^8A\M(,QQI\F0<I*G.?X><DG%?\ 9Q_Y*'J'_8*D_P#1
ML5 &Y\2/ NK^!/ -Y!H6KW=]X7F2.*\L]0E#M:L)@ZR0X"@ L0I '\62&ZIP
M?P2_Y*]H7_;Q_P"D\E>__&W_ ))#KO\ V[_^E$=> ?!+_DKVA?\ ;Q_Z3R4
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MSYN5.5!!'0@9!&09/'7P?U3QYKAO[_QAY5O'E;6T33\I;H>P_>\L<#+=\=@
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M?%*FF\J?^_N"",@@\$$@Y!H U/VCO^2>:?\ ]A6/_P!%2UP'[./_ "4/4/\
ML%2?^C8J];\>_#O6O'UE:V%YXFM+6S@=9O*@TLDO*$VEBS3$XR7P!C ;!+$
MUA^#O@MJG@?7/[6TGQ= TS1-#)'/I6Y)$.#@XF!'(4\$=/3((!S_ .TU_P R
MM_V]_P#M&C]F7_F:?^W3_P!K5V'Q ^%.J?$'48)K[Q1!;6MIO%K;PZ9G8&()
M+,9<LV H)X'R\ 9-1^ ?A'J7P_UF2]LO%,=Q!<(L=S;2V#!74,#D8FP' R Q
M!QN/!S0!S?[1_AAY[/3/$]M!N^SYM+MQN)"$YC)'W0H8N">.74<\8K_LR_\
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MFC7/RC<@8.<9R<+TZ<\=/X(^ 5CX>U2RUC6-4DOKRU>.>*"!/+BCE7GDY+.
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M'N3(D;EU5O);(#$ D9[X&?05R?@#X*:7X)UA-9GU*?4M2AWB!]GDQQAEVD[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OG_P"*?_)PO@K_ +<?_2MZ^@*^?_BG_P G"^"O^W'_ -*WH ^@
M*PY/#4,_C6'Q+<7$DKVUE]EM;9@"D#,Q,DJYZ.R[5R,< @YR,;E% !7SQX2\
M/7&A_M.:A8Z6V+&#SKBX2$"%$@EC#JFP'E5>2)0!_=!P,<>[ZYK-GX>T.]U>
M_?9:VD32O@@%L=%7) +$X &>20*\_P#@[X8N+>SU'QEJ\$":MXCE-VHBP1%
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M6V8 I S,3)*N>CLNU<C' (.<C&Y16?KFLV?A[0[W5[]]EK:1-*^" 6QT5<D
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MFW+KODWGRF=FBYR>/+*8'88'&,5VE1P00VMO%;V\4<,$2!(XXU"JB@8  '
M'&*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOG_XI_\ )PO@K_MQ_P#2MZ]XOKB6TLY)X;*>]D7&(("@=\D#@NRKQUY(Z>O%
M>%^,_#?CWQ#\4M.\4VGA*3['ICVYMX);RVCDD6-_,(<B5@"6+@$=L<9S0![Y
M4<\\-K;RW%Q+'#!$A>221@JHH&223P !SFJ^FWL]];M+<:9=Z>X<J(KIHF8C
M ^8>6[C'..N>#QTSYO\ %F'X@Z];OH'A;1I!IDB8N[W[7"C7 (YC4%P53LQ(
M!;I]W.X N6(M_BW>1ZE=0;O".FW9-E;S0D'49T!'G/N'^I7<RJ@^\=V_ILKT
M2>>&UMY;BXECA@B0O))(P544#)))X  YS7@$$'[0-K;Q6]O%'#!$@2..-=/5
M44#   X  XQ5_1] ^*_B3Q!IMCX\61_#:7 N+J-6M LAC!9%=8^70N%!4@CO
MP0" #N/BK/-=>'[+PQ9RR1WGB&]BL0T+$R10YW32[!RZ!5PPR!A^3CKW$$$-
MK;Q6]O%'#!$@2..-0JHH&  !P !QBN+^P7FM?&'[=<VDZ:9H&G^7:/-&462Z
MG^^\3#B11&-C9/RMT'>NXH **\G\?ZK\5M$\4/J/AVP@O_#T,2;;:*%96=B-
MIWJ")2P8Y^3Y=H7/\5:'_"2?$K7=.\C3_!,&AS7468M0O]321;?(SEH0F_=C
M@ CAB-PP"* .+^#&@+8_%SQK+9+'%I^FO-8I$68L TYV 9SD!82"2<].O.-3
M]H_1OM?A+3-71)WDL+LQ-L&42.5>6;CCYDC .0/FQR2*](\'>%+?P?H?V"*Y
MGO+B:5KF\NYV)>XG;&^0Y)QG X]N23DG4U72K'7-+N-,U.VCN;.X39+$_1A_
M,$'!!'((!&"* ,?X?3PW/PY\-O!+'*@TRW0LC!@&6,*PX[A@01V((KR/]I'_
M $S4?"NG6O[^^;[1BVB^:0[S$J?*.?F*L!ZD''2NL\&67C#X;6KZ!?Z3)K^A
MQOFPN]+,8EC+RD;)(W93@EMY;)"9.6*\I)X>\%Z[KOCX^-_&]I8PR0Q>5IFE
MHPE-IM<E69A\K,.2#\W+Y^0J  #8\9W/_"%?"J2QTMIY+I+2+2M.59=L\DC
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M!IXQ+<7<GS2;Y20IPQQN))VJ/O$#(!)XO\9KH-Q8Z+IL<=YXDU1Q'96C;BJ
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MM+Z!7*-):S+*H; ."5)&<$''N* +E%%8_B'Q5H7A2S%UKFIP64;?<#DEY,$
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M1D$#'M[UZ?XY\:?\*[\#17%Y=P7^MF)8;<2KY?VN8 !Y-B]%&2Q P.BY!(H
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M-8U-HVO)TD65T7:'*2,F['0$A03C R3@ <5UE !1110 4444 %%%% !1110
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MKL1@@=1@@X/(R#[)7D_Q<^)VA:7X7U;0+&^@O-9NHFM&@B!D6%6)20NP("L
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M#% 'KE>/_''PHD_@34-;N=8U6>:RE22&W>91  \JH%,:J =H=\-]_P";#,P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!\J?'KPNVA^/#JL4<:V>L)YR;$5 LJ@+(, Y))
MVN6(&3(>I!-2?#KX@7]CX+U#P;:W6S4]1NX;72'<R8@,Y*2L7!^15X8;1G>^
M<-SCV?XS^&_^$C^&M_MDV3:;_P 3"/+85O+5MP/!S\A? X^;;SC->6?LZ^%U
MOO$%]XDN(Y-FG((;4E&"F60$,0V<$JG!7!_UH/&!D ]+\?\ P_M[GX//X=T>
MU\R32XDFLEP=[/']XX0?-(ZF0=.6?/!Y'S!X5\0W'A3Q1IVN6J[Y+24.4R!Y
MB$8=,D'&Y2PSCC.1S7W/7R!XF^'CV?QA/A&Q2>.UO+N,VKB!FV028)8 G+K&
M-P+9Y\MB2.< 'O\ \*H;S4-.U7QAJ=MY%]XBN_M"(2=R6J#9 A&%' W$,!\R
MLI).>.H\67UQIG@W7+^SD\NZM=/N)H7V@[76-BIP>#@@=:T+"QM],TZVL+./
MR[6UB2&%-Q.U% "C)Y. !UHO[&WU/3KFPO(_,M;J)X9DW$;D8$,,CD9!/2@#
MXH\"?\E#\-?]A6U_]&K7T_\ &W_DD.N_]N__ *41U\X:=H]QX,^+6E:;K3P0
M2:?JML9Y?-'EA-Z,'W'HI4AN<8!Y .17T/\ '6^M[3X4:E#/)LDNY8(8!M)W
MN)%D(XZ?*C'GT]<4 >,? '4_L'Q0@MO)\S^T+2:VW;L>7@"7=C'/^JQCC[V>
MV#U_[37_ #*W_;W_ .T:9^SEX7OH[W4/%$\<D5F]N;.VW)Q.2X9V4YSA3&!T
MP2QYRI%1_M+WUO)J/AVP63-U#%/-(FT_*CE ISTY,;_E[B@#?_9NL;>/P;JU
M^L>+J;4/)D?<?F1(T*C'3@R/^?L*]HKQ_P#9Q_Y)YJ'_ &%9/_145>P4 ?('
MQM_Y*]KO_;O_ .D\=%S\1-4@^%&D^$]-AGM+,^?'>WF,?:"9&<PH?[H61-W<
M[@.%^\?&W_DKVN_]N_\ Z3QUZ?X:\"V_CS]GG1['$$>I1?:)+&ZE4GRG^T/D
M9'.U@-IZ]C@E10!VGPB\2Z1XA\!V4>F6]I92V*>3<V%N3B!LG#?-R0^"V23D
ME@68AC7>5\:?#_QG??#GQCYUQ'=K:;S!J5B/E9@,CE6'#HQR.AX*Y 8U]AV%
M];ZGIUM?V<GF6MU$DT+[2-R, 5.#R,@CK0!8KPO]I;39I=&T#5%:/R+>XEMW
M4D[BTBJRD<8QB)L\]QU[>Z5C^*O#UOXK\+ZCH=TVR.[B*!\$^6X.4? (SM8*
M<9YQ@\4 ?-'P!U/[!\4(+;R?,_M"TFMMV['EX EW8QS_ *K&./O9[8/U?7Q@
MD.N_";XBVLM[;;;RPE$@"D;+F$Y5MC$'Y74LN[&1D\!A@?8>E:K8ZYI=OJ>F
M7,=S9W";XI4Z,/Y@@Y!!Y!!!P10!8GGAM;>6XN)8X8(D+R22,%5% R22>  .
M<U\"5]9_&CQS8^&O!UYHZRQR:MJMNT$5OC=MB?Y7D;!&T;=P4]V[$!L>4?!C
MX83>)=4A\0ZQ:1G0;9R4CG4D7D@R  .Z*W))R"1MP?FP ?1?A.QN-,\&Z'87
MD?EW5KI]O#,FX':ZQJ&&1P<$'I7QAX3L;?4_&6AV%Y'YEK=:A;PS)N(W(TBA
MAD<C()Z5]OW]];Z9IUS?WDGEVMK$\TS[2=J*"6.!R< 'I7Q1X$_Y*'X:_P"P
MK:_^C5H ^WZ\'_:7OKB/3O#M@LF+6:6>:1-H^9T"!3GKP)'_ #]A7O%>3_'[
MPP^M>!H]4MH/,NM)E\UB-Q80,,284<'!",2>BHQR.<@'+_LR_P#,T_\ ;I_[
M6H_::_YE;_M[_P#:-9'[/'B?2]'US4](OY_(N-5\@6K/PCNF_P"0GLQWC'KC
M&<D Q_M >+M%\1ZIH]AH]['>G3TE::>!@\69/+(57!PQ 3G' R!G.0 #N_V<
M?^2>:A_V%9/_ $5%7A'Q'OKC4/B5XCFNI/,D74)H0=H&$C8QH./154>^.>:]
MK_9OU6Q;PKJ>CBYC_M!+UKHVYX;RF2-0X]1N4@XZ<9QD9\T^-WAA_#_Q%N[J
M.#R['5?]+A8;B"Y_UH)/\6_+$ G =>F<  ]KU;3?BSK.C7VEW#>"E@O;>2WD
M:,W08*ZE21D$9P?0UC_";X3:]X#\576J:I=Z;-!+9/;JMK([,&+HV3N11C"'
MOZ5<^&/Q<T+5/"]E8Z_K,%GK-K%Y<S7KF-9E4@*_F.2&8@KG)W%@QQCFNP\/
M^+/^$JUR^_L=()M L-UO)?[\F>Z^4[8@/^6:J3EC]XLNW(!) /"/VCO^2AZ?
M_P!@J/\ ]&RUZO\  JQM[3X4:;-!'LDNY9YISN)WN)&C!YZ?*BCCT]<UY!^T
M-?6]W\2HX8)-\EII\4,XVD;'+/(!SU^5U/'KZYKV?X)?\DAT+_MX_P#2B2@#
MT"BBB@ KX@\=_P#)0_$O_85NO_1K5]OU\0>._P#DH?B7_L*W7_HUJ /K_P "
M?\D\\-?]@JU_]%+7C_[37_,K?]O?_M&O6/AQ?6^H?#7PY-:R>9&NGPPD[2,/
M&HC<<^C*P]\<<5Y7^TS!,UOX:N%BD,"/<H\@4[59A$5!/0$A6('?:?2@#<_9
MQ_Y)YJ'_ &%9/_145<1^TC?7$GC+2;!I,VL.G^=&FT?*[R.&.>O(C3\O<UM_
M CQCX<\/^!=5M]7UBTLIXKU[DQS/M9HS$@!0=7.48;5R>G'(S'^T!H;ZKH>A
M>,K:PGAQ$(;M)T99HD?#QATY5-K%U/(^9U'/& #0^%O_  L?_A7&D_V!_P (
MI_9G[[R?M_VCSO\ 7/NW;/E^]NQCMBL^P^"GC#_A8=MXHU&]T/\ Y"J:A<1V
M\LW_ #U$C! 8_K@$_C5#X'?$[3M L[CPYXAOOLUJTHDL9I0Q1&8X=&;)"+G#
M#@*,N2>17K\OCNSU/Q#8Z#X6N+'5;N7%Q>31W >&UM5<!V+*3ND.=JJ.A(9L
M*.0#C_VCO^2>:?\ ]A6/_P!%2US_ .S+_P S3_VZ?^UJV/VD;ZWC\&Z38-)B
MZFU#SHTVGYD2-PQSTX,B?G[&L?\ 9E_YFG_MT_\ :U &!^T=_P E#T__ +!4
M?_HV6O7_ ()?\DAT+_MX_P#2B2O(/VCO^2AZ?_V"H_\ T;+7K_P2_P"20Z%_
MV\?^E$E 'S!X[_Y*'XE_["MU_P"C6K[?KX@\=_\ )0_$O_85NO\ T:U?;] !
M114<\\-K;RW%Q+'#!$A>221@JHH&223P !SF@#@_@E_R2'0O^WC_ -*)*Q_C
M#\++?Q5IUQK^E1>7KMK$7=8T)^VHH^X0!DR #"D#GA3Q@KJ? Z>&;X2:0D4L
M;O"\Z2JK E&\YVPWH=K*<'L0>]>B4 ?#'ACQ/JGA'7(=7TB?RKB/AE;E)4/5
M''=3@?D""" 1];_##4_[;\!6NK>3Y/VZ[O;GRMV[9ONI6VYP,XSC.!7E_P =
M/AC]_P 7:!8_WGU6*(_0B8)C_>WD'T;'WVKT#X)?\DAT+_MX_P#2B2@#S_\
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M_ 7698M'U3P;J3^7J>BW<@$#%/EC+88*5.6VR;\GD#>O/( K_'6X?Q!>>'/
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M .25Q_\ &ZW/!7BAO&.C3:U':26^GS7#+8>:%$CQ*JJS.%9@#YHE Z< <=R
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MF!$9<R; $W;0<'//XCM/$_B?2_".AS:OJ\_E6\?"JO+RN>B(.['!_(DD $@
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MKB]NUFDL($(,\\4B-D$9^9]ZCA>HSR6->YZ;XDT75]&;6+#5+2?3T0O)<+*
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MVUJW0BUNR.".OER8Y*$]^JDY'4ALO1M!^+MOIR:5?>*-#6'@#4A"]Q=Q* ,
M!E5'R5P2^6^9CDG%>H5Y7\6?%5]<6[^!_"D,E_KU^FR\BAB\S[-;.-IWMT0M
MN49/ 4DG;E30!YY\,=._X3#XY:EKDEW/J=C82S727=U!O\[YBD&[A0C8(=1@
M8\O 48X]W\:>++/P5X7NM:O$\WRL)# '"--(QPJ@G\2<9(4,<'&*I_#[P-8^
M!?#4-C!%&;^5%>_N =QFEQS@D [ 20HP,#GJ23S?Q\T:\U?X:M+9IYG]GW:7
MDR $L8PKHQ  /3>&.< *K'/% &/IGPS_ .%D^%Y?$OB^[G_M[6(A+9O&W[O3
MX<DQ*B!B&4@AB&.<-V;<QX#PGXA\0?!?QRV@ZZNW2IY5^U(2S1["<"YB(&3@
M#G ^8*5(# ;?>_AGJMCJWPYT%["YCG%O90VLVWK'*D:JR,.H(/Y@@C((-<'\
M>+&W\17GA;PW91^;XANKMC 0Q(A@88=G5<D*2%;=M/$3\C!R >T5Y_\ &W_D
MD.N_]N__ *41UZ!7G?QQGAA^$FKI++&CS/ D2LP!=O.1L+ZG:K' [ GM0!)\
M$O\ DD.A?]O'_I1)1\;?^20Z[_V[_P#I1'1\$O\ DD.A?]O'_I1)7::MIL.L
MZ-?:7<-(L%[;R6\C1D!@KJ5)&01G!]#0!Y7^SC_R3S4/^PK)_P"BHJZ#XTZ)
M_;?POU39;^=<6.V]B^?;LV'YVZ@'$9DX.?89Q7'_  -OG\,ZQX@\ ZQ)!!?P
M79FMT*LK7!VXD*EL97:D;+P"58MR.G:?&/7U\/\ PRU5MT?GWR?885=68,9
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M'7'@GP-#87W%_<2M=72!PZQNP "@@=E5<]?FW8)&* .XHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_0O?^3MQ_\ '*] HH KV-E%I]G':PO.\:9P9YWF<Y)/+N2QZ]SQTZ58HHH
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M:2T;.48XQR0>@]!6QJNE6.N:7<:9J=M'<V=PFR6)^C#^8(."".00",$5<HH
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M*JX#*,$;%" ,#A20,57TKX6>%]-U2WU>>"[U36('WC4=2NGGE9API8$["5&
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M'(Z;MC D9YP>,@'J!7)_\*2^'G_0O?\ D[<?_'*] HH \_\ ^%)?#S_H7O\
MR=N/_CE=I!I=I:Z-%I-NDD-G%;BVC6.5U9(PNT .#N! _BSGOG-7** //_\
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M&2 #T"BBB@ HHHH **** "BBB@ HHKC]9^*/A#P]J+V&KZE/972Y.R:PN!N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?_&W_
M ))#KO\ V[_^E$=>@5Y_\;?^20Z[_P!N_P#Z41T > ?!+_DKVA?]O'_I/)7U
MW//#:V\MQ<2QPP1(7DDD8*J*!DDD\  <YKXT^%NMZ=X<^(^DZMJUQ]GL8/.\
MR78S[=T+J.%!)Y(' KTCXP?&#1M?\.-X<\.-]MAO-CW5V\;QB,*X8(H8 EB5
M!)(P!P,D_* =O??#_2]!^+/A3Q%HUK!90SRSVMS;0C8F_P"RRE&1 ,+PC!L$
M?PG&2QJ3XO\ PVU+X@V^DMI=Y:03V+RADNMRJZN%Y#*"004'&.<GD8Y],KY_
M^/,^I^%=1TB\T7Q!KEG_ &C]H,\*:G-Y892A!52WR_ZPC ^4 # '.0#TSX8>
M!YO /A5]+N+Z.[GGN#=2-'&55&9$4H,G+ %/O8&<]!7SI\;?^2O:[_V[_P#I
M/'7M?P"U;4M9\"WUQJFH7=].NIR(LEU,TK!?*B. 6).,DG'N:\4^-O\ R5[7
M?^W?_P!)XZ /I_P)_P D\\-?]@JU_P#12UX_KO[/VL:WXYU/4?[:L8=,OKN6
MY\S8[3)O)?;Y?"G#';G>..?]FO6/"5E%J'PQ\.VLSSI&^E6F3!.\+C$:'AT(
M8=.QYZ=*^7/$OBGQ5HWBK5]+M_%OB!H+*]FMXVDU*4L51RH)P0,X'H* /LNB
MN;\?1%O NM7"7%W;SVEE/<PR6MS) RR)$Q4DHP)&>=IR#QD<5\T> ?''C:7Q
MOID-OJNI:K/,[Q1VMY>S/ 69&4/(H))1"=YXZ(>1U !]=T5\N?&+X>ZUX?M[
M?Q'JWBB37'N;@VSM-"8VB)#.H0;F 3A^!M"\8'/'I?P&\97GB;PO>:=J4T]S
M?:9*,W,S%VECD+,NYF8DL"KCL H3KS0!ZQ17@?QQ^)^I:;JG_"*Z#=R6CQ(D
MM[=0,R2AC\RQJW&T;=K$J3G<!D88'4\%_"#2=3\#6NLZG+._B;4HC?1ZJ+J4
MO;R2#=$X 9<LN58YR2V[G&* /:**^0/!>M>)/%7BBUT6\\?ZYIGVK*0SF[DD
M4R8RJD&5<;N0,9)8J,<Y'UGI-G-IVC6-E<7<EY/;V\<4ES)G=,RJ 7.23DD9
MZGKU- %RO-_CK8V]W\*-2FGCWR6DL$T!W$;',BQD\=?E=ASZ^N*](KS_ .-O
M_)(==_[=_P#THCH ^4+ZQU3PSKDEK=1SV&IV,H) ;:\3C!5E8?@0P//!!KZO
M^%GQ(L_'.AQV\TVS7;2)1>0O@&7& 9EP "I/4 ?*3CIM)P_C/\,(?$NES>(=
M'M)#KUL@+QP*";R,8!!'=U7D$9) VX/RX^=/#'B?5/".N0ZOI$_E7$?#*W*2
MH>J..ZG _($$$ @ ^H_CC!#-\)-7>6*-WA>!XF902C><BY7T.UF&1V)'>O0(
M((;6WBM[>*.&") D<<:A510,  #@ #C%>3^/_%%CXQ_9\U+6+"2,B5+831*^
MXP2^=%NC;@'()ZX&1@C@BO7* "BOE#XI>(-?\.?$?5M)TGQ'KEO8P>3Y<7]J
M3OMW0HQY9R3R2>37O^F:=/XG^%FC12ZG?6]]/I4$BWT-S*DBS- ,2,4=2^"V
MXJQP3UH ["BOCSP7XT\577CKP];W'B769H)=3MDDCDOY65U,J@@@M@@CC%?3
M_CZ(MX%UJX2XN[>>TLI[F&2UN9(&61(F*DE&!(SSM.0>,CB@#I**^,-"\<>.
M)/$.F1V>OZK>W37<0AM;B_E,<SEQM1P7 *DX!R1P>M=A\8/AWJF@:=%XEU?Q
M9/KEU<78ML36WE[ PDD^7YV"J"#A0 !NXQ0!]/T5\X?##QAXU\:6=YX+CUSR
M)#$UQ_;$^Z6Y@AR R)R-S%G3#%@5&[!)V[>+^(/AO4OAMXU@6#Q#=W6H3V_V
MPZ@@:"4,[2*WS!R23M.3GG<: /L.OD#XV_\ )7M=_P"W?_TGCKZ3^&FOWWBC
MX>:1K&IM&UY.DBRNB[0Y21DW8Z D*"<8&2< #BOFSXV_\E>UW_MW_P#2>.@#
MZ?\  G_)//#7_8*M?_12UT%>+Z9\+KCQS\/-&D\0>([Z-CI\!L;2R8"TMT$0
M$3/&PS))@DLV1]XJ"  :\T^'_P 0=:^'/BK^Q=7GD.DQW!M+VTED+K:$.0SQ
M[=V"K%B0N0W/?! !]9T5C^*O$-OX4\+ZCKETN^.TB+A,D>8Y.$3(!QN8J,XX
MSD\5XA\/HKSXU:YJ=YXSU&>YTW3?+:/2H6,,!:3S-I^4@_( P!Y8Y&6P"" ?
M0]%?.%QXLO/@Q\4+S184OI_";;'CL9W+>7&XW%H"W]UVD'HV"&.X;AZW\4M/
MO;GP'JE[I=_=V.H6%NUQ%-!>2P *I#R A" Q**P&X'!/;)- ':45\@>"?B%X
MLM_%]B6UC5=4DD\R&WL[B\>2.6>2-DA#AG V^8R$\C &>HJYXJ\#?$__ (36
M)[Z+4M5U(NCV^HVA=XD)8L-LF (@K$\':%ZC P2 ?6=%<7\5[_6M,^&^K76@
MF1;M$7?+$Q$D418;W3"GD+G)^7:,MD%1GQ#]GW4]:3QX--M)))-+>WEEO(&E
M.R,84"54W ;]PC7."<,?J #ZCHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \_\:>&+CQUXMTS0]0@GC\,V$7]H74J8 NI
MRS(D(;AEPH<DJ3P^#M)5JN:E\)_!&I:,NF'P_:6R(@6.>U01SJ0I4,9!RY&<
M_/N!(!(-=I10!\V?"*:^\$_&74?!THDD@NGEMW9X_*+&(.\<V""<%0V #@B0
M')P*];^+'C&X\$^!IK^QXO[B5;6U<H'6-V!)8@GLJMCK\VW((S7'_#&V_P"$
MO^*'BGX@,L$EBLK6-@XB^_@*HD&X[D81*F>!GS6Z8(K+_:9GF6W\-6ZRR"!W
MN7>,,=K,HB"DCH2 S 'MN/K0!W'P5\.0Z%\-].N&L8X+_44^TW$@(9I5+,8B
M3D\>65(7MD\ DUQ?Q/O'^'GQAT/QG;C%KJ$1BOHHW8O,$PLF5R!]QHMHSC<@
M)'&3ZQX$_P"2>>&O^P5:_P#HI:\?_::_YE;_ +>__:- 'LGC"\U>Q\)W\V@V
MDEUJS(L5I&F,B1V"!^01A=V\YXPIR0,D<_X7^$/A#PYI:6\VDVFJ7911/=7T
M"RF1AGE5;(0<D87L!DL1FMSP)_R3SPU_V"K7_P!%+704 ?,'Q<\"V_PXUS1O
M$'A<3VUN\NY$*F5+:>/:RD.V<[N2%;/W&ZC@?0<&OS77@6+Q';Z=)-/+I@OH
M[&-BS.QBWB($+DDGY<X_#M7F_P :1-XJ\0>%O %C)&)[VX-Y<,4):&-0RAQD
MA2-OGDKG)V#ID9]@@@AM;>*WMXHX8(D"1QQJ%5% P  .  .,4 >=^#OA3H]G
M9_VMXGT^#5?$>H;KB_DO(T=$DD(=D6,9C&#QN R?FP0#M'GGQO\ AAI&@:7%
MXET"TDM4:X\J\MH5+1+OW$2#_GF-V%P/E^90 /XOHNO*_CMJ4Q\)V'ABQ6.7
M4-?O8[>*%@06565LJV0JG?Y0^8]&/U !UGPZ\0W'BKX?Z/K%XN+J:(I,<CYW
M1FC9^  -Q4M@#C..U<OX4^'EGKUY<>-/&>D^=K6IRF9+"\4,EE#@I'&4& [;
M-N2ZY&!P&!)[SPWHD/ASPUINC0>64L[=(BZ1B,2,!\S[1T+-ECR>2>36I0!X
M?\8_A3H47A>\\1Z#I_V*^L]LDT%G&?+FCRJM\@X3:/GW* ,!L@YR.H^!WB&X
MU_X:VR72_O--E-@'R/G1%4IP ,85U7OG;DG)JY\8]?7P_P##+56W1^??)]AA
M5U9@QD!#CCH1'YA!/&0.O0Z'PV\+MX0\!Z;I4\<:WFPS7>U%!\USN(8@D,5!
M";LG(0=L"@#S/X[ZG$?&7A#2=7AGC\/+*MS>2[G\N93(%=<*.61 3D$L!+QC
M//O%</\ $WX=V_Q!T..(3?9]3L]SV4S$[ 6QN1P/X6VKR!D8!&>5/B&@_%OQ
M3X.T>\\&WGD+=VTOV.WOKIR_]G8;:X8*&\Q5P=N,XQT=<+0!W_@DV]M^T=XS
MM-,G_P!!EM#-+'',71I]T)<GD_,'>4?[.6''2O:*Y/P#X0TWPIHTCV6H2:I/
MJ3K=W.I2LKM<LRCY@PY*$Y8 EOOGDYS6AXM\2P^%/#\NI/;R7<Y=8;6SB($E
MS,YPD:#J23R< G ) .,4 <OXZU";Q-K-O\/-'GC\R[3SM:FCG*26EF&3*C (
MWR!MN#G@\KM;<.#_ &9?^9I_[=/_ &M7KG@SPU-X>TMY-3N([W7KY_.U*_ .
M9Y.=JC/1$4A5    R%7)%>1_LR_\S3_VZ?\ M:@#Z KA_B%XBO((K7PKX>E@
M/B76]T,"O,8S;0[6+W!*\C:%..02>0&VE3U&N:S9^'M#O=7OWV6MI$TKX(!;
M'15R0"Q. !GDD"N?\$:->'[3XHUU,ZWJWSJD@.^PM3AH[49 QMZMA5RQ.<D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(L;*21C<"N2!G 9?6O1_#WQ<TY? .A:)X;M9]3\5?9(;&'3FA90LB)M,CO\
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M9VX /I>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME'_RI?\ VJN ^&7Q-_X5S_:G_$H_M#[?Y7_+SY6S9O\ ]ALYW^W2OK^OG_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 8__  B?AO\ L[^SO^$?TK[#YOG_ &;[%'Y?F8V[]N,;L<9ZXJO_ ,()X/\
M^A4T/_P70_\ Q-=!10!AS>"_"MRX>?PUHTKA%0,]A$Q"JH51RO0*  .P %26
M/A/PWIEY'>6'A_2K2ZCSLF@LHXW7((.& R,@D?C6Q10!\^?&:SL?&GQ(TCPQ
MHEO(_B94$-Q/)+L@2+:90I!')52SY7L<8<D!</\ X9Q\8?\ 02T/_O\ S?\
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M"<,,$9X-4] \'>'/"R*NBZ/:6CA"GG*FZ5E+;B&D;+L,XX)/0>@K<HH Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2=-UFW6WU33[2^@5PZQW4*RJ&P1D!@1G!(S[FLO_ (03P?\ ]"IH?_@NA_\
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M&U&<Y(D)Z*>U:'Q'^)5G\.[.S:;3Y[VZO=_V>-'")\A3=N8Y(X?C"G.,<=:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_2B.O /@E_R5[0O^WC_TGDKW_P"-O_)(==_[=_\ THCKP#X)?\E>T+_MX_\
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M'QC\36FI>+_#WBSPY<W;HEN!;W4EB\<1DAF9@4:0#S"&;YAMP,#DY( ![O\
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M\$O^20Z%_P!O'_I1)0!Z!1110!\__M-?\RM_V]_^T:]@\"?\D\\-?]@JU_\
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MDTL4,D87."=T<K9V]2!E@"..1FG'\-M2/QRF\<RWEHNGA,Q0KN:5F^SB'##
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M19SSP3:K*XE:/ #P(OSH3U&2Z=.H# G!P?2/"FC?\(]X2TG2"D"26EI'%+Y
MPC2!1O8<#.6W')&3G)YH P_"OQ1\.>+-4ETF!KNPU:-W4V&H0^5*=F-V,$C(
MY^7.[Y6.,#-;&O\ C'PYX61FUK6+2T<('\EGW2LI;:"L:Y=AG/(!Z'T->-_M
M#>&_[/O-*\::?)]FNC*MK,\3;',B@O%(I SN 5@6)R-J =*] U#6+?QC\"+_
M %>5()OM.B32R*(CL6=(VW;0W/RR*<'G[H()X- %C2?BQX6U/PE/XFFGGT[3
M8;O[&3>1C>TFU6PJH6+<-VYX8XP,UAZ5^T!X-U/5+>Q>/4K$3OL^T7<4:Q(>
MVXJY(&>,XP,Y.!DCG_V== L9]!NM>G62:\M[V6WMA(V4MP8XR[(O0.P(5FZD
M*!P,YD_:1T:S?P]I.N;-M]%=_8]Z@#?&Z.^&.,G!3CG W-QS0![A16/X3OKC
M4_!NAW]Y)YEU=:?;S3/M W.T:EC@<#))Z5L4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'[Q?F7S OKE WR\Y(& 2%KYL^&FOV/A?XAZ1K&IM(MG \BRNB[B@>-DW8ZD
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MD)(R<%&.23][' 45TD.L?$M7.G3^%-&>XV,!JR:F5M-VTE3Y14RX'"D=R#R
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M$"*B7"-:,'&T=Y0')[$L,D@GGJ0#WB""&UMXK>WBCA@B0)''&H544#   X
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MR3\HP*ZC3?CGI6OW#6/A_P -^(-0U H3'"L,:KG( +N'.Q-Q4%R,#.:]4HH
MY?PAHEY:3ZKK^KV\%OK.M2QRW$$#EUMXT0)%$6SAF49+,  68XX KJ*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAD2X."#TKT>PU;XN:GX>MM9L[;P;)'=6B74,'^DB1@R!E7EMH8Y Y;&>^.:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%1SS+;6\L[B0I&A=A'&SL0!GA5!
M+'V )/:O _B/\;?$NEW@TO2]$GT-I(DF6XU&)6G9&"L"J<HO(=3G?W'RL"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2&'3E2<;ES@G%<':_#SPM:_ .>\.DP3WTVB-J+7DR@S+,8?,&UQ@JH( "CC
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M+^[@M+6/&^:>01HN2 ,L>!DD#\:X.?XR:!]GEO-+TOQ!K.GPH6FOK#3F,$)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\H7 921E6)S@&@#QCXA^';S6?"3_ !'FBG$FI:K(R(\)#K8LH2W,@'RIM\O
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M5U+_ -!FH ^GZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_^-O\ R2'7?^W?_P!*(Z]
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M1X^^&_CWQ?XWU/7;?PM);P7+H(XY+ZV+;414!.), D+G'.,XR<9H ][\"?\
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MPC'G?8;N*Y\K[?;KOV.&VYWG&<8S@T >W_&W_DD.N_\ ;O\ ^E$=>0?LX_\
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MM[>*.&") D<<:Z>JHH&  !P !QB@#W^>>&UMY;BXECA@B0O))(P544#)))X
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MT715>QN);NSCGFLI[*1LY@G*%TP2.2C,O/7@GKZ\58H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M\W^*$OB/PQX0U'Q%I'BN^BDMY4?[--:VLD>QY FQ?W088W@@DMPN#DG( /2*
M*^4-"^+7Q#UOQ#IFD_\ "3^3]NNXK;S?L%NVS>X7=C8,XSG&17M__")?$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L?Q#XJT+PI9BZUS4X+*-ON!R2\F" =J#+-C<,X!QG)XK4GC::WEB2:2!W
M0JLL84LA(^\-P(R.O((]0:^7/CGX)M_"VL:7?V^HWUXVI1,DIOI3-)OA6-=Y
MD/)W!AQV(.."%4 ^IZ*** ,_6=<TOP]ISW^KW\%E:KD;YGQN(!.U1U9L X49
M)QP*L6%];ZGIUM?V<GF6MU$DT+[2-R, 5.#R,@CK7SY\>/ L.D:7I_B/^U]2
MOKM[C[),;Z42%]WF2@K@ (!AEV* N", $$M[7X$_Y)YX:_[!5K_Z*6@#H***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.>@>'-8GTG5M%URWOH-OF1>7 ^W<H8<K,0>"#P:T/@E_R2'0O^WC_P!*)*\
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MQC;:I>Z]'/9V%Q%<6RPPE9)F7YL/DD( P'0MN&?NF@#W2BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^?\ ]IK_
M )E;_M[_ /:-?0%?/_[37_,K?]O?_M&@#Z HHHH \?\ VCO^2>:?_P!A6/\
M]%2UZ!X$_P"2>>&O^P5:_P#HI:\__:._Y)YI_P#V%8__ $5+7H'@3_DGGAK_
M +!5K_Z*6@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KS_XV_P#)(==_[=__ $HCKT"O/_B%H/C#QAX<OM LK70[6UN)
M5S<S7TSNT:.&7Y!" K$JN?F8#D<]0 ?,'@3_ )*'X:_["MK_ .C5K[+\2:)#
MXC\-:EHT_EA+RW>(.\8D$;$?*^T]2K88<CD#D5X!I/P"\;:-K-CJEOJ'A]I[
M*XCN(UDFF*ED8, <1@XR/45]!Z9-K$OF_P!K6-C:XQY?V2\>XW=<YW1)CMTS
MG)Z8Y -"O'_VCO\ DGFG_P#85C_]%2U[!7F?Q6\&^*O'ME!I.G#1K;3X+@7'
MG7%S+YLC!"H&U8R% W/W;/RGCD4 <7^S+_S-/_;I_P"UJ/VFO^96_P"WO_VC
M70?"SX=^,/AYJ-YY[:'>6-_Y0GV74RR1["<,N8L-P[?*<9./F'.3XI_#OQA\
M0]1L_(;0[.QL/-$&^ZF:23>1EFQ%A>$7Y1G!S\QXP '[./\ R3S4/^PK)_Z*
MBK@/VCO^2AZ?_P!@J/\ ]&RUZG\*?!OBKP%93Z3J(T:YT^>X-QYUO<R^;&Q0
M*1M:,!@=J=UQ\QYX%<O\0_A3XV\?^)5U:63P_9)';I;Q0K=S.0H+-EF\H9.Y
MFZ <8';) .T^"7_)(="_[>/_ $HDKP#XV_\ )7M=_P"W?_TGCKZ'^&?A[Q)X
M1\.0:!K*:5):VOF&"YL[B0N=S[MK(T8'5G^8-_=&WJ:\T\8?!;QMXP\67^O3
MW7A^W>[=2(4N)B$55"*,F+D[5&3QDYX'2@#T/X)?\DAT+_MX_P#2B2OF#P)_
MR4/PU_V%;7_T:M?3_@;P]XP\(?#^70G30Y[ZUW?V?(+B;RVWL6/F_N\_*6)&
MW[PP/EQN/E%A^S]XXTS4;:_L]6T..ZM94FA?S93M=2"IP8L'! ZT ?0?B/0+
M'Q3X?O-%U)9#:72!7\MMK*00RL#ZA@#SD<<@CBO!/ .E^(O"WC36K_P%:?\
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M X[9./4UV?BOX$/K.AV[V_B.^OO$,. UWJUPTB2IQE!U,:@[F7&[[S DY!4
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M;3OVHN 1R I+;<9R-V* /H^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *^?/VF9X6N/#5NLL9G1+EWC##<JL8@I
M(Z@$JP![[3Z5[_/"MS;RP.9 DB%&,<C(P!&.&4@J?<$$=JX_4OA1X.UFX6XU
M33KN^G5 BR76IW4K!<DX!:0G&23CW- ':45EZ)X?T_P];_9].^UK!L1%CFO9
MIUC51A0@D=@@ .,+CH/05J4 >-_M(3PKX%TRW:6,3OJ:ND98;F58I Q ZD L
MH)[;AZUZ)X$_Y)YX:_[!5K_Z*6L_4_AAX3UORO[6M+Z_\G/E_:]5NY=F<9QN
ME.,X'3T%:F@>$='\+HL6CQW<$"H46!KZ>6) 6W';&[E0<\Y SR?4T ;E%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)'&>\OKV+3[.2ZF2=XTQD00/,YR0.$0%CU[#CKTH L45Y_\ \+M^'G_0P_\
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MXW>27@N'<;48MM>4'9\N[.",]#GBO5)YX;6WEN+B6.&")"\DDC!510,DDG@
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MG_'?_)//$O\ V"KK_P!%-705S_CO_DGGB7_L%77_ **:@#XX\)_;/^$RT/\
ML[R/MW]H6_V?[1GR_,\Q=N_'.W.,XYQ7LGB^3XAO\1O!J^*X;2/2TUBU6W;3
M"WV627S%)8[B6WX) W8X5MH^\3Y'X$_Y*'X:_P"PK:_^C5K['\1Z-_;=C:1*
MD!FMM0M+R-YA]SRID=BIP<,4#J/][&0": -BN?\ '?\ R3SQ+_V"KK_T4U:&
MN:S9^'M#O=7OWV6MI$TKX(!;'15R0"Q. !GDD"N;U;4IM9^"=]JEPL:SWOAR
M2XD6,$*&>V+$#))QD^IH ^8/AIHJ^(?B'I&E2SR0P7#R"?86!DB$;-)'E2"
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M6U_]&K7U_P"._P#DGGB7_L%77_HIJ^0/ G_)0_#7_85M?_1JT ?;]?$'CO\
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M^P5)_P"C8J[_ /:._P"2>:?_ -A6/_T5+0!S_P"S+_S-/_;I_P"UJ]@\=_\
M)//$O_8*NO\ T4U>/_LR_P#,T_\ ;I_[6KV#QW_R3SQ+_P!@JZ_]%-0!\P?!
M+_DKVA?]O'_I/)7H?[1OBN:%-/\ "EN9$29!>W3#(#KN*QIP>1N5F((ZA"#P
M:\\^"7_)7M"_[>/_ $GDKJ/VD;&XC\9:3?M'BUFT_P F-]P^9TD<L,=>!(GY
M^QH ]#_9]TV:Q^&0N)6C*7][+<1!2<A0%BPW'7=&QXSP1]!XIXXFO/ _QMU2
M^L+G?=6^H?;D8@H#YH$IC8 Y*X<H>1N&>F<5[_\ !+_DD.A?]O'_ *425\\?
M&"^M]0^*^OS6LGF1K*D).TC#QQI&XY]&5A[XXXH ^F_$NI0ZS\(]7U2W618+
MW0IKB-9  P5X"P!P2,X/J:^6/AIHJ^(?B'I&E2SR0P7#R"?86!DB$;-)'E2"
M ZAD)!Z,>O2OI>>":U^ 4MO<120SQ>%RDD<BE61A:X((/((/&*^?/@E_R5[0
MO^WC_P!)Y* /1_C]X4\/Z1X-TZ_TS1;&QNAJ"PE[2!8MR-&Y((4 'E%Z].<8
MR<G[-%]<2:=XBL&DS:PRP31IM'RNX<,<]>1&GY>YK8_:._Y)YI__ &%8_P#T
M5+7/_LR_\S3_ -NG_M:@#T3XK> KGQ]X:@L["[CM[RVN!-'Y[N(G&"K!@N1G
M!R&VDC! P&)KE_@K\+M7\'7MYK>O+'!=SV_V>&VCF#E%+Y<O@$9^1"NUCP3G
MGIZIK.N:7X>TY[_5[^"RM5R-\SXW$ G:HZLV <*,DXX%4_#7C#0/&%O//H.I
M1WB0.$E 1D9"1D95@#@\X.,'!]#0!N4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG1M9L=4M_#D;3V5Q'<1K)>0%2R,& .) <9'J*]S_ .$M^(?_ $3#_P K]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:V\MQ<2QPP1(7DDD8*J*!DDD\  <YKQ?6_VD-%M+CRM&T6[U%%=U>6:46ZD
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M)S_K#M4H,[1G!'.3M S0![)1110 4444 %%%% !1110 4444 %%%% !1110
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MK5ROC#0_!/C&'Q]9:1::;/9ZW;RK<1M/'A(0C_ZXD@J8PR_>&0W0;B0#]GT
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M''A*VU:+Y;A<0WD80J(YPH+A<DY7D$<G@C/.0.HH P_%'A'1?&.EO8:Q91S
MHRQ3A0)8"<'=&^,J<JOL<8((XKQ#X"1WVA_$OQ)X<FFC9(;>1;A8QE7EAF5
MP) ./G?TSGD<#'T'?WUOIFG7-_>2>7:VL3S3/M)VHH)8X')P >E>3_!+PW>2
M2ZQX\UBU^SW^N2N]O&%*A87;S&906/RNQ&-PSA 02&H C_:&\47VC>&M/T>Q
MDDA&K/*+B5'P3$@7,?3.&,@R01PI!R&->D>#M 7PMX.TK156,/:VZK+Y;,RM
M*?FD8%N<%RQ[=>@Z5\^?M'?\E#T__L%1_P#HV6OI^@#Y_P#B!?/X!^/VE>)4
MDGBL=2BB%])(K&(IGRI% 7&[:BQOM^;#;3CH*]<\;Z1?>(?#XT2S\Q(M0N(X
M;VXCN/*:"VSNE(X.XLJ^7MQ@^9SP#7D?[37_ #*W_;W_ .T:]L\-:E-K/A72
M-4N%C6>]LH;B18P0H9T#$#))QD^IH --\-Z+I&C-H]AI=I!I[H4DMUB!64%0
MIWY^^2H );)/?-?.'QD\*0_#_P :Z7KOAX1V<5VYN88DP1!<1,K$JI& GS(0
MO(SN& ,"OJ.O%_'>DO\ $;XPZ1X;6'S=(T.(3ZG*L;#89,-Y3-D??5(P-O(W
M,>=I  /4/%46J7'A?4;;15SJ5Q$8('\_R?*+G89=X!(V!B_')VX')%1^%_".
MB^#M+2PT>RCA 15EG*@RSD9.Z1\98Y9O89P !Q6Y10!\X?'OX?Z7H,5CXCT:
MU@LH9Y?LMS;0C8F_:2C(@&%X1@V"/X3C)8U[OX3OKC4_!NAW]Y)YEU=:?;S3
M/M W.T:EC@<#))Z5YO\ &6VO/%^N>&_ >F+NDGE^WWL@B+&VA'[M9220NWYI
M<C.254<$C/K%A8V^F:=;6%G'Y=K:Q)#"FXG:B@!1D\G  ZT 6**** ,/1/"]
MCHU[?:CY<=QJE[<32S7SIF4H[Y2+<22$11&H4$#Y <#->5_M(Z-9OX>TG7-F
MV^BN_L>]0!OC='?#'&3@IQS@;FXYKV35=172=+N+][:[N1"F[R+2!II9#T"J
MB\DD_@.I( )KP#7_ (S*_P 0;!]=\)7<6GZ4Y:*RN9&2=)6*E;AXR-I=8\[$
M/0N2'Z$ 'N?A.QN-,\&Z'87D?EW5KI]O#,FX':ZQJ&&1P<$'I6Q5/2M5L=<T
MNWU/3+F.YL[A-\4J=&'\P0<@@\@@@X(JY0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@9;YE(4@UGI\59=(URUTKQMX;G\-M>X^RW37:7,#=0=\BX"8.T=\;@6VCD^
M?#SQ3;Z?\5[/Q+XAO/+C:6XFNKCRB<O)'(,[4'=F[#C/I7:?&_QEX/\ &>C:
M5+HFKR76H6=PZ^4()(U\IU^9CO09(9$ P>YX/8 ^DZ\O\<_&O2_!?BB+0_[-
MGOY(]IOG1_+\@, 0%!'[QMISC*CD#.<[;'P,UG^U_A?91,\\DVGRR6<CS'.<
M'>H4Y/RA'11TQMQC %<_X_\ @1_PD_BA]:TC4X++[9*AO()8?E7C#R(5ZL<
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MF.8*8P=VXDQF08;J=IY&XU[WX[_Y)YXE_P"P5=?^BFH \?\ V9?^9I_[=/\
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M69O-89.^96)  7)'\([ 5C_%_P )>)O'UQI-QI'A"[@GM4E2>2ZGM%9U)4H
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M,\4*);@G 9F\W!!'S#;DL 2H(KK+^^M],TZYO[R3R[6UB>:9]I.U%!+' Y.
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MQTOPUY<,_GWNI38,&F6">==S YRRQ@YV@*Q+' ^4\YP">!/^2>>&O^P5:_\
MHI:\G^%?BF;7/'/C;Q'#H5]JDEU+"(9(5MDD@@S($1M\B=52,':3DQY)S@D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<V\EG!5(U[NRAXPS*-H.3PM '@'P2_Y*]H7_ &\?^D\E>O\ [1W_ "3S3_\
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MW,DF[;YF[[BG&-R]?6M_XC^-=8^)%F/#W@72+[4-%EE2.ZU!+1PDL@*L(PS
M"-5)4EFP?HHRP!X9I.FS:SK-CI=NT:SWMQ';QM(2%#.P4$X!.,GT-?=\$$-K
M;Q6]O%'#!$@2..-0JHH&  !P !QBO)_A-\(&\&W":]K,\<NK26^Q+944K:%C
M\WS\[GVX7*X RX^8'->H:M)?0Z-?2Z7#'/J"6\C6L4APKRA3L4\C@M@=1]10
M!<HKXL\/:GXR3X@P2V$FI7'B1KA8I(II9/,F*$9BFRP)0; &#$ !>< <?:=
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M?X<TI?'FLV?C[6;:1+>)"-#TZ;=^Y3<?])D4\&5\ C;P%"'+$!AZ)7S_ /\
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MO)4'EV$=E*T[R$<1#"[2Y/R_>QGOCFH_!?@^XN_&FI_$/7+;[-?:A\EA8R1
M/:P85%>3).V8HH! /&Y@?O;5 /2**X?XE?$3_A7FG6-U_8T^H_:Y6CRLGE1Q
MX&?F?:WS'LN.0K'/'.?8_'7P#=V<<\VJ3V4C9S!/:2%TP2.2BLO/7@GKZ\4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)+6+]ZX;(,C$N^TX'R[F;&1G&,\UT% !114<YF6WE:WCCDG"$QI(Y16;' +
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M9P19Z21#]HZADE=8T;RRI(*CKNSD;1D X_\ 9E_YFG_MT_\ :U'[37_,K?\
M;W_[1K8\ ?"+Q3X0UR]1_$D$>A77$ZV0(GN57<$!++F'AV)*-N'0'.&'4?%C
MX=O\0-#M8[*:"#4[*4O!).6"%&P'0[<XSA3G:?N8XR30!Z!7S_\ M-?\RM_V
M]_\ M&N\\!^#/%>DBP'BO7[2_M]+39IUE:P +"1'Y:R&3:C,0C2)M8$?,#G(
M&,/XI_#OQA\0]1L_(;0[.QL/-$&^ZF:23>1EFQ%A>$7Y1G!S\QXP >@>!/\
MDGGAK_L%6O\ Z*6N3^.?A=O$/P^FN[>.,W>DO]L!*+N,0!$JAB1M&WYSUSY8
M&"<8ZCP18:]I'AJRTG78M-#V-O';Q36,[N)54;065T7:0H7H3DY/R\"NDH \
M#\&^(H?'G@/PSX$N!)<2O<&+4R8@1'9VQ65?N,"@?]S$'(Z[^I )]\KS?X7?
M#5/ EYK\TJ>9-/=F*SG9E<FT #)R%!#$L0XX!,8P, $^D4 ?-GAW6X? W[1>
MOC7/+M8+^XN(C-)( L*S2":)R1D8("#G&W?DD8-?2=>9_%;X4KX^2#4-/N([
M;6K=!"K3LWE2Q;B=K8!*D%F(('<@@Y!7SC3?AK\8UN&TU->N["SMD*0S-K$@
M@95(50BH2P&.0"HP!S@\4 >_P:W#=>);S1K?RY'L;>.6Z<2#,;2%O+3:,\[4
M9CDC *8#;CMU*Y_P=X4M_!^A_8(KF>\N)I6N;R[G8E[B=L;Y#DG&<#CVY).2
M>@H ***IZE)J45NK:7:6ES/O 9+JY:!0N#R&6-R3G'&.YYXY /FSP;_R=#<_
M]A74O_09J^GZ^?(?@Y\0;;QJ?%<&I^'XM0-ZUZ52>X5"S,69.$SL.2I&>02,
MU[OILFI2V[-JEI:6T^\A4M;EIU*X')9HT(.<\8[#GG@ N5\__LR_\S3_ -NG
M_M:O<-9?6$TY_P"PX+&6^.0OVZ9XXTX.&.Q6+8./E^7(S\PKR/X;?#+QM\/-
M9N[U9M&OH+FW\I[8:A-$I;<"KG]RP) # <?QGGU .L^-O_)(==_[=_\ THCH
M^"7_ "2'0O\ MX_]*)*D^)&@>*O%_A^\\/Z7#HT%G</&6NKJ[E\PJI#X$:Q8
M4[E'.YN > 3P?#?0/%7A#P_9^']4AT:>SMWD*W5K=R^8%8E\&-HL,=S'G<O!
M'!(Y /*/@1K</A/QKK/A?6?+M+N\=8%9Y!@7$+,OE<9!+;VP<XRH R6%?2=>
M/_%+X+OXQUA=<T.[@MM2EVI=I=NPCD"KA7! 8JP  QC!&#P0=W*:)\._C'J-
MQMU'Q/J6DP*Z!GFU>25F4GYBBQNP) '1BN<CGK@ ]WTO6X=7O]5AM?+>#3K@
M6CS+(&W3! [K@< *'09SG=O! V@MXG\+/^3A?&O_ &_?^E:5[)I6AKX3\)V^
MC^'K:.86B;88[NY9 Y+9=F<(Q!)+-PN,\  =/)]!^%_Q!T+X@R>+DO?#[SW%
MQ++=6R75PD<JR$ET_P!63C)R,YP54D'% 'NE>#^"YO\ A<WCG5]5URYGET'2
M)8GL='8;86W&01M*N2"P"DMUR6QG:-I]PL7O)+.-K^"""Z.=\<$QE1>3C#%5
M)XQ_"/3GK7A\'P<\:^%?%NHZGX(UO2K&UGWQP"?<SI"S!O+(:-QP0!NSD[<\
M9(H U/VAX(;7X::7;V\4<,$6IQ)''&H5440R@  <  <8KT3P)_R3SPU_V"K7
M_P!%+7G?BKX.:UXI\-12ZCXEDO\ Q0'1VDNF*VD8P0\<2(H" C82VTEC&#A=
MQQVGP_\ #.N^'M#MK?Q#K7V^ZMXA;P0P )!;PK@*HPJF1L*OS."1T&,L6 /+
M_A9_R<+XU_[?O_2M*^@*^9/"=GKUS\>/%DWAR[M(-0M;B^E$=[O\B=3<!"DF
MP@X^?>.OS(O'<>KZK<?$CQ&EQHMKHMIX:C=]DFL_VD+D^5NPWDHJJP<@Y!;;
M@ _=;! !P?P1_P")]\4_&'BBU^2QD\W$<O$G[^?S$X&1P(VSSU(QFC]IK_F5
MO^WO_P!HU[!X+\)V?@KPO:Z+9OYOE9>:<H$::1CEF('X 9R0H49.,UY_\4_A
MWXP^(>HV?D-H=G8V'FB#?=3-))O(RS8BPO"+\HS@Y^8\8 /0/ G_ "3SPU_V
M"K7_ -%+7AGP(UN'PGXUUGPOK/EVEW>.L"L\@P+B%F7RN,@EM[8.<94 9+"O
M;_!%AKVD>&K+2==BTT/8V\=O%-8SNXE51M!971=I"A>A.3D_+P*X/XI?!=_&
M.L+KFAW<%MJ4NU+M+MV$<@5<*X(#%6  &,8(P>"#N /8*R]+UN'5[_58;7RW
M@TZX%H\RR!MTP0.ZX' "AT&<YW;P0-H+>$:)\._C'J-QMU'Q/J6DP*Z!GFU>
M25F4GYBBQNP) '1BN<CGKCW?PYH%CX6\/V>BZ:L@M+5"J>8VYF))9F)]2Q)X
MP.> !Q0!Q_B3X?>&?BEH-EK(@DT^\O+=+F&]BC592'C&T3#D. -O&<C;@, 3
MGR30M,\4_"'XM:9I/G;]/U:[BMO-VGR;R%G"[L9^61-V<9RI/=6^;T/PEI'Q
M+^'?A^+2UTS1O$5A&["&WM;TV\\6X[B2\B!2F=W&"V7'.!@;">#]:\6>,=,\
M1^+TM+2TTM%FTW2;28RM'.=K,TTNU=Q#*O"Y4X'. =X!Z)17E?QI\$>(_&UO
MH5OH;1M!#</]JCDGV*NX*%E(Z$* XXRPW\ Y-7/@J^J1>$M1TC5KS[5-HVJS
MZ;&P.X*D:I\JD@$J"6QGH,#@   'I%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0D94Y4'(]!Z5<HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O#_V@=<\6:+_9!TJ_GL=(EW!YK-WCD,XS\KN.BE3E5!Y(<D':,>X44 >1
M^'=?OOBC;^%4MVNUL=,>*\UV[9?)\Z[B ,<*8^5P7'F,N,!2G*M@5ZY110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *YOQ'XMD\-6]Y>7'AS6;FPM$#R75H('7;@9(4RA\#/)V\8)Z#-=)7/^._\
MDGGB7_L%77_HIJ .3T#XV:-XIU1=-T70/$%W=E"^Q88%"J.I9FE 4=!DD<D#
MJ17I$$C36\4KPR0.Z!FBD*ED)'W3M)&1TX)'H37@?[,O_,T_]NG_ +6KZ H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?:?2@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?XC^*
M_#^G^#?$>G76M6,=^VGS0BT\]3,7DC(0>6#NYW+VX!R>.:[BB@#YD_9_\7:+
MX<U36+#6+V.R.H)$T,\[!(LQ^82K.3A20_&>#@C.< ^S_$;Q)HMC\.=6>XU2
MT4:CIDZ66)0QN2\>U?+ Y89=>1D ')P.:[2B@#YP_9RUS2]-U'7+"^OX+:ZO
MOLPM4F?;YQ4N"JD\%LNN%ZG/ .#C?_:,US2Y/#-EHD=_!)J::@DTEJC[GC01
M/RP'W?\ 6)C.,YR,X->X44 >7_ K7-+N_AQIND07\#ZE:>>9[7?B1 9F8-M/
M)7#K\PXR<9SD5Y9X^\/:O\)_B1'XIT.VC339;AI;-]@:)&93YD#*  HP7"@?
MP=#E3CZCHH \/7]H7^U-.CMM#\*7USXAFWA;0'S8UP&(8%!ODP "5VKQN^88
MR?2/ >CZII>ASW&NOG6=3NY+^]19=Z0N^ L:$_PJBHN,MC!P2,5L:9H6CZ)Y
MO]DZ58V'G8\S[);I%OQG&=H&<9/7U-:% 'D>A?%S4M5^,MUX/ETVT33UN+BU
MBD5F\U6A#'>QZ$'RV^4 8W#DXY]<JO\ 8+/^T?[1^R0?;O*\C[3Y8\SR\[MF
M[KMSSCIFK% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !116/?>+/#>F7DEG?^(-*M+J/&^&>]CC=<@$94G(R
M"#^- &Q17/\ _"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4 =!1
M6'!XT\*W5Q%;V_B71IIY7"1QQW\3,[$X  #9))XQ6Y0 4444 %%%% !1110
M445S<?C_ ,*2^)9O#RZY:#5(G\MH6)4%\@;%<C:SY8#:"3G(QP< '24444 %
M%%% !1110 4444 %%%<_KWCCPUX8U&SL-9U>"SNKOF)'#'C.-S$ A%S_ !-@
M<'G@X .@HJ.">&ZMXKBWECF@E0/')&P974C(((X((YS4E !1110 4444 %%%
M% !116?J>NZ/HGE?VMJMC8>=GR_M=PD6_&,XW$9QD=/44 :%%<__ ,)WX/\
M^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5 '0457L;^SU.SCO+"[@N[
M63.R:"02(V"0<,.#@@C\*L4 %%%% !1110 4444 %%%% !1110 4444 %%%1
MSSPVMO+<7$L<,$2%Y))&"JB@9))/  '.: )**Y__ (3OP?\ ]#7H?_@QA_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXY=U?<06P3UZ9YKO/'7C!_!FAF_AT6^U6;D^5;1MLC1>7>20*1&H'KU], D
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MV"W;H3E%WY)5V*-]W 4%@Q? #>L>-()KKP+XAM[>*2:>73+E(XXU+,[&)@
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M<,91)E=C*",,J9=06P2Z$CY0:]@O[ZWTS3KF_O)/+M;6)YIGVD[44$L<#DX
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M >4)S@=<=LD ^AZ*\+\)77Q(^*/AB+S-=DT'3XD9'U** >??R^9D; NS8B*
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M^'?B!#H8E\/^-Y[C4X8LR0W5A:A+E^.$(C'E_P 6 Q;J 2.6JO\ "?XH?\+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUW_MW_\ 2>.OHOX:>'M-T_X6Z/9);1RP7UDEQ=+*BMYS3(&</QAAAMHSGY0
M<XKYT^-O_)7M=_[=_P#TGCKZ?\"?\D\\-?\ 8*M?_12T ?(GP^GFMOB-X;>"
M62)SJ=NA9&*DJT@5AQV*D@CN"17UWX[_ .2>>)?^P5=?^BFKY \"?\E#\-?]
MA6U_]&K7U_X[_P"2>>)?^P5=?^BFH ^8/@E_R5[0O^WC_P!)Y*^OZ^0/@E_R
M5[0O^WC_ -)Y*^OZ /B#P)_R4/PU_P!A6U_]&K7U_P"._P#DGGB7_L%77_HI
MJ^0/ G_)0_#7_85M?_1JU]?^._\ DGGB7_L%77_HIJ /F#X)?\E>T+_MX_\
M2>2OKN>"&ZMY;>XBCF@E0I)'(H974C!!!X((XQ7R)\$O^2O:%_V\?^D\E?7]
M 'Q1XITFX^'_ ,1;NRLKG]]IEVDUI,<.0/EDB+94 L 5SQC(/45]5S>/+&#X
M9#QJZQF V2W'DI+O'FL !#O4'GS#L)QP<Y P:\W_ &C?"ZSZ7I_BB".0SVSB
MSN=J,P\ILLC,<X4*V1TY,HYX KE/@WJFJ:_>:;X-8SG3+'4%UEY8[C:8TB!(
MB*G(:,S&%MH'!W'OE0#W?X>>&$\(^!M,TOR/)NA$);P':6,[#+Y9>&P?E!Y^
M55&3BNHHHH *\#^(WP%:YN+C6/!RQAY'5FTD[44$D[FC<D!1T.PX ^;!^ZM>
MP>-)YK7P+XAN+>62&>+3+EXY(V*LC")B"".00><T>$?%%CXQ\-6FL6$D9$J
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M:8LH^PP3W*.4.UFDV;2<[N"$!))5B%YR>L^)GCZ'P!X:%XL4=QJ%RYBL[=W
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MLG_HJ*N _:._Y*'I_P#V"H__ $;+7?\ [./_ "3S4/\ L*R?^BHJ / /'?\
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MWE>:\UG59C]D5SM .8QE\A2@VA?NAAN&YJQ_VC_$.J0RZ9X?B6>#3)XC<32
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MSM'0:E\2M.\92VGAKP5=WUW>7\JK=WEI&T!L+4,OFR;I%X8J2JD#@G@[MH8
M]0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7/ZWX+T3Q'YZZLE]<0S[?,M_[2N4A;;C'[I9 @
MY / Z\]:Z"B@#S__ (4E\//^A>_\G;C_ ..4?\*2^'G_ $+W_D[<?_'*] HH
M \__ .%)?#S_ *%[_P G;C_XY7876BV5WIT%AMGMK6#:(DL;F2UV!1@*#$RG
M:!_#TX'' K0HH X_1OA=X0\/:BE_I&FSV5TN!OAO[@;@"#M8>9AER!E3D''(
MJO??"'P1J=Y)>7^DSW=U)C?-/J-S([8  RQDR<  ?A7<44 <OX>^'GACPI>&
MZT.QGLI&^^$OIRDF 0-R%RK8W'&0<9R.:\(_:._Y*'I__8*C_P#1LM?3]>%_
M$/X4^-O'_B5=6ED\/V21VZ6\4*W<SD*"S99O*&3N9N@'&!VR0"Y\/OA[X:\:
M_"'0)-9L/,NHXKJ**ZBD:.2,&XD[@X;!Y 8$ D\<G/:>$OA7X4\&7$5YIUE)
M+J$:,@O;J0O)ACS@<(IQ\N54'&1W.:_PWT#Q5X0\/V?A_5(=&GL[=Y"MU:W<
MOF!6)?!C:+#'<QYW+P1P2.>\H S]9T6RU_3GL-16=[5\ATAN9(=X((*L8V4L
MI!.5/!]*X_\ X4E\//\ H7O_ "=N/_CE>@44 8]YX8TV_P!#&C71OI;'Y@RM
MJ%QOD#9!5Y-^]U(8C:Q(Z<<#'+_\*2^'G_0O?^3MQ_\ '*] HH KV-E%I]G'
M:PO.\:9P9YWF<Y)/+N2QZ]SQTZ53U_PYI'BG2VTW6K&.[M"X?8Q*E6'0JRD%
M3U&01P2.A-:E% ')Z!\-/!_A?5%U/1]%C@O%0HLK322E >NW>Q ..,CG!(Z$
MT:_\-/!_BC5&U/6-%CGO&0(TJS21%P.F[8P!..,GG  Z 5UE% %/2M*L=#TN
MWTS3+:.VL[=-D42=%'\R2<DD\DDDY)K'\2^ ?"_B^X@N-=TF.ZG@0I'()'C;
M:3G!*,"1G) .<9..IKI** .?T'P3X=\,:=>6.BZ?]BAO/]>T4TGF-Q@?O"V\
M8!.,$8))&"2:PY_@SX"NKB6XN-$DFGE<O)))?W+,[$Y)),F22><UWE% &/X>
M\+Z3X5LS9Z/#/!:GI"]W+*B<D_*KL0N2Q)VXSWS5?Q)X'\->+O+.N:1!=R1X
M"S9:.0 9PN]"&V_,3MSC)SC-=!10!YW!\%_"YMXK?5KG6=;@MT"6L>HZ@Y6U
M4#!$8CV!00%!'/W1C%>@000VMO%;V\4<,$2!(XXU"JB@8  '  '&*DHH XO5
M?A/X*US5+C4]3TB2YO+A]\LKWMQEC_WW@ #  '   & *N:#\//#'AC[9_8MC
M/9?;(O)G\J^G^9>QY?AADX8889.",FNHHH \_P#^%)?#S_H7O_)VX_\ CE=A
MHVBV6@:<EAIRSI:I@(DUS)-L   53(S%5  PHX'I6A10 5EZWX?T_P 0V_V?
M4?M;0;'1HX;V:!9%888.(W4."!C#9ZGU-:E% 'G_ /PI+X>?]"]_Y.W'_P <
MH_X4E\//^A>_\G;C_P".5Z!10!CZ-X4\/^'MATC1;&RD6(0^=# HD9!CAGQN
M;H"<DY(R>:V*** ,/Q+X/T#QA;P0:]IL=XD#EXB79&0D8.&4@X/&1G!P/057
M\-> ?"_A"XGN-"TF.UGG0))(9'D;:#G +L2!G!(&,X&>@KI** .+U7X3>!]:
MU2XU*_T&-[NY??*Z3RQAF[G:C 9/4G')R3R378000VMO%;V\4<,$2!(XXU"J
MB@8  '  '&*DHH XO5?A-X'UK5+C4K_08WN[E]\KI/+&&;N=J,!D]2<<G)/)
M-=1I6E6.AZ7;Z9IEM';6=NFR*).BC^9).22>222<DU<HH Y?Q9\/?#7C7;)K
M-AYEU'$T45U%(T<D8/N#AL'D!@0"3QR<X>@?!+P1H+K*VGR:G.KEEDU%Q* "
MN-NP (1U(RI.3G/ QZ)10 5P>M_![P7K_B#^V;S3I%G=W>YCAF:..Y9AC+@<
M@@_-E2N226W9KO** (X((;6WBM[>*.&") D<<:A510,  #@ #C%2444 %%%%
M '+ZS\/?#GB'>-7@OKV-I3-Y,VJ71C5SGE4\S:O4@8 P#@<5<T#PCH_A=%BT
M>.[@@5"BP-?3RQ("VX[8W<J#GG(&>3ZFMRB@ JGJNE6.N:7<:9J=M'<V=PFR
M6)^C#^8(."".00",$5<HH IZ3IL.C:-8Z7;M(T%E;QV\;2$%BJ*%!. !G ]!
M5/Q#X5T+Q79BUUS3(+V-?N%P0\>2"=KC#+G:,X(SC!XK8HH \_M?@_X=MX)[
M&6^URZT:3=MTB;4I!:19?>-JIM/!Z;B>N3D\UW%C86>F6<=G86D%I:QYV0P1
MB-%R23A1P,DD_C5BB@#C]9^%WA#Q#J+W^KZ;/>W39&^:_N#M!).U1YF%7).%
M& ,\"M31?".C^'M+FTS2H[NWLY4*>4+Z=A&#NSY>YR8R2Q.4P<\]0*W** .#
MG^#/@*ZN);BXT22:>5R\DDE_<LSL3DDDR9))YS7:6-E%I]G':PO.\:9P9YWF
M<Y)/+N2QZ]SQTZ58HH \W\0_ [P5K]X+I+6?2Y/XQIK+$C\ #Y"K*N,?P@9R
M2<FNL\->#] \'V\\&@Z;'9I.X>4AV=G(&!EF).!S@9P,GU-;E% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%>+Z_\0M4\<^-(?!7@*_^RV_S_;]9
MCCW@( 0WED#A1G ?(W.5"LH^9ND@^#7ANYMXF\23:EXBU!4"M>W]]-N Q]U0
MK#:F[<0#DC<>30!Z)17E_BGPCXE\+Z'=WW@#7]5C\B) NC3;;U"B;5"P>=EH
M\+O;:-V[@ # %:GP9GFNOA3H]Q<2R33RO<O))(Q9G8W$A))/))/.: .\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IWFK:;I]Q:
MV][J%I;3W;[+:.:94:9L@80$Y8Y8# ]1ZU<KS/X@?""'Q]XJL]7N-9DM((+=
M+>2WCMPS.JNS$ARV%)#X^Z<8SSTH ],HHHH ***R]?T9M>TMK!=5U+3 SAFG
MTZ58I2!SMWE20,XSC!XQG!((!H">%KA[=98S.B*[QAAN56)"DCJ 2K 'OM/I
M4E?/_P"S+_S-/_;I_P"UJ^@* "BBO"_C9IFH>$M&L-:T'Q/X@M$>X%I+:G5+
MB16)5W#AF<D'Y2".0<CI@Y /=**\K\-?#V;6?"ND:I<>.O&JSWME#<2+'JY"
MAG0,0,J3C)]37&>)_$'CGX.>*+6.76I]<\/74KS0)?R"2250 'C9R"Z,H*X(
M^4D@XY9: /H>BLOPYK]CXI\/V>M::TAM+I"R>8NUE()5E(]0P(XR.."1S6I0
M 4444 %%%% !116?KNF?VWX>U/2?.\G[=:2VWF[=VS>A7=C(SC.<9% $FFZM
MINLV[7&EZA:7T"N4:2UF650V <$J2,X(./<5<K@_AG\,X?AU;ZBJZI)J$]\\
M9=S"(E54#;0%RQSEVR<^G QSWE !1110 45GVVLV=WKE_I$+[[JPBAEN,$$)
MYN_:IP<AL)D@@<,IYS6A0 4444 %%%% !1110 4444 %5[J_L['R/MEW!;^?
M*L$/G2!/,D;[J+GJQP< <FI)XVFMY8DFD@=T*K+&%+(2/O#<",CKR"/4&OFC
MQ9X>F\-_'CPG:2ZUJ6K))<6,L4NHS&66-3<%=F[N-RLPP!][&.Y /INBBB@
MHHHH **^?/!'Q/FU+XZZD);N-])UAS:6Q9C&BK%N^SE0_(+?,-@VY:8G&<"O
MH.@ HHHH **** "BBB@ HHHH **** "BL_7-9L_#VAWNKW[[+6TB:5\$ MCH
MJY(!8G  SR2!6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@(\'<6&-A;WQ7'^"[Q_$O[2?B&[U(>9)I<5S%9 .VV$1R+",#/=6<D=-SL<
M]/9/$>@6/BGP_>:+J2R&TND"OY;;64@AE8'U# 'G(XY!'% $?ACQ/I?B[0X=
M7TB?S;>3AE;AXG'5''9AD?F""003Q>J_&*TL?&ND^&[?0=29[^XBB-Q>QO:
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M#\W_ )!GV1_L_P!W_7;_ -[_ +7W?)Z\>G>OH^@#QN#]I#PJUO$UQI6LQSE
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MEE16\YID#.'XPPPVT9S\H .<4 7-$\=:7JGP_@\87A_LVP:)I)O/;/EE6*,
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MXL=+LK&35_$&H.!::9#($9ESR[M@A$ !Y(['L&*]97SAHW]H_P##5\G]J?\
M'Q]KN=GW?]3]F?R?N\?ZO9[^O.: /3_%?CSQ!X*L[?4=7\*03Z8THCN+C3M2
M:8VX) RRM"G7)QSC. 2,C-/PY\<?#/B;Q!9Z-9V&LI<7;E(VDME*@X)YV.Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7/^./#?_"7>"]4T,2>7)=1?
MNG+8 D4ATW'!^7<JYP,XSCFN@HH ^</@)XN_L#7+[P?K#?9%NI=UNDXV%+H8
M1HR"N=S  88C!CP!EJ^CZX/QS\)O#GCAY+R=)++5F0*+VW/+84A=Z'AP,CT;
M"@;@!7-_\(=\8M+_ -#TGQY8W5C'_JYK^+,S9Y.[='(>I(&7/ '3H #UR>>&
MUMY;BXECA@B0O))(P544#)))X  YS7+F:Y\<>!=;^R".*WU2WG@TQYHWB+1-
M%L620$9 9][ @?ZLH<9R*IV?@/4;Z4_\)GXGG\1VJ;3#9?9EM(-P8-F5(SB;
ME%P'RH^;@YX[B@#YX_9VUG^S-<UOPOJ#SP74VV6&VF.T+)'N65=I.1(05R ,
MXC.?NU]!SSPVMO+<7$L<,$2%Y))&"JB@9))/  '.:\[\2?"*SU+Q1'XH\/ZM
M/X?UL2B5YH(A)&[8.YBF1\S9&[G:PSE26)J0^$O&_B71DTSQ9XGM+6T*-#=1
M:);E9+Q"HP7FD^X2P.51 ""1T.  <'^S7HG_ "'-?EM_[EE;S[_^!RKMS_UQ
M.2/H>M'Q3_Y.%\%?]N/_ *5O7NFE:58Z'I=OIFF6T=M9VZ;(HDZ*/YDDY))Y
M)))R37E_BKX/:UXN\2Q:]?>,X[>\@1$M_LFF&,0!"6&T^<6SN);)).3QP
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M<\ 'L_B'Q7#I6LZ1H-F8Y]:U*X3R[;@[+<-F:5N1@"-9-O<L. V#CQ3]H/\
MM'2/B'H&OVW[K9:)]EG^5L30RLY^4YZ;T/(P<]^:]7^'?PRTOX?6<IBD^VZG
M/D37SQ["4SD(JY.U> 3R<GDGA0-CQCX.TOQQH?\ 9.K>>L*RK-') ^UXW&1D
M9!!X+#D'KZX( -32M5L=<TNWU/3+F.YL[A-\4J=&'\P0<@@\@@@X(KPOXI_\
MG"^"O^W'_P!*WK4\-?"GQ_X0OY[+0O&UI:Z+.X>20VOF2;@G40N"H.< D.,@
M GH!5S6O@7%JGBVTU:W\07UI';Q6_F7#RO/>7$R,=TAE9OW;;1& 0" 1PH &
M0#V"BL_1M(BT33DLXKJ^NL8+37UT]Q([8 )+.3C.,X7"Y)P!FM"@#'\5>(;?
MPIX7U'7+I=\=I$7"9(\QR<(F0#C<Q49QQG)XK'^&/AY_#W@:R2Z:=]2O_P#3
M[][@,)&GE +;PQ)# ;5/3)7) )-8_CWX;Z[X^Q;7GBR"UTR.7S8;.'2@<,-P
M5F<R[F;:Y!QA3C.T5VFB6NM6EOY6LZK::BZHBI+#9&W8D#YF?]XP)/!^4*!S
MQSP :E?*'C&&7X5?&W^TM,MO+M5E6^MH04 >&0$21K@$(N?-0<9  /H3]7UX
M_P",?@MJGCC7/[6U;Q= LRQ+#''!I6U(T&3@9F)/)8\D]?3  ![!7C_CO0;/
MQG\6M(T[2+W[!XATJT%]<:AD3)#&C@Q1^3_%)O<-R5 5LG?D =IX&\+ZUX2T
MN/2K[Q%'J]A A6W#V1CEB'&%W^8P*  X!7(R #@ 5YGXF^&MG\3/B9KUQINH
M3V4=GY<5[>2()XI;@(H\J%5VXV*OSEG)#,!M YH [S7O!/B/Q3X?CT+6?%5H
MU@SQ&[>UTGRI[E4()!8RLJDD Y5!@@<8R#V&E:58Z'I=OIFF6T=M9VZ;(HDZ
M*/YDDY))Y)))R37AY^"'C;0;=+?PMX[DC@=V>:,RS6:AL  @1EPQ(&"3CH.O
M;4\(Q_$#P3X[T+0/$NOP:M8:U]J(4S23O&T40?(=U##HH R5Y;@'F@#C+77U
M^&G[0VN3ZJT9L[NXF6YDB5G,<4Y$R,!P<@F/=P>-V 3BOI>">&ZMXKBWECF@
ME0/')&P974C(((X((YS7%_$3X9:7\0;.(RR?8M3@P(;Y(]Y"9R49<C<O)(Y&
M#R#RP/EFF_LV:D=99=4URT72T<E7M58SRJ&'!5@%0E<\Y?!QPU 'L_AKQ7#X
MIU35VTPQSZ/8O';1WB8Q-<#<90ISRBJ8L-@ DM@L,&O(_P#F[S_/_/A7N%CI
M-OHNAQZ7HD,%E#!$8[93&72,\X+#(+<G)^8%N><G->;_ /"I-=_X6!_PFG_"
M90?VMYOF8_L@>7MV[-FWS?N[/EZ[L<YSS0!ZQ7S_ /LR_P#,T_\ ;I_[6KV#
M5-,\2:AH9L8==L;2ZEBEBN+N+3Y 1NX5H@)P8V4'J2V3@\=*X_X?_"G5/A]J
M,\UCXH@N;6[V"ZMYM,QO"DD%6$N5;!8 \CYN0<"@#C_VFO\ F5O^WO\ ]HU[
MY)/#"\*2RQH\S[(E9@"[;2V%]3M5C@=@3VKC_B-\.;'XAZ7;03W4EG>6CEK:
MY5=X0-C>K)D!@0H[@@@<XR#7\#?#5?"CQW.IZU=Z[>6R&&QDNMP2RB*@%8D+
M,%)  )!Z   #.0#O**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.<9VDXS@]?0T :%%1F>%;A+=I8Q.Z,Z1EAN95(#$#J0"R@GMN'K4E !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\L^[4]2\LPP)R51)58NW]U?D('J>@X8@ T/@]\1+CQYH=S%J,.W4]-\M+B9
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M$##,>6/!P0Z@#HJ*,#C/K% '/^._^2>>)?\ L%77_HIJ\?\ V9?^9I_[=/\
MVM7L'CO_ ))YXE_[!5U_Z*:O'_V9?^9I_P"W3_VM0!] 5S_CO_DGGB7_ +!5
MU_Z*:N@KG_'?_)//$O\ V"KK_P!%-0!X!\"_!/AWQC_;W]OZ?]L^R_9_)_?2
M1[=WF;ON,,YVKU]*]?\ ^%)?#S_H7O\ R=N/_CE>?_LR_P#,T_\ ;I_[6KZ
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M?O<?CB@#N/"OB&W\5^%].URU79'=Q!RF2?+<'#ID@9VL&&<<XR.*^>/VCO\
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M]A.3;2@G)P!QD_,%# A@=O5_&#Q18^,?@QHFL6$D9$NIQ":)7W&"7R9=T;<
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M9^;"L!G)[G/644 %4]5TJQUS2[C3-3MH[FSN$V2Q/T8?S!!P01R" 1@BKE%
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M->J44 <?K/@.;7].>PU'QCXC>U?(=(7MH=X((*L8X5+*03E3P?2H_!GPWLO
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M@JHH&   F  .,5'??!VSU.SDL[_QEXRN[63&^&?4Q(C8((RI3!P0#^%>D44
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MI_LX^6N@\*> -"\'RW%U8QSW&I76?M.H7DIEGFRQ8Y;H,D\X S@$Y(S7444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG'? !Z!5>^O[/3+.2\O[N"TM8\;YIY!&BY( RQX&20/QJQ10!S__  G?@_\
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M#P01QBOD#QKILWP^^)^HOX8:[M(-,N(3!."6\EI8A($+$8((W@!L[E4@[N:
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M^!;>)KBZU[QOJUV-6U!_/DMK!U"VQ)/[O>^_< NU0!@+MP"PP:N?\,X^#_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M $ [L@'<6%C;Z9IUM86<?EVMK$D,*;B=J* %&3R< #K7A?CSX3^/O$?C&_\
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MO;1QW=^\KW4P^]*4E=%R?0*.!TY)ZDD@'I$$$-K;Q6]O%'#!$@2..-0JHH&
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M\?:!X<\.ZA'>":XN?M\D:G:%CA<JH++A@S8;<A_@[AJZ3_A!/!__ $*FA_\
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M4>(DTR?SM(L(K1+=]A7S'<2F1\,H8=%7!S]S(ZUL?\()X/\ ^A4T/_P70_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7DDDO[EF=B<DDF3))/.:Z31O#&FZ!L&G&^2-(A"D,VH7$T:(,8"I([*N, #
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M&X^W7TX#.+*)$(!< 8RPD. 2.=@. X->L000VMO%;V\4<,$2!(XXU"JB@8
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M_145>F:WXDT7PY;^?K.J6EBA1W032A6D"C+;%ZN1D<*">1ZUR?\ PI+X>?\
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MQ@@\.A##IV//3I7)S?"CP=<ZH-4GTZ[EU .KB[?4[II0RXVG>9,Y&!@YXP*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+UW0;3Q%9)97
M\MV+3>3+#;W#PB=2C(4<H02GS9QD9*C.1D'0@@AM;>*WMXHX8(D"1QQJ%5%
MP  .  .,5)10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M6/K?AG3O$4MM_:@GGM8,DV7G,L$S;D93*@($FTH,!LK\S9![;%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &/K?AG3O$4MM_:@GGM8,DV7G,L$S;D93*@($FTH,!LK\S9![
M;%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ?@W0[^\D\RZNM/MYIGV@;G:-2QP.!DD]*\7_::_YE;_ +>__:- 'T!1110
M4444 %%%% %>^O8M/LY+J9)WC3&1! \SG) X1 6/7L..O2N/OOB]X(TR\DL[
M_5I[2ZCQOAGTZYC=<@$94QY&00?QKN*\;_:!\.0ZKHVAW%I8QR:U/J<6GP2
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M-U#$$A.1\CNRQJ_((.TL&P1SC'>N/_9\L]+B^'375D=]]/=R"^8I@JZ_<0'
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MCJQ?@@YRJ,O;&[(.10!<O_BWX<AU3^S=(AU+Q%=JA>5-#MOM(C7Y>2V0"/F
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MOPEXVA\6^,?$UKI]Q'/I>EI:Q021D,LLC>:9'!P#C(5>I!V9!^:NTH ****
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M^.>I06<4BZ3>:/)/9EBS;1YL(:/<1R5;MDG:R9))H ]DHHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYO\ 3M\B2S,)'3;)LE1Y-QW89EV]?XN<!17M%?/_ ,+/^3A?&O\ V_?^E:4
M>B>,_%NI6_BS1/!GAZ:T@U;54DDENKF-G%K"%;YU7@,YVN0"<93!&&R*>K?"
MZ_?0Y8M'\=>*XM37<\,UWJLCHY.W".%QA>#@J,C>2=V M<)J41U;]JU;*[N+
MLP(@2/RKF2)HU^QE\(R,&4;B20",[CZFO8_^$-TO_GZUS_P>WO\ \>H \[^"
M'Q,OO%*2^'-8$D]_96_G17I.3+$&5<2=RX++\W\0Z\C+;'CKQSJ8\8Z7X$\*
MRQQ:Q>NCW-\1'+]CBY9L(QP7V*6(;'RXQDL"O0:!\-?"7A;5%U+1=,DM+L(4
MWK>3L&4]0RLY##H<$'D ]0*\D^'QM[[]I/Q'-J4_F74,MZ+(S3'=O63RPJ\_
M-B+> O.%'3Y> #T^\^&XET,65KXM\5V]\NXKJ#:O,[L><!TW!"H)'"A2=HYZ
MD^4? [^T?^%R>(O[7_Y"?V2Y^V?=_P!=]HCW_=^7[V>G'I7T?7S_ /"S_DX7
MQK_V_?\ I6E 'T!1110!YGXZ\<ZF/&.E^!/"LL<6L7KH]S?$1R_8XN6;",<%
M]BEB&Q\N,9+ KJ7GPW$NABRM?%OBNWOEW%=0;5YG=CS@.FX(5!(X4*3M'/4G
MS#X?&WOOVD_$<VI3^9=0RWHLC-,=V]9/+"KS\V(MX"\X4=/EX^AZ /G#X'?V
MC_PN3Q%_:_\ R$_LES]L^[_KOM$>_P"[\OWL]./2O5_B;\1+?X?:''*(?M&I
MWFY+*%@=A*XW.Y'\*[EX!R<@#'+#S?X6?\G"^-?^W[_TK2LS]H&]6'XEZ&M[
M%)>:?!913/9&9D5P9GW@$?=+*@!8<\#T% 'J^B>!]2N]&^T^)_$GB"76KVW0
MS_9]0:VCLY-N,11PD)D9 ).X,5SCD@\./'FK_"KX@OX9\4:C=ZKX=F19+2]N
M</<0QL3AV(RS@-N5@><("H PI]TKY_\ VFO^96_[>_\ VC0![9XCU^Q\+>'[
MS6M2:06EJ@9_+7<S$D*J@>I8@<X'/) YKA_"5EKWCVWB\4^(M5U+3["X=GT_
M1M/N'M52$C:#,Z[7D)P'!R!W'#[1Q?Q3_P"3>O!7_;C_ .DCUZY\/IX;GX<^
M&W@ECE0:9;H61@P#+&%8<=PP(([$$4 >.:UX@\4_"SXJVFDQ:UJNN:1>_9Y1
M:W<AO)Y(V)1E7(&)-P<J%(!^3.>E=O\ &73)['PAJ'B;3=<US3[ZV\O]W::C
M*D,FZ2./F/.!@$_=VY)).:]0KS_XV_\ )(==_P"W?_THCH L?""_O-3^%NC7
ME_=SW=U)Y^^:>0R.V)Y ,L>3@ #\*\L^-D6L^"=4TRXT7Q7X@AM-120?96U.
M=Q$T>S)5F<DAMX.#G!!YP0!Z7\$O^20Z%_V\?^E$E>?_ +37_,K?]O?_ +1H
M ]LUNUUJ[M_*T;5;33G9'5Y9K(W# D?*R?O% (Y/S!@>...?GSX1^,?&NN>,
MM51=0GU2[FT^:2**_NV6TAD,D9\QD'11D@*BY^8#Y5)9?I>OF#]G'_DH>H?]
M@J3_ -&Q4 ;_ ,0O!WCCPKX<OO$H^).JWGE2JT\"O+; !W"Y0+(5&&9?E
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M8W4N21G+9ZGU->QWWP^\/ZG9R6=^-5N[63&^&?6;R1&P01E3+@X(!_"@"O\
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M[XGNYX(]3LXVCM=UM T<C(^PQ*Q! $A7+%B0!DFOI.OF#QE_R=#;?]A73?\
MT&&@#V?XL>'TU[P#JAFU"^MX;&TFN_(MG54N'1"R"3*DE05S@$>O4 CS#X*>
M"_\ A(_!MY>?\)-XCTO9J#Q>3IE_Y$;8CC.XKM.6YQGT ]*]G\=_\D\\2_\
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M_HWW%;R]FW_5]MN>G%<?^TU_S*W_ &]_^T:]@\"?\D\\-?\ 8*M?_12UX_\
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M#"\SQ11H\S[Y650"[;0N6]3M51D]@!VKP#XC? 5;:WN-8\'+(4C16;23N=B
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M -=YX&\9V/CKPU'K%C')"0YAN('Y,,H )7.,,,,"".H(R <@2>._^2>>)?\
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MVLYO#^E26MKN^SPO91E(MQRVU2,+D\G'6J__  @G@_\ Z%30_P#P70__ !-
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M\\+>!=3MUEC,Z:FSO&&&Y5:*,*2.H!*L >^T^E>H:EX:T'6;A;C5-$TV^G5
MBR75JDK!<DX!8$XR2<>YJ.Q\)^&],O([RP\/Z5:74>=DT%E'&ZY!!PP&1D$C
M\: /%/VF9X6N/#5NLL9G1+EWC##<JL8@I(Z@$JP![[3Z5Z/I&BV/C/X(Z7H[
MSQM!=:/!#YJ'<(Y41<'Y2,E)%Y7(Y4@]ZZ"?P7X5NKB6XN/#6C33RN7DDDL(
MF9V)R225R23SFKFF:%H^B>;_ &3I5C8>=CS/LEND6_&<9V@9QD]?4T ?-'P^
M^(.H_";6-0\.>(]-G^P^:7G@15\Z";: &4D@.K +WQC#*>H;T?\ X7W8:U_Q
M+?"N@:K>Z[<_N[.&XCC6,N>[E9"0H&6/3@<E1\P]$U_P=X<\4HRZUH]I=N4"
M><R;954-N 61<.HSG@$=3ZFC0/!WASPLBKHNCVEHX0IYRINE92VXAI&R[#..
M"3T'H* ,?Q+9P^'?@YJ]E<7<;&'1YHI+F3">?,T9!<Y)^>21L]22S]237%_L
MW7UO)X-U:P63-U#J'G2)M/RH\:!3GIR8W_+W%>L:GH6CZWY7]K:58W_DY\O[
M7;I+LSC.-P.,X'3T%4X/!?A6UN(KBW\-:-#/$X>.2.PB5D8'(((7((/.: /-
M_P!I">%? NF6[2QB=]35TC+#<RK%(&('4@%E!/;</6O0/A]/#<_#GPV\$L<J
M#3+="R,& 98PK#CN&!!'8@BK$_@OPK=7$MQ<>&M&FGE<O)))81,SL3DDDKDD
MGG-6--\-:#HUPUQI>B:;8SLA1I+6U2)BN0<$J <9 ./84 ?/FB>(;?X>_M!>
M))M?7[/:W<MTCRY+^4DKB>-\(&+;@$&.V_G&"*]'\=W%O\0O@]KU]IT4#V</
M^DV%W,#^]2':TDB@KNC;B:( CG&<[6KO-2\-:#K-PMQJFB:;?3J@19+JU25@
MN2< L"<9)./<UJ4 >5_L^ZE-??#(6\JQA+"]EMXBH.2I"RY;GKND8<8X ^I]
M4KQ_PII5Y\+/B+<:-*<^%?$$I.G3;CLM[@9*PMN;Y6*Y7/)DVQXZ,![!0!P?
MPJ\;V/BSP=IT+7T;ZQ;6XBN[>2??.3'A3*<X+!LJV[D9;&20:X/QIX8TN?X[
M^&CX:@\S5OM<=]K,$'W(421&$K]E9AN)&>?E.,N"WIFI?#'P1JMNL%QX8TU$
M5PX-K"+=LX(Y:/:2.>F<=/05L:)X;T7PY;^1HVEVEBA1$<PQ!6D"C"[VZN1D
M\L2>3ZT :E?.GQ5TV'QG\>M%\/6[22$6\%O>",A&C7<\KD%A@D1-N[^G)XKZ
M#O[ZWTS3KF_O)/+M;6)YIGVD[44$L<#DX /2O*_A9X>N]=\0:E\3->MI(;S4
MG8:=;2HA\JW(4*X. <[0$!PI*@GY@X- 'KE%%% !7S!9>#M;TSXM:UX%T[S[
M/2-6YG:%Y0JV&\2!E8CE@H,.Y@R[G=23N)KZ?JF-*L5UE]8%M'_:#VZVIN#R
MWE*Q8(/0;F)..O&<X& ##^(?AA/%W@;4]+\CSKHQ&6S VAA.HRF&;A<GY2>/
ME9AD9KRO]GK3;O5$EUC46DFM-(1K'2E8H4A:1C).57&0_P R#=QD.5R0,#WR
MJ>G:58Z2EPEA;1P"XN)+J;;UDE=MS.QZDD_D  ,  4 27]C;ZGIUS87D?F6M
MU$\,R;B-R,"&&1R,@GI7RYH&N:O\#?B#?Z9J%K)/IL[A9P8PK7$(+>7/&<D9
MP6^7..64X(ROU767K?AO1?$=OY&LZ7:7R!'1#-$&:,,,-L;JA.!RI!X'I0!Y
MG_PT1X;N/W&G:)KEU?2?);P>3&/-D/"KD.QY.!P">>AZ5Z!X9M[C1_"XN]?E
M@AOYO,OM2E)"I&[$L5+%FRL:[8P2Q^6->P $>@> /"GA=UET?0[2"=7+K.P,
MLJ$KM.V1R6 QQ@'')]36QJ6DZ;K-NMOJFGVE] KAUCNH5E4-@C(# C."1GW-
M 'SY^S=K-G::YK6D3/LNK^**6WR0 _E;]RC)R6P^0 #PK'C%?1]<_P#\()X/
M_P"A4T/_ ,%T/_Q-;D$$-K;Q6]O%'#!$@2..-0JHH&  !P !QB@#Y<U9-4^!
MWQ5EOM.L]^DW.[[.D@^2>V8JS1!R6(9#@9SGY58@AL'T?_AH[P?_ - W7/\
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M8$,,CD9!/2OG#X6>&_$D7CF\\(7<D\.F:3J$6H7^QI%1I(2?*"Y&TK(Q1\,
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M">]N8X4A\1VMTX/+>5&&+N%')"Y&< ]1ZBO3*Y__ (03P?\ ]"IH?_@NA_\
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M.FW.EC2Y]/M)=/"*@M'A5H@JXVC81C P,#'&!0!R?PO\3:=K?@W1[/33//\
M8-/AM[J;R62.*9(T!CW,!N;DGY=P ')&5W=Q5>QL+/3+..SL+2"TM8\[(8(Q
M&BY))PHX&22?QJQ0!S_CO_DGGB7_ +!5U_Z*:N3^''Q=T7Q3I=C8:G?QVOB
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M&*^DZY__ (03P?\ ]"IH?_@NA_\ B:U--TG3=&MVM]+T^TL8&<NT=K"L2EL
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M#P Q) !(D\!Z WASP=86=PLG]H2I]IU"25E>22YD^:0NX^^0QV@Y)PHY.,T
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MJ#G(R!@L?H.N7U/X<^#M8U&*_OO#MC)=1RF8NL?E^8Y(),@7 DR1_'GJ?4Y
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M"RCC=<@@X8#(R"1^-2:EX:T'6;A;C5-$TV^G5 BR75JDK!<DX!8$XR2<>YH
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M:WTO3[2Q@9R[1VL*Q*6P!DA0!G  S["@"Y1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#@@CD$ C!%1Z-I]QI6G)97&HSZ@L6%BGN0#,4 '$C# =LY^; R,9R06;0HH
M**** .?U+PQ_;VHS?VU>?;-&_=-!I0BV1[T.XO*P.9LG&$.$P!E6.&KH***
M"BJ<FK:;#JD.ERZA:)J$R;XK1IE$KKSRJ9R1\K<@=CZ47FK:;I]Q:V][J%I;
M3W;[+:.:94:9L@80$Y8Y8# ]1ZT 7***C,\*W"6[2QB=T9TC+#<RJ0&('4@%
ME!/;</6@"2BBJ>FZMINLV[7&EZA:7T"N4:2UF650V <$J2,X(./<4 7****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP! RR$??0,<9X/3(&1GM* "BBN#O_B.TWC7_ (13POI,>MW\"%[^0WJV\5J
MRJ<L58N5+?,%!(Z<G( !WE%>7Z]\6KSP=XHL]*\5>&?L5C<\KJ5K>&XC*XY*
M@Q*3M) 8<,!R <KN]$U+4X-*MUGN([MT9P@%K:2W#9P3RL:L0..N,=/44 7*
M*\K\-?'+1?$.LZI$]G)IVDV%D;QKZ[F&X@-&NTQJ#@EGP,,2<  9.!GZ_P#'
M+4M#=II?A[K,&GEPD5SJ):U+L5SC'EL >&P QR!GV ![)167X<U^Q\4^'[/6
MM-:0VETA9/,7:RD$JRD>H8$<9''!(YJGXK\8Z7X/L[>6_P#/GN+J40VME:)Y
MD]PY(&$3(SC(SSW ZD @%S7]&;7M+:P75=2TP,X9I].E6*4@<[=Y4D#.,XP>
M,9P2#X1\%K.;3OC9XGLKB[DO)[>WNHI+F3.Z9EN8P7.23DD9ZGKU->IWGBWQ
M=I>AC6=2\%01VL6Z2\AAUA))[>%<EY-IC"-A5R%5\G(''./+/@MJ4.L_&SQ/
MJENLBP7MO=7$:R !@KW,; '!(S@^IH ^BZ**CGD:&WEE2&2=T0LL494,Y ^Z
M-Q R>G) ]2* *=]K-GI^IZ7ITS_Z5J4KQ6\8(R=D;2,Q!.=H"X)&<%E]:T*^
M:)/%7C:[^/=D]_HGGZG8>:MKH:7L:)$CP,<"7E2VPABW?&., #W/0-=U^\M[
M^?Q%X6DT1+9 \0CO%O6G&&+86(9R,#C!)W<4 <OJ?P@AU7XJ)XUGUF142X@N
M!9);@'=$BA1YA8\;D!/R],CCK7IE>;Z?\7+?5/B9;^#[?0[Z'S/,#W-Z# ZE
M4=P1"5W;655(+%3\W3CGJ/$_B^R\*V<UQ=6.JW7DQ><RV5A)* F<$F3 C7 !
M)W,, 9[C(!T%%>9^'?C)8ZSX5.L7&D7<=W)>O9VNEV)^UW%R41'9D7"\*KY/
M8 =<D"L.;X]7FD7ELOB7P%JNDVLV[$CN=[8'\*O&@;DKGYAC.?8@'M%%<'XJ
M^)2Z0\5MX<T6[\4WA1)IH]-W.D$3J2C.Z*X!<<J,<C)R!C.7X&^,MOXL\42^
M'-1T2?1]2^811O(9=SH"71OD4HP"D\CL1D' (!ZA14<\\-K;RW%Q+'#!$A>2
M21@JHH&223P !SFN#LOB%K/B+==>$_!T^I:0/,5-0N[U+-9G3=Q&A#,RM@ ,
M0/F)#;=I( /0**\W\-_%VSU+Q1)X7\0:3/X?UL2F)(9Y1)&[8&U0^!\S9.WC
M:PQAB6 KTB@ HHHH S]9TR75].>SBU2^TW?D--8E%D*D$$!G5MO7.5PP(&"*
M\(^#MK]A^.OBRS^T3W'D17D7G7#[Y)-MS&-SMW8XR3W-?0]?.G@'5;'0_CCX
M]U/4[F.VL[=+YY97Z*/M:?B23@ #DD@#)- 'T717C>O_ !RU+0W::7X>ZS!I
MY<)%<ZB6M2[%<XQY; 'AL ,<@9]AZAX<U^Q\4^'[/6M-:0VETA9/,7:RD$JR
MD>H8$<9''!(YH U**X._^([3>-?^$4\+Z3'K=_ A>_D-ZMO%:@,JG+%6+E2W
MS!02.G)R!EZ]\6KSP=XHL]*\5>&?L5C<\KJ5K>&XC*XY*@Q*3M) 8<,!R <K
MN /4**R]?O=7T_2VN-%TB/5KM7 ^RM=BW+*>I5F4C(X.#CC/.< ^7Z!\;-:\
M2>)5T"P\"2"_#E9EFU H+<*<,TG[G*A3P>,YP "2 0#V2BHYS,MO*UO'').$
M)C21RBLV. 6 ) SWP<>AKA_"/CO6O%'B74],?PO':6>EW$EK=:@+\R(94)&R
M,&)2Y)&>V <G!(! .\HKE_%/C>S\-WEEI4-K/J>NZAD6>FVI&]^#AW).(X\C
M!8],$X(5L<WKGQ)\4>%K"VU/7O ,D&FLZK<S6VJ).UMEROS*$ S@ CG:=RC<
M"<  ],HK'\,>)]+\7:'#J^D3^;;R<,K</$XZHX[,,C\P02""=B@#G_%GAJX\
M3:<MM;>(=5T:2/<R2:?*(]SD84OQN91_=#+G//(!'C_[,O\ S-/_ &Z?^UJ^
M@*^7/@QXYT7P+I?B6^UB60F5[1(;> !I9C^]SM!(& #DDD <#J0" ?4=%>%S
M?M%3:=J@LM8\%7=@Z.HG1[LB6-3@YV-&N3M.0"1GCD9S7M&E:K8ZYI=OJ>F7
M,=S9W";XI4Z,/Y@@Y!!Y!!!P10!<HKC_ !#X\33=<'AW1-+GUWQ"8O.:SMY%
MC2!..9I6XCR#D<'/RCC<I//Z]\5=9\'SV<GBGP1/9Z;<<?:[._2YVOLW;,;5
M&X'CEAG:Q4L!R >H453TK5;'7-+M]3TRYCN;.X3?%*G1A_,$'((/(((."*X^
M/XB7>N:I-:^#?#LFN6EK<?9[K4I+M+:U1CCE&(8R@9.[:O  (W!@2 =Y17E]
MM\8TT_Q0OA_QGX?G\.74FPQ3/<K/"0P/S,X  7( W#< <[BNTUUGBWQMIG@R
MPEN]1M]2E2-%<_9;*1UPS[1F3 C4Y[,P/3U&0#I**\S\._&2QUGPJ=8N-(NX
M[N2]>SM=+L3]KN+DHB.S(N%X57R>P ZY(%8:?'U[#7+6P\3^#K[0X9L%Y9I6
M+QH<@/Y9C4LN1SCT. 2,$ ]HHHHH **IZKJMCH>EW&IZG<QVUG;IOEE?HH_F
M23@ #DD@#)-<7X?\=>)?%6CSZSH_@^ Z;\YLWN]66*2["LRX"+&P1LKC#,!D
MC!(YH ] HKS_ .'WQ2M_&^HZAI-SI4^DZO999[25B^4!"L<[5VLK'!4@=1C/
M..@\3ZOXBTO[+_8'A?\ MSS-_G?Z?';>3C&W[X.[.6Z=-OO0!YWI^N0_$+XW
M:IH6J6L=UH>AV\WV:RN(P4:X1TB>5UR0Y^:0+G@ @@!LFJ?C3X/ZI8^+=,\0
M?#E8-.F\W$T:2;! Y9B91N)!CP=IC4=!@*P) \X^"FHZSIGC*\FT/0?[:NFT
M]T:W^V);;4\R,E]SC!P0!CW]J^C[C7/%4?A>TOX/!WG:O+*4GTO^TXE\E,MA
M_-(VMT7@?W_8T </XF\2?\))\;](\!7$?F:);_OKVV=<+=3"%ID#8/S1K^[.
MT@ MG(8 57^)GP<^U_9=:\"6,%CJUO*'D@MG\CS/NA6C.X)&R%<\;<Y)SD '
MS#PUJ.LP?'F>_M=!^TZN=0O7.E_;$3#LLN]/-(V_+EN>^WCK7TOI.NZH^ASZ
MAXC\/SZ1-%+L%K!)]O=T^7#@0J2>21@ XVY/% '#^#/@Y<:#XTC\7ZSX@^W:
MF?-FEBAMA&GGR@ASNS\R_.^,*O8\8Q7K%>=^#?BM#XS\:ZAX?@T2[L4L[=I3
M+=N%EW*R(R-$ =I#,?XC]WH,X&IXZ\6:[X1LSJ-CX7_MC38HC)<S1WHC>#!Y
MS'L)*X.=PSC#9  R0#L**\[^&?Q.F^(MQJ*KHD>GP6*1EW-X969G+;0%\M1C
M"-DY].#GB.^^)&NP_$63P;8^$X+ZZ&)!/'JHV)"<$22@1$QX!&5//(QNW*6
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M4 '<6'3C(!ZI17E?B'XQ7.GW$\N@^#M2US1X$8OJT6]+=BA(<HXC8,BX(+Y
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M:EBGG>7>?VO#!YF9G)^1AD8)(YZXSWH ]PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTD8%R9FB/?@&-0I X(SGJ<^Q^!/^2>>&O^P5:_\ HI:\?^*?_)PO@K_MQ_\
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MI5CK7[5K6&I6T=U:.Z.\,G*L4LPZY'<;E'!X/0Y'%?1=?/\ _P W>?Y_Y\*
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M4M=I\,]*L=)^'.@I86T< N+*&ZFV]9)7C5F=CU))_(  8  KB_VCO^2>:?\
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M,$$'@@CC%>!_"S_DX7QK_P!OW_I6E>^3SPVMO+<7$L<,$2%Y))&"JB@9))/
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M_(DD $CS/XX6VKZC\'-,N[VUCCO+>XMKC48XV&V%C&R,!R<@22!>">N>1DT
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M/N+B6.&")+)Y))&"JBBZ<DDG@ #G->_SSPVMO+<7$L<,$2%Y))&"JB@9))/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M((()!V** /G"Z_9KUA-1@2S\06,MB=OG330O'(G/S;4&X-@8(RRY/''6O9_
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M6'(/7UP1YGX:^%/C_P (7\]EH7C:TM=%G</)(;7S)-P3J(7!4'. 2'&0 3T
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MM,)C@,>"NQ7F; W#<1R"23WKURB@#F_$LD-G\/M7/B>]C:#[%,EU-9QB#<K
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M7\"-7T;Q NO67CR1=45W?[3)I@E8LX(8G?(020QY.>M=1/X,^(-S;RP/\4)
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MP#XO\.:SK6K>&?%=HXU&]DO&TK4+-OLY9V/5U<LI ;JH&XHH/'3TRB@#S]/
MNL>(?$.B:_XTU&QEFTG=);:?ID#QPI-O!$AD=B[\*AVX494=L[N@\8:'JGB/
M0[C2=/U>#38;N)X;F1[/SW9&P"%^=0N1N!R#][C!&:Z"B@#S/X??"[4OAY<7
M;67B*TNH+UXC<I-IK!BJ%N$8384D.>2&[<>O4>,_ VB^.M+2QUB*0&)]\-Q
M0LL)XSM)!&"!@@@@\'J 1TE% 'F>A>#_ (A^&K>/1+'Q?IMUHXM_*CN;RQ9K
MBS(#8$2!L.!E<;W( & N!@])X6\$6?AN\O=5FNI]3UW4,&\U*Z WOP,H@ Q'
M'D9"CI@#)"KCJ** ./\ '_A#5/&VCOHT&NP:;ILVPSI]@\Z20JVX#>9  N0I
MP%SE>N"14?@3P=K7@K2[;1V\06E_I<#NRQMIICE4-D[5<2D8W$MRI/)&>F.T
MHH \G\;_  BUCQ]J-M>:MXM@B^S1>5'#;:8ZQC))+;6G;YCP"1U"KZ5Z1HUM
MJEIIR0ZOJ,&H728'VB&U^S[P !EEWL-Q.22,#G@#%:%% 'D_PM^$5YX!\0WV
MK7FK077F126L,4,1&8RZ,KL2?E;Y""H! S]XUZQ110 5'.)FMY5MY(XYRA$;
MR(756QP2H()&>V1GU%244 >5^./A1K7C^XLY=6\66D26:,L,5KI)506(W,=T
MQ))VJ.N/E& .<]9X5T#Q!X>T[3M+NM>L;^PLHA"/^)8T4S(HP@WB8J,?*/N'
M('/)S7444 1SB9K>5;>2..<H1&\B%U5L<$J""1GMD9]17D\WP>UJ?QX/&3^,
MXQJ@N%G^33"B84!1'A9@=FT;",Y(SDG)->N44 <_JFF>)-0T,V,.NV-I=2Q2
MQ7%W%I\@(W<*T0$X,;*#U);)P>.E<?\ #_X4ZI\/M1GFL?%$%S:W>P75O-IF
M-X4D@JPERK8+ 'D?-R#@5ZA10!R_CKP+I?CS0S87X\JXCRUK=HN7MW/<>JG
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MI(LKHNT.4D9-V.@)"@G&!DG  XKK*S]#T:S\/:'9:18)LM;2)8DR "V.K-@
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M;!Z KT/))&3] 44 >9_#/X06/@5SJ=]/'J&M.@590F$M@5^98\\DDY&\X)'
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M*DHH \W^(GP>TOQY>1:C%=?V7J8PLUPD/F"= , ,NY?F'&&STX.<+MX3PO\
MLY7,>J)/XHU.TDLXG5OLUB78SCG*L[!2@SMZ D@GE3@U]!T4 1P00VMO%;V\
M4<,$2!(XXU"JB@8  '  '&*\3\:?L]V^JZC=:EX9OX-/:7##3YHB(0Y/S%77
M)1<<A=IP>!@$!?<** /'_AO\#K?PKJ,6LZ_<P:AJ47,$,2DPP."</EL%VQM(
MR!M.>"0&'H'C#0]4\1Z'<:3I^KP:;#=Q/#<R/9^>[(V 0OSJ%R-P.0?O<8(S
M7044 >=^ ?AWK7@"WDL;3Q-:7>GS7"SRPS:60P. &V.)N"R@#D,!@''7,?Q
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M@D'B]!\!^-?!$L5CX:\3V-WH32N3::M;,3:JS*<QE""[8W<91223C+9'J%%
M''^'O ::;KA\1:WJD^N^(3%Y*WEQ&L:0)SQ#$O$>0<'DY^8\;F!["BB@ K'\
M3^&-+\7:'-I&KP>;;R<JR\/$XZ.A[,,G\R"""0=BB@#YPNOV:]8348$L_$%C
M+8G;YTTT+QR)S\VU!N#8&",LN3QQUKV?P+X%TOP'H8L+ >;<28:ZNW7#W#CN
M?11DX7MGN22>HHH \O\ '/P:M_%GBB+Q'IVMSZ/J7RF61(S+N=  CK\ZE& 4
M#@]@< Y)DLOA"K:-J5OXB\07?B'4+BWEM[2[U%6E6Q#J!NCC=VP^X EL@_*
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M$>7G:-S#<,J#ST$$$-K;Q6]O%'#!$@2..-0JHH&  !P !QB@"2BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_ ]UKM]X+TNY\2V_D:O)%FX0H$/4[2RC[K%=I(XP21@=!T% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5.\U;3=/N
M+6WO=0M+:>[?9;1S3*C3-D#" G+'+ 8'J/6KE?.'CW1;+1/V@/",=DL_^D2V
M,TSSW,D[N_V@IDO(S-]U%'7M0!]'U3CU;39M4FTN+4+1]0A3?+:+,IE1>.63
M.0/F7DCN/6C4M,@U6W6"XDNT17#@VMW+;MG!'+1LI(YZ9QT]!7S1\.?#M]'\
M7/$?AW0]4DL+>%+FUGO#S<+;).BGRR!@2MA1NQA06(&0!0!]%WWBSPWIEY)9
MW_B#2K2ZCQOAGO8XW7(!&5)R,@@_C6Q7B_Q#^"_A6T\#:G?Z!I_V&_L8C=!S
M=2LKH@RZD,6ZKNQC'S!>0,UN? C6YM8^&5O#/YA?3KB2S$CR%RZ@!UZ] %D"
M <X"CZ  ](GGAM;>6XN)8X8(D+R22,%5% R22>  .<UEV/BSPWJ=Y'9V'B#2
MKNZDSLA@O8Y'; ).%!R< $_A7D]KJ'_"VOC#/93G[3X1\/[I8X/+W07,P^0,
M[*Q5LL69<Y!1"-OS/7HGC;P+IOBOP=/HR6=I#/%;E-.D\I5^S,-I4*=I*(2B
MJP4?=X]* /*_V9?^9I_[=/\ VM7O%]?V>F6<EY?W<%I:QXWS3R"-%R0!ECP,
MD@?C7@_[,O\ S-/_ &Z?^UJT/VC-%LD\,V6L[9VOFU!(0SW,C(B&)RP6,ML3
M)C0G:!G'- 'MD$\-U;Q7%O+'-!*@>.2-@RNI&001P01SFH[Z_L],LY+R_NX+
M2UCQOFGD$:+D@#+'@9) _&L?P)_R3SPU_P!@JU_]%+7E_AZYB^,OQ*U*]OF\
MWPMH6P6MAYK^7<R;G\N:2-A@Y D)&%.-BG<-V0#U2#QIX5NKB*WM_$NC33RN
M$CCCOXF9V)P  &R23QBMRO+_ (O_  \E\3^$K2+PYI-B=2LI8EC"JD3_ &=5
M=?*1C@!07#;20.#CG /6> 8=?MO!&F0>*#(=8C1TG,DBNQ =@F64D,=FWG))
M[\YH T-2\2Z#HUPMOJFMZ;8SL@=8[JZ2)BN2,@,0<9!&?8T:;XET'6;AK?2]
M;TV^G5"[1VMTDK!<@9(4DXR0,^XKROX*:%KL^L>(/$OB_2IQJ<\L7V>[U"W"
M3!@KB38& 9%VLB\ +CY1]W Y3XNB'P/\8]'\1Z7;1PETCO+B.WN!&T\@D82;
M@"2H=<*3C#9;[QW4 >]^)_$^E^$=#FU?5Y_*MX^%5>7E<]$0=V.#^1)( )'G
M?PL^(VE:EINO:IKVLZ;I]W>ZQ),EO=7<<;+%Y42H!G;N 50N['.T]\UV'Q'T
MG3=0\"ZY<7NGVES/::9=/;230J[0MY1.4)&5.5!R/0>E>;_ +PUH.L^!;ZXU
M31--OIUU.1%DNK5)6"^5$< L"<9)./<T >V?;[/^SO[1^UP?8?*\_P"T^8/+
M\O&[?NZ;<<YZ8HL;^SU.SCO+"[@N[63.R:"02(V"0<,.#@@C\*\S^-WA[3/^
M%87MXL$B/IR6Z6D4<\B00CS508A#"/.UV7.W.#CL*U/@E_R2'0O^WC_THDH
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MI[M]EM'-,J-,V0,("<L<L!@>H]:\;_9VU1]4\):WX?N#.8;25721;AE*I,K
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MZFZ<@@C@@CG-?0=?+GB3PI#X2_:$T2WM!&MG>ZG:7MO&F!Y2O. 4P   &5P
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M2EL$X!8@9P"<>QJOIOB70=9N&M]+UO3;Z=4+M':W22L%R!DA23C) S[BO'_
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M@X'TW0!\_P#[,O\ S-/_ &Z?^UJ]D@\:>%;JXBM[?Q+HTT\KA(XX[^)F=B<
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M'S ':3FY\>+#Q3K5GH>B^'[2^NK6[ED^UQVT9*%@8_+\QNBKDL?F(7C)^Z"
M#T#_ (3OP?\ ]#7H?_@QA_\ BJW()X;JWBN+>6.:"5 \<D;!E=2,@@C@@CG-
M<GXW\*Z/>?#75=)CTRQBM[>TFGM(@$@C@F5697!^54^8DDY P6SP37!_LWZW
M-=^&M7T:7S&2PN$EB=I"P"R@_(J_P@-&S<'DN>/4 ]@U+5M-T:W6XU34+2Q@
M9PBR74RQ*6P3@%B!G )Q[&C4M6TW1K=;C5-0M+&!G"+)=3+$I;!. 6(&< G'
ML:^=/VA/#5EHNHZ%>VLU]))=131.+N\DN,",J1AI"S#_ %C<9QP, '.?5_\
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M&H!$0*GG&%&SY@PX]'T#XIWWC>R6/PKX8N_MA0B6ZU%O+L;=PF2/,3+2$,4
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MO!] <  >Q^!M$\1ZQJD?C3QKY<6H&W,6GZ6D>U+&-L;GPV2LKXYYR 2"?X4
M/1*Y_P =_P#)//$O_8*NO_135T%1SP0W5O+;W$4<T$J%)(Y%#*ZD8((/!!'&
M* /%_P!FS4H9?"NLZ6JR>?;WHN'8@;2LB!5 YSG,39X[CKV],\=_\D\\2_\
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M: .IP2??]&N=4N].2;5].@T^Z?!^SPW7VC8" <,VQ1N!R"!D<<$YH T*^?\
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MW+SCG+B4]21],5[!7RYK?@OQ?\(/&/\ ;7AI+N]TU$>5;E(6D7R1R\=R%X
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MZ#-7T_7S!X8M=;L/C:?%=UX4\1Q:9-J%U,2=+E+QI,) I90#TW@G&>AQGO\
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MG:AHFNZ)JME'-=QRVCOI=Q\[N-C[G"E54;(^6QC))..@!G_M-?\ ,K?]O?\
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M(+(2K[<D8(.#]X'QB2?XE_!%X4EECN-'=]D2LQGM';:6PO1XSEV.!LW%2?F
MKU?Q+X@UKPO\5TO(/#VLZKHMWH\<-S_9UF92DJ2RLASC!(#$%=PX?/. *R_'
M?C+2?B'X$U#0/!ZWVM7]U+;Q;;:QE"0_O0X:1W551?D(R3^@) !8^(?B&W\5
M_L\WFN6J[([N*W<IDGRW%Q&'3) SM8,,XYQD<58^ .I_;_A?!;>3Y?\ 9]W-
M;;MV?,R1+NQCC_6XQS]W/? ZCPMX.M]$^'5IX4O?])A^R/#=@.<.9-QE"L I
MVY=@.AQCO7D'A?3?$OP1\4:E)J&DWVJ^&KF)O,N].A5^(QN65AU3 9@0S*/F
M8@MM&0#V?QW_ ,D\\2_]@JZ_]%-7E?[-.FS1:-K^J,T?D7%Q%;HH)W!HU9F)
MXQC$JXY['IWZ3Q/XJO/'GAR;1/ NGWUVNIQ>6^KS6Y@LXH2^R7YI5!=L9!55
M)PQ(.5Q78>"_"=GX*\+VNBV;^;Y67FG*!&FD8Y9B!^ &<D*%&3C- '05E^(]
M?L?"WA^\UK4FD%I:H&?RUW,Q)"JH'J6('.!SR0.:U*Y/XEZ!?>*/AYJ^CZ8L
M;7DZ1M$CMM#E)%?;GH"0I S@9(R0.: ./\,)XC^+=@^L>(+V32_"\SLMKI>F
MR[&NU5V5O/D^\4(W(5&W=C.%P"W&>.M#TOP]\=? ]AI%A!96J_8#LA3&XBY8
M;F/5FP!ECDG')JY\.?%OCKPEX?M_#C_#W6=0 N&^S22(]LL2N0=I)B(QN+-N
M8\;NP%4_B%HWCBW^)V@^(+K3)]>FM(K6Y9-*L)5@B,<A8P*_SD\@G<W/S] ,
M"@#Z/KY@_9Q_Y*'J'_8*D_\ 1L5>YVVNZKHVC27WB:TNYKZ[>2>'3M*L9+K[
M,@5=L!=%(9^Y9BH+,P'RK7B'P8L=9\'>-9KW6O#7B""TGLI+?SETJ=PC%D<%
M@JDX^0C@'DCMD@ ^FZ^8/!O_ "=#<_\ 85U+_P!!FKZ+DU^SBTN'46AU(P2O
ML5%TVX:4'G[T03>H^4\E0.GJ,_.GABUUNP^-I\5W7A3Q'%IDVH74Q)TN4O&D
MPD"EE /3>"<9Z'&>X!]/U\__  L_Y.%\:_\ ;]_Z5I7MD>OV<NES:BL.I"")
M]C(VFW"RD\?=B*;V'S#D*1U]#CP3P-)K^C_&;4O$-SX8URVTC5);OS9)M)G9
MXXY&,B?*BGYMRH#U')^H /H^O&_C+HLWCV_L?#OA^SCO-8TU)+JZF\XHMI&R
M#;$W\.^4A=H)R-F>%)8=QXS\6WN@^&DO-%T+4M6U"[3_ $6WBLI2$R =TP"Y
M0#(^4X8GCCDK3^%NGV]OX7:_?3KZTUJ_E:;5GU"U,$TMR3EC@@#R\L=NW@ _
MWMU '+_ CQ__ &_H?_"-7\F=2TR(>01%M#VJ[57)'&Y20IX&05ZG<:Z#XV_\
MDAUW_MW_ /2B.O+/B'H^LZ9\7E\2>"]"UF9XW2>=HM-G6(W"LRR*-J+N1U +
M$$AM[<G->UZ;J,7CSPE=V=]IFJZ3)=VC6]W;75L\+Q>8K*=CN@5^Y!&>HR 3
MB@#'^"VM_P!M_"_2]]QYUQ8[K*7Y-NS8?D7H <1F/D9]SG->@5\J-I_CKX(>
M);VZL()+K3-@#W)@=K2XC)(0R8/R.&/3<""< E6^;L_#VM_$#XPV9TZ^A@T7
MPU+S=W]G!)&]S'D@PQ,[,&W$$,1P,'.<[6 -#]H"^M]3^%FC7]G)YEK=:A!-
M"^TC<C02E3@\C((ZUWGPQU*'5?AEX=N(%D5$LDMR' !W1#RF/!/&Y"1[8Z=*
MD\:>#;/Q3X&NO#T4,$&V(?8<*%2"1!^[Q\IVKQM.T9VE@.M>(>#O&GB7X.7G
M]A>,-)OO[&EW-"@"N8GP&)A?.QU)8;E#<$YX.X, =O\ M'?\D\T__L*Q_P#H
MJ6O0/ G_ "3SPU_V"K7_ -%+7D?Q?O?$WC+PAIIM?#%W:6$FI[8+:X1CJ$[K
M"YW>0H(1 !+U))PK8 Z^D?#>?Q&?"NEV>L^'X]*@M+**"-I+S?/+M1 &,00!
M 1G@MN!&".] ':5S?CGQG8^!?#4FL7T<DQ+B&W@3@S2D$A<XPHPI))Z ' )P
M#TE>;_&[PQJGBCP"(=(@^T7%G=K=M OWY$5'4A!_$WS@X[X.,G (!3\/>&]:
M^(^C0:SX\OY/[/O$6:VT/3Y##;F)E!5IBIWN20K@%OE(Z\E1QEC86>F?M8QV
M=A:06EK'G9#!&(T7-B2<*.!DDG\:U_ _C3X@6NAZ7X7'@*^:\BB^S1:E?B2W
M@C49V-(/*'RHH4$!MS;>/F-8%]IGC70?CW)KXT*^\12+* L\%HUK!+YD 0 /
MAU14WA<DG[G)SDT =?\ M'?\D\T__L*Q_P#HJ6O0/ G_ "3SPU_V"K7_ -%+
M7E?Q?B\0ZMX*TWP_)I^I:QKD=[]KO)]/TN;[+&-KD(C[<, )54$9)"$MAN*]
M \!:Y&O@K2[*ZTW6;.[T[3(UN(;G2YT/[I0AVG9AR<9"J2Q!Z9R  >9_%/\
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M#E594 )&3DX!Z%OEJ/X<>!M8TG7-8\6^*98)-=U;&(H9'<6L9PS1Y)P<$(H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV(%W8R<9QG&36A110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^!/^2>>&O^P5:_\ HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHKF_%OBN'PT=&MP8VO-5U.WLH(VP?E:11(^,@X"DC(SAF3(P
M: .DHHHH *XO3OBCX<U/QY<>#[=KO^T(7DC$C0XBDDC&713G.1AN2 #M."<C
M/:5S>G> ?"^E>);CQ%9Z3&FK3O([W+2.YW2'+E0S$*3D\@#@D="10!TE%%%
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M 8ZXV/#7C#0/&%O//H.I1WB0.$E 1D9"1D95@#@\X.,'!]#7-_!+_DD.A?\
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M;WNC:99VUN9WTVVVRRQH,L=S21E6=5/.U@#L^49/.'_S=Y_G_GPKZ H \_\
MA#XZN/'/A)YM1,']IV4OD7'EL 9!M!64H/N[N1Z$HV,=!8^(/Q _X1+^S],T
MRW@U#Q#J<HAM+)YMF-V561O]G?M&"5SDX(VG'F_[,O\ S-/_ &Z?^UJDDGFF
M_:YA2661TA39$K,2$7[$6POH-S,<#N2>] '8:MI7CW1O M]JEQX_D;5+*WDN
MY%CTRV,!5(BQC&4#9W#[^1Q_!4GP>^(EQX\T.YBU&';J>F^6EQ,@ 2</NVN
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M?WDGEVMK$\TS[2=J*"6.!R< 'I5BO)_VAKZXM/AK'#!)LCN]0BAG&T'>@5Y
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M&_1!#OD!)7<#M!5QM"%5!/R\'=D>T5YW+\'M&NO&,'BF]UC6;O5(KB&XWR/
MJNT6W:"J1*,80#C%>B4 %?/_ ,>M(\16GAY;W4?%'V_3)M5'V?3_ +!'%]GR
MDI7]X#N;:N5YZYS7T!7C_P"T=_R3S3_^PK'_ .BI: *_P?T/Q5/X)T"_M?&/
MV;2!*[G2_P"S(GRBSOO3S2=WS8;GMNXZ5G_%OQ'XW^'MYIS6'C&>YM=0\S9'
M/I]MOB\L)G+",!LES_",8QSUKN/@E_R2'0O^WC_THDKS_P#::_YE;_M[_P#:
M- 'O%];RW=G)!#>SV4C8Q/ $+I@@\!U9>>G(/7UYKP?P7X^\97'QH3PIJVO?
M;K&&[N[:3_0X8O-\I),-\JY7E < ^W-?0%?,'@W_ ).AN?\ L*ZE_P"@S4 >
MC_'O3-4N_ ES>Q:S]GTRS\MIK!(.;IVE506DW?=7<"%V]1DY^7;C_"WP[XRO
MOAQI-SI/CO\ LNQ?SO+L_P"R(9_+Q,X/SL<G)!//3..U=A\;?^20Z[_V[_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9W!A@  L!C&'+ @G.>M &YX%U;5/$_V_Q+>6T]CIM[Y<6F64WWO(3<?/8;B
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M;64@AE8'U# 'G(XY!'%5_"GA+2/!FC#2]&ADC@+^9(TDA=I)-JJ7.> 2%'
M'H!0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5 0DC$,<$A5W*I.<UYG\$+W5/">C:KI?B#0M9LX&N$N+9AH]U(SLR[7!V(0
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M9;R>"61-PWDH"A4 JD;.<D\'.  2?1-"U/\ MOP]IFK>3Y/VZTBN?*W;MF]
MVW.!G&<9P* -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ_X@DNXX;I\0F9]F[O\ *G85]%_!>XN[GX:V#W;.SAG"ESDE03B@#T&BBB@
MHHHH *CGGBM8))YY%CBC4LSL<!0.YI[,%4LQ  Y)-?.'Q:^(]QXIU,>%?#A>
M6V\P1R-%UG?.-H_V: -/Q7^T)+;ZJ]MX=LH9K:,X,\V?WGT'I7J_@'Q4?&7A
M*UU=X5AED++)&IR%8''%>>^%O@5IUOX4N$UE$FU>ZA.';D6Y(XQ[CUKN/AOX
M/G\$^%AI=Q<I<2F9I2R# &<<#\J .PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1X)\,2:HL"SS;A'%&QP"Q]:V/#^KKKWA^PU5$""Z@64H#G:2.1GVH TJ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)?C
MQX;O-7\,VVIV*N\NG.7<)U"'J1],"N:^&WQQB@MHM(\5RO\ ( L5\03D>C]_
MQ_.O?F174JRAE(P01P:\:\:? .PUBYFO]!N_L-Q(=QMW4>43[8&10!ZO8ZWI
M>IVZSV6H6T\3=&CE!HO]<TK2X#/?:C:V\0ZM)* *^4+_ .$?CS19F,6F3R@?
M\M+1]W'X55M/ACXZU>< Z->Y)QYEQ\H_,T >F_$WXV:?<Z7<:+X9=IVG4I->
M8(55[A?4GUZ5P/P4LOMOQ-L6(SY"O+^F/ZU2\9_#74/ VE65SJEY;FYNG*K;
MQ$DJ .23T]/SKJ/V>;,S>-;JY#,!#;'(&,') H ^C+KP]HM]?)>W>DV4]TGW
M9I8%9A^)%:( 4    = *6B@"KJ&FV6K6<EGJ%K%<V\@PT<JA@?SKYH^)'P]O
M?AWK</B#P\TJ:?Y@:-U.3;O_ '3[5]0U2U;2[76M+N-.O8P]O.A1@1Z]Q[T
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M?FEN"V/8"NO^$%P;CX8Z.6))1&3\F->4_M'WYD\0:5IXD.(K<RE>,?,V,_\
MCM>C? QBWPTM069MLKCYL<<]J /2:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:=NW1)/%:@>BC[WZDU]0P1+!;QQ( %10H [ 4 24444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 444R:00PO(QPJ*6/X4 ?(WQIOS??$[4QN
M#)!LB7!Z849'YDU[C\"@1\-;;(QF9\?G7S?K9?7_ !%KNI%N!(\Q/KEL#^=>
MA^$?C/:^#O!UAI%KIKW=RC,9F=MJC)Z#N>* /IBBJ6D:BFKZ1::A&A1;B)9
MI[9&:NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2,=JDGL,TM4]6N5L]'O+EONQ0.YYQT!- 'Q5XRO/MWC'5[C.0]
MT^#[9Q7TA\ [46_PWCEQCS[F23^2_P!*^6;F0S7,LK'+.Q)KH] \8>+?!:1M
MIMY=6MM(=XBE3,3^X5AC\10!]J45XWX#^.]AK<L>G^(XXM/O&PJ7"G]S(??/
MW#]>/I7L2NKJ&1@RD9!!R#0 ZBBHYYXK:"2>>18XHU+.['  '4T <WX_\40^
M$_"%]J#L/.*&.!/[SD8'^/X5\>Z+ILNNZ_::?$"9+F94X]SS78_%CX@OXUU\
MPVC,NE6A*0+G_6'NY'OV]JZ3]GOPR+_Q!=:].F8K)-D61_RT;O\ @,_G0!UO
MQG\)06_PSL/L<04:4548'\)&#_2F^ _&JZ7\"[F^9P9M-5X5!/\ $3\GZL*]
M4\3:0FN^&M0TQP"+B!D&>S8X/YU\9_VSJ.EZ/J/AP_)!-.K3(PY#(3Q^?\J
M/6OV>;>2_P#$NN:O-\SB-5+'NSL3_P"RU[9XOUZ/PUX5U#59&"F"$F//=SPH
M_/%>=?L\:>+?P5=WI7#W-T1GU50 /U)KCOCSXY35-13PW83![>T;=<LIX:3^
M[^'\Z .M^!'BG7O$BZU_:][->11.AC>9LE2V[('MP*]EKS'X$Z='9?#N&=4
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M[37SG\+K>'_A>6KK8Q)';0+, B+@*H8+P!7T90 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]K?QR)L4?4FO4O"?[/+B2.Y\3WJ[0<FUMSG/L6_PH \$VMMW[6V],XXKZI^
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MUCH98PQ'XU+8Z;8Z;#Y-C:06T?\ =BC"C]*M44 %%%% !1110 4444 %%%%
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M^ +GPYHUM%:,P#Q2$9)=3D%CUYZ?C7B2_ CQSO\ L^VT$).2?M/R_7%?55%
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M7)[7XKZAJD*J9;>ZRBOR 1TJ_P"!/"^J?%#QF^H:M+)+:QN)+J9N_H@_STH
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MLF4_UKP;Q%^SK>BZDDT#486@)RL-SD,OMN[URDOP6\?V#$06JO@];>Y'/\J
M/J[SX?\ GK'_ -]"D:ZMT7<T\2CU+@5\AR_#SXD0G#:5J?MB<'^34Z'X:_$B
MZ ']EZAM/=[@ ?\ H5 'T_K/C?PWH-LT]_J]J@ X1) ['V %?.WQ ^)>I?$7
M4(M%T6"5-/:0+'"H^>=NQ;V]JDTSX!>+[^4-?26EFA^\SR%V'X#_ !KV?P'\
M*=%\$?Z2N;S42,&YD'W?]T=J )/A?X$C\$^'%CE"MJ%SB2X?T/91["NZHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9"6![[3[UZAX=\.Z=X8T>'3--@6*&,8) Y<]R3W-:M% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#>W\#:69)]DVK3@>=,!]T?W5]JZ+PUX.T+PE:?9]'L(X,_?D/S2/]6/)K=H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&<,,;C]S/&0* /0*\+\;Z!<_$NX\:7]NLEPGA]$L=(1&<*TZ$270\L9+2_\
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M//B3^T_!=QH;Q[9-(E^5PN T<I9QDYY8,),\ 8V]3F@#V"BBB@#Y_P#VFO\
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MUTT31:7I! (T^%L99B1GSF  )X."0>H1/0*\K^$WQ9A\96Z:/K#QP^((DX.
MJWB@<LHZ!P.64?[PXR%]4H \_P#C;_R2'7?^W?\ ]*(Z/@E_R2'0O^WC_P!*
M)*/C;_R2'7?^W?\ ]*(ZQ_A!X:L-0^%NC74UQJJ2/Y^1!JUU"@Q/(.$20*.G
M8<]>M '<>(M3T[[=IGAB^A\__A(/M%LT6YE_<K"[2-D#_=7&0?GR.AKH*\K_
M .%76GA[XK:!XFT5;MH)[BY%^DTSS>6S6[[7W,"V"P;<78_,Z@=:]4H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF7.#G&<<UT%<WX^\-3>+_!&IZ%;W$=O/<HACDD!*[D=7 ..0"5QGG&<X.,4
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MJK,#%P1&9&=,(N[]TS JI&=#XE>/O'G@#[#=?9-#N;&]W#*VTY^SR#GRV?>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF/'FF^-;CXG>&O%6H^%IWM;?[-)]GTD->/$L<GF.DC  >9ECV"G( )P36O\
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M8ZSX_P!7CDL[O5D\FUT]DVM#;#8$,HR<2E8TRH.%YSR<* 8?[1W_ "3S3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>7^,?C19^"O&G]A7^A7SVJQ+(]XC %M
MP)'EH<!USA2VX<AACY>?4*KS6%G<7EM>36D$EU:[OL\SQ@O%N&&VL>5R.#CK
M0!R_@.WUBYBU+Q'X@L?L.I:O*C1VAE=S;6J+B*-@W"MDR.0 .9#D _*O8444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(1@CHV,G H ]0KP?X'0_V'\0_&_AZUMIY;&"4H+MSG9Y,KHBM@8W,&8]ON'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7-^,_'.B^!=+2^UB60F5]D-O  TLQXSM!(& #
MDDD <#J0#TE?(GQJ\1S:[\2-1MUOI)[#3G^S6\9!58F"J)0!@<^8&!;O@<D
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M$ $C+;GQ ^(C^&M6TKPWH\,$_B'598DA^UAA!"CR; [E>3D@@!>F"3T 8 ]
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M0=W." NAXI\:>)-*^%6E^,M-32C(UI;W%[!<PR$'S0@_=E7&,,_1LY!ZY&&
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M3R /9_\ FWK_ +E3_P!M*SYO@'X*ET.VTT+?1R0RM*;Y)5\^7=U5B5VE1A<
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M&68D@< &'X6@\40?!:[\-V?A^351=6\\6GWUM*D$$D,P)WMY[)+D%Y"/W8#
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MN !P<'/%=!I.I0ZSHUCJENLBP7MO'<1K( &"NH8 X)&<'U- %RBBB@ HHHH
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MB0$@,&ZDY'4A>PO/^2AZ-_V"K_\ ]&VE</\ %CP+JEQ>6OC7P>/(\0Z=EIA
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538896472240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIORESTORATIVE
THERAPIES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001505497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-1341024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40
    Marcus Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-8100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityBankruptcyProceedingsReportingCurrent', window );">Entity Bankruptcy Proceedings, Reporting Current</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,667,641<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityBankruptcyProceedingsReportingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12, 13, 15d<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityBankruptcyProceedingsReportingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897581440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,783,646<span></span>
</td>
<td class="nump">$ 1,676,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments held in marketable securities</a></td>
<td class="nump">9,831,719<span></span>
</td>
<td class="nump">13,072,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">403,559<span></span>
</td>
<td class="nump">363,082<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">12,043,924<span></span>
</td>
<td class="nump">15,128,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">314,070<span></span>
</td>
<td class="nump">261,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">183,738<span></span>
</td>
<td class="nump">241,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">758,565<span></span>
</td>
<td class="nump">803,438<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">13,300,297<span></span>
</td>
<td class="nump">16,434,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">276,048<span></span>
</td>
<td class="nump">170,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">386,325<span></span>
</td>
<td class="nump">130,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">150,480<span></span>
</td>
<td class="nump">139,328<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">812,853<span></span>
</td>
<td class="nump">440,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">83,580<span></span>
</td>
<td class="nump">162,317<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">896,433<span></span>
</td>
<td class="nump">602,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value; Authorized, 75,000,000 shares; 3,982,608 and 3,677,775 issued and outstanding at June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">173,695,154<span></span>
</td>
<td class="nump">168,457,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(161,305,671)<span></span>
</td>
<td class="num">(152,640,897)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">12,403,864<span></span>
</td>
<td class="nump">15,832,072<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">13,300,297<span></span>
</td>
<td class="nump">16,434,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 15,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897432576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,982,608<span></span>
</td>
<td class="nump">3,677,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,982,608<span></span>
</td>
<td class="nump">3,677,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,543,158<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,518,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">1,518,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538896256048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 64,500<span></span>
</td>
<td class="nump">$ 71,100<span></span>
</td>
<td class="nump">$ 95,800<span></span>
</td>
<td class="nump">$ 87,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">967,891<span></span>
</td>
<td class="nump">1,075,224<span></span>
</td>
<td class="nump">2,479,136<span></span>
</td>
<td class="nump">1,850,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,213,160<span></span>
</td>
<td class="nump">3,624,504<span></span>
</td>
<td class="nump">6,512,313<span></span>
</td>
<td class="nump">7,918,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,181,051<span></span>
</td>
<td class="nump">4,699,728<span></span>
</td>
<td class="nump">8,991,449<span></span>
</td>
<td class="nump">9,769,521<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,116,551)<span></span>
</td>
<td class="num">(4,628,628)<span></span>
</td>
<td class="num">(8,895,649)<span></span>
</td>
<td class="num">(9,682,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (income) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (income) expense</a></td>
<td class="num">(96,187)<span></span>
</td>
<td class="nump">46,613<span></span>
</td>
<td class="num">(114,403)<span></span>
</td>
<td class="nump">75,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainOnPppLoanForgiveness', window );">Gain on PPP loan forgiveness</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GrantIncome', window );">Grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(39,812)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(116,472)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expense</a></td>
<td class="num">(135,999)<span></span>
</td>
<td class="nump">46,613<span></span>
</td>
<td class="num">(230,875)<span></span>
</td>
<td class="num">(191,030)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,980,552)<span></span>
</td>
<td class="num">$ (4,675,241)<span></span>
</td>
<td class="num">$ (8,664,774)<span></span>
</td>
<td class="num">$ (9,491,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic</a></td>
<td class="num">$ (0.77)<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (2.28)<span></span>
</td>
<td class="num">$ (2.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Share - Diluted</a></td>
<td class="num">$ (0.77)<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (2.28)<span></span>
</td>
<td class="num">$ (2.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Common Shares Outstanding - Basic</a></td>
<td class="nump">3,886,309<span></span>
</td>
<td class="nump">3,638,383<span></span>
</td>
<td class="nump">3,803,323<span></span>
</td>
<td class="nump">3,581,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Common Shares Outstanding - Diluted</a></td>
<td class="nump">3,886,309<span></span>
</td>
<td class="nump">3,638,383<span></span>
</td>
<td class="nump">3,803,323<span></span>
</td>
<td class="nump">3,581,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainOnPppLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on PPP loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainOnPppLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538892855216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
<td class="nump">$ 155,727,292<span></span>
</td>
<td class="num">$ (134,146,128)<span></span>
</td>
<td class="nump">$ 21,596,949<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,520,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">- restricted share units</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">1,164,125<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,164,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">- options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,138,949<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,138,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">- common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">72,818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">72,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,816,150)<span></span>
</td>
<td class="num">(4,816,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">- common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
<td class="nump">159,103,184<span></span>
</td>
<td class="num">(138,962,278)<span></span>
</td>
<td class="nump">20,156,702<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,631,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
<td class="nump">155,727,292<span></span>
</td>
<td class="num">(134,146,128)<span></span>
</td>
<td class="nump">21,596,949<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,520,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,491,391)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">162,207,334<span></span>
</td>
<td class="num">(143,637,519)<span></span>
</td>
<td class="nump">18,585,612<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,643,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
<td class="nump">159,103,184<span></span>
</td>
<td class="num">(138,962,278)<span></span>
</td>
<td class="nump">20,156,702<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,631,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">- restricted share units</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,190,349<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,190,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">- options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,865,297<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,865,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">- common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">48,504<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">48,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,675,241)<span></span>
</td>
<td class="num">(4,675,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">- common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">162,207,334<span></span>
</td>
<td class="num">(143,637,519)<span></span>
</td>
<td class="nump">18,585,612<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,643,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 15,182<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">168,457,418<span></span>
</td>
<td class="num">(152,640,897)<span></span>
</td>
<td class="nump">15,832,072<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">1,518,158<span></span>
</td>
<td class="nump">3,677,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">- restricted share units</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">1,148,750<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,148,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">- options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,190,428<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,190,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">- common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,684,222)<span></span>
</td>
<td class="num">(5,684,222)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 15,182<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">171,796,596<span></span>
</td>
<td class="num">(158,325,119)<span></span>
</td>
<td class="nump">13,487,037<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="nump">1,518,158<span></span>
</td>
<td class="nump">3,767,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 15,182<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">168,457,418<span></span>
</td>
<td class="num">(152,640,897)<span></span>
</td>
<td class="nump">15,832,072<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="nump">1,518,158<span></span>
</td>
<td class="nump">3,677,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,664,774)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">173,695,154<span></span>
</td>
<td class="num">(161,305,671)<span></span>
</td>
<td class="nump">12,403,864<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">3,982,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">$ 15,182<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">171,796,596<span></span>
</td>
<td class="num">(158,325,119)<span></span>
</td>
<td class="nump">13,487,037<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="nump">1,518,158<span></span>
</td>
<td class="nump">3,767,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">- restricted share units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,164,135<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,164,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">- options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">321,534<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">321,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">- common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,980,552)<span></span>
</td>
<td class="num">(2,980,552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">411,701<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 411,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of Series B preferred to common stock</a></td>
<td class="num">$ (1,200)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of Series B preferred to common stock, Shares</a></td>
<td class="num">(120,000)<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 13,982<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 173,695,154<span></span>
</td>
<td class="num">$ (161,305,671)<span></span>
</td>
<td class="nump">$ 12,403,864<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="nump">3,982,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480513/718-10-30-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480843/718-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538894452640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (8,664,774)<span></span>
</td>
<td class="num">$ (9,491,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">80,877<span></span>
</td>
<td class="nump">57,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain on marketable securities</a></td>
<td class="num">(22,392)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,824,865<span></span>
</td>
<td class="nump">6,480,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_GainOnPppLoanForgiveness', window );">Gain on PPP loan forgiveness</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">58,022<span></span>
</td>
<td class="nump">58,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid assets and other current assets</a></td>
<td class="num">(40,477)<span></span>
</td>
<td class="nump">61,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">105,146<span></span>
</td>
<td class="nump">327,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">256,253<span></span>
</td>
<td class="num">(20,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(67,585)<span></span>
</td>
<td class="num">(57,751)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,479,065)<span></span>
</td>
<td class="num">(2,845,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">3,263,504<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(89,071)<span></span>
</td>
<td class="num">(247,247)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">3,174,433<span></span>
</td>
<td class="num">(247,247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from issuance of common stock in at-the-market offering</a></td>
<td class="nump">411,701<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">411,701<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">107,069<span></span>
</td>
<td class="num">(3,093,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">1,676,577<span></span>
</td>
<td class="nump">21,026,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">$ 1,783,646<span></span>
</td>
<td class="nump">$ 17,933,724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_GainOnPppLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on PPP loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_GainOnPppLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897971776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAwKW7UmS0Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 - <span id="xdx_820_zQd2QG33gsnf">NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#8220;Stem Pearls&#8221;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#8220;BRT&#8221; or the &#8220;Company&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 29, 2022, the Company reincorporated from Delaware to Nevada. The reincorporation was structured as a statutory merger of BioRestorative
Therapies, Inc., a Delaware corporation, with and into its wholly-owned subsidiary, BioRestorative Therapies, Inc., a Nevada corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern,
which contemplates realization of assets and satisfying liabilities in the normal course of business. For the six months ended June 30,
2023, the Company had a net loss of $<span id="xdx_908_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230630_zKoiWk4KgFD4" title="Net loss">8.7</span> million (of which, $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20230630_zvOp6hjAWosd" title="Share based compensation">4.8</span> million was attributable to non-cash stock-based compensation) and negative
cash flows from operations of $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20230630_zScWMEPdCnSa" title="Cash flows from operations">3.5</span> million. The Company&#8217;s operating activities consume the majority of its cash resources. The
Company anticipates that it will continue to incur net losses as it executes its development plans throughout 2023 and beyond, as well
as other potential strategic and business development initiatives. In addition, the Company has had and expects to have negative cash
flows from operations, at least into the near future. The Company has previously funded, and plans to continue funding, these losses
primarily through current cash on hand, investments in marketable securities and additional infusions of cash from equity and debt financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 14, 2023, the Company entered into a sales agreement with JonesTrading Institutional Services LLC for an at-the-market (&#8220;ATM&#8221;)
offering of the Company&#8217;s Common Stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230414__dei--LegalEntityAxis__custom--JonesTradingInstitutionalServicesLLCMember_znwIUkHC1pl4" title="Common stock, par value">0.0001</span> per share, at an aggregate offering price of up to $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230413__20230414__dei--LegalEntityAxis__custom--JonesTradingInstitutionalServicesLLCMember_zXl7Ym7zK01j" title="Net proceeds">3.7</span> million. During
the three months ended June 30, 2023, net proceeds of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230401__20230630_zp4eB2lfLCTa" title="Issuance of common stock">411,710</span> were received from the issuance of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630_ztCFAExsLfj1" title="Issuance of common stock, shares">93,551</span> shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 13, 2023, the Company sold an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp0ZL0amDKMj" title="Sale of aggregate shares">685,033</span> shares of Common Stock to several institutional buyers and accredited investors
in a registered direct offering at an offering price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2JsrEU10Mmi" title="Offering price">3.03</span> per share. The offering closed on July 13, 2023, with net proceeds of approximately
$<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQh5mOxRcrJ3" title="Net proceeds offering price">1.8</span> million. The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its
lead cell therapy candidate, <i>BRTX-100</i>, pre-clinical research and development with respect to its metabolic <i>ThermoStem Program
</i>and for general corporate purposes and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on cash on hand as of June 30, 2023, the Company believes it has sufficient cash to fund operations for the twelve months subsequent
to the filing date of this Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations.
If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development,
marketing and promotional activities, which would have a material adverse effect on the Company&#8217;s business, financial condition
and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;GAAP&#8221;), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying
condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue
as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#8217;s
website is at <span style="text-decoration: underline">www.biorestorative.com</span>. The information contained in our website is not intended to be incorporated by reference
into this Quarterly Report. BRT is currently developing a Disc/Spine Program referred to as &#8220;brtxDISC&#8221;. Its lead cell therapy
candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal stem cells collected
from the patient&#8217;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders
or as a complimentary therapeutic to a surgical procedure. BRT is investigating the expansion of the clinic application of <i>BRTX-100
</i>to other indications within the body. BRT is also engaging in research efforts with respect to a platform technology utilizing brown
adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled this initiative
its ThermoStem Program. Further, BRT has licensed a patented curved needle device that is a needle system designed to deliver cells and/or
other therapeutic products or material to the spine and discs or other potential sites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538900914432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zTN69WmswyIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_823_zFIIUySPA5Wa">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRlhrC4DEtT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zA8eCeh1sJN1">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#8217;s condensed consolidated financial statements. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations
of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in
financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules
and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022,
filed with the SEC on March 27, 2023 (the &#8220;Annual Report&#8221;). The summary of significant accounting policies presented below
is designed to assist in understanding the Company&#8217;s condensed consolidated financial statements. Such condensed consolidated financial
statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity and objectivity.
Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected
for the entire year or for any other subsequent interim period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zREhKsxX6Td5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_znlhd3ELGaOi">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts
and transactions have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--UseOfEstimates_zwtoat1ghDr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zMN58ygL53si">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent
liabilities at the date of the condensed consolidated financial statements. The Company bases its estimates and assumptions on historical
experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects
cannot be determined with precision, actual results could differ from these estimates which may cause the Company&#8217;s future results
to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zcSACGDy8Ha2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_z3WbZdua1oW4">Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Deposit Insurance Corporation coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20230630_zNayDp0CxbU5" title="FDIC insured limit">250,000</span>. As of
June 30, 2023, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
royalties related to the Company&#8217;s sublicense comprised all of the Company&#8217;s revenue during the three and six months ended
June 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Summary
of Significant Accounting Policies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting
Standards, in the Annual Report. During the three and six months ended June 30, 2023, the Company did not make any changes to its significant
accounting policies, except as described below with respect to recent accounting pronouncements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_znOeGAyqEkBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zv8XAjWsqIHb">Fair
Value Measurements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
defined in ASC 820, <i>Fair Value Measurements and Disclosures </i>(&#8220;ASC 820&#8221;), fair value is the price that would be received
for an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price).
The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed
    methodologies that result in management&#8217;s best estimate of fair value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p id="xdx_892_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zW4jbsJByhDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zkdefYQKHU2a" style="display: none">SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value measurements at reporting date using:</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Quoted
    prices in active markets for identical liabilities (Level 1)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant
    other observable inputs (Level 2)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant
    unobservable inputs (Level 3)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities
    as of June 30, 2023</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zu4oQGXJlX26" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">9,831,719</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38Gcg8zLNid" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">9,831,719</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPFGOiLkX45f" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqRy9nOQf8h" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities as of
    December 31, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6URVs2noVp9" style="text-align: right" title="Assets fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">13,072,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxIcGBmbuG7b" style="text-align: right" title="Assets fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">13,072,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze6juTXqxlij" style="text-align: right" title="Assets fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJp5ylMONiFj" style="text-align: right" title="Marketable securities fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zG5lvpiaknp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvVPxBCuna8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zr12olmF0qe2">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of cash, accounts receivable, and accounts payable approximate their fair values based on the short-term maturity of these
instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zWpy9BeM7Nc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zNIGYNH3Uw17">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year.
All outstanding options and warrants are considered potential Common Stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered Common Stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of Common Stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#8217;s
computation of diluted net loss per common share for the three and six months ended June 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zWDwDFjj1aO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_8BE_zmG1LMRaRtJf" style="display: none">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zoVAZU1l0674" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,466,890</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zdKOjnSs6JIl" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">864,609</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zc0EPtjDys1g" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,791,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zz6X9pJJlLg1" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,739,733</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zi9d04LG8wFc" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">97,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zmpUhm1zxDDk" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">214,303</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred
    stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zYSf03qkG40a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif">1,398,158</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjfyRiVBMauh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630_fKDIp_zwj5cmepYbYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">7,753,947</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630_fKDIp_zSi4gJoWHmgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">5,818,645</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z5wLvddjCTp3" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,466,890</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zsQQw2lkcHx1" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">864,609</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zZeocQHQDFe4" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,791,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoRAybkNxNi5" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,739,733</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zjC70CZjP5p7" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">97,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zs5G9aXwP524" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">214,303</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred
    stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zInpt4CcrdUa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif">1,398,158</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zY4Dlp2Gxwfl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630_fKDIp_zAxmQ19gtKFk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">7,753,947</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630_fKDIp_zBZIpuo4UaQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">5,818,645</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zjZWA5yxsR65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ0NnOo8kjS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z7grb1Ai6bb5">Recently
Adopted Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses,</i> which requires entities to estimate all expected
credit losses for financial assets measured at amortized cost basis, including trade receivables, held at the reporting date based on
historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted this guidance on January 1,
2023. The adoption of this accounting standard did not have a material impact on the Company&#8217;s condensed consolidated financial
statements.</span></p>

<p id="xdx_85B_zmb5KKwrIRR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897964480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_z3DXiu3SB77f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 - <span style="text-transform: uppercase"><span id="xdx_821_zElumeMfieWh">INTANGIBLE ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a license agreement with a stem cell treatment company (the &#8220;SCTC&#8221;) (as amended) (the &#8220;SCTC Agreement&#8221;).
Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from the SCTC
to utilize or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or
spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or
sublicense a certain method for culturing cells. Pursuant to the license agreement with the SCTC, certain performance milestones (or
payouts in lieu of performance milestones) had to be satisfied in order for the Company to maintain its exclusive rights with regard
to the disc/spine technology. The Company did not timely satisfy the third of these performance milestones (which needed to be satisfied
by February 2022). Accordingly, such rights became non-exclusive. However, in November 2022, the Company entered into an amended agreement
under which it paid $<span id="xdx_902_eus-gaap--PaymentsToAcquireIntangibleAssets_c20221101__20221130_zfN1MS780mae" title="Payment to acquire intangible assets">175,000</span> and issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzGeSwEB3yh1" title="Stock issued new issues">51,370</span> warrants, with a fair value of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221101__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zW5ak0HvlSg3" title="Fair value of warrants">117,030</span>, in exchange for renewed exclusivity. The consideration
transferred to the SCTC in exchange for exclusivity was capitalized to intangible assets on the Company&#8217;s consolidated balance
sheet as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2017, the Company received authorization from the Food and Drug Administration (the &#8220;FDA&#8221;) to proceed with a Phase
2 clinical trial. In March 2022, the United States Patent and Trademark Office issued a patent relating to the Company&#8217;s BRTX-100
clinical program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEsmIKeehgfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zEJ0LcKDLXHk" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Patents
    and Trademarks</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    Amortization</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zPmzRQOFS9ti" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,676</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z1wPZDTV3Ii7" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,593,530</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zR0Kbv10m0F6" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"><span style="font-family: Times New Roman, Times, Serif">(793,768</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20230101__20230630_zh0qufzFys61" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"><span style="font-family: Times New Roman, Times, Serif">803,438</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Amortization expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zm9CaSx6pvKa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zYD1fTeq1AK6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zvtZDmGgQd9i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"><span style="font-family: Times New Roman, Times, Serif">(44,873</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20230630_z8wIyterxqFh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"><span style="font-family: Times New Roman, Times, Serif">(44,873</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zokTDpGmZh0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"><span style="font-family: Times New Roman, Times, Serif">3,676</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z8fOX4SaPKl2" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,593,530</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zcMTvQKJmnk8" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance"><span style="font-family: Times New Roman, Times, Serif">(838,641</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20230101__20230630_z34utZSYBoOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, ending balance"><span style="font-family: Times New Roman, Times, Serif">758,565</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining amortization
    period as of June 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zpOAMVBGgBB" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zJZJ9QiTOoY3" title="Finite Lived Intangible Assets, weighted average amortization period">10.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AD_zK8LVrSyr5u7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z5pJulk0Orfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
amortization of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zD7VQS2J3io7" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Patents
    and Trademarks</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    Amortization</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCPGaWTdyY6" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">3,676</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zE8ZCjlwtaCe" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">790,092</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zu9jAk4IM1v2" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">793,768</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Amortization expense</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zfpzkjcjS488" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zNYR99kmrBo" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"><span style="font-family: Times New Roman, Times, Serif">44,873</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zQZSJjW6XJ66" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"><span style="font-family: Times New Roman, Times, Serif">44,873</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 30, 2023</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zIMAWTvQfMM6" style="padding-bottom: 0pt; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">3,676</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBqs1aRGbARb" style="padding-bottom: 0pt; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">834,965</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zBEKEeHprqm9" style="padding-bottom: 0pt; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif">838,641</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_z7JoxfcYog0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538898871520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zCUPEIRoNF0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 - <span id="xdx_828_zItoCNvh5ZLa">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z9DuZrOyjTga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zHg3RGG5qemd" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20230630_zLROBTFFOyng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20221231_zmNRx7NXLmr8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zAPVwqYApceg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued payroll</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">325,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,250</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zA5adVmI4qOc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued general and
    administrative expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,325</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">103,822</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zZLVspUdYBX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">386,325</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,072</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AB_zddjRb6QZT8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538900150512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zoRQVbwCoSn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE
5 - <span id="xdx_827_zEOZJQqo4s7g">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
A Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2021, in connection with the Company&#8217;s public offering, the Company&#8217;s Board of Directors adopted a resolution
allowing for the designation and issuance of <span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjtg6zP4wu3" title="Preferred stock, shares issued">1,543,158</span> shares of the Company&#8217;s Preferred Stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zPcorMWtAGzb" title="Preferred stock, par value">.01</span> par value per share, designated
as Series A Preferred Stock (&#8220;Series A&#8221;). The Series A had a liquidation preference of $<span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBWqdUyzvWgg" title="Preferred stock, liquidation preference">0.001</span> per share. On September 8,
2022, the Company issued <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDgoLAd9PQUj" title="Preferred stock, shares issued">1,543,158</span> shares of Series B Preferred Stock (&#8220;Series B&#8221;) to Auctus Fund, LLC (&#8220;Auctus&#8221;)
in exchange for an equal number of shares of the Company&#8217;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#8217;s Board
of Directors cancelled the Series A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series
B Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
September 8, 2022, the Company issued <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zIbqBFEI0Wd2" title="Preferred stock, shares issued">1,543,158</span> shares of Series B to Auctus in exchange for an equal number of shares of the Company&#8217;s
outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of Common Stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is <span id="xdx_901_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7vIuiqhpq9h" title="Preferred stock voting rights">9.99</span>% of the then outstanding Common Stock of the Company instead of <span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7bA92hignrj" title="Preferred stock voting rights">4.99</span>% as
provided for the Series A. The Company shall, at all times, reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to redemption
by the Company or any Series B holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting
Rights</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7DagVLZRLVh" title="Preferred stock voting percentage">9.99</span>% of the then outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional
Conversion - <span id="xdx_90F_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwlfxZg9vp6c" title="Preferred stock conversion term">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock</span>; provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than <span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUl1gl7nslOc" title="Preferred stock voting percentage">9.99</span>% of the outstanding
shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic
Conversion &#8211; From time to time, if an event occurs, including adjustment due to merger, consolidation, etc., subdivision or combination
of Common Stock, adjustment due to distribution, purchase rights, and notice of adjustments, which has the effect of reducing a Series
B holder&#8217;s beneficial ownership of shares of Common Stock to less than <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zw67XtWAPFv3" title="Ownership percentage">9.5</span>% of the then publicly disclosed outstanding shares of
Common Stock, then, within five (5) business days, the Series B holder shall provide notice to the Company to such effect, which notice
shall state the number of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard
thereto, including the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have
the effect of a notice of conversion with respect to the conversion of such number of shares of Series B as would increase the Series
B holder&#8217;s beneficial ownership of Common Stock to<span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zf3oOpgUB7h4" title="Preferred stock voting percentage"> 9.99</span>% of the then publicly disclosed outstanding shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 4, 2023, Auctus converted <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zWtGfk0zZb9c" title="Number of shares converted">120,000</span> shares of Series B into <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20221024__20221025__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJGmPqTA1sdc" title="Number of shares issued in conversion">120,000</span> shares of Common Stock. As of June 30, 2023, the number of shares
of Series B remaining outstanding after giving effect to such conversion was <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z2eOiDOJAP05" title="Preferred stock, shares outstanding">1,398,158</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant
and Option Valuation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221;
method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined
from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument
being valued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options granted during the three months ended June 30, 2023. The Company granted options for the purchase of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_z3B7ZJCvZfma" title="Number of options, granted">629,017</span> shares
of Common Stock during the six months ended June 30, 2023. The grant date fair value of options issued during the six months ended June
30, 2023 was $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_c20230101__20230630_zM9otZTzI5s2" title="Grant date fair value of options granted">1,745,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no stock options granted during the three months ended June 30, 2022. The Company granted options for the purchase of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220630_znjJhKiPETHh" title="Number of options, granted">25,000</span> shares
of Common Stock during the six months ended June 30, 2022. The grant date fair value of options issued during the six months ended June
30, 2022 was $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_c20220101__20220630_zje6NeHpe1Nf" title="Grant date fair value of options granted">122,117</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW0R13kT1jL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted during the six months ended June 30, 2023, the Company used
the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zDq2cHk08Thc" style="display: none">SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the <br/>
Six
    Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the <br/>
Six
    Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDSkZ37Igyd" title="Risk free interest rate">4.22</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZtgZ8QUyqe1" title="Risk free interest rate">2.42</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBhSZaQxdAFg" title="Expected term (years)">3.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5JzdB8fjNlb" title="Expected term (years)">3.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zby1UAbkAsBb" title="Expected volatility">175</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqv9Sd8BWgk9" title="Expected volatility">286</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividends</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zu9HApWxUHLg" title="Expected dividends">0.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNbPFihnX0Jh" title="Expected dividends">0.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<p id="xdx_8A1_zdLgnTYG7sX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zod8JJGBmmSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity during the six months ended June 30, 2023 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zrv49KVB03V9" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January
    1, 2023</span></td><td style="width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230630_zmqPO3psl6J7" style="width: 15%; text-align: right" title="Number of options, beginning balance"><span style="font-family: Times New Roman, Times, Serif">864,639</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630_zb1G2Hk2oxs9" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">5.08</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_zpHlNPQJ4TKg" style="text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif">629,017</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230630_z5w0JgAU9F9l" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.91</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230630_zIPI50soujR" style="text-align: right" title="Number of options, expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230630_zVH5uKxRXHW5" style="text-align: right" title="Weighted average exercise price, expired"><span style="font-family: Times New Roman, Times, Serif"> <span style="-sec-ix-hidden: xdx2ixbrl0792">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230630_zCG2iBNn9Uic" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Forfeited"><span style="font-family: Times New Roman, Times, Serif">(26,766</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230630_zYgN6ZaK0Rwc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font-family: Times New Roman, Times, Serif">5.08</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, June 30, 2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230630_zDrmnGBj3Ef1" style="text-align: right" title="Number of options, ending"><span style="font-family: Times New Roman, Times, Serif">1,466,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630_zGCpZj59PtKd" style="text-align: right" title="Weighted average exercise price, ending"><span style="font-family: Times New Roman, Times, Serif">4.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, June 30, 2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630_z8Ycbbk55yaj" style="text-align: right" title="Number of options, exercisable"><span style="font-family: Times New Roman, Times, Serif">1,041,062</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630_zSqvYqqK8Ig1" style="text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif">4.66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A8_zgnbMQlAn8k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Company&#8217;s 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;), the Company may grant restricted stock units (&#8220;RSUs&#8221;)
to employees, consultants or non-employee directors (&#8220;Eligible Individuals&#8221;). The number, terms and conditions of the RSUs
that are granted to Eligible Individuals are determined on an individual basis by the 2021 Plan administrator. On the distribution date,
the Company shall issue to the Eligible Individual one unrestricted, fully transferable share of the Company&#8217;s Common Stock (or
the fair market value of one such share in cash) for each vested and nonforfeitable RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zhR277GmpHve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s unvested RSUs as of June 30, 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zwEfQhs2PAyi" style="display: none">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 75%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    December 31, 2022</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z51dUu8f06R5" style="padding-bottom: 0pt; width: 20%; text-align: right" title="Number of shares outstanding beginning"><span style="font-family: Times New Roman, Times, Serif">201,870</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgLen2L5AgGl" style="padding-bottom: 0pt; text-align: right" title="Number of shares granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztOMKQsc9xX2" style="padding-bottom: 0pt; text-align: right" title="Number of shares forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztkwfcWR3sgk" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Number of shares vested"><span style="font-family: Times New Roman, Times, Serif">(104,043</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    June 30, 2023</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCp5KXNFgd39" style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: right" title="Number of shares outstanding ending"><span style="font-family: Times New Roman, Times, Serif">97,827</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A2_zvALObrIoyMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p id="xdx_89F_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z5AzYWxXfpoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents stock compensation by award type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zdyvbNup9OG8" style="display: none">SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Three Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDfpQS5NlEh" style="width: 16%; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">321,534</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG5gfN4kthq5" style="width: 16%; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">1,865,297</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDCbt1c6FTBi" style="text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">1,164,135</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEREzz7ndOCb" style="text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">1,190,349</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zIZEKXG43Udh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zWM796kT5zmc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">48,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230401__20230630_zEck7EsYqcil" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">1,485,669</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_zVmnkKQX3n58" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">3,104,150</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Six Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB9UH8kS7oW1" style="width: 16%; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">2,511,962</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOFgeN6j0zrk" style="width: 16%; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">4,004,246</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeLbOukUuin3" style="text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">2,312,885</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbVB9R9W6a64" style="text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">2,354,474</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zNFeSSDDOuA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zShdxp6AJlyj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">121,322</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230630_zRFHHQtJjHG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">4,824,847</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220630_z9sj7xmEFZoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">6,480,042</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A4_zGgBDZacKlS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation is included in General and administrative expenses on the consolidated statements of operations. As of June 30, 2023,
unrecognized stock based compensation expense is $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20230630_zaXfXzTG0NE3" title="Unrecognized expense">1,201,875</span> with a weighted average remaining amortization period of <span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230630_zzXeczZvZeW4" title="Weighted average remaining amortization period">1.04</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538896422704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zlndkIz3u3Ra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note
6 - </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_824_zsvL3sbPbRXg">LEASES</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to a lease for <span id="xdx_908_eus-gaap--AreaOfLand_iI_usqft_c20230630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zzXYDXB53ZZa" title="Area of land">6,800</span> square feet of space located in Melville, New York (the &#8220;Melville Lease&#8221;) with respect
to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIVoJ2NitjW1" title="Rent expense">132,600</span> and
$<span id="xdx_902_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zaqC6PgIdX0j" title="Rent expense">149,260</span>. In June 2019, <span id="xdx_90A_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zWLSS1zQlkkh" title="Lease extension description">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zkDAc3ek9uY3" title="Rent expense">153,748</span> and $<span id="xdx_90A_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zCtVMBWdIMC5" title="Rent expense">173,060</span>.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230630_zHdPrF0PBv24" title="Weighted average incremental borrowing rate">12</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zW5SqB6eDYq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zFNMTlnW2HMg" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20230101__20230630_zAJjbLhIF7F9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220101__20220630_zqNvy7oBLJN" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zMljgG65GQGi" style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost (cost resulting
    from lease payments)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">84,014</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">81,566</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zEVxoxlUHLL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">84,014</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">81,566</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zJOh96MPVHUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease &#8211; operating cash flows
    (fixed payments)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">84,014</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">81,566</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFcU1cz1j3j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease &#8211; operating cash flows
    (liability reduction)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,751</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current leases &#8211; right of use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20230630_zxxShXwMOek2" style="text-align: right" title="Non-current leases - right of use assets"><span style="font-family: Times New Roman, Times, Serif">183,738</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220630_z2Kh8pieJBnd" style="text-align: right" title="Non-current leases - right of use assets"><span style="font-family: Times New Roman, Times, Serif">299,783</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities &#8211; operating lease
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20230630_zLaiciFlln7e" style="text-align: right" title="Current liabilities - operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">150,480</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220630_zH65EMzxLRQa" style="text-align: right" title="Current liabilities - operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">128,899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current liabilities &#8211; operating lease
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20230630_zEZAX9TMYJq9" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">83,580</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20220630_zwIinaSkCiz7" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">234,060</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zGyTbXHJAoy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3ofkMUnbeXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of June 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z6KIOPVmJpBa" style="display: none">SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fiscal
    Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20230630_zUokooBdJQwi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zI2y2IqCMy29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 78%"><span style="font-family: Times New Roman, Times, Serif">Remainder of 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">84,014</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zeF8mVF1zE7h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">173,060</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zERuRTZ5vC1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">257,074</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za99u9rqEpjk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Amount representing
    interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_z3L2pUZXwTNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of net
    future minimum lease payments</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">234,060</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538898740096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zg5RXeDPMMX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-transform: uppercase"><b>Note 7
&#8211; </b></span><b><span id="xdx_827_zQN5OASAr6P4">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 13, 2023, the Company
sold an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsjcrJCDwMMi" title="Number of shares issued">685,033</span> shares of Common Stock to several institutional buyers and accredited investors in a registered direct offering
at an offering price of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMx5DgJZkt91" title="Offering price">3.03 </span>per share. The offering closed on July 13, 2023, with net proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH6DD6F5Zq4a" title="Procceds fom offering">1.8</span> million. The Company
intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy candidate,
<i>BRTX-100</i>, pre-clinical research and development with respect to its metabolic <i>ThermoStem Program </i>and for general corporate
purposes and working capital.</p>

<p id="xdx_8AD_zQlp4Tjb2c7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Note
Regarding Forward-Looking Statements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q includes a number of forward-looking statements that reflect management&#8217;s current views with respect
to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial
performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;should,&#8221;
&#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221;
&#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements include
statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions
on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of
future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such
forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors,
including the risks set forth in the section entitled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 27, 2023, any of
which may cause our company&#8217;s or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.
These risks and factors include, by way of example and without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financing needed to complete our clinical trials and implement our business plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully develop and commercialize BRTX-100, our lead product candidate for the treatment of chronic lumbar disc disease,
    as well as our metabolic ThermoStem Program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect our proprietary rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to achieve and sustain profitability of the existing lines of business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain world-class research and development talent;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain key science, technology and management personnel and to expand our management team;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of estimates regarding expenses, future revenue, capital requirements, profitability, and needs for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from geo-political actions, including war and terrorism or disease outbreaks (such as the recent outbreak
    of COVID-19);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain customers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to navigate through the increasingly complex therapeutic regulatory environment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity or performance. Except as required by applicable law, including the securities laws of the United States, we do not intend
to update any of the forward-looking statements to conform these statements to actual results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Readers
are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the
SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated
events or changes in the future operating results over time, except as required by law. We believe that our assumptions are based upon
reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or
the results of our future activities will not differ materially from our assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221;
and &#8220;our&#8221; refer to BioRestorative Therapies, Inc., a Nevada corporation (&#8220;BRT&#8221;), and its wholly-owned subsidiary,
Stem Pearls, LLC, a New York limited liability company (&#8220;Stem Pearls&#8221;). Unless otherwise specified, all dollar amounts are
expressed in United States dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intellectual
Property</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report includes references to our federally registered trademarks, <i>BioRestorative Therapies and Dragonfly </i>design, <i>BRTX-100,
ThermoStem, </i>and <i>BRTX</i>. The <i>Dragonfly</i> logo is also registered with the U.S. Copyright Office. This report may also include
references to trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks
and trade names referred to in this report appear without the &#174;, <sup>SM</sup> or &#8482; symbols, and copyrighted content appears
without the use of the symbol &#169;, but the absence of use of these symbols does not reflect upon the validity or enforceability of
the intellectual property owned by us or third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
History</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
offices are located in Melville, New York where we have established a laboratory facility in order to increase our capabilities for the
further development of possible cellular-based treatments, products and protocols, stem cell-related intellectual property and translational
research applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, our accumulated deficit was $161,305,671. We have historically only generated a modest amount of revenue, and our losses
have principally been operating expenses incurred in research and development, marketing and promotional activities in order to commercialize
our products and services, plus costs associated with meeting the requirements of being a public company. We expect to continue to incur
substantial costs for these activities over at least the next year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business
Overview</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
develop therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells.
We are currently pursuing our <i>Disc/Spine Program</i> with our initial investigational therapeutic product being called <i>BRTX-100</i>.
In March 2022, a United States patent was issued in our <i>Disc/Spine Program</i>. We submitted an IND application to the FDA to obtain
authorization to commence a Phase 2 clinical trial investigating the use of <i>BRTX-100</i>, our lead cell therapy candidate, in the
treatment of chronic lower back pain arising from degenerative disc disease. We have received such authorization from the FDA and have
commenced such clinical trial through the execution of a CRO agreement with Professional Research Consulting, Inc., d/b/a PRC Clinical (&#8220;PRC&#8221;),
the execution of clinical trial site agreements, patient enrollment, the commencement of patient procedures, the purchase of manufacturing
equipment and the expansion of our laboratory to include capabilities for clinical production. We have received a license from the New
York State Department of Health to act as a tissue bank for mesenchymal stem cell processing. In June 2023, we received a unanimous recommendation
from the Data Safety Monitoring Board (&#8220;DSMB&#8221;) to continue our Phase 2 clinical trial without any changes. We have obtained
a license to use technology for investigational adult stem cell treatment of disc and spine conditions, including protruding and bulging
lumbar discs. The technology is an advanced stem cell injection procedure that may offer relief from lower back pain, buttock and leg
pain, and numbness and tingling in the leg and foot. We are investigating the expansion of the clinic application of <i>BRTX-100</i>
to other indications within the body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also developing our <i>ThermoStem Program</i>. This pre-clinical program involves the use of brown adipose (fat) in connection with
the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
United States patents related to the <i>ThermoStem Program</i> were issued in September 2015, January 2019, March 2020, March 2021, and
July 2021; a notice of allowance was issued in February 2023 by the United States Patent Office for a patent application related to our
<i>ThermoStem</i> Program; Australian patents related to the <i>ThermoStem Program</i> were issued in April 2017, October 2019, and August
2021; Japanese patents related to the <i>ThermoStem Program</i> were issued in December 2017, June 2021, and February 2022; a notice
of allowance was issued in May 2023 by the Japanese Patent Office for a patent application related to our <i>ThermoStem Program</i>;
Israeli patents related to our <i>ThermoStem Program</i> were issued in October 2019, May 2020, and March 2022; European patents related
to the <i>ThermoStem Program </i>were issued in April 2020 and January 2021; and a notice of allowance was issued in February 2023 by
the European Patent Office for a patent application related to our <i>ThermoStem</i> Program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have licensed a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products or
materials to the spine and discs or other potential sites. We anticipate that FDA approval or clearance will be necessary for this device
prior to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to <i>BRTX-100</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
derived all of our revenue pursuant to a license agreement with the SCTC entered into in January 2012, as amended in November 2015 and
November 2022. Pursuant to the license agreement, the SCTC granted to us an exclusive license to use certain intellectual property related
to, among other things, stem cell disc procedures and we have granted to the SCTC a sublicense to use, and the right to sublicense to
third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual
property. In consideration of the sublicenses, the SCTC has agreed to pay us royalties on a per disc procedure basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Results
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Three Months Ended June 30, 2023 to the Three Months Ended June 30, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial results for the three months ended June 30, 2023 are summarized as follows in comparison to the three months ended June 30,
2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Three Months Ended,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(unaudited)</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">64,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">967,891</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,075,224</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,213,160</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,624,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,181,051</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,699,728</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,116,551</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,628,628</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    (income) expense:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Interest (income) expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(96,187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,613</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(39,812</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total other (income) expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(135,599</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46,613</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,980,552</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,675,241</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended June 30, 2023 and 2022, we generated $64,500 and $71,000, respectively, of royalty revenue in connection with
our sublicense agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development
expenses are expensed as they are incurred. For the three months ended June 30, 2023, research and development expenses decreased by
$107,333, or 10.0%, compared to the three months ended June 30, 2022. The decrease was primarily the result of a difference in the timing
of payments made for PRC service expenses. A milestone payment in the amount of $150,000 was paid on June 30, 2022 compared to the three
months ended June 30, 2023 in which no milestone payment was due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our research and development expenses will increase in subsequent fiscal periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees, as well
as corporate expenses such as legal and professional fees, investor relations and occupancy-related expenses. For the three months ended
June 30, 2023, general and administrative expenses decreased by $1,411,344, or 38.9%, as compared to the three months ended June 30,
2022, primarily driven by a $1,618,481 decrease in stock-based compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
(income) expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended June 30, 2023, interest income was $96,187 compared to interest expense of $46,613 for the three months ended
June 30, 2022. The change was primarily due to our investments in marketable securities during the three months ended June 30, 2023,
which generated interest income. During the three months ended June 30, 2022, we did not have any such investments and only incurred
interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other
income, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended June 30, 2023, Other income, net primarily relates to gains from settlements of certain accrued expenses and realized
and unrealized gain on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of the Six Months Ended June 30, 2023 to the Six Months Ended June 30, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial results for the six months ended June 30, 2023 are summarized as follows in comparison to the six months ended June 30, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Six Months Ended,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-style: italic; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(unaudited)</span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">95,800</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">87,100</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,479,136</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,850,561</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,512,313</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,918,960</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,991,449</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,769,521</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,895,649</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,682,421</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    (income) expense:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Interest (income) expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(114,403</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">75,624</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Gain on PPP loan forgiveness</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(250,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Grant income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16,654</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(116,472</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total other income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(230,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(191,030</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,664,774</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,491,391</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenues</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2023 and 2022, we generated $95,800 and $87,100, respectively, of royalty revenue in connection with our
sublicense agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research
and Development</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development
expenses are expensed as they are incurred. For the six months ended June 30, 2023, research and development expenses increased by $628,575,
or 34.0%, compared to the six months ended June 30, 2022. The increase was primarily driven by increased salaries and wages of $836,000,
increased lab site fees of $84,000, and increased consulting fees of 95,000, offset by a decrease in PRC service expenses of $532,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our higher level of research and development expenses will continue in subsequent fiscal periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
and Administrative</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees, as well
as corporate expenses such as legal and professional fees, investor relations and occupancy-related expenses. For the six months ended
June 30, 2023, general and administrative expenses decreased by $1,406,647, compared to the six months ended June 30, 2022. The decrease
was primarily driven by a $1,655,195 decrease in stock-based compensation, offset by an increase in salaries and wages of $167,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our general and administrative expenses will increase as we expand our staff, develop our infrastructure and incur additional
costs to support the growth of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Interest
(income) expense</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2023, interest income was $114,403 compared to interest expense of $75,624 for the six months ended June
30, 2022. The change was primarily due to our investments in marketable securities during the six months ended June 30, 2023, which generated
interest income. During the six months ended June 30, 2022, we did not have any such investments and only incurred interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Other
income, net</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2023, Other income, net primarily relates to gains from settlements of certain accrued expenses and realized
and unrealized gain on investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Gain
on PPP loan forgiveness</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the U.S. Small Business Administration&#8217;s Paycheck Protection Program (&#8220;PPP&#8221;), our $250,000 PPP loan was
forgiven during the six months ended June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Grant
income</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
income of $16,654 during the six months ended June 30, 2022 consists of funding received under a $256,000 National Institutes of Health
Small Business Technology Transfer (STTR) Phase 1 grant, which we were awarded in September 2021. There was no grant income during the
six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Capital Resources</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure our liquidity in a number of ways, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash, Cash
    Equivalents, and Investments</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,615,365</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,749,408</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Working Capital</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,231,071</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,688,188</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working
capital decreased by $3,457,117 primarily due to the $3,479,065 of cash used to fund our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Availability
of Additional Funds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon our accumulated deficit of $161,305,671 as of June 30, 2023, along with our forecast for continued operating losses and our need
for financing to fund our current and contemplated clinical trials, we will eventually require additional equity and/or debt financing
to continue our operations. However, based on cash on hand as of June 30, 2023 and the recent offerings discussed below, we believe we
have sufficient cash to fund operations for the twelve months subsequent to the filing date of this Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating needs include the planned costs to operate our business, including amounts required to fund our clinical trials, working capital
and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including
our ability to successfully commercialize our products and services, competing technological and market developments, and the need to
enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service
offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to raise sufficient additional capital when we need it or raise capital on favorable terms. Future financing may require
us to pledge certain assets and enter into covenants that could restrict certain business activities or our ability to incur further
indebtedness and may contain other terms that are not favorable to our stockholders or us. If we are unable to obtain adequate funds
on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing
agreements on unattractive terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#8220;At-the-Market&#8221;
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, we entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (the &#8220;Sales Agent&#8221;)
under which we have the ability to issue and sell shares of our Common Stock, from time to time, through the Sales Agent, up to an aggregate
offering price of $4,200,000 in what is commonly referred to as an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;) program. During the
three months ended June 30, 2023, we sold 93,551 shares of our Common Stock under the ATM program with the Sales Agent at a weighted-average
gross price of approximately $5.74 per share and raised approximately $536,600 of gross proceeds. The total commissions and related legal
fees were approximately $125,000, and we received net proceeds of approximately $412,000. As of June 30, 2023, we had remaining capacity
to sell up to an additional $3,663,407 of Common Stock under the ATM program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registered
Direct Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we sold an aggregate of 685,033 shares of our Common Stock in a registered direct offering. We received net proceeds of approximately
$1,831,000 from the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023 and 2022, our sources and uses of cash were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,479,065</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,845,765</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by (used in) investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,174,433</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(247,247</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net cash provided by
    financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">411,701</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net increase (decrease)
    in cash</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">107,069</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,093,003</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $3,479,065 for the six months ended June 30, 2023, primarily due to cash used to fund the net loss
of $8,664,774, which was partially offset by non-cash expenses of $4,824,865 related primarily to stock-based compensation. Cash flows
were also impacted by routine fluctuations in our operating assets and liabilities. Net cash used in operating activities was $2,845,756
for the six months ended June 30, 2022, primarily due to cash used to fund the net loss of $9,491,391 and a non-cash gain of $250,000
on forgiveness of our PPP loan, which were partially offset by non-cash expenses of $6,480,055 related primarily to stock-based compensation
and $300,032 of cash provided by changes in the levels of operating assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities increased by $3,421,680 for the six months ended June 30, 2023 compared to the six months ended
June 30, 2022, primarily due to a sale of marketable securities, which provided $3,263,504 of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financing
Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities increased by $411,701 for the six months ended June 30, 2023 compared to the six months ended June
30, 2022, due to the net proceeds from the ATM offerings of the Company&#8217;s Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Effects
of Inflation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that inflation had a material impact on our business, revenues or operating results during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Critical
Accounting Policies and Estimates</i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies are more fully described in the notes to our unaudited condensed consolidated financial statements included
herein for the quarter ended June 30, 2023, and in the notes to our audited consolidated financial statements included in our Annual
Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_009"></span>Item
3. Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable. As a smaller reporting company, we are not required to provide the information required by this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_010"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934, as amended (&#8220;the Exchange Act&#8221;), that are designed to ensure that information required to be disclosed in our reports
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and
forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal
financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures,
our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls
and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance
of achieving the desired control objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our principal executive officer and principal financial officer,
we are required to perform an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the
Exchange Act, as of June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has completed such evaluation and has concluded that our disclosure controls and procedures were not effective to provide reasonable
assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is appropriate to allow
timely decisions regarding required disclosures. As a result of the material weakness in internal controls over financial reporting described
below, we concluded that our disclosure controls and procedures as of June 30, 2023 were not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Weaknesses in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
assessed the effectiveness of our internal control over financial reporting as of June 30, 2023 based on the framework established in
Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based
on this assessment, management has determined that our internal control over financial reporting as of June 30, 2023 was not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness, as defined in the standards established by Sarbanes-Oxley, is a deficiency, or a combination of deficiencies, in internal
control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated
financial statements will not be prevented or detected on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ineffectiveness of our internal control over financial reporting was due to the following material weaknesses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of adherence to formal policies and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of risk assessment procedures on internal controls to detect financial reporting risks in a timely manner; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of sufficient formal management testing over documented formal procedures and controls, and time to evaluate continuous effectiveness
    of controls to achieve complete and accurate financial reporting and disclosures, including documented controls over the preparation
    and review of journal entries and account reconciliations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Plan to Remediate the Material Weaknesses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weaknesses
are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    management personnel, including our Chief Financial Officer, who is overseeing the financial reporting process and implementation
    of enhanced controls and governance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement
    of external financial consulting firm to continue to enhance financial reporting, financial operations and internal controls; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documentation
    of key procedures and controls using a risk-based approach.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.6pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
is committed to maintaining a strong internal controls environment and implementing measures designed to help ensure that control deficiencies
contributing to the material weaknesses are remediated as soon as possible. We have documented key procedures and controls using a risk-based
approach and have, therefore, made progress toward remediation. We continue to implement our remediation plan, which includes continued
engagement of an external financial consulting firm to enhance financial reporting and operations as well as design and implementation
of controls. We will consider the material weaknesses remediated after the applicable controls operate for a sufficient period of time,
and Management has concluded, through testing, that the controls are operating effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing
basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than described above, there have been no changes in our internal control over financial reporting that occurred during our second quarter
of 2023 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_012"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
investment in our Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in
the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC
on March 27, 2023, in addition to other information contained in that report and in this quarterly report in evaluating the Company and
its business before purchasing shares of our Common Stock. The Company&#8217;s business, operating results and financial condition could
be adversely affected due to any of those risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_013"></span>Item
2. Unregistered Sales of Equity Securities and Use Of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended June 30, 2023, we did not have any unregistered sales of equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="a_014"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated
    by Reference</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex33-certificatetoaccompanya.jpg" style="-sec-extract: exhibit">Amended and Restated Articles of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/5/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex34-certificateofdesignatio.jpg" style="-sec-extract: exhibit">Certificate of Designations of Preferred Stock (Series B)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/5/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_5.htm" style="-sec-extract: exhibit">Bylaws</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/5/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><a href="ex31-1.htm"><span style="font-size: 10pt">Certification
    of Principal Executive Officer</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><a href="ex31-2.htm"><span style="font-size: 10pt">Certification
    of Principal Financial Officer</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif"><a href="ex32-1.htm"><span style="font-size: 10pt">Section
    1350 Certification of Principal Executive Officer and Principal Financial Officer</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Date File (embedded within the Inline XBRL document)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Filed
    herewith.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>**</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In
    accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIORESTORATIVE
    THERAPIES, INC.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lance Alstodt</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President, and Chairman of the Board</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert E. Kristal</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E. Kristal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    11, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538896261808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRlhrC4DEtT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zA8eCeh1sJN1">Basis
of Presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#8217;s condensed consolidated financial statements. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations
of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in
financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules
and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022,
filed with the SEC on March 27, 2023 (the &#8220;Annual Report&#8221;). The summary of significant accounting policies presented below
is designed to assist in understanding the Company&#8217;s condensed consolidated financial statements. Such condensed consolidated financial
statements and accompanying notes are the representations of Company&#8217;s management, who is responsible for their integrity and objectivity.
Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected
for the entire year or for any other subsequent interim period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zREhKsxX6Td5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_znlhd3ELGaOi">Principles
of Consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts
and transactions have been eliminated upon consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zwtoat1ghDr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zMN58ygL53si">Use
of Estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent
liabilities at the date of the condensed consolidated financial statements. The Company bases its estimates and assumptions on historical
experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects
cannot be determined with precision, actual results could differ from these estimates which may cause the Company&#8217;s future results
to be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zcSACGDy8Ha2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_z3WbZdua1oW4">Concentrations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Deposit Insurance Corporation coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20230630_zNayDp0CxbU5" title="FDIC insured limit">250,000</span>. As of
June 30, 2023, the Company has not experienced losses on this account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
royalties related to the Company&#8217;s sublicense comprised all of the Company&#8217;s revenue during the three and six months ended
June 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Summary
of Significant Accounting Policies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting
Standards, in the Annual Report. During the three and six months ended June 30, 2023, the Company did not make any changes to its significant
accounting policies, except as described below with respect to recent accounting pronouncements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_znOeGAyqEkBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zv8XAjWsqIHb">Fair
Value Measurements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
defined in ASC 820, <i>Fair Value Measurements and Disclosures </i>(&#8220;ASC 820&#8221;), fair value is the price that would be received
for an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price).
The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed
    methodologies that result in management&#8217;s best estimate of fair value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p id="xdx_892_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zW4jbsJByhDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zkdefYQKHU2a" style="display: none">SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value measurements at reporting date using:</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Quoted
    prices in active markets for identical liabilities (Level 1)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant
    other observable inputs (Level 2)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant
    unobservable inputs (Level 3)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities
    as of June 30, 2023</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zu4oQGXJlX26" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">9,831,719</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38Gcg8zLNid" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">9,831,719</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPFGOiLkX45f" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqRy9nOQf8h" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities as of
    December 31, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6URVs2noVp9" style="text-align: right" title="Assets fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">13,072,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxIcGBmbuG7b" style="text-align: right" title="Assets fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">13,072,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze6juTXqxlij" style="text-align: right" title="Assets fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJp5ylMONiFj" style="text-align: right" title="Marketable securities fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A5_zG5lvpiaknp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvVPxBCuna8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zr12olmF0qe2">Fair
Value of Financial Instruments</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of cash, accounts receivable, and accounts payable approximate their fair values based on the short-term maturity of these
instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zWpy9BeM7Nc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zNIGYNH3Uw17">Net
Loss per Common Share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year.
All outstanding options and warrants are considered potential Common Stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered Common Stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of Common Stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#8217;s
computation of diluted net loss per common share for the three and six months ended June 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zWDwDFjj1aO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_8BE_zmG1LMRaRtJf" style="display: none">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zoVAZU1l0674" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,466,890</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zdKOjnSs6JIl" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">864,609</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zc0EPtjDys1g" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,791,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zz6X9pJJlLg1" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,739,733</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zi9d04LG8wFc" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">97,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zmpUhm1zxDDk" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">214,303</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred
    stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zYSf03qkG40a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif">1,398,158</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjfyRiVBMauh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630_fKDIp_zwj5cmepYbYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">7,753,947</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630_fKDIp_zSi4gJoWHmgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">5,818,645</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z5wLvddjCTp3" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,466,890</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zsQQw2lkcHx1" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">864,609</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zZeocQHQDFe4" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,791,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoRAybkNxNi5" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,739,733</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zjC70CZjP5p7" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">97,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zs5G9aXwP524" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">214,303</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred
    stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zInpt4CcrdUa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif">1,398,158</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zY4Dlp2Gxwfl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630_fKDIp_zAxmQ19gtKFk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">7,753,947</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630_fKDIp_zBZIpuo4UaQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">5,818,645</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_zjZWA5yxsR65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ0NnOo8kjS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z7grb1Ai6bb5">Recently
Adopted Accounting Pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses,</i> which requires entities to estimate all expected
credit losses for financial assets measured at amortized cost basis, including trade receivables, held at the reporting date based on
historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted this guidance on January 1,
2023. The adoption of this accounting standard did not have a material impact on the Company&#8217;s condensed consolidated financial
statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897930672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE RECURRING BASIS</a></td>
<td class="text"><p id="xdx_892_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zW4jbsJByhDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zkdefYQKHU2a" style="display: none">SCHEDULE
OF FAIR VALUE RECURRING BASIS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value measurements at reporting date using:</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair
    value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Quoted
    prices in active markets for identical liabilities (Level 1)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant
    other observable inputs (Level 2)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant
    unobservable inputs (Level 3)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities
    as of June 30, 2023</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zu4oQGXJlX26" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">9,831,719</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38Gcg8zLNid" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">9,831,719</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPFGOiLkX45f" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqRy9nOQf8h" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0593">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities as of
    December 31, 2022</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6URVs2noVp9" style="text-align: right" title="Assets fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">13,072,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxIcGBmbuG7b" style="text-align: right" title="Assets fair value disclosure"><span style="font-family: Times New Roman, Times, Serif">13,072,831</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze6juTXqxlij" style="text-align: right" title="Assets fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJp5ylMONiFj" style="text-align: right" title="Marketable securities fair value disclosure"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zWDwDFjj1aO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#8217;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_8BE_zmG1LMRaRtJf" style="display: none">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zoVAZU1l0674" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,466,890</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zdKOjnSs6JIl" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">864,609</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zc0EPtjDys1g" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,791,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zz6X9pJJlLg1" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,739,733</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zi9d04LG8wFc" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">97,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zmpUhm1zxDDk" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">214,303</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred
    stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zYSf03qkG40a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif">1,398,158</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjfyRiVBMauh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630_fKDIp_zwj5cmepYbYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">7,753,947</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630_fKDIp_zSi4gJoWHmgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">5,818,645</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z5wLvddjCTp3" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">1,466,890</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zsQQw2lkcHx1" style="width: 15%; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">864,609</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zZeocQHQDFe4" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,791,072</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoRAybkNxNi5" style="text-align: right" title="Total potentially dilutive shares"><span style="font-family: Times New Roman, Times, Serif">4,739,733</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unvested RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zjC70CZjP5p7" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">97,827</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zs5G9aXwP524" style="text-align: right" title="Unvested"><span style="font-family: Times New Roman, Times, Serif">214,303</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred
    stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zInpt4CcrdUa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif">1,398,158</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zY4Dlp2Gxwfl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630_fKDIp_zAxmQ19gtKFk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">7,753,947</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630_fKDIp_zBZIpuo4UaQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif">5,818,645</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897370672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEsmIKeehgfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zEJ0LcKDLXHk" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Patents
    and Trademarks</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    Amortization</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zPmzRQOFS9ti" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"><span style="font-family: Times New Roman, Times, Serif">3,676</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z1wPZDTV3Ii7" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,593,530</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zR0Kbv10m0F6" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"><span style="font-family: Times New Roman, Times, Serif">(793,768</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20230101__20230630_zh0qufzFys61" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"><span style="font-family: Times New Roman, Times, Serif">803,438</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Amortization expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zm9CaSx6pvKa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0669">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zYD1fTeq1AK6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zvtZDmGgQd9i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"><span style="font-family: Times New Roman, Times, Serif">(44,873</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20230630_z8wIyterxqFh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"><span style="font-family: Times New Roman, Times, Serif">(44,873</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zokTDpGmZh0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"><span style="font-family: Times New Roman, Times, Serif">3,676</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z8fOX4SaPKl2" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, ending balance"><span style="font-family: Times New Roman, Times, Serif">1,593,530</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zcMTvQKJmnk8" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance"><span style="font-family: Times New Roman, Times, Serif">(838,641</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20230101__20230630_z34utZSYBoOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, ending balance"><span style="font-family: Times New Roman, Times, Serif">758,565</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining amortization
    period as of June 30, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zpOAMVBGgBB" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zJZJ9QiTOoY3" title="Finite Lived Intangible Assets, weighted average amortization period">10.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES</a></td>
<td class="text"><p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z5pJulk0Orfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
amortization of intangible assets consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zD7VQS2J3io7" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Patents
    and Trademarks</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    Amortization</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 52%"><span style="font-family: Times New Roman, Times, Serif">Balance as of January 1, 2023</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCPGaWTdyY6" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">3,676</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zE8ZCjlwtaCe" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">790,092</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zu9jAk4IM1v2" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">793,768</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Amortization expense</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zfpzkjcjS488" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zNYR99kmrBo" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"><span style="font-family: Times New Roman, Times, Serif">44,873</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zQZSJjW6XJ66" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"><span style="font-family: Times New Roman, Times, Serif">44,873</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of June 30, 2023</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zIMAWTvQfMM6" style="padding-bottom: 0pt; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">3,676</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBqs1aRGbARb" style="padding-bottom: 0pt; text-align: right" title="Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">834,965</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zBEKEeHprqm9" style="padding-bottom: 0pt; text-align: right" title="Ending Balance"><span style="font-family: Times New Roman, Times, Serif">838,641</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538899844384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z9DuZrOyjTga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zHg3RGG5qemd" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20230630_zLROBTFFOyng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_495_20221231_zmNRx7NXLmr8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zAPVwqYApceg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued payroll</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">325,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,250</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zA5adVmI4qOc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued general and
    administrative expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,325</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">103,822</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zZLVspUdYBX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">386,325</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,072</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538896404192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW0R13kT1jL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
applying the Black-Scholes option pricing model to stock options granted during the six months ended June 30, 2023, the Company used
the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zDq2cHk08Thc" style="display: none">SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the <br/>
Six
    Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For the <br/>
Six
    Months Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June
    30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk free interest rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDSkZ37Igyd" title="Risk free interest rate">4.22</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZtgZ8QUyqe1" title="Risk free interest rate">2.42</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBhSZaQxdAFg" title="Expected term (years)">3.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5JzdB8fjNlb" title="Expected term (years)">3.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zby1UAbkAsBb" title="Expected volatility">175</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqv9Sd8BWgk9" title="Expected volatility">286</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividends</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zu9HApWxUHLg" title="Expected dividends">0.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNbPFihnX0Jh" title="Expected dividends">0.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zod8JJGBmmSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity during the six months ended June 30, 2023 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zrv49KVB03V9" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise
                                            Price</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January
    1, 2023</span></td><td style="width: 2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230630_zmqPO3psl6J7" style="width: 15%; text-align: right" title="Number of options, beginning balance"><span style="font-family: Times New Roman, Times, Serif">864,639</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630_zb1G2Hk2oxs9" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"><span style="font-family: Times New Roman, Times, Serif">5.08</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_zpHlNPQJ4TKg" style="text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif">629,017</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230630_z5w0JgAU9F9l" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">2.91</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230630_zIPI50soujR" style="text-align: right" title="Number of options, expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230630_zVH5uKxRXHW5" style="text-align: right" title="Weighted average exercise price, expired"><span style="font-family: Times New Roman, Times, Serif"> <span style="-sec-ix-hidden: xdx2ixbrl0792">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230630_zCG2iBNn9Uic" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Forfeited"><span style="font-family: Times New Roman, Times, Serif">(26,766</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230630_zYgN6ZaK0Rwc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font-family: Times New Roman, Times, Serif">5.08</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, June 30, 2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230630_zDrmnGBj3Ef1" style="text-align: right" title="Number of options, ending"><span style="font-family: Times New Roman, Times, Serif">1,466,890</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630_zGCpZj59PtKd" style="text-align: right" title="Weighted average exercise price, ending"><span style="font-family: Times New Roman, Times, Serif">4.17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, June 30, 2023</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630_z8Ycbbk55yaj" style="text-align: right" title="Number of options, exercisable"><span style="font-family: Times New Roman, Times, Serif">1,041,062</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630_zSqvYqqK8Ig1" style="text-align: right" title="Weighted average exercise price, exercisable"><span style="font-family: Times New Roman, Times, Serif">4.66</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zhR277GmpHve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s unvested RSUs as of June 30, 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B7_zwEfQhs2PAyi" style="display: none">SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares</span></td><td style="padding-bottom: 0pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 75%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    December 31, 2022</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z51dUu8f06R5" style="padding-bottom: 0pt; width: 20%; text-align: right" title="Number of shares outstanding beginning"><span style="font-family: Times New Roman, Times, Serif">201,870</span></td><td style="padding-bottom: 0pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgLen2L5AgGl" style="padding-bottom: 0pt; text-align: right" title="Number of shares granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztOMKQsc9xX2" style="padding-bottom: 0pt; text-align: right" title="Number of shares forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztkwfcWR3sgk" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Number of shares vested"><span style="font-family: Times New Roman, Times, Serif">(104,043</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding,
    June 30, 2023</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCp5KXNFgd39" style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: right" title="Number of shares outstanding ending"><span style="font-family: Times New Roman, Times, Serif">97,827</span></td><td style="padding-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z5AzYWxXfpoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents stock compensation by award type:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zdyvbNup9OG8" style="display: none">SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Three Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDfpQS5NlEh" style="width: 16%; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">321,534</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG5gfN4kthq5" style="width: 16%; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">1,865,297</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDCbt1c6FTBi" style="text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">1,164,135</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEREzz7ndOCb" style="text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">1,190,349</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zIZEKXG43Udh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zWM796kT5zmc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">48,504</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230401__20230630_zEck7EsYqcil" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">1,485,669</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_zVmnkKQX3n58" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">3,104,150</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Six Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Options</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB9UH8kS7oW1" style="width: 16%; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">2,511,962</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOFgeN6j0zrk" style="width: 16%; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">4,004,246</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeLbOukUuin3" style="text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">2,312,885</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbVB9R9W6a64" style="text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">2,354,474</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares issued for services</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zNFeSSDDOuA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zShdxp6AJlyj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">121,322</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230630_zRFHHQtJjHG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">4,824,847</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220630_z9sj7xmEFZoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"><span style="font-family: Times New Roman, Times, Serif">6,480,042</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538898838000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zW5SqB6eDYq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents net lease cost and other supplemental lease information:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zFNMTlnW2HMg" style="display: none">SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_498_20230101__20230630_zAJjbLhIF7F9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20220101__20220630_zqNvy7oBLJN" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zMljgG65GQGi" style="vertical-align: bottom; background-color: White">
    <td style="width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost (cost resulting
    from lease payments)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">84,014</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">81,566</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zEVxoxlUHLL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net lease cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">84,014</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">81,566</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zJOh96MPVHUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease &#8211; operating cash flows
    (fixed payments)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">84,014</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">81,566</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFcU1cz1j3j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease &#8211; operating cash flows
    (liability reduction)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,585</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,751</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current leases &#8211; right of use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20230630_zxxShXwMOek2" style="text-align: right" title="Non-current leases - right of use assets"><span style="font-family: Times New Roman, Times, Serif">183,738</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220630_z2Kh8pieJBnd" style="text-align: right" title="Non-current leases - right of use assets"><span style="font-family: Times New Roman, Times, Serif">299,783</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities &#8211; operating lease
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20230630_zLaiciFlln7e" style="text-align: right" title="Current liabilities - operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">150,480</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220630_zH65EMzxLRQa" style="text-align: right" title="Current liabilities - operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">128,899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-current liabilities &#8211; operating lease
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20230630_zEZAX9TMYJq9" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">83,580</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20220630_zwIinaSkCiz7" style="text-align: right" title="Non-current liabilities - operating lease liabilities"><span style="font-family: Times New Roman, Times, Serif">234,060</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3ofkMUnbeXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of June 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_z6KIOPVmJpBa" style="display: none">SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fiscal
    Year</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20230630_zUokooBdJQwi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zI2y2IqCMy29" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 78%"><span style="font-family: Times New Roman, Times, Serif">Remainder of 2023</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">84,014</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zeF8mVF1zE7h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">173,060</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zERuRTZ5vC1a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total future minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">257,074</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za99u9rqEpjk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Amount representing
    interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(23,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_z3L2pUZXwTNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Present value of net
    future minimum lease payments</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">234,060</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897460160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 13, 2023</div></th>
<th class="th"><div>Apr. 14, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,980,552<span></span>
</td>
<td class="nump">$ 5,684,222<span></span>
</td>
<td class="nump">$ 4,675,241<span></span>
</td>
<td class="nump">$ 4,816,150<span></span>
</td>
<td class="nump">$ 8,664,774<span></span>
</td>
<td class="nump">$ 9,491,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,824,865<span></span>
</td>
<td class="nump">6,480,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,479,065<span></span>
</td>
<td class="nump">2,845,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411,701<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds offering price</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of aggregate shares</a></td>
<td class="nump">685,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price</a></td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=BRTX_JonesTradingInstitutionalServicesLLCMember', window );">Jones Trading Institutional Services L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=BRTX_JonesTradingInstitutionalServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=BRTX_JonesTradingInstitutionalServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897389600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities fair value disclosure</a></td>
<td class="nump">$ 9,831,719<span></span>
</td>
<td class="nump">$ 13,072,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities fair value disclosure</a></td>
<td class="nump">9,831,719<span></span>
</td>
<td class="nump">13,072,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities fair value disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Marketable securities fair value disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538896324256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7,753,947<span></span>
</td>
<td class="nump">5,818,645<span></span>
</td>
<td class="nump">7,753,947<span></span>
</td>
<td class="nump">5,818,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,466,890<span></span>
</td>
<td class="nump">864,609<span></span>
</td>
<td class="nump">1,466,890<span></span>
</td>
<td class="nump">864,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">4,791,072<span></span>
</td>
<td class="nump">4,739,733<span></span>
</td>
<td class="nump">4,791,072<span></span>
</td>
<td class="nump">4,739,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">97,827<span></span>
</td>
<td class="nump">214,303<span></span>
</td>
<td class="nump">97,827<span></span>
</td>
<td class="nump">214,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538895690976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC insured limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538894457552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite Lived Intangible Assets, Net, beginning balance</a></td>
<td class="nump">$ 803,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(44,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite Lived Intangible Assets, Net, ending balance</a></td>
<td class="nump">758,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember', window );">Patents and Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, gross, beginning balance</a></td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, ending balance</a></td>
<td class="nump">$ 3,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite Lived Intangible Assets, weighted average amortization period</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_LicensesMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, gross, beginning balance</a></td>
<td class="nump">$ 1,593,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite Lived Intangible Assets, ending balance</a></td>
<td class="nump">$ 1,593,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite Lived Intangible Assets, weighted average amortization period</a></td>
<td class="text">10 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember', window );">Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite Lived Intangible Assets, Accumulated amortization, beginning balance</a></td>
<td class="num">$ (793,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite Lived Intangible Assets, Amortization expense</a></td>
<td class="num">(44,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite Lived Intangible Assets, Accumulated amortization, ending balance</a></td>
<td class="num">$ (838,641)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538894458160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 44,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember', window );">Patents and Trademark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">3,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">790,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">44,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">834,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember', window );">Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Beginning Balance</a></td>
<td class="nump">793,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">44,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Ending Balance</a></td>
<td class="nump">$ 838,641<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_PatentsAndTrademarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=BRTX_AccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538899035696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment to acquire intangible assets</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new issues</a></td>
<td class="nump">51,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Fair value of warrants</a></td>
<td class="nump">$ 117,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538899017632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="nump">$ 26,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_AccruedGeneralAndAdministrativeExpenses', window );">Accrued general and administrative expenses</a></td>
<td class="nump">61,325<span></span>
</td>
<td class="nump">103,822<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses</a></td>
<td class="nump">$ 386,325<span></span>
</td>
<td class="nump">$ 130,072<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_AccruedGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_AccruedGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538895730208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS (Details) - Share-Based Payment Arrangement, Option [Member]<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.22%<span></span>
</td>
<td class="nump">2.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">175.00%<span></span>
</td>
<td class="nump">286.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538893730112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance</a></td>
<td class="nump">864,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="nump">629,017<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of options, expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Forfeited</a></td>
<td class="num">(26,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending</a></td>
<td class="nump">1,466,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending</a></td>
<td class="nump">$ 4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable</a></td>
<td class="nump">1,041,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 4.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538896356256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding beginning</a></td>
<td class="nump">201,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="num">(104,043)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares outstanding ending</a></td>
<td class="nump">97,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897538208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation award</a></td>
<td class="nump">$ 1,485,669<span></span>
</td>
<td class="nump">$ 3,104,150<span></span>
</td>
<td class="nump">$ 4,824,847<span></span>
</td>
<td class="nump">$ 6,480,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation award</a></td>
<td class="nump">321,534<span></span>
</td>
<td class="nump">1,865,297<span></span>
</td>
<td class="nump">2,511,962<span></span>
</td>
<td class="nump">4,004,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation award</a></td>
<td class="nump">1,164,135<span></span>
</td>
<td class="nump">1,190,349<span></span>
</td>
<td class="nump">2,312,885<span></span>
</td>
<td class="nump">2,354,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=BRTX_SharesIssuedForServicesMember', window );">Shares Issued for Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation award</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 48,504<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 121,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=BRTX_SharesIssuedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=BRTX_SharesIssuedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538896165136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 04, 2023</div></th>
<th class="th"><div>Oct. 25, 2022</div></th>
<th class="th"><div>Sep. 08, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629,017<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,745,000<span></span>
</td>
<td class="nump">$ 122,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,201,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Preferred stock conversion term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Beneficial Ownership [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock voting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,398,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | Auctus Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Auctus Fund LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments options grants in period grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BRTX_BeneficialOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=BRTX_BeneficialOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=BRTX_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=BRTX_AuctusFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=BRTX_AuctusFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538894341872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost (cost resulting from lease payments)</a></td>
<td class="nump">$ 84,014<span></span>
</td>
<td class="nump">$ 81,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">84,014<span></span>
</td>
<td class="nump">81,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease &#8211; operating cash flows (fixed payments)</a></td>
<td class="nump">84,014<span></span>
</td>
<td class="nump">81,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_OperatingLeaseLiabilityReduction', window );">Operating lease &#8211; operating cash flows (liability reduction)</a></td>
<td class="nump">67,585<span></span>
</td>
<td class="nump">57,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Non-current leases - right of use assets</a></td>
<td class="nump">183,738<span></span>
</td>
<td class="nump">299,783<span></span>
</td>
<td class="nump">$ 241,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current liabilities - operating lease liabilities</a></td>
<td class="nump">150,480<span></span>
</td>
<td class="nump">128,899<span></span>
</td>
<td class="nump">139,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current liabilities - operating lease liabilities</a></td>
<td class="nump">$ 83,580<span></span>
</td>
<td class="nump">$ 234,060<span></span>
</td>
<td class="nump">$ 162,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_OperatingLeaseLiabilityReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability reduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_OperatingLeaseLiabilityReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538898070736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_BRTX_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 84,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">173,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">257,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amount representing interest</a></td>
<td class="num">(23,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of net future minimum lease payments</a></td>
<td class="nump">$ 234,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_BRTX_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">BRTX_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>BRTX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538897349600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseOptionToExtend', window );">Lease extension description</a></td>
<td class="text">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $153,748 and $173,060.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 153,748<span></span>
</td>
<td class="nump">$ 132,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember', window );">Melville Lease [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
<td class="nump">$ 173,060<span></span>
</td>
<td class="nump">$ 149,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessor's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=BRTX_MelvilleLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140538893713104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Procceds fom offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411,701<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Procceds fom offering</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">685,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Offering price</a></td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Procceds fom offering</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:BRTX="http://biorestorative.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="brtx-20230630.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-14_custom_JonesTradingInstitutionalServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-14</instant>
        </period>
    </context>
    <context id="From2023-04-132023-04-14_custom_JonesTradingInstitutionalServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-13</startDate>
            <endDate>2023-04-14</endDate>
        </period>
    </context>
    <context id="From2023-07-122023-07-13_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-12</startDate>
            <endDate>2023-07-13</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-13_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-13</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PatentsAndTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_AccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_PatentsAndTrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">BRTX:PatentsAndTrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-08</instant>
        </period>
    </context>
    <context id="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-08</startDate>
            <endDate>2022-09-08</endDate>
        </period>
    </context>
    <context id="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-08</startDate>
            <endDate>2022-09-08</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">BRTX:BeneficialOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">BRTX:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-04</endDate>
        </period>
    </context>
    <context id="From2022-10-242022-10-25_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">BRTX:AuctusFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-24</startDate>
            <endDate>2022-10-25</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember37476781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember37476781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember37476781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_SharesIssuedForServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_SharesIssuedForServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember37476796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_SharesIssuedForServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_SharesIssuedForServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">BRTX:SharesIssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_MelvilleLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">BRTX:MelvilleLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-122023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-12</startDate>
            <endDate>2023-07-13</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-13</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-06-30">0001505497</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-06-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GrantIncome
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GrantIncome
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GrantIncome
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0368"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0406"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0416"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0454"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0464"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0623"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30_us-gaap_ConvertiblePreferredStockMember"
      id="xdx2ixbrl0643"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-06-30_custom_PatentsAndTrademarksMember"
      id="xdx2ixbrl0669"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-06-30_custom_LicensesMember"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="AsOf2023-06-30_custom_PatentsAndTrademarksMember"
      id="xdx2ixbrl0685"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-06-30_custom_PatentsAndTrademarkMember"
      id="xdx2ixbrl0697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0790"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0792"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687"
      id="xdx2ixbrl0810"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687"
      id="xdx2ixbrl0812"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_custom_SharesIssuedForServicesMember"
      id="xdx2ixbrl0828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-06-30_custom_SharesIssuedForServicesMember"
      id="xdx2ixbrl0844"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-01-01to2023-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-06-30">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-06-30">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-06-30">001-37603</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-06-30">BIORESTORATIVE THERAPIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-06-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-06-30">30-1341024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-06-30">40     Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-06-30">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-06-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-06-30">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-06-30">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-06-30">760-8100</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-06-30">Common     Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-06-30">BRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-06-30">false</dei:EntityShellCompany>
    <dei:EntityBankruptcyProceedingsReportingCurrent contextRef="From2023-01-01to2023-06-30">true</dei:EntityBankruptcyProceedingsReportingCurrent>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-08-08" decimals="INF" unitRef="Shares">4667641</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">1783646</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1676577</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">9831719</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13072831</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">25000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">403559</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">363082</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">12043924</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15128490</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">314070</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">261003</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">183738</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">241760</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">758565</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">803438</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">13300297</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16434691</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">276048</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">170902</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">386325</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">130072</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">150480</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">139328</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">812853</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">440302</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">83580</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">162317</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">896433</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">602619</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1518158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1518158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">15182</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">13982</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">15182</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">3982608</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">3982608</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">3677775</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">3677775</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">399</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">369</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">173695154</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">168457418</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">-161305671</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-152640897</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">12403864</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15832072</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">13300297</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16434691</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">64500</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">71100</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">95800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">87100</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">967891</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">1075224</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">2479136</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">1850561</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">2213160</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3624504</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">6512313</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">7918960</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">3181051</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">4699728</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">8991449</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">9769521</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-3116551</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-4628628</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">-8895649</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-9682421</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">96187</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-46613</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">114403</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-75624</us-gaap:InterestIncomeExpenseNet>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">250000</BRTX:GainOnPppLoanForgiveness>
    <BRTX:GrantIncome
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">16654</BRTX:GrantIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">39812</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">116472</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">135999</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-46613</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">230875</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">191030</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-2980552</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-4675241</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">-8664774</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-9491391</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-2.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-2.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-2.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-2.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">3886309</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">3886309</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">3638383</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">3638383</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">3803323</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">3803323</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Shares">3581110</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Shares">3581110</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1518158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">15182</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3677775</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">369</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">168457418</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-152640897</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">15832072</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">89840</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1148750</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">1148759</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2190428</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">2190428</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5684222</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">-5684222</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1518158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">15182</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3767615</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">378</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">171796596</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-158325119</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">13487037</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1442</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1164135</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">1164135</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">321534</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">321534</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">93551</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">411701</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">411710</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">-120000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">-1200</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">120000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">12</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1188</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2980552</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-2980552</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1398158</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">13982</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3982608</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">399</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">173695154</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-161305671</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">12403864</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3520391</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">353</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">155727292</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-134146128</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21596949</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">97828</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1164125</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">1164135</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2138949</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">2138949</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">72818</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">72819</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4816150</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-4816150</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3631719</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">364</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">159103184</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-138962278</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">20156702</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3631719</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">364</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">159103184</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-138962278</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">20156702</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6220</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1190349</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">1190350</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1865297</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">1865297</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5770</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">48504</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">48504</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4675241</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-4675241</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3643709</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">365</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">162207334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-143637519</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">18585612</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3643709</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">365</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">162207334</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-143637519</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">18585612</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">-8664774</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-9491391</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">80877</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">57526</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">22392</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">4824865</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">6480055</us-gaap:ShareBasedCompensation>
    <BRTX:GainOnPppLoanForgiveness
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">250000</BRTX:GainOnPppLoanForgiveness>
    <BRTX:NoncashLeaseExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">58022</BRTX:NoncashLeaseExpense>
    <BRTX:NoncashLeaseExpense
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">58022</BRTX:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">9000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">11000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">40477</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-61688</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">105146</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">327406</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">256253</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-20311</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">-67585</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-57751</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">-3479065</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-2845756</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">3263504</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">89071</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">247247</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">3174433</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-247247</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">411701</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">411701</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">107069</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">-3093003</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1676577</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21026727</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">1783646</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">17933724</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zAwKW7UmS0Nf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 - &lt;span id="xdx_820_zQd2QG33gsnf"&gt;NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Corporate
History&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioRestorative
Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (&#x201c;Stem Pearls&#x201d;). BioRestorative Therapies, Inc. and its
subsidiary are referred to collectively as &#x201c;BRT&#x201d; or the &#x201c;Company&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 29, 2022, the Company reincorporated from Delaware to Nevada. The reincorporation was structured as a statutory merger of BioRestorative
Therapies, Inc., a Delaware corporation, with and into its wholly-owned subsidiary, BioRestorative Therapies, Inc., a Nevada corporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern,
which contemplates realization of assets and satisfying liabilities in the normal course of business. For the six months ended June 30,
2023, the Company had a net loss of $&lt;span id="xdx_908_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230630_zKoiWk4KgFD4" title="Net loss"&gt;8.7&lt;/span&gt; million (of which, $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20230630_zvOp6hjAWosd" title="Share based compensation"&gt;4.8&lt;/span&gt; million was attributable to non-cash stock-based compensation) and negative
cash flows from operations of $&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20230630_zScWMEPdCnSa" title="Cash flows from operations"&gt;3.5&lt;/span&gt; million. The Company&#x2019;s operating activities consume the majority of its cash resources. The
Company anticipates that it will continue to incur net losses as it executes its development plans throughout 2023 and beyond, as well
as other potential strategic and business development initiatives. In addition, the Company has had and expects to have negative cash
flows from operations, at least into the near future. The Company has previously funded, and plans to continue funding, these losses
primarily through current cash on hand, investments in marketable securities and additional infusions of cash from equity and debt financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 14, 2023, the Company entered into a sales agreement with JonesTrading Institutional Services LLC for an at-the-market (&#x201c;ATM&#x201d;)
offering of the Company&#x2019;s Common Stock, par value $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230414__dei--LegalEntityAxis__custom--JonesTradingInstitutionalServicesLLCMember_znwIUkHC1pl4" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, at an aggregate offering price of up to $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230413__20230414__dei--LegalEntityAxis__custom--JonesTradingInstitutionalServicesLLCMember_zXl7Ym7zK01j" title="Net proceeds"&gt;3.7&lt;/span&gt; million. During
the three months ended June 30, 2023, net proceeds of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230401__20230630_zp4eB2lfLCTa" title="Issuance of common stock"&gt;411,710&lt;/span&gt; were received from the issuance of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230401__20230630_ztCFAExsLfj1" title="Issuance of common stock, shares"&gt;93,551&lt;/span&gt; shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 13, 2023, the Company sold an aggregate of &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp0ZL0amDKMj" title="Sale of aggregate shares"&gt;685,033&lt;/span&gt; shares of Common Stock to several institutional buyers and accredited investors
in a registered direct offering at an offering price of $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2JsrEU10Mmi" title="Offering price"&gt;3.03&lt;/span&gt; per share. The offering closed on July 13, 2023, with net proceeds of approximately
$&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQh5mOxRcrJ3" title="Net proceeds offering price"&gt;1.8&lt;/span&gt; million. The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its
lead cell therapy candidate, &lt;i&gt;BRTX-100&lt;/i&gt;, pre-clinical research and development with respect to its metabolic &lt;i&gt;ThermoStem Program
&lt;/i&gt;and for general corporate purposes and working capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on cash on hand as of June 30, 2023, the Company believes it has sufficient cash to fund operations for the twelve months subsequent
to the filing date of this Form 10-Q.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations.
If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development,
marketing and promotional activities, which would have a material adverse effect on the Company&#x2019;s business, financial condition
and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#x201c;GAAP&#x201d;), which contemplate continuation of the Company as a going concern and the realization
of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented
in the condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying
condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue
as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
Operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BRT
develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT&#x2019;s
website is at &lt;span style="text-decoration: underline"&gt;www.biorestorative.com&lt;/span&gt;. The information contained in our website is not intended to be incorporated by reference
into this Quarterly Report. BRT is currently developing a Disc/Spine Program referred to as &#x201c;brtxDISC&#x201d;. Its lead cell therapy
candidate, &lt;i&gt;BRTX-100&lt;/i&gt;, is a product formulated from autologous (or a person&#x2019;s own) cultured mesenchymal stem cells collected
from the patient&#x2019;s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders
or as a complimentary therapeutic to a surgical procedure. BRT is investigating the expansion of the clinic application of &lt;i&gt;BRTX-100
&lt;/i&gt;to other indications within the body. BRT is also engaging in research efforts with respect to a platform technology utilizing brown
adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled this initiative
its ThermoStem Program. Further, BRT has licensed a patented curved needle device that is a needle system designed to deliver cells and/or
other therapeutic products or material to the spine and discs or other potential sites.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="-5"
      unitRef="USD">-8700000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-06-30"
      decimals="-5"
      unitRef="USD">4800000</us-gaap:ShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-06-30"
      decimals="-5"
      unitRef="USD">-3500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-04-14_custom_JonesTradingInstitutionalServicesLLCMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-04-132023-04-14_custom_JonesTradingInstitutionalServicesLLCMember"
      decimals="-5"
      unitRef="USD">3700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">411710</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">93551</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-122023-07-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">685033</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-07-13_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">3.03</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-07-122023-07-13_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">1800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_801_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zTN69WmswyIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2013; &lt;span id="xdx_823_zFIIUySPA5Wa"&gt;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRlhrC4DEtT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zA8eCeh1sJN1"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#x2019;s condensed consolidated financial statements. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations
of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and footnote disclosures normally included in
financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules
and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022,
filed with the SEC on March 27, 2023 (the &#x201c;Annual Report&#x201d;). The summary of significant accounting policies presented below
is designed to assist in understanding the Company&#x2019;s condensed consolidated financial statements. Such condensed consolidated financial
statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity and objectivity.
Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected
for the entire year or for any other subsequent interim period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zREhKsxX6Td5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_znlhd3ELGaOi"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts
and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zwtoat1ghDr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zMN58ygL53si"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent
liabilities at the date of the condensed consolidated financial statements. The Company bases its estimates and assumptions on historical
experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects
cannot be determined with precision, actual results could differ from these estimates which may cause the Company&#x2019;s future results
to be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zcSACGDy8Ha2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_z3WbZdua1oW4"&gt;Concentrations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Deposit Insurance Corporation coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20230630_zNayDp0CxbU5" title="FDIC insured limit"&gt;250,000&lt;/span&gt;. As of
June 30, 2023, the Company has not experienced losses on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
royalties related to the Company&#x2019;s sublicense comprised all of the Company&#x2019;s revenue during the three and six months ended
June 30, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Summary
of Significant Accounting Policies&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting
Standards, in the Annual Report. During the three and six months ended June 30, 2023, the Company did not make any changes to its significant
accounting policies, except as described below with respect to recent accounting pronouncements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_znOeGAyqEkBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zv8XAjWsqIHb"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
defined in ASC 820, &lt;i&gt;Fair Value Measurements and Disclosures &lt;/i&gt;(&#x201c;ASC 820&#x201d;), fair value is the price that would be received
for an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price).
The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed
    methodologies that result in management&#x2019;s best estimate of fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_892_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zW4jbsJByhDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zkdefYQKHU2a" style="display: none"&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value measurements at reporting date using:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Quoted
    prices in active markets for identical liabilities (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Significant
    other observable inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Significant
    unobservable inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable securities
    as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zu4oQGXJlX26" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,831,719&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38Gcg8zLNid" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,831,719&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPFGOiLkX45f" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqRy9nOQf8h" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable securities as of
    December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6URVs2noVp9" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,072,831&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxIcGBmbuG7b" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,072,831&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze6juTXqxlij" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJp5ylMONiFj" style="text-align: right" title="Marketable securities fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zG5lvpiaknp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvVPxBCuna8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zr12olmF0qe2"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of cash, accounts receivable, and accounts payable approximate their fair values based on the short-term maturity of these
instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zWpy9BeM7Nc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zNIGYNH3Uw17"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year.
All outstanding options and warrants are considered potential Common Stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered Common Stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of Common Stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#x2019;s
computation of diluted net loss per common share for the three and six months ended June 30, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zWDwDFjj1aO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span id="xdx_8BE_zmG1LMRaRtJf" style="display: none"&gt;SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zoVAZU1l0674" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466,890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zdKOjnSs6JIl" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;864,609&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zc0EPtjDys1g" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,791,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zz6X9pJJlLg1" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,739,733&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zi9d04LG8wFc" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zmpUhm1zxDDk" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214,303&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Convertible preferred
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zYSf03qkG40a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,398,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjfyRiVBMauh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630_fKDIp_zwj5cmepYbYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,753,947&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630_fKDIp_zSi4gJoWHmgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,818,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z5wLvddjCTp3" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466,890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zsQQw2lkcHx1" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;864,609&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zZeocQHQDFe4" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,791,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoRAybkNxNi5" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,739,733&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zjC70CZjP5p7" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zs5G9aXwP524" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214,303&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Convertible preferred
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zInpt4CcrdUa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,398,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zY4Dlp2Gxwfl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630_fKDIp_zAxmQ19gtKFk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,753,947&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630_fKDIp_zBZIpuo4UaQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,818,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zjZWA5yxsR65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ0NnOo8kjS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_z7grb1Ai6bb5"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments - Credit Losses,&lt;/i&gt; which requires entities to estimate all expected
credit losses for financial assets measured at amortized cost basis, including trade receivables, held at the reporting date based on
historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted this guidance on January 1,
2023. The adoption of this accounting standard did not have a material impact on the Company&#x2019;s condensed consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85B_zmb5KKwrIRR6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zRlhrC4DEtT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zA8eCeh1sJN1"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying condensed consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting
policies presented below is designed to assist in understanding the Company&#x2019;s condensed consolidated financial statements. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations
of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and footnote disclosures normally included in
financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules
and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022,
filed with the SEC on March 27, 2023 (the &#x201c;Annual Report&#x201d;). The summary of significant accounting policies presented below
is designed to assist in understanding the Company&#x2019;s condensed consolidated financial statements. Such condensed consolidated financial
statements and accompanying notes are the representations of Company&#x2019;s management, who is responsible for their integrity and objectivity.
Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected
for the entire year or for any other subsequent interim period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zREhKsxX6Td5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_znlhd3ELGaOi"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts
and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zwtoat1ghDr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zMN58ygL53si"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent
liabilities at the date of the condensed consolidated financial statements. The Company bases its estimates and assumptions on historical
experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects
cannot be determined with precision, actual results could differ from these estimates which may cause the Company&#x2019;s future results
to be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zcSACGDy8Ha2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_z3WbZdua1oW4"&gt;Concentrations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution.
The Company maintains deposits in its cash account in excess of the Federal Deposit Insurance Corporation coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20230630_zNayDp0CxbU5" title="FDIC insured limit"&gt;250,000&lt;/span&gt;. As of
June 30, 2023, the Company has not experienced losses on this account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
royalties related to the Company&#x2019;s sublicense comprised all of the Company&#x2019;s revenue during the three and six months ended
June 30, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Summary
of Significant Accounting Policies&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting
Standards, in the Annual Report. During the three and six months ended June 30, 2023, the Company did not make any changes to its significant
accounting policies, except as described below with respect to recent accounting pronouncements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_znOeGAyqEkBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zv8XAjWsqIHb"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
defined in ASC 820, &lt;i&gt;Fair Value Measurements and Disclosures &lt;/i&gt;(&#x201c;ASC 820&#x201d;), fair value is the price that would be received
for an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price).
The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions
about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated,
or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and
the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent
measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted
    prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in
    which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing
    basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed
    equities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pricing
    inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as
    of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
    These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities,
    time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant
    economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
    can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.
    Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options
    and collars.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pricing
    inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed
    methodologies that result in management&#x2019;s best estimate of fair value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_892_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zW4jbsJByhDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zkdefYQKHU2a" style="display: none"&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value measurements at reporting date using:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Quoted
    prices in active markets for identical liabilities (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Significant
    other observable inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Significant
    unobservable inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable securities
    as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zu4oQGXJlX26" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,831,719&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38Gcg8zLNid" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,831,719&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPFGOiLkX45f" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqRy9nOQf8h" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable securities as of
    December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6URVs2noVp9" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,072,831&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxIcGBmbuG7b" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,072,831&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze6juTXqxlij" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJp5ylMONiFj" style="text-align: right" title="Marketable securities fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zG5lvpiaknp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_892_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zW4jbsJByhDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zkdefYQKHU2a" style="display: none"&gt;SCHEDULE
OF FAIR VALUE RECURRING BASIS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value measurements at reporting date using:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fair
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Quoted
    prices in active markets for identical liabilities (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Significant
    other observable inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Significant
    unobservable inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 35%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable securities
    as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zu4oQGXJlX26" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,831,719&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z38Gcg8zLNid" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,831,719&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zPFGOiLkX45f" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0591"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRqRy9nOQf8h" style="width: 12%; text-align: right" title="Cash and cash equivalents, fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0593"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable securities as of
    December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_z6URVs2noVp9" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,072,831&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxIcGBmbuG7b" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;13,072,831&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ze6juTXqxlij" style="text-align: right" title="Assets fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0599"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJp5ylMONiFj" style="text-align: right" title="Marketable securities fair value disclosure"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0601"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">9831719</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">9831719</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">13072831</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">13072831</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84B_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvVPxBCuna8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_zr12olmF0qe2"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying value of cash, accounts receivable, and accounts payable approximate their fair values based on the short-term maturity of these
instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zWpy9BeM7Nc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zNIGYNH3Uw17"&gt;Net
Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year.
All outstanding options and warrants are considered potential Common Stock. The dilutive effect, if any, of stock options and warrants
are calculated using the treasury stock method. All outstanding convertible preferred stock is considered Common Stock at the beginning
of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of Common Stock equivalents
is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company&#x2019;s
computation of diluted net loss per common share for the three and six months ended June 30, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zWDwDFjj1aO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span id="xdx_8BE_zmG1LMRaRtJf" style="display: none"&gt;SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zoVAZU1l0674" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466,890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zdKOjnSs6JIl" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;864,609&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zc0EPtjDys1g" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,791,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zz6X9pJJlLg1" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,739,733&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zi9d04LG8wFc" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zmpUhm1zxDDk" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214,303&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Convertible preferred
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zYSf03qkG40a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,398,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjfyRiVBMauh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630_fKDIp_zwj5cmepYbYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,753,947&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630_fKDIp_zSi4gJoWHmgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,818,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z5wLvddjCTp3" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466,890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zsQQw2lkcHx1" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;864,609&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zZeocQHQDFe4" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,791,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoRAybkNxNi5" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,739,733&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zjC70CZjP5p7" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zs5G9aXwP524" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214,303&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Convertible preferred
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zInpt4CcrdUa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,398,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zY4Dlp2Gxwfl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630_fKDIp_zAxmQ19gtKFk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,753,947&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630_fKDIp_zBZIpuo4UaQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,818,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zjZWA5yxsR65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zWDwDFjj1aO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these
potential shares was antidilutive due to the Company&#x2019;s net loss position even though the exercise or conversion price could be
less than the average market price of the common shares:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span id="xdx_8BE_zmG1LMRaRtJf" style="display: none"&gt;SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zoVAZU1l0674" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466,890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zdKOjnSs6JIl" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;864,609&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zc0EPtjDys1g" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,791,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zz6X9pJJlLg1" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,739,733&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zi9d04LG8wFc" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zmpUhm1zxDDk" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214,303&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Convertible preferred
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zYSf03qkG40a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,398,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zjfyRiVBMauh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230401__20230630_fKDIp_zwj5cmepYbYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,753,947&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220401__20220630_fKDIp_zSi4gJoWHmgd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,818,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z5wLvddjCTp3" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466,890&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zsQQw2lkcHx1" style="width: 15%; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;864,609&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zZeocQHQDFe4" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,791,072&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoRAybkNxNi5" style="text-align: right" title="Total potentially dilutive shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,739,733&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zjC70CZjP5p7" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,827&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zs5G9aXwP524" style="text-align: right" title="Unvested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;214,303&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Convertible preferred
    stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zInpt4CcrdUa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,398,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zY4Dlp2Gxwfl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230630_fKDIp_zAxmQ19gtKFk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,753,947&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220630_fKDIp_zBZIpuo4UaQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,818,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1466890</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">864609</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4791072</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4739733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">97827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">214303</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">7753947</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">5818645</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1466890</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">864609</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4791072</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">4739733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">97827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">214303</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1398158</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">7753947</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Shares">5818645</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zJ0NnOo8kjS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_z7grb1Ai6bb5"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments - Credit Losses,&lt;/i&gt; which requires entities to estimate all expected
credit losses for financial assets measured at amortized cost basis, including trade receivables, held at the reporting date based on
historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted this guidance on January 1,
2023. The adoption of this accounting standard did not have a material impact on the Company&#x2019;s condensed consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_z3DXiu3SB77f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - &lt;span style="text-transform: uppercase"&gt;&lt;span id="xdx_821_zElumeMfieWh"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a license agreement with a stem cell treatment company (the &#x201c;SCTC&#x201d;) (as amended) (the &#x201c;SCTC Agreement&#x201d;).
Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from the SCTC
to utilize or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or
spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or
sublicense a certain method for culturing cells. Pursuant to the license agreement with the SCTC, certain performance milestones (or
payouts in lieu of performance milestones) had to be satisfied in order for the Company to maintain its exclusive rights with regard
to the disc/spine technology. The Company did not timely satisfy the third of these performance milestones (which needed to be satisfied
by February 2022). Accordingly, such rights became non-exclusive. However, in November 2022, the Company entered into an amended agreement
under which it paid $&lt;span id="xdx_902_eus-gaap--PaymentsToAcquireIntangibleAssets_c20221101__20221130_zfN1MS780mae" title="Payment to acquire intangible assets"&gt;175,000&lt;/span&gt; and issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzGeSwEB3yh1" title="Stock issued new issues"&gt;51,370&lt;/span&gt; warrants, with a fair value of $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221101__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zW5ak0HvlSg3" title="Fair value of warrants"&gt;117,030&lt;/span&gt;, in exchange for renewed exclusivity. The consideration
transferred to the SCTC in exchange for exclusivity was capitalized to intangible assets on the Company&#x2019;s consolidated balance
sheet as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2017, the Company received authorization from the Food and Drug Administration (the &#x201c;FDA&#x201d;) to proceed with a Phase
2 clinical trial. In March 2022, the United States Patent and Trademark Office issued a patent relating to the Company&#x2019;s BRTX-100
clinical program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEsmIKeehgfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zEJ0LcKDLXHk" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents
    and Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    Amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zPmzRQOFS9ti" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,676&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z1wPZDTV3Ii7" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,593,530&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zR0Kbv10m0F6" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(793,768&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20230101__20230630_zh0qufzFys61" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;803,438&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zm9CaSx6pvKa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0669"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zYD1fTeq1AK6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zvtZDmGgQd9i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(44,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20230630_z8wIyterxqFh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(44,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zokTDpGmZh0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,676&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z8fOX4SaPKl2" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,593,530&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zcMTvQKJmnk8" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(838,641&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20230101__20230630_z34utZSYBoOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;758,565&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average remaining amortization
    period as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zpOAMVBGgBB" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zJZJ9QiTOoY3" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;10.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zK8LVrSyr5u7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z5pJulk0Orfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accumulated
amortization of intangible assets consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zD7VQS2J3io7" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents
    and Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    Amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCPGaWTdyY6" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,676&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zE8ZCjlwtaCe" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;790,092&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zu9jAk4IM1v2" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;793,768&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zfpzkjcjS488" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0697"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zNYR99kmrBo" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zQZSJjW6XJ66" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zIMAWTvQfMM6" style="padding-bottom: 0pt; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,676&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBqs1aRGbARb" style="padding-bottom: 0pt; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;834,965&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zBEKEeHprqm9" style="padding-bottom: 0pt; text-align: right" title="Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;838,641&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_z7JoxfcYog0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-11-012022-11-30"
      decimals="0"
      unitRef="USD">175000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-012022-11-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">51370</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-11-012022-11-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">117030</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zEsmIKeehgfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zEJ0LcKDLXHk" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents
    and Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    Amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zPmzRQOFS9ti" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Gross, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,676&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z1wPZDTV3Ii7" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, gross, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,593,530&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zR0Kbv10m0F6" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(793,768&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20230101__20230630_zh0qufzFys61" style="width: 10%; text-align: right" title="Finite Lived Intangible Assets, Net, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;803,438&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zm9CaSx6pvKa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0669"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zYD1fTeq1AK6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zvtZDmGgQd9i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(44,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20230630_z8wIyterxqFh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(44,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zokTDpGmZh0a" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,676&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z8fOX4SaPKl2" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,593,530&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zcMTvQKJmnk8" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated amortization, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(838,641&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20230101__20230630_z34utZSYBoOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;758,565&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average remaining amortization
    period as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zpOAMVBGgBB" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0685"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zJZJ9QiTOoY3" title="Finite Lived Intangible Assets, weighted average amortization period"&gt;10.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_PatentsAndTrademarksMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_LicensesMember"
      decimals="0"
      unitRef="USD">1593530</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">793768</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">803438</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-06-30_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">44873</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">44873</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-06-30_custom_PatentsAndTrademarksMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-06-30_custom_LicensesMember"
      decimals="0"
      unitRef="USD">1593530</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-06-30_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">838641</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">758565</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="AsOf2023-06-30_custom_LicensesMember">P10Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_z5pJulk0Orfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accumulated
amortization of intangible assets consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zD7VQS2J3io7" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents
    and Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    Amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zCPGaWTdyY6" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,676&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zE8ZCjlwtaCe" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;790,092&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zu9jAk4IM1v2" style="padding-bottom: 0pt; width: 12%; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;793,768&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zfpzkjcjS488" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0697"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zNYR99kmrBo" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zQZSJjW6XJ66" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Amortization expense"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44,873&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zIMAWTvQfMM6" style="padding-bottom: 0pt; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,676&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zBqs1aRGbARb" style="padding-bottom: 0pt; text-align: right" title="Beginning Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;834,965&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zBEKEeHprqm9" style="padding-bottom: 0pt; text-align: right" title="Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;838,641&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_PatentsAndTrademarkMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">790092</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">793768</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">44873</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-06-30_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">44873</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-06-30_custom_PatentsAndTrademarkMember"
      decimals="0"
      unitRef="USD">3676</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">834965</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-06-30_custom_AccumulatedAmortizationMember"
      decimals="0"
      unitRef="USD">838641</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_808_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zCUPEIRoNF0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 - &lt;span id="xdx_828_zItoCNvh5ZLa"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z9DuZrOyjTga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zHg3RGG5qemd" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230630_zLROBTFFOyng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_zmNRx7NXLmr8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zAPVwqYApceg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;325,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,250&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zA5adVmI4qOc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued general and
    administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;61,325&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;103,822&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zZLVspUdYBX" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;386,325&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,072&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zddjRb6QZT8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_z9DuZrOyjTga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consist of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zHg3RGG5qemd" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230630_zLROBTFFOyng" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_zmNRx7NXLmr8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zAPVwqYApceg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;325,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,250&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zA5adVmI4qOc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued general and
    administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;61,325&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;103,822&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zZLVspUdYBX" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;386,325&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;130,072&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">325000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">26250</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <BRTX:AccruedGeneralAndAdministrativeExpenses contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">61325</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <BRTX:AccruedGeneralAndAdministrativeExpenses contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">103822</BRTX:AccruedGeneralAndAdministrativeExpenses>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">386325</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">130072</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zoRQVbwCoSn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;NOTE
5 - &lt;span id="xdx_827_zEOZJQqo4s7g"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
A Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 8, 2021, in connection with the Company&#x2019;s public offering, the Company&#x2019;s Board of Directors adopted a resolution
allowing for the designation and issuance of &lt;span id="xdx_908_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjtg6zP4wu3" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of the Company&#x2019;s Preferred Stock, $&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zPcorMWtAGzb" title="Preferred stock, par value"&gt;.01&lt;/span&gt; par value per share, designated
as Series A Preferred Stock (&#x201c;Series A&#x201d;). The Series A had a liquidation preference of $&lt;span id="xdx_903_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBWqdUyzvWgg" title="Preferred stock, liquidation preference"&gt;0.001&lt;/span&gt; per share. On September 8,
2022, the Company issued &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDgoLAd9PQUj" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of Series B Preferred Stock (&#x201c;Series B&#x201d;) to Auctus Fund, LLC (&#x201c;Auctus&#x201d;)
in exchange for an equal number of shares of the Company&#x2019;s outstanding Series A. Simultaneously, the stock certificate representing
the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company&#x2019;s Board
of Directors cancelled the Series A.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
B Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
September 8, 2022, the Company issued &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zIbqBFEI0Wd2" title="Preferred stock, shares issued"&gt;1,543,158&lt;/span&gt; shares of Series B to Auctus in exchange for an equal number of shares of the Company&#x2019;s
outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things,
the limitation on beneficial ownership of Common Stock of the Company upon a conversion of the Series B into Common Stock, and the limitation
on the number of votes attributable to the Series B, is &lt;span id="xdx_901_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7vIuiqhpq9h" title="Preferred stock voting rights"&gt;9.99&lt;/span&gt;% of the then outstanding Common Stock of the Company instead of &lt;span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7bA92hignrj" title="Preferred stock voting rights"&gt;4.99&lt;/span&gt;% as
provided for the Series A. The Company shall, at all times, reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to redemption
by the Company or any Series B holder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Dividends&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders
of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Voting
Rights&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Series
B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders
of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes
for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares
of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law.
The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares
of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled
to vote more than &lt;span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7DagVLZRLVh" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the then outstanding shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Conversion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Optional
Conversion - &lt;span id="xdx_90F_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwlfxZg9vp6c" title="Preferred stock conversion term"&gt;Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock&lt;/span&gt;; provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B
to the extent that such conversion would result in beneficial ownership by such Series B holder of more than &lt;span id="xdx_906_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUl1gl7nslOc" title="Preferred stock voting percentage"&gt;9.99&lt;/span&gt;% of the outstanding
shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Automatic
Conversion &#x2013; From time to time, if an event occurs, including adjustment due to merger, consolidation, etc., subdivision or combination
of Common Stock, adjustment due to distribution, purchase rights, and notice of adjustments, which has the effect of reducing a Series
B holder&#x2019;s beneficial ownership of shares of Common Stock to less than &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zw67XtWAPFv3" title="Ownership percentage"&gt;9.5&lt;/span&gt;% of the then publicly disclosed outstanding shares of
Common Stock, then, within five (5) business days, the Series B holder shall provide notice to the Company to such effect, which notice
shall state the number of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard
thereto, including the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have
the effect of a notice of conversion with respect to the conversion of such number of shares of Series B as would increase the Series
B holder&#x2019;s beneficial ownership of Common Stock to&lt;span id="xdx_90F_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zf3oOpgUB7h4" title="Preferred stock voting percentage"&gt; 9.99&lt;/span&gt;% of the then publicly disclosed outstanding shares of Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 4, 2023, Auctus converted &lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zWtGfk0zZb9c" title="Number of shares converted"&gt;120,000&lt;/span&gt; shares of Series B into &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20221024__20221025__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJGmPqTA1sdc" title="Number of shares issued in conversion"&gt;120,000&lt;/span&gt; shares of Common Stock. As of June 30, 2023, the number of shares
of Series B remaining outstanding after giving effect to such conversion was &lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z2eOiDOJAP05" title="Preferred stock, shares outstanding"&gt;1,398,158&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
and Option Valuation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used
for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and
directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#x201c;simplified&#x201d;
method to develop an estimate of the expected term of &#x201c;plain vanilla&#x201d; employee option grants. The Company is utilizing an
expected volatility figure based on a review of the historical volatilities, over a period of time equivalent to the expected life of
the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined
from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument
being valued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no stock options granted during the three months ended June 30, 2023. The Company granted options for the purchase of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_z3B7ZJCvZfma" title="Number of options, granted"&gt;629,017&lt;/span&gt; shares
of Common Stock during the six months ended June 30, 2023. The grant date fair value of options issued during the six months ended June
30, 2023 was $&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_c20230101__20230630_zM9otZTzI5s2" title="Grant date fair value of options granted"&gt;1,745,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no stock options granted during the three months ended June 30, 2022. The Company granted options for the purchase of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20220630_znjJhKiPETHh" title="Number of options, granted"&gt;25,000&lt;/span&gt; shares
of Common Stock during the six months ended June 30, 2022. The grant date fair value of options issued during the six months ended June
30, 2022 was $&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue_c20220101__20220630_zje6NeHpe1Nf" title="Grant date fair value of options granted"&gt;122,117&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW0R13kT1jL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted during the six months ended June 30, 2023, the Company used
the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zDq2cHk08Thc" style="display: none"&gt;SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For the &lt;br/&gt;
Six
    Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For the &lt;br/&gt;
Six
    Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDSkZ37Igyd" title="Risk free interest rate"&gt;4.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZtgZ8QUyqe1" title="Risk free interest rate"&gt;2.42&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBhSZaQxdAFg" title="Expected term (years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5JzdB8fjNlb" title="Expected term (years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zby1UAbkAsBb" title="Expected volatility"&gt;175&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqv9Sd8BWgk9" title="Expected volatility"&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zu9HApWxUHLg" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNbPFihnX0Jh" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zdLgnTYG7sX7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zod8JJGBmmSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity during the six months ended June 30, 2023 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zrv49KVB03V9" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 61%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, January
    1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230630_zmqPO3psl6J7" style="width: 15%; text-align: right" title="Number of options, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;864,639&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630_zb1G2Hk2oxs9" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.08&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_zpHlNPQJ4TKg" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;629,017&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230630_z5w0JgAU9F9l" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230630_zIPI50soujR" style="text-align: right" title="Number of options, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230630_zVH5uKxRXHW5" style="text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt; &lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230630_zCG2iBNn9Uic" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(26,766&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230630_zYgN6ZaK0Rwc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230630_zDrmnGBj3Ef1" style="text-align: right" title="Number of options, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466,890&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630_zGCpZj59PtKd" style="text-align: right" title="Weighted average exercise price, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630_z8Ycbbk55yaj" style="text-align: right" title="Number of options, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,041,062&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630_zSqvYqqK8Ig1" style="text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zgnbMQlAn8k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Company&#x2019;s 2021 Stock Incentive Plan (the &#x201c;2021 Plan&#x201d;), the Company may grant restricted stock units (&#x201c;RSUs&#x201d;)
to employees, consultants or non-employee directors (&#x201c;Eligible Individuals&#x201d;). The number, terms and conditions of the RSUs
that are granted to Eligible Individuals are determined on an individual basis by the 2021 Plan administrator. On the distribution date,
the Company shall issue to the Eligible Individual one unrestricted, fully transferable share of the Company&#x2019;s Common Stock (or
the fair market value of one such share in cash) for each vested and nonforfeitable RSU.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zhR277GmpHve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s unvested RSUs as of June 30, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zwEfQhs2PAyi" style="display: none"&gt;SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt; width: 75%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z51dUu8f06R5" style="padding-bottom: 0pt; width: 20%; text-align: right" title="Number of shares outstanding beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;201,870&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgLen2L5AgGl" style="padding-bottom: 0pt; text-align: right" title="Number of shares granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0810"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztOMKQsc9xX2" style="padding-bottom: 0pt; text-align: right" title="Number of shares forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztkwfcWR3sgk" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Number of shares vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(104,043&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCp5KXNFgd39" style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: right" title="Number of shares outstanding ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,827&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zvALObrIoyMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z5AzYWxXfpoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents stock compensation by award type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zdyvbNup9OG8" style="display: none"&gt;SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDfpQS5NlEh" style="width: 16%; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;321,534&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG5gfN4kthq5" style="width: 16%; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,865,297&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDCbt1c6FTBi" style="text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,164,135&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEREzz7ndOCb" style="text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,190,349&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issued for services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zIZEKXG43Udh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zWM796kT5zmc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,504&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230401__20230630_zEck7EsYqcil" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,485,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_zVmnkKQX3n58" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,104,150&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB9UH8kS7oW1" style="width: 16%; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,511,962&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOFgeN6j0zrk" style="width: 16%; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,004,246&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeLbOukUuin3" style="text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,312,885&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbVB9R9W6a64" style="text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,354,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issued for services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zNFeSSDDOuA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0844"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zShdxp6AJlyj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;121,322&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230630_zRFHHQtJjHG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,824,847&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220630_z9sj7xmEFZoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,480,042&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zGgBDZacKlS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
based compensation is included in General and administrative expenses on the consolidated statements of operations. As of June 30, 2023,
unrecognized stock based compensation expense is $&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20230630_zaXfXzTG0NE3" title="Unrecognized expense"&gt;1,201,875&lt;/span&gt; with a weighted average remaining amortization period of &lt;span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230630_zzXeczZvZeW4" title="Weighted average remaining amortization period"&gt;1.04&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1543158</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockVotingRights contextRef="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember">9.99</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockVotingRights contextRef="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember">4.99</us-gaap:PreferredStockVotingRights>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into
one share of Common Stock</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-06-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember"
      decimals="INF"
      unitRef="Pure">0.095</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-06-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">120000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-10-242022-10-25_custom_AuctusFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">120000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-06-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1398158</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">629017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">1745000</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">122117</BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zW0R13kT1jL" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
applying the Black-Scholes option pricing model to stock options granted during the six months ended June 30, 2023, the Company used
the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zDq2cHk08Thc" style="display: none"&gt;SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For the &lt;br/&gt;
Six
    Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For the &lt;br/&gt;
Six
    Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDSkZ37Igyd" title="Risk free interest rate"&gt;4.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZtgZ8QUyqe1" title="Risk free interest rate"&gt;2.42&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBhSZaQxdAFg" title="Expected term (years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5JzdB8fjNlb" title="Expected term (years)"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zby1UAbkAsBb" title="Expected volatility"&gt;175&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqv9Sd8BWgk9" title="Expected volatility"&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zu9HApWxUHLg" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNbPFihnX0Jh" title="Expected dividends"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515"
      decimals="INF"
      unitRef="Pure">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515"
      decimals="INF"
      unitRef="Pure">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515"
      decimals="INF"
      unitRef="Pure">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515"
      decimals="INF"
      unitRef="Pure">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zod8JJGBmmSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity during the six months ended June 30, 2023 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zrv49KVB03V9" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted
                                            Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise
                                            Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 61%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, January
    1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230630_zmqPO3psl6J7" style="width: 15%; text-align: right" title="Number of options, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;864,639&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630_zb1G2Hk2oxs9" style="width: 16%; text-align: right" title="Weighted average exercise price, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.08&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_zpHlNPQJ4TKg" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;629,017&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230630_z5w0JgAU9F9l" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230630_zIPI50soujR" style="text-align: right" title="Number of options, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230630_zVH5uKxRXHW5" style="text-align: right" title="Weighted average exercise price, expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt; &lt;span style="-sec-ix-hidden: xdx2ixbrl0792"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230630_zCG2iBNn9Uic" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(26,766&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230630_zYgN6ZaK0Rwc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230630_zDrmnGBj3Ef1" style="text-align: right" title="Number of options, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,466,890&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230630_zGCpZj59PtKd" style="text-align: right" title="Weighted average exercise price, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercisable, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630_z8Ycbbk55yaj" style="text-align: right" title="Number of options, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,041,062&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20230630_zSqvYqqK8Ig1" style="text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">864639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">629017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">2.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">26766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">5.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">1466890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30"
      decimals="INF"
      unitRef="USDPShares">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">1041062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30"
      decimals="INF"
      unitRef="USDPShares">4.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_893_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zhR277GmpHve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s unvested RSUs as of June 30, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B7_zwEfQhs2PAyi" style="display: none"&gt;SCHEDULE
OF UNVESTED RESTRICTED STOCK UNITS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt; width: 75%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z51dUu8f06R5" style="padding-bottom: 0pt; width: 20%; text-align: right" title="Number of shares outstanding beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;201,870&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgLen2L5AgGl" style="padding-bottom: 0pt; text-align: right" title="Number of shares granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0810"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztOMKQsc9xX2" style="padding-bottom: 0pt; text-align: right" title="Number of shares forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztkwfcWR3sgk" style="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; text-align: right" title="Number of shares vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(104,043&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding,
    June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCp5KXNFgd39" style="border-bottom: Black 2.5pt double; padding-bottom: 0pt; text-align: right" title="Number of shares outstanding ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97,827&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">201870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687"
      decimals="INF"
      unitRef="Shares">104043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">97827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_89F_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z5AzYWxXfpoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents stock compensation by award type:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zdyvbNup9OG8" style="display: none"&gt;SCHEDULE
OF STOCK COMPENSATION BY AWARD TYPE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUDfpQS5NlEh" style="width: 16%; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;321,534&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zG5gfN4kthq5" style="width: 16%; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,865,297&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDCbt1c6FTBi" style="text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,164,135&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEREzz7ndOCb" style="text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,190,349&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issued for services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230401__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zIZEKXG43Udh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220401__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zWM796kT5zmc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,504&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20230401__20230630_zEck7EsYqcil" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,485,669&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20220401__20220630_zVmnkKQX3n58" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,104,150&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB9UH8kS7oW1" style="width: 16%; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,511,962&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOFgeN6j0zrk" style="width: 16%; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,004,246&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeLbOukUuin3" style="text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,312,885&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbVB9R9W6a64" style="text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,354,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issued for services&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zNFeSSDDOuA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0844"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220630__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zShdxp6AJlyj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;121,322&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230630_zRFHHQtJjHG3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,824,847&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220630_z9sj7xmEFZoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,480,042&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember37476781"
      decimals="0"
      unitRef="USD">321534</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember37476781"
      decimals="0"
      unitRef="USD">1865297</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476781"
      decimals="0"
      unitRef="USD">1164135</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember37476781"
      decimals="0"
      unitRef="USD">1190349</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_custom_SharesIssuedForServicesMember"
      decimals="0"
      unitRef="USD">48504</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">1485669</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">3104150</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515"
      decimals="0"
      unitRef="USD">2511962</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember37476515"
      decimals="0"
      unitRef="USD">4004246</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember37476687"
      decimals="0"
      unitRef="USD">2312885</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember37476796"
      decimals="0"
      unitRef="USD">2354474</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30_custom_SharesIssuedForServicesMember"
      decimals="0"
      unitRef="USD">121322</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">4824847</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">6480042</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">1201875</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2023-01-01to2023-06-30">P1Y14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zlndkIz3u3Ra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;Note
6 - &lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_824_zsvL3sbPbRXg"&gt;LEASES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a party to a lease for &lt;span id="xdx_908_eus-gaap--AreaOfLand_iI_usqft_c20230630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zzXYDXB53ZZa" title="Area of land"&gt;6,800&lt;/span&gt; square feet of space located in Melville, New York (the &#x201c;Melville Lease&#x201d;) with respect
to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option
of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $&lt;span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIVoJ2NitjW1" title="Rent expense"&gt;132,600&lt;/span&gt; and
$&lt;span id="xdx_902_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zaqC6PgIdX0j" title="Rent expense"&gt;149,260&lt;/span&gt;. In June 2019, &lt;span id="xdx_90A_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zWLSS1zQlkkh" title="Lease extension description"&gt;the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $&lt;span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zkDAc3ek9uY3" title="Rent expense"&gt;153,748&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zCtVMBWdIMC5" title="Rent expense"&gt;173,060&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated
incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was &lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230630_zHdPrF0PBv24" title="Weighted average incremental borrowing rate"&gt;12&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zW5SqB6eDYq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents net lease cost and other supplemental lease information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zFNMTlnW2HMg" style="display: none"&gt;SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20230630_zAJjbLhIF7F9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20220630_zqNvy7oBLJN" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zMljgG65GQGi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease cost (cost resulting
    from lease payments)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;84,014&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;81,566&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zEVxoxlUHLL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;84,014&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;81,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zJOh96MPVHUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease &#x2013; operating cash flows
    (fixed payments)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;84,014&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;81,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFcU1cz1j3j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease &#x2013; operating cash flows
    (liability reduction)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,751&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current leases &#x2013; right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20230630_zxxShXwMOek2" style="text-align: right" title="Non-current leases - right of use assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183,738&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220630_z2Kh8pieJBnd" style="text-align: right" title="Non-current leases - right of use assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;299,783&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current liabilities &#x2013; operating lease
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20230630_zLaiciFlln7e" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,480&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220630_zH65EMzxLRQa" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;128,899&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current liabilities &#x2013; operating lease
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20230630_zEZAX9TMYJq9" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,580&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20220630_zwIinaSkCiz7" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;234,060&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zGyTbXHJAoy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3ofkMUnbeXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_z6KIOPVmJpBa" style="display: none"&gt;SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fiscal
    Year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230630_zUokooBdJQwi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zI2y2IqCMy29" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;84,014&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zeF8mVF1zE7h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;173,060&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zERuRTZ5vC1a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;257,074&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za99u9rqEpjk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount representing
    interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_z3L2pUZXwTNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of net
    future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;234,060&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2023-06-30_custom_MelvilleLeaseMember"
      decimals="INF"
      unitRef="sqft">6800</us-gaap:AreaOfLand>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-06-30_custom_MelvilleLeaseMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">132600</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-06-30_custom_MelvilleLeaseMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">149260</us-gaap:PaymentsForRent>
    <us-gaap:LessorOperatingLeaseOptionToExtend contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor
whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $153,748 and $173,060.</us-gaap:LessorOperatingLeaseOptionToExtend>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">153748</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">173060</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2023-06-30" decimals="INF" unitRef="Pure">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zW5SqB6eDYq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents net lease cost and other supplemental lease information:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zFNMTlnW2HMg" style="display: none"&gt;SCHEDULE
OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20230630_zAJjbLhIF7F9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20220630_zqNvy7oBLJN" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_zMljgG65GQGi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease cost (cost resulting
    from lease payments)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;84,014&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;81,566&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_zEVxoxlUHLL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;84,014&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;81,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zJOh96MPVHUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease &#x2013; operating cash flows
    (fixed payments)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;84,014&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;81,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_zHFcU1cz1j3j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease &#x2013; operating cash flows
    (liability reduction)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67,585&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,751&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current leases &#x2013; right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20230630_zxxShXwMOek2" style="text-align: right" title="Non-current leases - right of use assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183,738&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220630_z2Kh8pieJBnd" style="text-align: right" title="Non-current leases - right of use assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;299,783&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current liabilities &#x2013; operating lease
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20230630_zLaiciFlln7e" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;150,480&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220630_zH65EMzxLRQa" style="text-align: right" title="Current liabilities - operating lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;128,899&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current liabilities &#x2013; operating lease
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20230630_zEZAX9TMYJq9" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;83,580&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20220630_zwIinaSkCiz7" style="text-align: right" title="Non-current liabilities - operating lease liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;234,060&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">84014</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">81566</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">84014</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">81566</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">84014</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">81566</us-gaap:OperatingLeasePayments>
    <BRTX:OperatingLeaseLiabilityReduction
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">67585</BRTX:OperatingLeaseLiabilityReduction>
    <BRTX:OperatingLeaseLiabilityReduction
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">57751</BRTX:OperatingLeaseLiabilityReduction>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">183738</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">299783</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">150480</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">128899</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">83580</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">234060</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z3ofkMUnbeXa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of June 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_z6KIOPVmJpBa" style="display: none"&gt;SCHEDULE
OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fiscal
    Year&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230630_zUokooBdJQwi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zI2y2IqCMy29" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 78%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;84,014&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zeF8mVF1zE7h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;173,060&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_zERuRTZ5vC1a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;257,074&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_za99u9rqEpjk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount representing
    interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(23,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_z3L2pUZXwTNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of net
    future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;234,060&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">84014</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">173060</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">257074</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">23014</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">234060</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zg5RXeDPMMX6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-transform: uppercase"&gt;&lt;b&gt;Note 7
&#x2013; &lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;span id="xdx_827_zQN5OASAr6P4"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On July 13, 2023, the Company
sold an aggregate of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsjcrJCDwMMi" title="Number of shares issued"&gt;685,033&lt;/span&gt; shares of Common Stock to several institutional buyers and accredited investors in a registered direct offering
at an offering price of $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_c20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMx5DgJZkt91" title="Offering price"&gt;3.03 &lt;/span&gt;per share. The offering closed on July 13, 2023, with net proceeds of approximately $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230712__20230713__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH6DD6F5Zq4a" title="Procceds fom offering"&gt;1.8&lt;/span&gt; million. The Company
intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy candidate,
&lt;i&gt;BRTX-100&lt;/i&gt;, pre-clinical research and development with respect to its metabolic &lt;i&gt;ThermoStem Program &lt;/i&gt;and for general corporate
purposes and working capital.&lt;/p&gt;

&lt;p id="xdx_8AD_zQlp4Tjb2c7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_008"&gt;&lt;/span&gt;ITEM
2. MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Note
Regarding Forward-Looking Statements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
Quarterly Report on Form 10-Q includes a number of forward-looking statements that reflect management&#x2019;s current views with respect
to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial
performance. In some cases, you can identify forward-looking statements by terminology such as &#x201c;may,&#x201d; &#x201c;should,&#x201d;
&#x201c;expects,&#x201d; &#x201c;plans,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d;
&#x201c;potential&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other comparable terminology. These statements include
statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions
on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of
future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such
forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors,
including the risks set forth in the section entitled &#x201c;Risk Factors&#x201d; in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 27, 2023, any of
which may cause our company&#x2019;s or our industry&#x2019;s actual results, levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.
These risks and factors include, by way of example and without limitation:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to obtain financing needed to complete our clinical trials and implement our business plan;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to successfully develop and commercialize BRTX-100, our lead product candidate for the treatment of chronic lumbar disc disease,
    as well as our metabolic ThermoStem Program;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to protect our proprietary rights;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to achieve and sustain profitability of the existing lines of business;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to attract and retain world-class research and development talent;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to attract and retain key science, technology and management personnel and to expand our management team;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    accuracy of estimates regarding expenses, future revenue, capital requirements, profitability, and needs for additional financing;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;business
    interruptions resulting from geo-political actions, including war and terrorism or disease outbreaks (such as the recent outbreak
    of COVID-19);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to attract and retain customers; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;our
    ability to navigate through the increasingly complex therapeutic regulatory environment.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity or performance. Except as required by applicable law, including the securities laws of the United States, we do not intend
to update any of the forward-looking statements to conform these statements to actual results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Readers
are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the
SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated
events or changes in the future operating results over time, except as required by law. We believe that our assumptions are based upon
reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or
the results of our future activities will not differ materially from our assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the terms &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d;
and &#x201c;our&#x201d; refer to BioRestorative Therapies, Inc., a Nevada corporation (&#x201c;BRT&#x201d;), and its wholly-owned subsidiary,
Stem Pearls, LLC, a New York limited liability company (&#x201c;Stem Pearls&#x201d;). Unless otherwise specified, all dollar amounts are
expressed in United States dollars.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Intellectual
Property&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
report includes references to our federally registered trademarks, &lt;i&gt;BioRestorative Therapies and Dragonfly &lt;/i&gt;design, &lt;i&gt;BRTX-100,
ThermoStem, &lt;/i&gt;and &lt;i&gt;BRTX&lt;/i&gt;. The &lt;i&gt;Dragonfly&lt;/i&gt; logo is also registered with the U.S. Copyright Office. This report may also include
references to trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks
and trade names referred to in this report appear without the &#xae;, &lt;sup&gt;SM&lt;/sup&gt; or &#x2122; symbols, and copyrighted content appears
without the use of the symbol &#xa9;, but the absence of use of these symbols does not reflect upon the validity or enforceability of
the intellectual property owned by us or third parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Corporate
History&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
offices are located in Melville, New York where we have established a laboratory facility in order to increase our capabilities for the
further development of possible cellular-based treatments, products and protocols, stem cell-related intellectual property and translational
research applications.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, our accumulated deficit was $161,305,671. We have historically only generated a modest amount of revenue, and our losses
have principally been operating expenses incurred in research and development, marketing and promotional activities in order to commercialize
our products and services, plus costs associated with meeting the requirements of being a public company. We expect to continue to incur
substantial costs for these activities over at least the next year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
Overview&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
develop therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells.
We are currently pursuing our &lt;i&gt;Disc/Spine Program&lt;/i&gt; with our initial investigational therapeutic product being called &lt;i&gt;BRTX-100&lt;/i&gt;.
In March 2022, a United States patent was issued in our &lt;i&gt;Disc/Spine Program&lt;/i&gt;. We submitted an IND application to the FDA to obtain
authorization to commence a Phase 2 clinical trial investigating the use of &lt;i&gt;BRTX-100&lt;/i&gt;, our lead cell therapy candidate, in the
treatment of chronic lower back pain arising from degenerative disc disease. We have received such authorization from the FDA and have
commenced such clinical trial through the execution of a CRO agreement with Professional Research Consulting, Inc., d/b/a PRC Clinical (&#x201c;PRC&#x201d;),
the execution of clinical trial site agreements, patient enrollment, the commencement of patient procedures, the purchase of manufacturing
equipment and the expansion of our laboratory to include capabilities for clinical production. We have received a license from the New
York State Department of Health to act as a tissue bank for mesenchymal stem cell processing. In June 2023, we received a unanimous recommendation
from the Data Safety Monitoring Board (&#x201c;DSMB&#x201d;) to continue our Phase 2 clinical trial without any changes. We have obtained
a license to use technology for investigational adult stem cell treatment of disc and spine conditions, including protruding and bulging
lumbar discs. The technology is an advanced stem cell injection procedure that may offer relief from lower back pain, buttock and leg
pain, and numbness and tingling in the leg and foot. We are investigating the expansion of the clinic application of &lt;i&gt;BRTX-100&lt;/i&gt;
to other indications within the body.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
are also developing our &lt;i&gt;ThermoStem Program&lt;/i&gt;. This pre-clinical program involves the use of brown adipose (fat) in connection with
the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
United States patents related to the &lt;i&gt;ThermoStem Program&lt;/i&gt; were issued in September 2015, January 2019, March 2020, March 2021, and
July 2021; a notice of allowance was issued in February 2023 by the United States Patent Office for a patent application related to our
&lt;i&gt;ThermoStem&lt;/i&gt; Program; Australian patents related to the &lt;i&gt;ThermoStem Program&lt;/i&gt; were issued in April 2017, October 2019, and August
2021; Japanese patents related to the &lt;i&gt;ThermoStem Program&lt;/i&gt; were issued in December 2017, June 2021, and February 2022; a notice
of allowance was issued in May 2023 by the Japanese Patent Office for a patent application related to our &lt;i&gt;ThermoStem Program&lt;/i&gt;;
Israeli patents related to our &lt;i&gt;ThermoStem Program&lt;/i&gt; were issued in October 2019, May 2020, and March 2022; European patents related
to the &lt;i&gt;ThermoStem Program &lt;/i&gt;were issued in April 2020 and January 2021; and a notice of allowance was issued in February 2023 by
the European Patent Office for a patent application related to our &lt;i&gt;ThermoStem&lt;/i&gt; Program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have licensed a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products or
materials to the spine and discs or other potential sites. We anticipate that FDA approval or clearance will be necessary for this device
prior to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to &lt;i&gt;BRTX-100&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
derived all of our revenue pursuant to a license agreement with the SCTC entered into in January 2012, as amended in November 2015 and
November 2022. Pursuant to the license agreement, the SCTC granted to us an exclusive license to use certain intellectual property related
to, among other things, stem cell disc procedures and we have granted to the SCTC a sublicense to use, and the right to sublicense to
third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual
property. In consideration of the sublicenses, the SCTC has agreed to pay us royalties on a per disc procedure basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Results
of Operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Comparison
of the Three Months Ended June 30, 2023 to the Three Months Ended June 30, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
financial results for the three months ended June 30, 2023 are summarized as follows in comparison to the three months ended June 30,
2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Three Months Ended,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-style: italic; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;64,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71,100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;967,891&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,075,224&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,213,160&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,624,504&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,181,051&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,699,728&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,116,551&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,628,628&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    (income) expense:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(96,187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,613&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(39,812&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(135,599&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;46,613&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,980,552&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,675,241&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended June 30, 2023 and 2022, we generated $64,500 and $71,000, respectively, of royalty revenue in connection with
our sublicense agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development
expenses are expensed as they are incurred. For the three months ended June 30, 2023, research and development expenses decreased by
$107,333, or 10.0%, compared to the three months ended June 30, 2022. The decrease was primarily the result of a difference in the timing
of payments made for PRC service expenses. A milestone payment in the amount of $150,000 was paid on June 30, 2022 compared to the three
months ended June 30, 2023 in which no milestone payment was due.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
expect that our research and development expenses will increase in subsequent fiscal periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;General
and Administrative&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees, as well
as corporate expenses such as legal and professional fees, investor relations and occupancy-related expenses. For the three months ended
June 30, 2023, general and administrative expenses decreased by $1,411,344, or 38.9%, as compared to the three months ended June 30,
2022, primarily driven by a $1,618,481 decrease in stock-based compensation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Interest
(income) expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended June 30, 2023, interest income was $96,187 compared to interest expense of $46,613 for the three months ended
June 30, 2022. The change was primarily due to our investments in marketable securities during the three months ended June 30, 2023,
which generated interest income. During the three months ended June 30, 2022, we did not have any such investments and only incurred
interest expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Other
income, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended June 30, 2023, Other income, net primarily relates to gains from settlements of certain accrued expenses and realized
and unrealized gain on investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Comparison
of the Six Months Ended June 30, 2023 to the Six Months Ended June 30, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
financial results for the six months ended June 30, 2023 are summarized as follows in comparison to the six months ended June 30, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Six Months Ended,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June
    30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-style: italic; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;95,800&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;87,100&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,479,136&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,850,561&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,512,313&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,918,960&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,991,449&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,769,521&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,895,649&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(9,682,421&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    (income) expense:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(114,403&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;75,624&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gain on PPP loan forgiveness&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(250,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Grant income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,654&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other
    income, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(116,472&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total other income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(230,875&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(191,030&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,664,774&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(9,491,391&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Revenues&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the six months ended June 30, 2023 and 2022, we generated $95,800 and $87,100, respectively, of royalty revenue in connection with our
sublicense agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific
Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development
expenses are expensed as they are incurred. For the six months ended June 30, 2023, research and development expenses increased by $628,575,
or 34.0%, compared to the six months ended June 30, 2022. The increase was primarily driven by increased salaries and wages of $836,000,
increased lab site fees of $84,000, and increased consulting fees of 95,000, offset by a decrease in PRC service expenses of $532,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
expect that our higher level of research and development expenses will continue in subsequent fiscal periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;General
and Administrative&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees, as well
as corporate expenses such as legal and professional fees, investor relations and occupancy-related expenses. For the six months ended
June 30, 2023, general and administrative expenses decreased by $1,406,647, compared to the six months ended June 30, 2022. The decrease
was primarily driven by a $1,655,195 decrease in stock-based compensation, offset by an increase in salaries and wages of $167,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
expect that our general and administrative expenses will increase as we expand our staff, develop our infrastructure and incur additional
costs to support the growth of our business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Interest
(income) expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the six months ended June 30, 2023, interest income was $114,403 compared to interest expense of $75,624 for the six months ended June
30, 2022. The change was primarily due to our investments in marketable securities during the six months ended June 30, 2023, which generated
interest income. During the six months ended June 30, 2022, we did not have any such investments and only incurred interest expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Other
income, net&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the six months ended June 30, 2023, Other income, net primarily relates to gains from settlements of certain accrued expenses and realized
and unrealized gain on investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Gain
on PPP loan forgiveness&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms of the U.S. Small Business Administration&#x2019;s Paycheck Protection Program (&#x201c;PPP&#x201d;), our $250,000 PPP loan was
forgiven during the six months ended June 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Grant
income&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grant
income of $16,654 during the six months ended June 30, 2022 consists of funding received under a $256,000 National Institutes of Health
Small Business Technology Transfer (STTR) Phase 1 grant, which we were awarded in September 2021. There was no grant income during the
six months ended June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity
and Capital Resources&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
measure our liquidity in a number of ways, including the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 61%; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash, Cash
    Equivalents, and Investments&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,615,365&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,749,408&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Working Capital&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,231,071&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,688,188&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Working
capital decreased by $3,457,117 primarily due to the $3,479,065 of cash used to fund our operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Availability
of Additional Funds&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
upon our accumulated deficit of $161,305,671 as of June 30, 2023, along with our forecast for continued operating losses and our need
for financing to fund our current and contemplated clinical trials, we will eventually require additional equity and/or debt financing
to continue our operations. However, based on cash on hand as of June 30, 2023 and the recent offerings discussed below, we believe we
have sufficient cash to fund operations for the twelve months subsequent to the filing date of this Form 10-Q.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
operating needs include the planned costs to operate our business, including amounts required to fund our clinical trials, working capital
and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including
our ability to successfully commercialize our products and services, competing technological and market developments, and the need to
enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service
offerings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
may be unable to raise sufficient additional capital when we need it or raise capital on favorable terms. Future financing may require
us to pledge certain assets and enter into covenants that could restrict certain business activities or our ability to incur further
indebtedness and may contain other terms that are not favorable to our stockholders or us. If we are unable to obtain adequate funds
on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing
agreements on unattractive terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#x201c;At-the-Market&#x201d;
Offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2023, we entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (the &#x201c;Sales Agent&#x201d;)
under which we have the ability to issue and sell shares of our Common Stock, from time to time, through the Sales Agent, up to an aggregate
offering price of $4,200,000 in what is commonly referred to as an &#x201c;at-the-market&#x201d; (&#x201c;ATM&#x201d;) program. During the
three months ended June 30, 2023, we sold 93,551 shares of our Common Stock under the ATM program with the Sales Agent at a weighted-average
gross price of approximately $5.74 per share and raised approximately $536,600 of gross proceeds. The total commissions and related legal
fees were approximately $125,000, and we received net proceeds of approximately $412,000. As of June 30, 2023, we had remaining capacity
to sell up to an additional $3,663,407 of Common Stock under the ATM program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Registered
Direct Offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2023, we sold an aggregate of 685,033 shares of our Common Stock in a registered direct offering. We received net proceeds of approximately
$1,831,000 from the offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash
Flows&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023 and 2022, our sources and uses of cash were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Six
    Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,479,065&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,845,765&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net cash provided by (used in) investing activities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,174,433&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(247,247&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net cash provided by
    financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;411,701&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net increase (decrease)
    in cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;107,069&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,093,003&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Operating
Activities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
cash used in operating activities was $3,479,065 for the six months ended June 30, 2023, primarily due to cash used to fund the net loss
of $8,664,774, which was partially offset by non-cash expenses of $4,824,865 related primarily to stock-based compensation. Cash flows
were also impacted by routine fluctuations in our operating assets and liabilities. Net cash used in operating activities was $2,845,756
for the six months ended June 30, 2022, primarily due to cash used to fund the net loss of $9,491,391 and a non-cash gain of $250,000
on forgiveness of our PPP loan, which were partially offset by non-cash expenses of $6,480,055 related primarily to stock-based compensation
and $300,032 of cash provided by changes in the levels of operating assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Investing
Activities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
cash provided by investing activities increased by $3,421,680 for the six months ended June 30, 2023 compared to the six months ended
June 30, 2022, primarily due to a sale of marketable securities, which provided $3,263,504 of cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Financing
Activities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
cash provided by financing activities increased by $411,701 for the six months ended June 30, 2023 compared to the six months ended June
30, 2022, due to the net proceeds from the ATM offerings of the Company&#x2019;s Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Effects
of Inflation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
do not believe that inflation had a material impact on our business, revenues or operating results during the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Critical
Accounting Policies and Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
significant accounting policies are more fully described in the notes to our unaudited condensed consolidated financial statements included
herein for the quarter ended June 30, 2023, and in the notes to our audited consolidated financial statements included in our Annual
Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span id="a_009"&gt;&lt;/span&gt;Item
3. Quantitative and Qualitative Disclosures about Market Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Not
applicable. As a smaller reporting company, we are not required to provide the information required by this Item.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span id="a_010"&gt;&lt;/span&gt;Item
4. Controls and Procedures&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Evaluation
of Disclosure Controls and Procedures&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
maintain disclosure controls and procedures as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934, as amended (&#x201c;the Exchange Act&#x201d;), that are designed to ensure that information required to be disclosed in our reports
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and
forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal
financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures,
our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls
and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood
of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance
of achieving the desired control objectives.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the supervision and with the participation of our management, including our principal executive officer and principal financial officer,
we are required to perform an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the
Exchange Act, as of June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has completed such evaluation and has concluded that our disclosure controls and procedures were not effective to provide reasonable
assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is appropriate to allow
timely decisions regarding required disclosures. As a result of the material weakness in internal controls over financial reporting described
below, we concluded that our disclosure controls and procedures as of June 30, 2023 were not effective.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Material
Weaknesses in Internal Control over Financial Reporting&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
assessed the effectiveness of our internal control over financial reporting as of June 30, 2023 based on the framework established in
Internal Control&#x2014;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based
on this assessment, management has determined that our internal control over financial reporting as of June 30, 2023 was not effective.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
material weakness, as defined in the standards established by Sarbanes-Oxley, is a deficiency, or a combination of deficiencies, in internal
control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated
financial statements will not be prevented or detected on a timely basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
ineffectiveness of our internal control over financial reporting was due to the following material weaknesses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lack
    of adherence to formal policies and procedures;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lack
    of risk assessment procedures on internal controls to detect financial reporting risks in a timely manner; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lack
    of sufficient formal management testing over documented formal procedures and controls, and time to evaluate continuous effectiveness
    of controls to achieve complete and accurate financial reporting and disclosures, including documented controls over the preparation
    and review of journal entries and account reconciliations.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.6pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.6pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Management&#x2019;s
Plan to Remediate the Material Weaknesses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weaknesses
are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;New
    management personnel, including our Chief Financial Officer, who is overseeing the financial reporting process and implementation
    of enhanced controls and governance;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Engagement
    of external financial consulting firm to continue to enhance financial reporting, financial operations and internal controls; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Documentation
    of key procedures and controls using a risk-based approach.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -35.6pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
is committed to maintaining a strong internal controls environment and implementing measures designed to help ensure that control deficiencies
contributing to the material weaknesses are remediated as soon as possible. We have documented key procedures and controls using a risk-based
approach and have, therefore, made progress toward remediation. We continue to implement our remediation plan, which includes continued
engagement of an external financial consulting firm to enhance financial reporting and operations as well as design and implementation
of controls. We will consider the material weaknesses remediated after the applicable controls operate for a sufficient period of time,
and Management has concluded, through testing, that the controls are operating effectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing
basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Changes
in Internal Control Over Financial Reporting&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
than described above, there have been no changes in our internal control over financial reporting that occurred during our second quarter
of 2023 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_011"&gt;&lt;/span&gt;PART
II - OTHER INFORMATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span id="a_012"&gt;&lt;/span&gt;Item
1A. Risk Factors&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
investment in our Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in
the &#x201c;Risk Factors&#x201d; section of our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC
on March 27, 2023, in addition to other information contained in that report and in this quarterly report in evaluating the Company and
its business before purchasing shares of our Common Stock. The Company&#x2019;s business, operating results and financial condition could
be adversely affected due to any of those risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span id="a_013"&gt;&lt;/span&gt;Item
2. Unregistered Sales of Equity Securities and Use Of Proceeds&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended June 30, 2023, we did not have any unregistered sales of equity securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"&gt;&lt;b&gt;&lt;span id="a_014"&gt;&lt;/span&gt;Item
6. Exhibits&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Incorporated
    by Reference&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.75in"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exhibit&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exhibit
    Description&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.5in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Form&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.5in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exhibit&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; width: 0.75in; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Filing
    Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex33-certificatetoaccompanya.jpg" style="-sec-extract: exhibit"&gt;Amended and Restated Articles of Incorporation&lt;/a&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8-K&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1/5/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex34-certificateofdesignatio.jpg" style="-sec-extract: exhibit"&gt;Certificate of Designations of Preferred Stock (Series B)&lt;/a&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8-K&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1/5/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177123000002/ex3_5.htm" style="-sec-extract: exhibit"&gt;Bylaws&lt;/a&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8-K&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1/5/2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31.1*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;a href="ex31-1.htm"&gt;&lt;span style="font-size: 10pt"&gt;Certification
    of Principal Executive Officer&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31.2*&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;a href="ex31-2.htm"&gt;&lt;span style="font-size: 10pt"&gt;Certification
    of Principal Financial Officer&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32.1**&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;a href="ex32-1.htm"&gt;&lt;span style="font-size: 10pt"&gt;Section
    1350 Certification of Principal Executive Officer and Principal Financial Officer&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101.INS&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inline
    XBRL Instance Document&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101.SCH&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inline
    XBRL Taxonomy Extension Schema Document&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101.CAL&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inline
    XBRL Taxonomy Extension Calculation Linkbase Document&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101.DEF&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inline
    XBRL Taxonomy Extension Definition Linkbase Document&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101.LAB&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inline
    XBRL Taxonomy Extension Label Linkbase Document&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101.PRE&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inline
    XBRL Taxonomy Extension Presentation Linkbase Document&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;104&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cover
    Page Interactive Date File (embedded within the Inline XBRL document)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 0pt; white-space: nowrap; vertical-align: top; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Filed
    herewith.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;**&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;In
    accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_015"&gt;&lt;/span&gt;SIGNATURES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BIORESTORATIVE
    THERAPIES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 46%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;By:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;/s/
    Lance Alstodt&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lance
    Alstodt&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief
    Executive Officer, President, and Chairman of the Board&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Principal
    Executive Officer)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Date:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;August
    11, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;By:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;/s/
    Robert E. Kristal&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Robert
    E. Kristal&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chief
    Financial Officer&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Principal
    Financial Officer)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Date:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;August
    11, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-122023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">685033</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">3.03</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-07-122023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">1800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MZGOY]*MH!'DEWT*FJOI/GFJL;X_(8JNTS)I@N((LR>O/Z&N3B), X,$#6!/
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M>QCG/PS&<667T)X+XY=X1+H&*8Q3J0WSV,,XOP#&3W>&X13:#,T4BXQ=\%O
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M:&5E=#<N>&ULK5C;<MNV%GWG5V#43J=G1I8HR4[<Q/:,;">-,HGMVG+/;?H
MD5LB3D"  4 I[M=W;9"ZN8Y[VNF+11+ OJR]]@+@DY5UGWQ!%,274AM_VBE"
MJ%[U^SXKJ)2^9RLR&)E;5\J 5[?H^\J1S..B4O>':?JB7TIE.F<G\=N-.SNQ
M==#*T(T3OBY+Z1[.2=O5:6?067^X58LB\(?^V4DE%W1'X;ZZ<7CK;ZSDJB3C
ME37"T?RT,QZ\.C_D^7'"SXI6?N=9<"8S:S_QRR0_[:0<$&G* EN0^%G2!6G-
MAA#&Y]9F9^.2%^X^KZV_C;DCEYGT=&'U/U4>BM/.<4?D-)>U#K=V]8[:?([8
M7F:UCW_%JIV;=D16^V#+=C$B*)5I?N67%H?_9\&P73",<3>.8I27,LBS$V=7
MPO%L6..'F&I<C>"4X:+<!8=1A77A[&H\O;]](Z[?BND[_-S^.+Z:_&<\G5Q?
M=<6'R4_WD\O)]-]=,;ZZ%.?W=Y.K-W=W)_T Q[R\G[5.SALGPZ\X>2$^6A,*
M+]Z8G/+]]7T$O(EZN([Z?/BLP?>UZ8E1VA7#=#AZQMYH@\(HVAM]Q=ZU6TBC
M?I5,E*ZXL,9;K7+9\,;DXL:1)Q.:#W8NWBHC3::D%G?X2"!I\.*_XYD/#C3[
MY2F$F@ .GPZ 6^^5KV1&IYV*?;DE=<Z^^V;P(GW]3'J'F_0.G[/^=Q7Y#YQ<
M3]\D W$@_H(W0.XJZP!E\DZ!\^Y!G"M[2_PHN6V3:4%.5HI\5TQ,UA.%],(:
M$JO":OUP8%>&<BC+S*M<05RZ* R5XH:DTUCRX<.%^/Z[;XZ'P_3USD#\,GC]
MC]XC;^*Q-^: "C[9.A#2$8L2.0?'P0HT8E2:)6D,>M%Z.[^=MEZ$=2(4M!ZX
ML&4ES4,[V!/7)KFDC,H9.3'\(3)[V(T+VIGPIDRVQBD7<V=+<4E:KC@41'!%
M2YG+'@>_-Y<YNT)$(&>=A9KCQ9O$NPQUQ+HDMX!;$/MYU+M8M?&X8[X+T0I%
M@Y)!)(#JZX5Y'FIVT22RZZ G/JC/-2R$!UZ0R"QK0%%F@7E0%>/A)MLT+N.S
MZ5&_[=%"PN6,R BT6249"Z##*$/:E<>3#'N@KY36;#<H4U.#V\*V7C-RIINL
M"I45<0J5E88G#_2E;M6$097>$WPS/!X?_3R&K96<*:T"4@=JT:GA?8;=U<X3
MKYS5'EWF?4^\;=GCU1=1-F)*+*8"4D@LA0E+X3YA"HE*"X.=75OOV=ZWXKCW
M4ASVCL6H=\24&U=.:3$X;)1T?SD (P8HEA1TD1J1RH6CB&53\O?H03]U,N>,
M)L8'!4HA;59&B)C*L(2;#Z<'Y"]D.("' VS_GQ#5NB/'TX_K3DSL'"W%QA#M
M3C \/GCYVO,[TD=WV^Q35Z""8BDU*O.M2'MIF@Z0&!(<#+HO!ZGX8=0].AIP
MGN]K=.5@]%2:8$P>8UL@M07JQZY?'!]UT]$(UM*1&  O]/&_#@9I&OE:VD9$
MG%TX62;G.!7D":+*I"^83P676D;$U^5YPO&,M*(E5S]$.?/U?*XRQ=A&0T!]
M7L,0#F!-%_@((YL(*](@<DL$[B[Z7&-A@C4\/@>Q@&'>9A,*4)L/,6*0'OS4
M$Q<U5 NSV;P'Z[A=Y,S"8J0[/B"XW7A@EHR<:=I+( :()A?<C)K@BQL_1T[:
M5I$C\<S54)P)$ ).B>@\.U<A6MNFUDLF>P47B+AN75IA9W&EK]%IAHAY+W.H
M0<.TMM.9-"BC"#@T(JC8T/N(E_*A40#6Z]K!IGX<<C=IR,G6N(H(MK2MGVTV
M$+S8]2M;@SS1I(1U] OKC<R7Q U,X'(6U@+SF,GKWN[N*!5+6<PJ8=\X".!L
M&6FT!:H;P\)WQ?Z0YVZ"68P'M0-1LF9?RI7?R!?GNL,F-J2CKL)2[V\75A0,
MZ_C>P++=[! P7YL(+H0'1BK6E 49Q,1$PCA5\)&T@GAO%'N,AZR(PQA;E<KD
M1CI^'(]OUMJQ+LJ.%*^5>R/%NV#]7LPC(B%NGQL!3YX2<)FM#?XY%>>M.9/.
M17AER5CX1SO$KL&J.79N\?@S%<EM;&2#0X7W$C+_(*J:=]38SBA28WR=:VQ'
MW-8H!-T(?!36-NA=7B1_(0K46M<Y[##N^?]PKVF&XWY;\LV)6;N.%:)<1";O
MR^6.(*PIG?R^B#C,M7@GUUNN0[^3MLW9*Y\Y"#M5Q@V>XUC4@%]2#G;I=@*7
M@$W!-&Z-#3F4]V@D+,(&9/EH"1Z7#;K*+*U>QLKFZ$^@@#V"5P+#]AC(C9^L
M"(<A%DOXQ#:Z6O5FRKKMD:@'J+?[S?KAJ6M ?^?>%\]P?+OU(O98<P7<?-U<
MH,?-O7$[O;E]?Y1NH8"3ICF6IKV71QWAFAMM\Q)L%6^1,QMP)XV/!<F<'$_
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MIZ\4TA$%KJAXUO'QZ9]0DT1:@UKSTOO,U1OP:R;^X.@)'[V7\6J/#=ZLT%<
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M0(+U95.KWZ:KCDY UP7M!;JB6'@)!00\Y@MV57^H4E<#T<8Y;F1-5%HRLMT
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MW_3N"Z4+1M!$QHIOR_GN745=S@S-)HQ],B&S!4C:5"3!LX6F=W9J""J/&'W
MIT@4FJ:$#TJNF#"K@QDR19*UPW,ET]JD1^8+PP7_B2#MI)O5<:$8*&L74HQY
MQ 1-BD?:HQ@:&Q*:I@Z%Q=33W-:<FU%R#CK'B,]YY(*H;<FV2-9%-%<R+B*J
MV+77,17N6L#3.?E(@:0*+QVTR=(6T$K.9+S:=^6_X2_L.7]CZ]Y(<^;V1VI!
M_'C&]M\4CJT >#L"8!(9.X\C&I6%TW?.->'7/.XHJRK>?@V:HW('4D8A3;E
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MV>4&+Z]<D0&^7TG\BAX>*,#Q.MS['U!+ P04    " "W@ M7>; ;1X(D  #
M;P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6SM75MSV\AR?I]?,>4X
M*>D41/&JB[V[5;(L9[7QVCJ2=C>I5!Y 8DCB& 2X "B9^?7YNGMF,.!%DIV3
M2A[RL%Z1P-QZ^O)U3T_SA\>B_%+-C:GUUT665S^^FM?U\LWQ<369FT5<=8JE
MR?%D6I2+N,;'<G9<+4L3)]QHD1WWN]V3XT6<YJ]^^H&_NRE_^J%8U5F:FYM2
M5ZO%(B[7[TQ6//[XJO?*?7&;SN8U?7'\TP_+>&;N3/W;\J;$IV/?2Y(N3%ZE
M1:Y+,_WQU47OS;LAO<\O_)Z:QRKX6]-*QD7QA3Y<)S^^ZM*$3&8F-?40XW\/
MYM)D&76$:?QI^WSEAZ2&X=^N]P^\=JQE'%?FLLC^2)-Z_N.KLU<Z,=-XE=6W
MQ>//QJYG1/U-BJSB?_6CO-L_?Z4GJZHN%K8Q9K!(<_E__-72(6APUMW3H&\;
M]'G>,A#/\GU<QS_]4!:/NJ2WT1O]P4OEUIA<FM.FW-4EGJ9H5_]T]]N[NZN_
M_G;UZ5Y?_8Y_[WXXKM$M/3R>V"[>21?]/5V<Z%^+O)Y7^BI/3-)N?XSI^#GU
MW9S>]9_L\)=5WM&#;J3[W?[@B?X&?HT#[F^P;XVK<67^7)F\UE</^+?2_WXQ
MKNH2'/$?NY8KO0UW]T92\J9:QA/SXRN(067*!_/JIW_ZA]Y)]^T3<QWZN0Z?
MZOUE^_%D%[LG^*FHC3Y5__0/9_U>[ZW>&D9_SO4OJVRM>P.A>Z3KN=&7Q6(9
MYVM5%5FB8PC1;%::68R^BJD^.1M%W<% #SK=@>YUSO2[V_M_/>IUN_I^;LI%
M<5>;A;XIBUD9+S1-0-VB;9FD^4Q#I![QY]%'R"M]OJO1Z8(WYWZ>5NJOJ[BL
M38D)W9IE4=8:$DQBJ'O=H[_J-)]DJ\14.M;Y:C$V)4UG:KO,;)=5TV4]CVM2
M(:0+(#TYU T]8&J<OJT@:&5)[/% 0@\)K.=XNUKB;547>KJJ5Z711G@GSA,]
M3?,XGZ1QII>F9,V83TS'+VK'#&)TL"R+OXDRJK "-P)/O35"@>6L2O>E'TNU
MQKK.=54LC)Y )5617A<K_)GK-$$7Z73]%#7&:PW20ID463%;0Q]/YCJN-%&C
MWWV[B-<1_PDVL5]5\V*5)>Y;9;\U7VGZU>;+RRS.M[Z,,:E)NL04MAZ-399B
MX5O?FZI.%[L:@*F3-!C8S6<)#L,P<>;>!QWMHPD45)JO3/"$N#LG5H91H"W
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M.#B>')Q)  :Z ,2S:[3G[HTUW%AS1[]_<6]B6),T82>,H;Q/% DGSGR:<X!
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M4>00&Q>XJ\UN><Q;%B*$%\&DVU: 80JZB,LF-&:K?6$^?P/O<!X&FK@=M)$
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M:-RA>,R0OX0))6; 3H"1$_$$T-&%]3C1%,@N53GU @5/6(J":ZI69Q%0$E4
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MC?D60&D5S/Y*"/TTL0Z:KXO1OU!+ P04    " "W@ M7 ?XW!+X"   3!@
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M^X7H5@GO3^HNN.LN: >ZH*-;FA<+CKQ\2J8=^E"NMR3ZOAB.9DRTMS&YUJ3
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MTU* ..+.@QT_&",E94'I@YJ,EAW-4!D! 5<H"BR_MM #0A23S.//GE1+UU3
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M_\*2.T@R$32,C_$+*N2E(!YNY+T-F J0[U>4BN>)NAFD-T'G+U!+ P04
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M T4K+FA:",L5I'&V^2?/A2-V!"2G7L I!)Q] >\5 ;<0<(_5X!4"WK$:6H5
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MDT":S39? 38W@B[S8^X'*@1-\\L%D"DP-4$^GU$J7FZ4@O);3/\_4$L#!!0
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M[WI?+6B=!JUC19M)EMX@(D0)&:)J1YMB*XW5Z.5I5LR56;0W-%_"*/*;D7D
M$S4PD17F%!..-C@O ;$%VNJ]0=MGQNKS6I;HR31W?#_VO7:8;@/3M<)<5^FC
MW^=0S('_:<.P.KP6XXW,'L#&#6S\5LLP?K)R(C^,'^\I:[C_A.DU,+TW6H:]
MIS\(/_;"QS#6<*^%<?<.H@+XTIS/ J6LI+(ZDYK6Y@HP-">?^Z][=7\XQWQ)
MJ$ Y+)34.XS5K/#J3*XJDJW-L39G4AV2IKA2UQC@NH/ZOF!,[BHZ0',Q2OX"
M4$L#!!0    ( +> "U=ZKU9+G@(  'D&   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;*U574_;,!3]*U8V32!MY*LMC*612A+43@RJ?FR3ICVXR6UK
MX<3!=EOX][.=$!4:*A[VDOC:]QR?<QW?!#O&[\4:0*+'G!:B;ZVE+"]M6Z1K
MR+$X8R44:F7)>(ZE"OG*%B4'G!E03FW/<7IVCDEAA8&9&_,P8!M)20%CCL0F
MSS%_N@+*=GW+M9XG)F2UEGK"#H,2KV *<EZ.N8KLAB4C.12"L )Q6/:M@7L9
M=76^2?A)8"?VQD@[63!VKX-1UK<<+0@HI%(S8/7:0@24:B(EXZ'FM)HM-7!_
M_,Q^;;PK+PLL(&+T%\GDNF]=6"B#)=Y0.6&[(=1^C,"446&>:%?EGG^U4+H1
MDN4U6"G(25&]\6-=ASV VWD#X-4 [[T OP;XQFBES-B*L<1AP-D.<9VMV/3
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MC4);XS1M:Q:I_VE$Y;9,6092=?:<K5::]3?VET2YE<M&N?O-@F'S-(8!7=,
MDZ#,N&[S[Z.=-^R.AF34[+V:&R-?FE8D8,Y6B<PJ4K%:=+N.*?)OUKNJ"V9-
MZQ4F:Z%#PI<T$1#A0D$ZRD0+>-:6LHEDJ:GL,R95GS##4'5RY#I [2\8D[N)
M/J#X-O#_ %!+ P04    " "W@ M7E[S=5J4#  !?#P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6RUEVV/VC@0Q[^*E9ZJ5FK)(P'V(!++4G7OK@5U
MMZVJT[TPR0!1DSBU#6R__=E."&P2LI!MWT#L>/XSOTSLS QWA'YG:P".'N(H
M82-MS7EZI>O,7T.,68>DD(@[2T)CS,60KG264L"!,HHCW3(,5X]QF&C>4,W-
MJ3<D&QZ%"<PI8ILXQO3G-41D-]),;3_Q*5RMN9S0O6&*5W '_',ZIV*D%RI!
M&$/"0I(@"LN1-C:O)F97&J@57T+8L:-K)%$6A'R7@]M@I!DR(HC YU("B[\M
M3""*I)*(XT<NJA4^I>'Q]5[]G8(7, O,8$*BKV' UR.MKZ$ EG@3\4]D]QYR
M(!6@3R*F?M$N6]OM:<C?,$[BW%A$$(=)]H\?\@=Q9"!TZ@VLW, J&S@G#.S<
MP%:@660*ZP9S[ TIV2$J5PLU>:&>C;(6-&$BTWC'J;@;"CONW4W>3V\^_S-%
MLW?H[GXV^1O-YO>WLX]H/+F__7)[_PV]N@&.PXB]1F_1'TA';(TIL*'.A7>I
MH?NYI^O,DW7"DXL^D(2O&9HF 02/[741=1&ZM0_]VFH4_&N3=)!MO$&68=DU
M\4S.-[<:PK&+)VDK/?N$WO3')N0_T;_C!>-4O)W_U3VB3,*IEY!;]HJEV(>1
M)O8D [H%S7OYPG2-/^OX?I'8(UJGH'6:U+V/FW@!%)$E(JG<C^P-6L J3)(P
M68E]%>'$A[H'D*EVE:H\8K9>WW5<>S#4M\=HC<Y;HG4+M&XCVE>U]2% > M4
M'&4('H#Z(0.4TM"',T$S'[TCT&['Z)<P&P-IB>D6F.ZE&5Q1G/#RWLQPW$K>
M7&M@F+T24'69U34,HUCU*-)>$6GO>0EIB+M728/5&9BEJ!O=MTQ#OX#K7YH&
M>$A#6H_3J%4?*:H[.EKH/$D\*(@'STMG W^C\@7\+72>Y#>-PS?7.#/GLRSG
M2)0D2PA/O,.YVO&N>FNY/=<MO<;-7MM2'542YGEY'>=YG>[S.I=Y?8+1/.>\
M;(Z@+:%U(+0NWJM)(#X$M416)6NFX[K]@5&&:G3:%NI0MIB-=<(9V_$THEU)
MFM.I?!.:_;?E.Q0JYL652DZ(%U'MI]NL%BFFX9B&:Y7)?D>98A[J%/.9A<I3
MG-4:Q>E43Y5?6J3H1ZU*#'2E.CB&?+))>%;Z%[-%ESA6O5%I_EIVCZH%.LAD
MK><'3$5]QE $2R%I='H"@&;=7#;@)%4-T8)PT5ZIR[7H@('*!>+^DA"^'T@'
M14_M_0]02P,$%     @ MX +5\;I)&36 @  <@<  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S N>&ULG95M;]HP$,>_RBF3IDY:FQ >UT$DH$QEZP,BI7M1
M[85)CF UL9EMH/WVLYV0L38@L3?QX_WO=Q?[W-UR\2R7B I>LI3)GK-4:G7I
MNC):8D;D!5\ATRL++C*B]% DKEP))+$URE+7][R6FQ'*G*!KYR8BZ/*U2BG#
MB0"YSC(B7@>8\FW/J3F[B2E-ELI,N$%W11(,4<U6$Z%';JD2TPR9I)R!P$7/
MZ=<N!QVSWVYXI+B5>WTPD<PY?S:#<=QS/ .$*4;**!#=;'"(:6J$-,;O0M,I
M71K#_?Y._9N-7<<R)Q*'//U)8[7L.1T'8ER0=:JF?'N-13Q-HQ?Q5-HO;(N]
MG@/16BJ>%<::(*,L;\E+D8<] []VP, O#'S+G3NRE%=$D: K^!:$V:W53,>&
M:JTU'&7FIX1*Z%6J[500#J]'5[.;$=Q_@]G=XRA\&%W!5#?3\=!TPX?[X0^]
M,GX(X>P*%:&I_ 3G,$6I!(T4QA J'CW#C%$EX6P:SO3ZTRUF<Q2_NJ[2C,:3
M&Q4\@YS'/\#3@EO.U%+"B,48_VOOZMC* /U=@ /_J.#W-;N NO<9?,^O@UP2
M@?*(;+W,6]W*U@_ES0B=#_1YB&'(,WU')+''K"\$80GJ<ZM@_@K[^R;DU4[W
MMT3$\'2C)6&L,).5><K]-ZK]F[MZ*5<DPIZC+Z-$L4$G^/BAUO*^'HFN44;7
M.*8>W*W-[P.^*!(&^CI+15A,60)S3"ACNE=%G>LVK:XI")O ]VJ=MM=U-Q4\
MS9*G>1I/HI.LWIZ/G."H4G7>X$C*6B5BZS1$73 72 ] 'M4Z';)=0K9/@]SH
M:UQ-V'[W(\]K7L-KU*O_9*<DZ/S_R4+;5-%TWM%\:7?\]AL6=Z\.9B@26^TE
M1'S-5%X2R]GR0>GG=?3O]OPUNB5"GW()*2ZTJ7?1UKY%7N'S@>(K6U7G7.D:
M;;M+_2BB,!OT^H)SM1L8!^4S&_P!4$L#!!0    ( +> "U>Q &K\&P0  )05
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;,5886_B.!#]*U;N=.I*
MVR9VG  ]0 *2U?9NNT50;K5:W0<#!J(F,6>;LOWWYSAI2B#-M3U+_0*),_/&
M,V]XQ-/=,WXG-I1*\#.)4]&S-E)N+VU;+#8T(>*";6FJGJP83XA4MWQMBRVG
M9*F=DMA&CN/;"8E2J]_5:V/>[[*=C*.4CCD0NR0A_&%(8[;O6=!Z7)A$ZXW,
M%NQ^=TO6=$KE;#OFZLXN49910E,1L11PNNI9 W@90C=ST!9_170O#JY!ELJ<
ML;OLYFK9LYQL1S2F"YE!$/5U3T<TCC,DM8]_"E"KC)DY'EX_HG_2R:MDYD30
M$8N_14NYZ5EM"RSIBNQB.6'[S[1(R,OP%BP6^A/L<]M6QP*+G9 L*9S5#I(H
MS;_)SZ(0!PX*I]X!%0[HV $_X^ 6#NY+(^#" ;\T@E<XZ-3M/'==N(!(TN]R
MM@<\LU9HV86NOO96]8K2K%&FDJNGD?*3_>GH<QC,OH3@YA.8WMZ,_@2CF^MQ
M^'4ZN+VZ^0J&W\'@VV 2@-OOXQ"<!522*!8?P#F830-P]NN'KBW5+C(L>U%$
M'.81T3,177#-4KD1($R7=%GC'S3[^PW^MLJ^+ %Z+,$0-0+^L4LO@.M\!,A!
M;LU^1B]W1W7I_+_HX9NC5XKAEOW@:CSWN7[8$$[/A^JGMP0CEB@]$D3_H@><
MDW1-E49(,'\ AW9C\J"7!WO"E^#'%P4)KB1-Q-]UW9''Q_7Q,UV\%%NRH#U+
M"9^@_)Y:_=]^@;[S>QTU)L$"DV"A(; *B;@D$3>A]Z>2+>[.YYJ<Q2&))&.H
MCI0<S]=XV7_+?1_BMN?[G:Y]?UCO4SL7.AAZ3M4N.+7#;83;N%6U"T_M?-QV
M'(Q*NTH!O+( 7G,!ZKKSJ8$_@INMKL>/:YK,*:_MT\8(K^U3DV"!2;#0$%B%
M)K^DR7]GL?%-DF@2+# )%AH"JY#8*DEL&1:;',\[%!$$/1<?:<VI&6S['NH<
M:4AP:H<\"#L^.M*:4SN<*0WVZ[6F7>;?;LQ_0H7DT4*J]'4IP"R-I !GD^E,
MO2@U*4PC[FN;TR188!(L- 16(:=3DM-Y9X7IF"31)%A@$BPT!%8A$3I/AQ3'
ML,84@!7U@#Z&KG>D,K6&'<?%1Z\^08TA<B%JMX\0PUI##^,6KA<:>'!6@__]
M6B/ E1 [58@5XV"J2ATMU%J3SC2COK9'C:(%1M%"4VA5?M 3/^B=U:;8@"DJ
M3:(%1M%"4VA5*I^.P;#Q@/86Q7G#B0_4LN+6')X\!Q_KD:%X84T\B*"+CL]@
M]L&4*:%\K<=[0E5GE\I\P%"NEB/$@1Z<':T/X>4(UJP'V<A13[6>X/-YY37A
MZR@5(*8K%<JY:"EQY?D(,+^1;*MG7',F)4OTY8:2)>69@7J^8DP^WF0!RD%L
M_U]02P,$%     @ MX +5W-Y?K1-"   @58  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&ULM9Q;;^.V%H7?^RL(]Z!H@9Q8%U^GB8'$HL1IYW8FG5,<
M'/1!L6E;&$ET*=J9*?KC*\F*9"8R8Q6K+[%UV=^FI&5IDTOAU8.0G[,-YXI\
M2>(TN^YME-J^ZO>SQ88G878IMCS-MZR$3$*5+\IU/]M*'B[+H"3N.Y8UZB=A
ME/9F5^6Z#W)V)78JCE+^09)LER2A_'K+8_%PW;-[CRL^1NN-*E;T9U?;<,WO
MN/JT_2#SI7Y-648)3[-(I$3RU77OQG[%W&$14.[QWX@_9$??27$H]T)\+A9>
M+Z][5M$B'O.%*A!A_K'G<Q['!2EOQ^\5M%?G+ */OS_2_?+@\X.Y#S,^%_&O
MT5)MKGN3'EGR5;B+U4?QP'AU0&4#%R+.RK_DX;#OV.V1Q2Y3(JF"\Q8D47KX
M#+]4)^(HP!Z<"'"J .?< +<*<,\-&%0!@R<!$^M$P+ *&)Z;850%C,X-&%<!
MXW,#)E7 I+RZA\M17DLO5.'L2HH'(HN]<UKQI11$&9U?PB@MM'NG9+XURN/4
M[.Z7]_.?V?LW'OUX]]VW$\<>_TCH?SZ]_N5_Y'N/JS"*,_(NE#(L)/8#^3?Y
M=.>1[__UPU5?Y=D+1G]19:*'3,Z)3"/R5J1JDQ&:+OE2C^_GK:Z;[CPV_=8Q
M F^V\I)8@POB6([;TIZY.?S]0ET29UB&.RWAGCG\CF_S[).3X=0<_M,NO22N
M=;+Q_OGA;=D#<[C'%WFX?3*<F</?B7U][+;A2KJU"-V2YY[@S>,PRXA8D3LE
M%I_)_]_DV\EKQ9/LMY;&W1Y@@W98<;-_E6W#!;_NY7?SC,L][\V^^]8>63^V
MB00)\Y PBH3Y2%B A#$03!/>H!;>P$2??<@?E%Q*OB19H;P+L@TEV8?QCK?I
MSLCJJCLDS$/"Z $V+F%%Z;.?69=6_C/?'^L)F3$X)R,#9=1T,JQU,C3JY-TN
MN>>RN$.);5%R91=D+<-4/7V.'71B9'75"1+F(6'T !L>7;61,[7L\1.E/-_-
M&5J6I>\5(%O&0#!-*J-:*B.C5()"%V09*DY6853=38Z48Q*.D=Q5.$B8AX31
M VQTI A[/'BN";]E/\>QGPHL0+:-@6":=,:U=,9&Z7Q*)5^(=1K]D3^0^)>\
M>YJU/H>,E*XR0<(\)(R.6RZ_94_&PR<R028-D# &@FEBFM1BFAC%]&O9:\^%
M%.ZY#-><2%X,943IFH2)D"KZ(RP'#[9<1J+U;F3D=Y49$N8A8=1\&FWRE><U
MH3W(;^E?L[;*&MF8  EC()@FOVDMOZGQO-WELN(9N2%-B5UU[M[RHI9J[=@9
MD5T5AX1Y2!A%PGPD+$#"& BFR<^VFG$M"SFF4-% VH/2/"B-0FD^E!9 :0Q%
MTQ5X-+)J=QM<R#9AGH=$6;9KK__-P,XB1-(\*(U":3Z4%D!IK*(=]W_MX<"U
MAY.ZC-7UY33Z<H"#5V989VTA:1Z41J$T'TH+H#16T4X.G.G":D;C;>.8ZW-A
MQ='ONVA9]1?*C3Q=M*L,.C8/I7E0&H72?"@M@-)81;-M768G==8,OMN=1M_)
M7JBB>RJ+CFM;5^O6S.NL+N@0_ O'.KB<3EMEA&R$#Z4%4!I#T72Q-2/XMGD(
MO^J0WG;JD)J9G04''<N'TBB4YD-I 93&4#1=AXT]8(^@_5*H)P"E>5 :A=)\
M*"V TAB*IBNP<1ELL\WP-_JE4,<!2O,JFJE_5>D+F=:'T@(HC:%HNKX:X\$V
M#YEW+^N@3@.4YKUPK--391VR$3Z4%D!I#$73Q=;8#+;99S@AMBV7"YZJ<-W>
M2X4:#5":!Z71BC;5NV[30K2:APK-&D!I#$737S)MC 3'.$S\3&$+D>ZY+-_=
M5EPF;?HR$[OJ"TKSH#3ZPKFCX6)S*"_*BO>Q"Y:OB6-RSZMSJ:+[F%^04)$P
M_4I4E/#\RY*LI$@.2TJ4G^4N:L.K5VD*9+%48S<B7G)Y0:)4B6]$7E;7F><B
M2?* LN1NN\%"3TH I3$439=_XV(X9A?CQ7XS^9/<\I2OHD44QN3]0YK_.#;1
MUMBO-N?L_ .!&AU0&H72?"@M@-(8BJ;KM'%#' ?9KW:@=@B4YD%I%$KSH;0
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M2VFPRW/#'!MQ4-8 ]U=2FL/$'M"T]M,?4$L#!!0    ( +> "U=)N\]][@,
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M'>';)!<HI1N%= 8C=;7P:CZBVI!L7[YP7S$I65:N[BA94ZX/4+]O&)//&SI
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M^F!Y_)S$7OZ1)DD4Q3$VH^.QU\$8F[<XAA^_&N8-&%@>R/1G<XVO-EXA^^L
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "W@ M7W6QQ7*<#  "+&
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MZ=QLDED01U^"-%K%+\@B^@ @7R&0K^Q"7@4L8AWC.J&,QFG/1X)X2EBV7 8
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M<F]P<R]A<' N>&UL4$L! A0#%     @ MX +5^0]D/CM    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ MX +
M5YE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " "W@ M7VV+NT_8%  #%'P  &
M@($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ MX +
M5Z\1*9S7!0  /1<  !@              ("!. X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( +> "U=C28JS% ,  &0+   8
M      " @444  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" "W@ M7-J"289\%  #Z&0  &               @(&/%P  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ MX +5^L>3^0E"@  P50  !@
M             ("!9!T  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( +> "U?GKM7*[ 4  $(8   8              " @;\G  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "W@ M7K?4%3@T'  !B
M$   &               @('A+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ MX +5V"D=C0<#0  42(  !@              ("!)#4
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( +> "U?9)0#3
MS04  %0-   8              " @79"  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " "W@ M7]0=Y8K\"   V!@  &0
M@(%Y2   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( +>
M"U<7K,24\@H  "D;   9              " @6]+  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ MX +5[#6Z/@)!0  &@L  !D
M         ("!F%8  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " "W@ M7>; ;1X(D  # ;P  &0              @('86P  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +> "U<D709]I@T  $8F
M   9              " @9&   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ MX +5QD./$J)!   00H  !D              ("!;HX
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "W@ M7E!S?
MA5,#  !I"   &0              @($NDP  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( +> "U<!_C<$O@(  !,&   9
M  " @;B6  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MMX +5QM75AX-!0  = P  !D              ("!K9D  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " "W@ M7WYM9A!($   *"@  &0
M            @('QG@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( +> "U=G%7B=U 4  +,O   9              " @3JC  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ MX +5Z"/L^$: P
M%0X  !D              ("!1:D  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " "W@ M7$Y?2!ET$  "7&0  &0              @(&6
MK   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( +> "U?!
M*8/,- (  $<$   9              " @2JQ  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ MX +5\[-ZNOC P  ^A$  !D
M     ("!E;,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +> "U>7O-U6I0,  %\/   9              "
M@6#$  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ MX +
M5\;I)&36 @  <@<  !D              ("!/,@  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " "W@ M7L0!J_!L$  "4%0  &0
M        @(%)RP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( +> "U=S>7ZT30@  (%6   9              " @9O/  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ MX +5]H]+:JJ P  N0P
M !D              ("!']@  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " "W@ M7//?G+J("  !0!@  &0              @($ W
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( +> "U?ODR&Z
MG0,  .8+   9              " @=G>  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ MX +5TF[SWWN P  (1H  !D
M ("!K>(  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "W
M@ M7U^Q4YS(#  !.$P  #0              @ '2Y@  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( +> "U>7BKL<P    !,"   +              "  2_J
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +> "U?=;'%<IP,  (L8   /
M          "  1CK  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "W@ M7
MUOKYL7@!   #%@  &@              @ 'L[@  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "W@ M7ZXBZY94!  ""%@  $P
M        @ &<\   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +  L .L+
(  !B\@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>129</ContextCount>
  <ElementCount>184</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness</Role>
      <ShortName>NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IntangibleAssets</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/StockholdersEquity</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biorestorative.com/role/Leases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative</Role>
      <ShortName>NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/IntangibleAssetsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails</Role>
      <ShortName>SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails</Role>
      <ShortName>SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/StockholdersEquityTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails</Role>
      <ShortName>SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/LeasesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://biorestorative.com/role/SubsequentEvents</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>brtx-20230630.xsd</File>
    <File>brtx-20230630_cal.xml</File>
    <File>brtx-20230630_def.xml</File>
    <File>brtx-20230630_lab.xml</File>
    <File>brtx-20230630_pre.xml</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="489">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>54
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 489,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "contextCount": 129,
   "dts": {
    "calculationLink": {
     "local": [
      "brtx-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "brtx-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "brtx-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brtx-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "brtx-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 301,
   "entityCount": 1,
   "hidden": {
    "http://biorestorative.com/20230630": 7,
    "http://fasb.org/us-gaap/2023": 84,
    "http://xbrl.sec.gov/dei/2023": 4,
    "total": 95
   },
   "keyCustom": 6,
   "keyStandard": 178,
   "memberCustom": 10,
   "memberStandard": 17,
   "nsprefix": "BRTX",
   "nsuri": "http://biorestorative.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://biorestorative.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://biorestorative.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://biorestorative.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://biorestorative.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "14",
     "role": "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://biorestorative.com/role/IntangibleAssetsTables",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://biorestorative.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://biorestorative.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://biorestorative.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
     "shortName": "NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-07-122023-07-13_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails",
     "shortName": "SCHEDULE OF FAIR VALUE RECURRING BASIS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails",
     "shortName": "SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFDICInsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_custom_PatentsAndTrademarkMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-11-012022-11-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - INTANGIBLE ASSETS (Details Narrative)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
     "shortName": "INTANGIBLE ASSETS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-11-012022-11-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails",
     "shortName": "SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember37476515",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://biorestorative.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
     "shortName": "SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
     "shortName": "SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "0",
      "lang": null,
      "name": "BRTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails",
     "shortName": "SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails",
     "shortName": "SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - LEASES (Details Narrative)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://biorestorative.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://biorestorative.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-07-122023-07-13_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://biorestorative.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://biorestorative.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness",
     "shortName": "NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - INTANGIBLE ASSETS",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://biorestorative.com/role/IntangibleAssets",
     "shortName": "INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 31,
   "tag": {
    "BRTX_AccruedGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued general and administrative expenses.",
        "label": "Accrued general and administrative expenses"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpenses",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_AccumulatedAmortizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Amortization [Member]",
        "label": "Accumulated Amortization [Member]"
       }
      }
     },
     "localname": "AccumulatedAmortizationMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_AuctusFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auctus Fund LLC [Member]",
        "label": "Auctus Fund LLC [Member]"
       }
      }
     },
     "localname": "AuctusFundLLCMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_BeneficialOwnershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Ownership [Member]",
        "label": "Beneficial Ownership [Member]"
       }
      }
     },
     "localname": "BeneficialOwnershipMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "terseLabel": "Schedule Of Future Minimum Payments Under Non-cancelable Leases For Operating Leases",
        "verboseLabel": "Schedule Of Net Lease Cost And Other Supplemental Lease Information"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://biorestorative.com/20230630",
     "xbrltype": "stringItemType"
    },
    "BRTX_GainOnPppLoanForgiveness": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on PPP loan forgiveness.",
        "label": "GainOnPppLoanForgiveness",
        "negatedLabel": "Gain on PPP loan forgiveness"
       }
      }
     },
     "localname": "GainOnPppLoanForgiveness",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_GrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Income.",
        "label": "GrantIncome",
        "negatedLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncome",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_JonesTradingInstitutionalServicesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jones Trading Institutional Services L L C [Member]"
       }
      }
     },
     "localname": "JonesTradingInstitutionalServicesLLCMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_LicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License [Member]",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicensesMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_MelvilleLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melville Lease [Member]",
        "label": "Melville Lease [Member]"
       }
      }
     },
     "localname": "MelvilleLeaseMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense.",
        "label": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_OperatingLeaseLiabilityReduction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability reduction.",
        "label": "Operating lease \u2013 operating cash flows (liability reduction)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityReduction",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_PatentsAndTrademarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents and Trademark [Member]",
        "label": "Patents and Trademark [Member]"
       }
      }
     },
     "localname": "PatentsAndTrademarkMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents and Trademarks [Member]",
        "label": "Patents and Trademarks [Member]"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "BRTX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments options grants in period grant date fair value.",
        "label": "Grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "BRTX_SharesIssuedForServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued for Services [Member]",
        "label": "Shares Issued for Services [Member]"
       }
      }
     },
     "localname": "SharesIssuedForServicesMember",
     "nsuri": "http://biorestorative.com/20230630",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r450",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r154",
      "r155",
      "r156"
     ],
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r205",
      "r284",
      "r298",
      "r327",
      "r328",
      "r379",
      "r382",
      "r386",
      "r387",
      "r389",
      "r408",
      "r409",
      "r416",
      "r419",
      "r424",
      "r427",
      "r476",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r205",
      "r284",
      "r298",
      "r327",
      "r328",
      "r379",
      "r382",
      "r386",
      "r387",
      "r389",
      "r408",
      "r409",
      "r416",
      "r419",
      "r424",
      "r427",
      "r476",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Line Items]"
       }
      }
     },
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Table]"
       }
      }
     },
     "localname": "PlatformOperatorCryptoAssetTable",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r198",
      "r205",
      "r230",
      "r231",
      "r232",
      "r283",
      "r284",
      "r298",
      "r327",
      "r328",
      "r379",
      "r382",
      "r386",
      "r387",
      "r389",
      "r408",
      "r409",
      "r416",
      "r419",
      "r424",
      "r427",
      "r430",
      "r473",
      "r476",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r198",
      "r205",
      "r230",
      "r231",
      "r232",
      "r283",
      "r284",
      "r298",
      "r327",
      "r328",
      "r379",
      "r382",
      "r386",
      "r387",
      "r389",
      "r408",
      "r409",
      "r416",
      "r419",
      "r424",
      "r427",
      "r430",
      "r473",
      "r476",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r149",
      "r150",
      "r324",
      "r325",
      "r326",
      "r381",
      "r384",
      "r388",
      "r391",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r420",
      "r430",
      "r479",
      "r496"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r149",
      "r150",
      "r324",
      "r325",
      "r326",
      "r381",
      "r384",
      "r388",
      "r391",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r420",
      "r430",
      "r479",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r13",
      "r426"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r55",
      "r426",
      "r498"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r312",
      "r468",
      "r469",
      "r470",
      "r482",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r234",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock-based compensation award"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r4",
      "r29",
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization expense",
        "negatedLabel": "Finite Lived Intangible Assets, Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r79",
      "r95",
      "r109",
      "r136",
      "r142",
      "r146",
      "r157",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r243",
      "r245",
      "r258",
      "r290",
      "r348",
      "r426",
      "r438",
      "r474",
      "r475",
      "r486"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r91",
      "r99",
      "r109",
      "r157",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r243",
      "r245",
      "r258",
      "r426",
      "r474",
      "r475",
      "r486"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Marketable securities fair value disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r18",
      "r93",
      "r411"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r18",
      "r66",
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "periodStartLabel": "Cash and cash equivalents - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r66"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "FDIC insured limit"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r88",
      "r96",
      "r97",
      "r98",
      "r109",
      "r125",
      "r126",
      "r128",
      "r130",
      "r134",
      "r135",
      "r157",
      "r169",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r180",
      "r181",
      "r184",
      "r187",
      "r194",
      "r258",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r336",
      "r357",
      "r374",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r459",
      "r466",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r134",
      "r180",
      "r181",
      "r182",
      "r184",
      "r187",
      "r192",
      "r194",
      "r307",
      "r308",
      "r309",
      "r310",
      "r419",
      "r459",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r468",
      "r469",
      "r482",
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r54",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r54",
      "r336",
      "r354",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r54",
      "r292",
      "r426"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, $0.0001 par value; Authorized, 75,000,000 shares; 3,982,608 and 3,677,775 issued and outstanding at June 30, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r50",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Number of shares converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Number of shares issued in conversion"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r180",
      "r181",
      "r184",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r12",
      "r37",
      "r40",
      "r53",
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Preferred stock conversion term"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r4",
      "r139"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r6",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r105",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r123",
      "r125",
      "r128",
      "r129",
      "r130",
      "r132",
      "r255",
      "r256",
      "r288",
      "r297",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net Loss Per Share - Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r105",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r125",
      "r128",
      "r129",
      "r130",
      "r132",
      "r255",
      "r256",
      "r288",
      "r297",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net Loss Per Share - Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r49",
      "r495"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accrued payroll"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r8",
      "r89",
      "r102",
      "r103",
      "r104",
      "r110",
      "r111",
      "r112",
      "r114",
      "r120",
      "r122",
      "r133",
      "r158",
      "r159",
      "r195",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r276",
      "r299",
      "r300",
      "r301",
      "r312",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r48",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "SCHEDULE OF FAIR VALUE RECURRING BASIS"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r178",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r257",
      "r280",
      "r281",
      "r282",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r178",
      "r199",
      "r204",
      "r257",
      "r280",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r178",
      "r199",
      "r204",
      "r257",
      "r281",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r178",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r257",
      "r282",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r178",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r280",
      "r281",
      "r282",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFairValueRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r7",
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r94",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedPeriodEndLabel": "Finite Lived Intangible Assets, Accumulated amortization, ending balance",
        "negatedPeriodStartLabel": "Finite Lived Intangible Assets, Accumulated amortization, beginning balance",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r71",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "periodEndLabel": "Finite Lived Intangible Assets, ending balance",
        "periodStartLabel": "Finite Lived Intangible Assets, gross, beginning balance"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r30",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r71",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite Lived Intangible Assets, Net, ending balance",
        "periodStartLabel": "Finite Lived Intangible Assets, Net, beginning balance"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Assets, weighted average amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62",
      "r359"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r460",
      "r465"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid assets and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r28",
      "r31"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "negatedLabel": "Interest (income) expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r270",
      "r425"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Amount representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessor's operating lease.",
        "label": "Lease extension description"
       }
      }
     },
     "localname": "LessorOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r109",
      "r157",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r244",
      "r245",
      "r246",
      "r258",
      "r335",
      "r414",
      "r438",
      "r474",
      "r486",
      "r487"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r59",
      "r80",
      "r294",
      "r426",
      "r467",
      "r472",
      "r483"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r92",
      "r109",
      "r157",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r244",
      "r245",
      "r246",
      "r258",
      "r426",
      "r474",
      "r486",
      "r487"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member] [Default Label]",
        "verboseLabel": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Investments held in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized gain on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash flows from operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r60",
      "r68",
      "r81",
      "r90",
      "r100",
      "r101",
      "r104",
      "r109",
      "r113",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r127",
      "r136",
      "r141",
      "r145",
      "r147",
      "r157",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r256",
      "r258",
      "r296",
      "r356",
      "r372",
      "r373",
      "r415",
      "r436",
      "r474"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other (income) expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (income) expense:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r136",
      "r141",
      "r145",
      "r147",
      "r415"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r271",
      "r425"
     ],
     "calculation": {
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost (cost resulting from lease payments)"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of net future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfFutureMinimumPaymentsUnderNon-cancelableLeasesForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease liability, current portion",
        "verboseLabel": "Current liabilities - operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease liability, net of current portion",
        "verboseLabel": "Non-current liabilities - operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r269",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating lease \u2013 operating cash flows (fixed payments)"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use asset",
        "verboseLabel": "Non-current leases - right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/ScheduleOfNetLeaseCostAndOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r273",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r52",
      "r77",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payment to acquire intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r181",
      "r380",
      "r383",
      "r385",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred stock voting percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r37",
      "r38",
      "r53",
      "r466",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred stock, liquidation preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [
      "r428",
      "r429",
      "r432",
      "r433",
      "r434",
      "r435",
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r53",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r53",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r53",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r53",
      "r336",
      "r354",
      "r499",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r53",
      "r291",
      "r426"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, value"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockVotingRights": {
     "auth_ref": [
      "r37",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Preferred stock voting rights"
       }
      }
     },
     "localname": "PreferredStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r1"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Net proceeds from issuance of common stock in at-the-market offering",
        "terseLabel": "Procceds fom offering",
        "verboseLabel": "Net proceeds offering price"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r289",
      "r295",
      "r426"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r51",
      "r240",
      "r494"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r56",
      "r75",
      "r293",
      "r302",
      "r303",
      "r311",
      "r337",
      "r426"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r89",
      "r110",
      "r111",
      "r112",
      "r114",
      "r120",
      "r122",
      "r158",
      "r159",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r247",
      "r249",
      "r250",
      "r252",
      "r254",
      "r299",
      "r301",
      "r312",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r137",
      "r138",
      "r140",
      "r143",
      "r144",
      "r148",
      "r149",
      "r151",
      "r196",
      "r197",
      "r285"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of aggregate shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Offering price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r30",
      "r32",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsAmortizationExpensesDetails",
      "http://biorestorative.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r30",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "SCHEDULE OF INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r9",
      "r10",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF STOCK OPTIONS GRANTED ASSUMPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r73",
      "r74",
      "r75",
      "r96",
      "r97",
      "r98",
      "r134",
      "r180",
      "r181",
      "r182",
      "r184",
      "r187",
      "r192",
      "r194",
      "r307",
      "r308",
      "r309",
      "r310",
      "r419",
      "r459",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r462",
      "r463",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r462",
      "r463",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://biorestorative.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Number of shares forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares outstanding ending",
        "periodStartLabel": "Number of shares outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of options, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted average exercise price, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of options, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, ending",
        "periodStartLabel": "Number of options, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending",
        "periodStartLabel": "Weighted average exercise price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockCompensationByAwardTypeDetails",
      "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails",
      "http://biorestorative.com/role/ScheduleOfUnvestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price, expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Offering price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/ScheduleOfStockOptionsGrantedAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r88",
      "r96",
      "r97",
      "r98",
      "r109",
      "r125",
      "r126",
      "r128",
      "r130",
      "r134",
      "r135",
      "r157",
      "r169",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r180",
      "r181",
      "r184",
      "r187",
      "r194",
      "r258",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r336",
      "r357",
      "r374",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r459",
      "r466",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r8",
      "r17",
      "r89",
      "r102",
      "r103",
      "r104",
      "r110",
      "r111",
      "r112",
      "r114",
      "r120",
      "r122",
      "r133",
      "r158",
      "r159",
      "r195",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r276",
      "r299",
      "r300",
      "r301",
      "r312",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r133",
      "r285",
      "r306",
      "r323",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r133",
      "r285",
      "r306",
      "r323",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/BalanceSheetsParenthetical",
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/LeasesDetailsNarrative",
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r41",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "- options"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r8",
      "r37",
      "r53",
      "r54",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Conversion of Series B preferred to common stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r53",
      "r54",
      "r75",
      "r307",
      "r374",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock, shares",
        "terseLabel": "Number of shares issued",
        "verboseLabel": "Stock issued new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r8",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "restricted stock units, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r53",
      "r54",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "- common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r8",
      "r17",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Conversion of Series B preferred to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r8",
      "r53",
      "r54",
      "r75",
      "r312",
      "r374",
      "r393",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock",
        "verboseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r8",
      "r53",
      "r54",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "- restricted share units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r45",
      "r53",
      "r54",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "- common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r70",
      "r338",
      "r354",
      "r375",
      "r376",
      "r426",
      "r438",
      "r467",
      "r472",
      "r483",
      "r499"
     ],
     "calculation": {
      "http://biorestorative.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets",
      "http://biorestorative.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r108",
      "r179",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r195",
      "r253",
      "r377",
      "r378",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [
      "r265",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r265",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r265",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r265",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r265",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/NatureOfOrganizationLiquidityAndBusinessDetailsNarrative",
      "http://biorestorative.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r277",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationRelatedText": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional textual information about cash receipts or disbursements in the period required to be supplementally disclosed.",
        "label": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationRelatedText",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r83",
      "r84",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r428",
      "r429",
      "r432",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/IntangibleAssetsDetailsNarrative",
      "http://biorestorative.com/role/ScheduleOfWeightedAverageDilutiveCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r124",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Common Shares Outstanding - Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r123",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Common Shares Outstanding - Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://biorestorative.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350-30/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r441": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r442": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r443": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r444": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r445": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r446": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r447": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r448": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r449": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r451": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r452": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r453": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r454": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r455": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r456": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r457": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r458": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001493152-23-027825-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-027825-xbrl.zip
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M=!3]NBZZ4_+YUG/6SS@[6HNS:1G]:@6;"NG"[X[B']-%;4K3*:%]^[,?:3*
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M;5A*Q$OB)FD:6Y.W21X.MHH_E3!8"K41:K(HSV=)]2PQJ78G7P>'.$G3[)%
M;?.F)0:*,6)L4J[DXHC)VR?)*/2T*%+)V2%("Z:8'H400'(TD751@TC;),:5
MG[A.D&.Y(K^)[@50R)HFB!1NFR2<("BBR-!)R9(KE)QA*E8)\RMV8CVZU"3M
MD(6#*J9*)0:0*&UL732A\E9(,LSBN(%:/N/(18U]E.T 6WV?E<B!($H'..ZK
M;2[>((JE&6C$;D6AE\M/,T%8AEC$%#=DX$I.M)^#X(($%'<S8WX=#95#N:"5
MEB^_$H0I/7HD-:<M9I8!8I!-%C1E #%!"$S"AITL.PEFA1%#,C+%3C ./?ST
M-_PLM8N3,\L)"<PF*5I"@%@A1B:A12&,F#0BXE:(,8_]C1,_+WVW8ZK@!<U2
M0P:TR8VV%"!R2*!)V%%(H^5X:',FN7&>QAXAJK_V7?;1N8,E4GFS9.F W>2,
M1!@0==0()0PB2JBI99-(X]"-XFU4"W<81AD9 )^'D2?W4#JTS))*RX0FM90J
M@ BF@U-"LX;J61Z3@F@"Q+P 1$NPPKB!YY&*2HK_3/P0OY?:+Y0URRX%W":G
M!(* F"1')^%/(7E6_@%1'30+H9#F0P]3/]@GS0==TGP 39H/^Y#FYC$"0IJ/
M/4S]:)\T'W5)\Q$T:3[N11K2\%;'FB'YXRR^B1Y%P=E222N4X:$*";,3@T<7
M#EL76:@"]6>HBDV:,,=J%L_CZ,$/7;G++!.W0A@):"%K6K+PJ",&V,6?RB$N
M]:R.-;E3WME)2C$[HTP3I'B(R67@D:0)K'-PR:5M4F(>):D3_+>_52[$Q<)6
MZ"$$+"1)0Q(>543PN@B3ZR"B9&-A7="5?M 0'B5K/3=W!%@ :W<$N/80! E$
MB/@CP/GN22YDNIDI1V/L2$:$YF-CC2P 5;5Q[1F,)N8!<2W,^C61L=&1)Q&-
MD;J/0GF  "]BJJ5EX,K6;C\'T>(24%S2[HC%FE$Y2[OQ3RD.$_'P77MF;&9O
MPZDF\O(!B-9MH^&FZ?*YX=;\)?93\N9AM-ED8?&51Q0W*)$SU<I*F&6+"X5
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M=X9RS7.FBO[)E(^4865_DDW\$(]3O&F?&M=7 T VS@@-PE4ZT$G7!MJ;>+0
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MPGG2$TO1IT=Q_<S&FN;#RBA4MJ,VYKYMB4-/<T!YC?Z/E0CQ^0L;O,N8PWE
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M!ZA"ZO(-!GZ6$ H8/BFNC 44XNK:/T'_O,1K)PM2Q#['V8I18%DD$D7>A88
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M?UMKX%U9M@Y$%PFU;J*!^UOFTR/<= V6/L^)02GA//U L-UTI GKU@;4V?<
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M%$_\!SJAI:0Z:!Z4?,.'0!;O>'?I "*6-M0V&7+%<Z:)=JJH# 1FVO#:3'(
MO&<K2DKY\L=3:-<N\'U;6G8^'E[C2V)ZU!JGT5GK0/LVH/D@GRH(7KJCU['/
MJ:4(R''MAU=V7%Z\-6E_0W+O0UW%&:[:U^T\-Z7T@_XA7P*H8Q_/-F% P3DK
M!]7?A0;-<V]UN>*%B+WQ#!7O; 0ED$&$O??T"=C*U3UZPK'K)QW9/X__ZM=)
M5BV+C5&XRK9>P$$E'C2WF![UI=4]>MKZQ1*J/"5[#!X+7@-H_CVF=<?D9^V]
M+ 2!O?E$B7@5Q6OLT_NACDI$P6M>$1%5UAV3B+7WGBX1^1P"U(&^N7?"PLYI
MQ#XC8>\(;FC?E[^&&7]OFX] Y1P+JH$IUD\I@;,C>H7H5%W:SCK_S,P[RA#<
M\]VO85S>UV1[#,\!61_%64*A891(KFTM'@*B"(])>.?8&:(RUBK5ZKVYD!KK
M)?CYAJ6EG=6C /.FKHJD$?Z[0E%>*LJ+M3F#Z-Q: J?5!*#$B9MD"_+Z3Q/R
M)_)S^1/Y%TWC1'[Y_U!+ P04    " "W@ M72A(H-X@M  "V\@( %0   &)R
M='@M,C R,S V,S!?<')E+GAM;.U]:W/;.);V][?J_0_:3-74;-4ZB9WI2[JG
MWRU9DAWMR))&EV2R7[IH$I8YH4@U2-K6_/H7("F)(HD;+SJ@HZG==&(#(,[S
M'%S. <[!W_[[9>UTGA#V;<_][<WEV_=O.L@U/<MV5[^]6<XONO/></BFXP>&
M:QF.YZ+?WKC>F__^?__W_W3(__[V'Q<7G1L;.=8OG;YG7@S=!^_7SMA8HU\Z
MM\A%V @\_&OGL^&$]"?>C>T@W.EYZXV# D1^$7_XE\X/;R\_WG<N+B3:_8Q<
MR\/+V7#?[F,0;/Q?WKU[?GY^ZWI/QK.'O_EO36\MU^ \,(+0W[?V_N5]\K^X
M^M\<V_WV"_WCWO!1A^#E^K^\^/9O;^AWD\\^?WCKX=6[J_?O+]_]\VXT-Q_1
MVKBP78J;B=[L:M%6BNI=?OSX\5WTVUW17,F7>^SLOO'AW:X[^Y;);VU.^51/
M?/L7/^K>R#.-(*)=^)D.LP3]U\6NV 7]T<7EU<6'R[<OOO5F!WZ$(/8<-$,/
M'?I?PM[^J_>VAY%/](1TY@E1VM[1(N]Z'E%+TM^H\B-&#[^]N<?!"_G&U8?W
M/WYX3[_PIZ-"P79#U-.WJ7:]Z;RK]/5KPZ%XS1\1"GQ1+PH+-]:;J8&1&SRB
MP#8-1ZEKA37K["<=2FA-ON%/'B8;.OR)?@GAX]=JJG^]1\-=(7_HS@//_/;H
M.1:9C 9_A':P5>FP1#.-26#XCS>.]ZP$<*Y2G;T;DYD4(\(B7AFN_>^(R)%-
MP+ ('%W7N@Y]VT6^L,.J[=0[UGR;X#0EOR2(19\F7YR'Z[6!MY.'N;UR[0<R
M@-R@:YI>Z 9DJ9QZCFW:2&*BJ-YVG;(.22?<E7WOH*[O2TQTK/)U]HE(CD-D
M#5XVR/613_"9D"D+]T),)Z^1;=S;CAU(@*W<4+WC5'U2.<7\,4)DG19"=URJ
M5ES">Q_]$1("!D]T0A*BPBBORX@_Q<AO<@:HTJ^%02:"1B4__D*3,Y^<+/Q:
M(+.@7,=+-M?LC"C7=5&]^F='N7X5E8782_518-B./S9PW$)=>RM6N[7J!#%$
MK= AO;DQ;!P9X#-D$J4D<T T;R2=$.J(8CO-R/ %V:O' %E=8I,:*]2WG9 6
M[7GKM>?.'XGQI2Z/>INZK ZJ>MG$MYKA.;L**),J:. TO>ZN/1PDXW^W+E26
M1*+1)E=Q59V3K=\,(]*+LC(M95MN1LYH!9]L(J_.+28#F$QGOA^NXY\H"Z?4
M7.,2=4U2B*R<5<1@M-%,WY?N$RF K!GY$]LF^5O4DZ5KEYC)%!IKD EZH$ 4
M/9IUKK?=9P-;"_*U<I3(-=;LSEAU'I-OH1D6QBB(ML,]SP]VD\T\W)!O4*^C
MX42_I&<N>!WAJLQ,Q0\TM&<-Z4[ZSG;M=;B>&MO(P[IT"0ECS[TPJ=_=H>9!
M;"G<>#AQ;KNK^"?JF]MZ/UB_Y:2JM_Q:3?J=E$>89'U>GS>IK>V(_."H"GH)
M$&'2VC5$>ZUV1A;8 :V2'%Y>=B[H26=(=83\-2Z9=&?7(<<SC_K@T!-!+W/H
MMCM=C<[]?&2^77E/[RQDOZ/XT+]$0$4@D7_\'GVH>T^6 \,,=BT1K41.U/[O
MI$RFR+L3]&J'!)W)BSMU7"+;IS1U76QV/$P&'<%ZUY:!S2/"\@>E28EWF^@,
M[L)\M)T]UP_86[/029#P&!U- T4^<1HTN^3[%NW#C6.LBN',%)'$\Q("T$)I
MH!#M(]_$=K0K% ![5%(2WRM0? MD.S',N[$S0RN;]I=V97\XRI\7&%4D@?\
M.5-PI05BH.NZH>',T,;# N"/2TKB_5=(O(MD X+Y'Z&! X2=K0S2N<*28/\
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MIX[?BT)^4@'H-^0OQ; SBLH"#A,BR1/OU%"'EDU3?D1=NK%=PS6)275(<<I
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M@RDQ.!>,O#TB7@35H&_YE.%("@EPOK)9>T1$L<I#W_@IPQ!?=G!JSFD F&D
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MK0)/&6)B,_- '1AJ,^:'I#5W17.G9RX6'XWCC]EQ/"1#=WP[O!X-.MWY?+
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M?L0LL ,T(K3FNJL^9A4:>P5WW"J "#YM<WJ<?I DN0LGO9Y7:A5Z$J]#)^K
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M1] WW>&L\[D[6@XZLP&-A:#AS'$H].[,^1S,G)7"QT%* O*O0^_)/WZ?.D9
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MEY?M2*JR3HX4-?*X:&C&W&<OL-W5C.9(XKCO>76@KX:4YZE(=LWH23]$1>8
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M:V5P:AVV;)]@\AOZQ[WA(_*3_P]02P,$%     @ MX +5SWQZY1P!P  IRT
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MZEUH_T^9=\3?O23U+H2%:X#0E4"/,Z1*U5G <[M_$RJ31@)H+WKRA9?.#1Q
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MD!,OV$.BYTJ$$U'U #,>5J&&QT1G+$!G+A/&DP7+D\SD@B$U92)&6B2\<0
M@)1<L8@':#),Q]"H3'N['8-$!,):;A9D$O,'@7'7?%JTA0@&0RH2/AJ## )I
M@CR&68+NB"04ALVG,I@RF]._5?^Y,*)P0A.(I56"AS*9 "39%!.TJ0A<@.0W
M16@ZQ#2!$BS*>+&^#$>^O!&^G+]-O@@6R02()'"O$%@%66".VV;MODPBY&ED
M9?B12:#R$#Z!\C6X5<$02;D]!4B)7\0[I58$*K!KMX8&1T-)CJMDD2L8@#4:
MT';#61=/P.V414K/;4DI(R8H,PS'0)P:?=R(LKK&#%L&LQ/MD1QOA!R_O"HY
M1AM(^MG8S[ENV0+^1?U*R5='D<2EPUB?<2,<FH%..5:"4,=0MO"QDG9*YF06
M0WA(?.@ZE#90VN;H1Y)DM/*P3HT.1(AFRTZ XE" %AZJO2_!E"<3P;K(]L-<
MP:)QSFN-BQ/QP75M7(3^RE]*JO,33R?RST@2UECF44^Q'#Q0M#%0A(%HGMO<
M@P55>LTCGP[BTRKJ?6C_KLP[X1]>DWK7PL(U0.A*H&\SI$K56<!S>W@7*I/&
M F@O1O*%E\X-'$ @9M(ZV8&52)P?VJFN!&M=](Q0W-&GJ+Q6%*@6@D@W)<0+
ML5BM9,@S%^C8RE!RXS8QTM>'3H83\I1;JME<MK&NP',BI:U 0!E$D3JEG#"6
M*T[:BFFY(%:U'WKX2G*] ,:WL2!#R!_ZB[!UI.>[H^?X#='S8'G98>GAPG0P
M64'PF0R)@]SJA),"<PO^TNZ*B,E-6)($M)5\+)7,%E0X[AN64H;CDZ.*9_N&
MZ=KNS G]EV)":6Y24-6Z0C<(M E= &Z?-A$)ZE<%QN*.2"D5D GVH)Z52!DR
MA=8>>?G^>!F\*B][,ZYRIRT$6A%%V%+)&>!F]VR-E@7M 5KI+_?OEAP-T1$Z
M9_V>;*SS[/$(#E%SOK06M.&,OGV@P<;E5M9E%N%7 O&TR/F12>^.2>'K*IP'
MZ2[8Z;2PV!2Y.WL9]01=HZ)2!T%N"-)K%=P>K[&V&=KI9QOXLGBR[+,_-&<G
MCW2)P$THSI9U$7@ QKB#3CH#3?)E7!]\5%-NE^4N:97CL@B=B+OU* 1VP91\
M$*HX]=RRK_[/2W0\C'DCAS$7[_ PQOW.%)9<KJY$@C1KG4\KO2!&/*&BW=GR
M+4/CV/9EVMAE$>D:X#*.998)\15%'FN4J70_E(C/.3D!ZR" E@06G[3Y+%.%
M^)Q+A._20IX$[F#TP_',Y?U)WNN>N705MC-P+D$@.KVC<\! "B"^* "79Q]S
MP1^HHO/;&U?3N8V9^XFL/)M_$H^*8PI_=KI'5WB(CE8L9>51SA7;.70!<;#K
MJOJRTF+>-H\!8$S83::0\[V_8AQ+QO?)G]<]%.FB,HP,DGP5:!9.E\ ']T-M
M09RJ+ZQD,M-J)JBZ2OBD^+W9%%(FXE3IA<#=^51[_>(;M 2-GJ7T_+^HJUJ0
M4A,*4PNT4CRU>%CEMR7V=X&RS0+_[MC2\07Y_>K\]J&O"*1\#VVL>/# &A\O
M,!]W)-QB>\AWP)C/!^!VOU.W]:TWM=KU?F<_4IZ:-5YZQP:2-5DWG\ U:S2J
M[.ST[/PU\\'V.K[8&GX-=2\\QWM_6(F\<K/,,'>^ G_)]+*32?Y1JR$"H<(F
MNT=*;:''YQRE"P7:8G>IJXF;;,"!C5JM7*;K_K_+(#9>&DVSG==&_TEM6Q2^
MW*8P5G:5TM93V':*VTP)N[EI*X?M,O6KN-E,%$I$KL>V)I^?_[0!G3T6OWS3
M8ML'/>?R&;?K6-]RJ=<>4)V>$#V%YX5 G5ZS]N]=T^O9?P-02P,$%     @
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M_0  >PP.  P   !F;W)M,3 M<2YH=&WL?6ESVLKR]_M4Y3OH^M[SKZ1*)%I
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MG/> MUHB9;,A*0!?;G;H4 K!+OMUL\.>6RX;[Q(I]/D=,.^X4'AWPVO/T(C
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M O)R_4T!FMZ7AAA?035WU37CM EI(IHRJ'?MY.T;8/15N%1[!;HQ2^F>_Q:
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M_K,A*6O6%M/NN5@W#<O;@(QO2]7V4!(=@!:H0GL\$)]&%^KK&WB9HO+"2LZ
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M]3?_WM='4H!.<,C*OZJ\ MVP2T_V@2RBFNZ#Z9SMT>C3F2_Q*U21C$K#1">
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M)C3?<;'+APYX3>B7%/$<O )9':):)XXCB<K06ME$=V]B>\P-E,[[JU:[UZ6
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M./4N4Q_6Y"80N)38B?(6=F)END;UYYUY?EV[*F</WT[LNK<;J9T(<9#T%Z:
M[02V$]A..*JSN,5Z@EYTL%^N7MB_CXQN\!L<[,38B;.MUA-+TV5OWT9_7Y[*
M=TSN\.W$[CD$4:\HPALF@VT%MA785LS4)[O%FH)>=+)YYO6B>',%<B,A);9B
MNS7%TG2O1S^+O]6[*_VJ<_BV8M=LE:C7%&$-DOG"N94_.' [@;-N\+;F\6YK
M8M!@T&#08-#$/AX,&@P:G'6S0(_? /$<B/:H2W#B? \0-7/0@0LOM4N4U<$
MKB5L]YVHFX9N\ IZ.\[+B8-=*6['M2XY9X)"!W\V_.I=&W5SH-N0M//<R?T]
M'Q9'W-]9TL[DT;M@.PFA%7HSF1SI6Z&6-Z'NNMV7X:-1*%U(^Q(JQJ#,^H#'
M5I@*/@5G&OWP%Y[9DK41C)<E"P6.9"FWNL\'%Z[![2333^>([5=A;_NUFDST
MFZ' &-"_?N8/QG[E K!?*X2J-HOO?\^5X2\:8/L53OY2#/8KV/&R) ?79&S!
MK20ZME_8?B6.SA';+Q\+BXWKKZ6LGS+='&E_]8HBB0=COWPL4WVLOY8(U=!_
MWH\8Y:*LR]A^A957%<\*+- 1PS48Q9(L@VT8MF&IH'/$-JP4P!IL*1M)T2I_
M.OG'F^P=?3 V+!O(&FR)4#?B358O_WIH@+V#K0=LP_9*I8IG#1;@>%DR5Z!)
MFG;KJ7$,]FNZM?C5X#LR@)\_?O@^W'XV U[K2<ID@%^'03QHD1P"@%#0=IZ]
M75 LHTMC8 ]DA1RI&'.Z1MOJ@X\?>$%0!_")(Z1*NZIJ**H!GX(R9I$-@._L
M:;P,@:X92 T;?: #**B\*4I(44,5(*+..M8GJTT0C[[N2@JO"!*\$6H+ PS@
MV/4OZ:*.*_[@J/^3R1 7$I#%4^(6:LEO\ $O)E $>&/V&_' RR;\Q!"9S,2M
M$Z77R8 VMUBR)SB]@K-090D_G*(L._K&JCZ'_@X')TS^OO@.095E?JC#L4P^
M?2/>)-'HH_E1_[B!USM_P5"'KC7E9IIUE1<+KX/7SM%M0K%O1&LTA.\O:7Q'
M$KX1-6B.;*K65$3 [/Q-7R=WH5]FZG&B&K]_A71V([D&^.=,!T K!)\]M#CF
M$!G.*D447J#F!)QKJ3!//$14&Y-!6) C5O+.TPV-5W3DV9P2YG (-('7 7Q)
MY\=9M=ZH-%OU1JE5?:A\_-"ZJC1*M]5*DR2JM?(7HE0[)YKW9\WJ>;74^//]
M:R=51F/3[&<KAVZ;HG)3BUBNU\XKM6;E_..'\KR=:+9*K<I-I=9J6C[^5:EV
M66E"0L$?ZN5?5_7K\TJC^7__+3!T_AM1N;NOMOX0::.919A/]Q.3^3F5XY\(
MZNK0_:G.R6*2A8M FLZVQV=YM3-X>6,'9SFH6,T!G,[(N@2:AXG+ )=VY:E_
ML8B;J5=AX:;/*STX(PFN#PU5>.ZK,E30^O_Q0U6'L'DQ)6-$S''@9'MJ^]/Y
M)\N)@**D#V4>DAPN5>"E[GF!<SE_(49E,F_6\LYNO1)2^ H2!7W][PFS;"PW
M=)5<&%R@<#[Y82\F8Z%,S"R8]OXY*[:G 9RIZ-AR48;>/\0FE*32NZ3/+KO5
M0!=H&ESW(XFZ 2@6X/*0,HJXU+O61=8#!%.'C(97P*$"_0Q*K05ZJ"-<GSBN
M/><JX)'KLSD^09@I#513,8X1,XEA 1;;[!FSM=C:8=(%";N_[E_=EN2?I4LZ
M0>P]7@F;L3>[-7M+T,-"X4Y>ON4EL:J4^:%D\/*$U>:?.W%X?O/W7$F2,G4&
M>=R\SFW-ZP8P>$D!XN3D]83)JGY5>6^8?XK9IP0Q^1QT)4$Z>H$>J[6?9OFW
M^?:W\YP@[MA(BX<Y]B;&QM-1![@*XDX\7QVTLV1YV\09,>=OQR6*H0M<@L>+
MIY^ M4OHKNO4"<,BAC$6#L9::FP>L^_SS =ML>/WV:;Q,GN<UIK^Z-SK)#'$
MCJT<,S>BTW\HO)&1%$SA\+P803 'ILROK[N J;SGPFQ^/]+>Q\96'6]K'+'$
MQ<^"X]UZ2 P+L!3$S@(L!;&SX(@WQA+#@R/>MTH,#^+?G;+]XNE&'GN^<NZ:
M9></O,^[]?;HVU*S/2[1=Y7K:K_W&YWF6NME[U@+T,DU9//_N'(ER.-(9[S,
MHVQ[WFFK^9-73%X;$31)(()X<,L9(/-/N =D)SF7_P3:ZMY=0J?G( OSM6A6
M3SI" +@=V$? \;OWOR']SD_^W=8)>"_%9H/*#F^NKIZGYS#/0$]24-(!1*F%
M I+0[2-Y2PS(+3' .K.[SP'=M0<4-QQ!+$%"6 </:28#B>[<U7:=MDVEMC\B
M[76&D29S=(&D<V[M3=:)4"38/@2I]>KW$0]$5PQ#LC!*+?95@/#,D72!P=B,
MQZ*4HK,H+IFA/U_EIR;W*O$/_<-4_2MSWK<B6#Y/YO-N#4BPM&!-OA?D5A0S
MR[E53L4XPSBS<+8V$WQG9X KD-E<GLS2V%L]#.QM:#RV(_C<4]/]H\ZUQQ?R
M11F2RU)DH>C67SY"^'EU:<3(VW:>SFP#!.$>"YT"RY!4/GF+G5#;NX56\BU4
M$8C*E@2/>!\O"F-"F!N8&Y@;F!N8&Y@;F!N8&Y@;L7KE/O;RPZTF:BVJ,AW>
M+LTX& )%Y]%BYQ0C+K&(P]S W,#<P-S W,#<P-S W,#<"-:+G^;W4LQR+F]5
MUTT@GIL:]+]OX<-4T:KDW0"ZH4F"X:1:E=YX3;S45%UOCYMR];GS^+L*ACND
M^OH+VM/[+0$RA#8=OIW$8VV)+!^[P6A=IAM6&\E@Q,*-&1T(&>D]TY=$$<"'
M0T%FI/>.)E-,GIEG&N;='@F)/A2CG0[GK1E#35ED1*UCMJIG$I.;IBS.:SET
MK:WE5O(6(T[IV9IPZSK"V9_8\'(;"T6RD'5KLX.E*1&:<!>\K?=@(H+;2AZ&
M[ZQ&#+*C UDX28TDG2V0^1S6;HD%GE\_+X?]O,3Q+BZEL:\Z2(@=\AF?N-1X
M2))5(EK^F[7+5Y[;Y&N/'_O7M\(%?UW\^13.2>2 (Q7J$(T;AR9P:"(=C/!K
ML@H4-EE)XQT6HH0PPK<0T5B($L>[S7[?=CY+$I:*#$D7*3++^#[]AF&75)7!
M8I61.-[%HS(.1!FX+Q0IGQO9%@'/5M>)ER6]E,]?_>X,=UDG>FUC;TIMW7NY
M*%C1:'N[!XL==G=3P0C?MHO#MBMIO,-"E!!&^!:B/!:BU/*N@'F76MX5,>_2
MRKMBW,'JS9MA-6!4%>C]@VLK";?;ZE2$%XZ^+=#A;'-YKV0F]9*M2LG!GMV#
MD[0'(L-)>C#"=1B!<F.%%IL+14<E'-N-)"S?SP,)41$!(R R!/A6H)L3D3%H
MC@4T6&T<.P)\JXW-FQ48-!@T2Z#)8M!@T#A#V5#F<V'5M.5&>TBU/G,D5X K
M+\9W-<;PP>Q5]1/C.,4X/GR@NG<P.G/.X&6G9_ X=F6S>+6#4;YXR6MR\>U/
MC@EP/]B:G'NKH@F5F.##*$X'(WLTO$ZH7>*&UX0^P:[O8>0ZM!CDW7HO(:IF
M1P:1=J7(^N]*L0BO)/<YX@N&?)7M5J_9PA;-+K9D3!*:8"P;\+3U/_+0#'%Y
MK0<G_5YUP),%=7\UP6/#^IY]E##&X[5PQ>@LG$L1@]?<B'F]>'F[;FW3=RE9
M\KF3*0JZ'U.>RY,<[;L?$Y8Z;%EVM2S!]77*8T\(XS5TO(932B%/D_DB1^:*
M',8PQK#_P-V.( ZMSU2!9!GHL-.^BP"$#V._T6>,X.1KX9WU*TMF"WF28GWW
M/XM%O=H1Y[#JXJ\)%N->5D=0L15S W,#<P-S W,#<P-S W,#<R,HCSW@#K.;
M3OGC!E;'!C/,#<P-S W,#<P-S W,#<P-S(U@7?= &UC5Z]);ZU=M<*^%='8>
M-[-* ')QX:*$,,+GN3Z6PL5O@LKRY()L9A5"'BC(O;0NA]++XU \EF96V>GA
M+"X#R1A.8BA-9K.^4[&Q,"55$>)*4LGC773=7CPT15@MHK@L2;.^,\DQ\!*J
M-&C<*B!YO(M+:1R(.@BI153_N?92S+_?7#63V\ :MX7"B_PT,<*WF<(EOA/'
M.RQ$"6&$;R'");Z3Q[NH>KQ$N3QD&9K,L=ED>(,8=+LK#!Q12A[OXE$8!Z$*
MPFD)-3[+2K]OGYZ+?X6H:ZKC[E#8ZSU61O@U8LSF&N.8=UB(CI,1OH4(MP=-
M+^^RF'>IY5T.\RZUO(L[9NV^W#GSN=R!;[)^T=OCJS_O#W*)O]3Z43:]W6]5
M@\:.R@*B*L9X?8-=L]0QPK>:P?FO0>6_^C@D8*=,SG1CJ/FN2KX[SOWIRBU3
MF.:[>NFUI&:\3DD5:X9KD25S.3H94<BTRTM2\+7HI40$KY4 M^^*>!A4!P^J
M4#93LS1-YBFLNQ(+,Y]^&HLS;9/'NZA4Q%["3U/)$'[W>$+)9SS![B.AP]'7
MN_?HC%9[_/BDU'^=E0=OSWP\.Z?[A1AF,T+../H27GU&#"==,NSA&.KAQA\\
M&D2L6P^LPB!MC9'$LVN^F?L]*,BSQDCE.0X3DC5U0E((\"[T>:4'D/3/ #)]
M+-&T5V[-\%9N?NI,^V;5ENY0M(V45FM73X\W,A1)47$HT>4:U>F6]L3 T]V>
M)!6=:^JJDPR&98!&*!NW$7*)X;'W_>SHHG[UZRDW9RW6.P[+/D.H%B)& Q'P
M*?;8U#Q>;(6[V(H+9ZL''7&5!(RNJ$[8%WSWO<)@2VK,#Q^@2"WOLE0BTW?F
M]Z@7VKNWQ[][9QK#CN\NWK*1I.DL-6P/,K0&9V8/1(8S\Z"^ZS "98&_1D_6
M>PE=E24QNCYMVXTDK*0@#R1$102,@,@0X%MK;DYZQ* Y%M!@M7'L"/"M-C:7
M)L"@P:!9 LWFS%<,FF,!S8:=I(6ETI8!GI"ZZC)DL4"1N9SOF&+X8/;;4Q?C
M.$4X/GR@ND9*V)+KIM[2#N%"B^*V5&F/J]UJ7GU_H'YV=SGLM%^_WJ6NQ$%&
M5,YX&1T;L$?#ZVCC\:>I (*E2 (1QR<K#ZZ;]J8]Y87T-FNGL6X:NL$KB"P(
M,,&= (DNA6E0N1;N7GZ5*:8[W92N6#."D+9PLG*<)%G=Q9<9X=5</,9\))<J
MZVRQ0-(YW]LZL?0J/R+1_]\V!C\VJ*]8J61A?77GDH7NPLZN L9XM.:M$)UY
M<TF.:HW&E=&OO'3/,D=DAX)->[+$C>0H;%82(G*';%8"RZ1BB[X/3F*\8KSN
MBM=P<K/R+,D5<]"5]UW7$F/X*##LYSC#]B .*?Y,<W!%2N5(+N_[<''X,/8;
M@<8(3KX6WCW+FLQ2+%G@DJU>[:@SBCD'EFL79, 79X,&^B*<FXNY@;F!N8&Y
M@;F!N8&Y@;F11&ZX9X*<63L8#$4[.Q@,JL:T(1.DV1[?_&R^5OABMW<-(L\$
M"3#E@^ -XB>OF+PV(F@KV8,Y* 3/-K/H]9M9S>EFUC(4DIRKP9IOCVS^Z?&^
MQ4_WR,Y 3U*4==MD<>3C<K@2[;[1GEC8AAND!*6 V.@4D,MN^M/+Y1E#CQZ:
MA:>X-$4 N^5TAF8RD"1A[9;G&(IDB[B>9A(U5A#!YZ#PL[IEG6,Q:(X$-.'L
M&^=R9)[)DTP1EY%)()""V;Q=1E)8F[=LEJ2S'$DS<52)26L!N;3IHUTU#6JZ
M6N3(8C8AU>GGPS*!;9:&6]S78E3&ZI:+:O%-^[V>IA3ZQQ#]P]S W,#<P-S
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M<]KOJ<!H..VL[+U]RV-3*5R"L-.4WNT1WL";^CI1@19*3"!\%DS4L0.(21"
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M7<O,TTR&I7?V.$DNSY&Y6"KL8ZU\ /BC]\,?0Y,4PY%Y)B$ C,K'#'&K"^\
M)&,'8'L^X(T@#(/8,@A*L3G;E?;X_->PR=:?;GY*T63;3NC-!*]^R]/&U&Z.
M./3! 2IM[^%]>^&"B4D^K?<2HFIV9! H+/^WC6QZC^+ G:M]P\EDOL"2G/]F
M*Q[B$9=5PJ@_2M3OV_DQ3Q99%BXI?->$B07V.)I]:"MU',W&W%CC8&?G'.RF
M.1S* )6FX&6D02]D]:VJV/H.*JJ%DVA7BEX<](JL<K/+B9!X M'S\[-]8'0L
MC9!F4\1'T)*+7\R-)'%C\][8!FW2 #(//;46'"5*^(<JI?A3[3R:1M8T=DFP
M2D:16=1+%GF(6)$D%[J8&TGBQE21?+6*=,+/Z/_?A_./M^L#KG_X-U19M2<I
M^XGQ-\*Z5I?&P'[IRIB'/P(8W^(R3H Z$FA!CKG5!Q\_\(*@#N 31VAGO:NJ
MAJ(:\"F\!@CX&@F^LZ=!1VC(:^@D*V'T@0[@JI6'*V6HF-$:6$1M+ZU/5@@:
MZ>O)R21XHV[ +ZQ:9U^"I4[HW(,C_$\F0UQ(0!9/B5N^![[!![R80!'@C=PW
MXH&73?B)(3*9B8"+TJO_4+T]F>D5G#4GN^BO &39,3M6F #]'0Y.F/Q]\1W0
MN,G\4(=CF7SZ1KQ)HM%'\Z/^<9GPFI6[H0Y=XP?NHFZC<N%U\-HYNDTH]HUH
MC8;P_26-[TC"-Z+&#X!-U9J*",C-W_1U<A?Z9:8!)M+__2NDLQO)-< _9SH
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M:$W?T%^!6LBN;<M/<)PK HJEJH"6E@#_A>U3;H?RJ/$*5 XV(R@6H*(-M,8
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M0T>:6 #3KP+W1DU_$RK6Z0DNF(CP"R5Q/L5WZF!$BPW"EV+BJONV@2*<Y<[
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M.F0ZAVIV155E'8\%?GD!BX)%$#CD\;E'A+:MJK $V(O9!O$/GZ?]F9U-3X*
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MW0WKF-SU^JN&WA+3)*3*"+#6N25PD69($=#HA0=?9K_8'*F:_%P>)>Q$3=P
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MM:$.6#L0KRZ6J 7)>#*;=LIM+QY'Y^GVTA[+GNS,6BG?<V2QM$A94*DUL6<
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MUVW^S#F"/,&*'6MSHVE?(Q;44"#6]:FG=LBQ9UY;;[((?V%D=CH<,(H <L<
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M%?1%O],)6<1!^K+(?)-0<VF$2JF(3RJ$OAP!U/; DV !&// SZ3B9P.L!;8
MGHA7#UBK5/Z\5;X"L<TK"16([025.1\(VT)5KY9K?Z:@Y<LV-Z9I: YB6ZGH
M1J,R$XCMB'+U1N'!)^MXHUI3NC5GNG463AR%?Z>SA7^DTQ 'W$[6I2(6.*>=
MP(07Q584!TR::_ '#-E%=,HV-[A5#4P<Q@,XH1$Q<Q>L:G31.]S&CD,',\45
MR^1=(RO Y)Q2<,:@VQ2X9%%V]#!>,J^*N1_&:W-CL6C)#ZUP#"HY@UH\ 2OY
M?JWZITC)=S;OV?H?C\ J;2BL4OSC_+!*&PJK]"ZD1 ZP2C,'=2UUU5]+%U,O
M#0,]A[NS4DMHN0#H#QD0SQ'^/(?T>#:V]^SQ3*#PYL9#9=)KOQ_/AK!?D'1<
M9H#)UJ>SC;]\V3K?TL[[INMJ.R)T,1*>]KW_^W_J1:/V+@1S;6CU&-BQIX$?
MB>P$^+$;F'WM-7ZK6'@'W$ _&>_>Z.01O1*%R"F?@/.TN2&9969GJ/ALW8YU
M7,CL8@(KJJ7]H<1"[A8R0A\1\L9JXMG/I;P:(8G2 =+C8P&S&!QOF[,"1NJ+
M%;HM!\^/!U.UE@<+C.*(1]H_@.40]38WQB31!;-Z'NCL[E"[@)F&'7C9Z_.+
MB[,WVFD/0[N&UL45R$C)#8/_8_CVQ@QLBEW R@<1I4S@; T*XP0\@N/Y_&$9
M/DJ7O+EQOUTU9UDTUY/I),SIS/FDS7F:1\ZOV+&=:,BMQUUS@'BLF'X">L/"
MU,<\+V 1$F"N&]Q.-_A_MMLO;">7<2_59V:(5T5HY;ARJU'BF)H7D\ !N79C
M#NEB%J,P4IYV?-?U;^"W?]>-*(^*G<V^AMFB;'\]&D%[>LAR4=5.]**%P8C?
MB\%^9^@%(*RC ES)RE_&%N^!U42"HV2L:)O_!*<^!Z=L2IN8Y7'&P]<]B^8=
M-$L?5X*YNA.KR(7D>F1?FQR>_+7H[)4A?X[G^]*7O^B*;6%'5HV_9R[5?L)^
M[9IA3]?PWWPB^^ =7)LN7H/P2H!6>B\R10J("1?_GO_LYE.^*RWS"1NZFDI>
M.:'*V(R># QKZ%6CHI>JT]KQ9'9B\06^]VI:Q31_RC35>3--6:^5&WJY4,\I
MT\RUGT^.-<NS:/&IL!04-5;<7GE>>N32#ZXP$"K"_:ICR4H[EH!M4RP9>J&V
MNHXEC^H>I?A@07Q0UJOUNF[4IYDKJ[51YM>^YL5?7''QN[EAB>O6T9J]DEZN
MU'3#J-TM;\";*_Q[K:$7JA5*#<2N!W'(2RSPYI^NPE+<SQS?DJ_![6WSVG1<
ML^VX=$,.V]U,"M&T ]CL</ZWNL^[1&DIB: [>)0V-^(!]@#!ZD'+BOLQK[JU
M6<>QG$ADV1AZJ5#1JS4#RQ/AH['$7=/UP4J2S7\PN9+!>8NH7$FV";#E88-O
M8@= D96+W_<83@._W'$\T[/H[CES2JFVQXM$KQ OPDIDFJ3E.AZ:DUH4.*8;
M4M4055-B<Z(H-EU*'/X5.YAEDW(D?A)A5:V]#6/:K!VE V]NP,A):X,Q&:%]
M\&_@U8&N\7I=V#>2*_#?'E5XWMT<FC2*(\PRHHXJ'8:9.R&U-(E#$F;,]6]H
M\O"3 P/ CYL;5/84QAVD SY)(R7;DDPJJ0F+;I@+3XA$H$Q'!B$/.W Z86-M
M+-6F?$HGQ(KJ/C##V\\J83%'"SG!!EKI:<'CD?;R05("^WL>DXUSL)R/OLQ&
MBGJSF1QF'P0)]=BAPS"J!.^>(N'V"+7+4YZD#J:<>CA*<8 E^2=XW&.J0I9?
M$&.D%7HX8].&3TUK*"N/3:XP7$;3$#70-L-7XVGJ8[E?Q[0B/\BN W8%G^5Z
MAI<V6Q8LM1/C2;?\?I\%ED-I_33*(/#MV!+3"'D_FI!7^#/:VDBF[-'Z\5N\
M"C+;]D1$P7$52 D8=G.#;M2PV-#GZ1]M7YY&+@2ID(&*.CTLHO11MG(Q-.%/
MZ21X?0/S0)A83//Y]WA]0W8]V>6@MA42905GN/@T'^<Y'V+*NC*'(-*UV"-.
M!](&IA.."/6,5I+GYZ;'/-0%Q&RH@0/QF/R"CVVQKH'CZ*68'[\%1A:=P51_
MXM#B)(*&)[X"3K*[+"V2 =TCCL8(.X/J-/'H4@\#RX]=+)T)038 X\EGI8P!
MMHZ<:UXI#/,<.YV\)T$G#F1=%ZI:9O,'Z:P-2=52_0V="Y[M3R-CARZL_LTL
MU1?]$'SKJN>[X'+2H#$LO]7!'<-'TKWVVWR9)'DB(6BH"@1]"-]+MX]4KZ!5
M5D*&P"_8U@RV \5+C&MW<4A4W8F)D&IBW $^*!=JX*30SB(]:',S5D;2%#%$
M>L*LHRB@S90DG?<16$:A7SLYOO.W]I<U?ZH,:49O@1_??B)E(&I$-C=.A*1=
MY^7-D3P3A>H#X8&E++3E;6XT!P&<5=&8@/%SR/L#^)J9Y&_#T=MC?91%YZ8+
M8S3EJ>1Z_- '6741F&1#R1H +JW/A36A'1WM:J_1.!"L(U\$+Y'%12" J;(@
M2?LGTY[,HHRP#,.8"<T.ME#8 VD62G-I%TP;F.LYBCZ=ESY&L =DVCM8+!GU
M8$N[/7II9@:Z%@_P2["Q9A?6U@5!F%H,&#>Q>"%%62\6>.D32*\;E+].2 85
MM5<(&#P@A**)LELNUN3GI)\])TEY5?/BD]P!M%RP]"K; @+KNV"W[V\IP3#'
MR=8:);U2,>[9%%&[@<N'8>5PG(IC>Z*A<M%X<A*SWP(I K,+LP&F#,-T2\P!
MO.36Z<..P0Z\JFS5RMC4CL^!%Y2B5K;O?+%4U:NPC_ *^4;?0@N>-^6(",$(
M=]:A?EBR-I4[M-0Q"UQA;+/(:T-&7VX4*VF'QAN6EJ[P8ED^T(39EPW>=E%K
M3G+?B2-Q$GW07<+P-RT*Y: 61'9,V2@U6%Z5]&JUI)<+-7SGP]181Y7VQ-X;
M< I4[XUY]MXH%E3O#=5[8W&"(Y?1]3/6=4*R7S8W]L Y 4=L<:9H+JGW)Z;F
MO"W*PQ@TZ:A9DC6K4 =6ZZ">2Z7[[!0JN0H2@H(K2?24)MF6=CFK5M_<>&7H
M=;P0!VN#FX0]EK[H!7#%GP:KUN0""DX^S\H]</T;=8.VPE@>=UH>":Y!L2I>
M'4R?QJ('.MWC<.,^%.65X9R+*U=$V36KN'SF%435'%40G3NW?(:?^,G9'SDY
MJK8HWYR4LUHT53JX5N1:T]+!)]9N%>=;-7+,HDP*&]Z7)>D!Z17<0X4VB\U%
M76ZYS*(*J%XG68,/U\(L# I1T>[/:%?4Z^6*7ELI[1:"/;X(23((_&O'YKFT
MKX58>2.:8-XK5U2-S=A )=VHE?5R:9IAHHJ>EDR0U\5R38=_%D^/.9[]N50\
M/=7 G"0=^#32U*('#8X5 -<_;.DNBX\?-Y.G<GK9,/1:8=:"J*7@V2L^6 $?
MO,T3!RS%!)I_M2?*O@2&Z;6L-7K#9^+P5']5^K?:TK]"#5RS1I[J_A03+)L)
MP$4O-."?PJR!P/GSP12S;WZEGVMY-S?GR\\3&>+:W&AF3$YU#;JJ:U!0D%B+
M^T 4DB.;I<6W]V*69;(0[Q3QWBW9Y34X$=4/4IGIJ[I>K9;U&KC?,KL6T<Y,
M,#:H^"^%T$R0ST?@J,MZO0C_P"QE!F8Z"TQ]G(+-N47MLK0.7MUN;O"[7#?T
M-:<_@'W@(14P:B*$*^^XB-)H\@H!Q\N6%.*VI448KL.S@1VLJYHIWLMW6@2]
M*E5>0CD+N-HCMYJVJJ&7&X9>:A@<RS+=4 Z?TDG $ZC$(H.O(=-@)*9"VOX<
MMFUV4E7U<AW>7WDDJ7CQVJL29C>7BLG]>S;XQ7'RB#BX:L+!YK-^B$SY%9_+
MQ*R:I\QOR?"CDOEYD_G9(S,I2ISX3DEWAJ*A5^N%&17 @[C+HRC/DZ28B<C(
ME(@W$<M2"IYD(3#'8K6D5PIE*1=4&?3JCOY!6ARWUD=_H55PN9$ D\+!8Q)
MQ";G=?[',&[U;*^7D439)!<6:T_2?@L"0VJ72J^'"5!4-CM7'?]5G1GG/_M
M*"OB9GW+Z[ADO<T?5D5I_L<4L-L^U6#+MB14F.U(XE#1F*EA-CHVCA#>CR::
MR:1M* +LQA(S7A^=F-0!"V,W&@&8AK\YOHT5<RS$Q"/[6>#2/Z):S%#58O.M
M%C-4M=@:5(LM]'3+A:Z'! %%N(O>BH5EP$W+PK8]*!Y/X71;CJ@DV(=A4>I.
M0AW+_Q*?C8*D-DV9'B'8/TW2:Y#0*\ *=VS-0CV*;!9:@=/F,3VR7'V!:HPZ
M,_;,V':HLYF/L^;!+(]$.X6\A-4-RC:,X />/T1TA@('&=$"'2\QN'_%9H"-
M72:&6Y&1)LTA,X,9QY51S:;GQ<BV9VS@!V0'R/9B'Y,I#9DIYY,%$!(6/1;$
M."[\+:W;W]_%%WTR W#<B[6%(!H^'XZ?WZ3%ZR/"L00J_JO% S#/P UDY.'R
M<1S[?_\R_ULH-/Z28J@%S $^VI;V.883X0"S8$<;Y#7XP)6_[SFAY?H(2 <'
MI.W'D<8[K6AG3GCU0DI:5RV]CGUPZ\W! .04*GYJ#6%J(4*:PID,Z Q3+PCN
M+^NRP1+Z ]DF22(H0*<57 /@%>X<)-]I#WFO062-%Q8Q7]%Y- ICY[&\I>W"
M^P+?Y0;$*89*;#Q^:QA?6^()7$Y3IOUK\/G$997?R0C'%1-M=0U6GE677=X(
MT.%M[NR4N%:6N(.$N&@$49P%V\!A%R;LQ.MQ*^LLQBY&1LE\:U1>LS?TI%&Q
MQ6]ITYWSY,Y#V[_EUYM:TXJ(O8Q&J4R6%OC*9(?)=DWX8/;;LG>3GO;C ^L5
MMI3+?;!.<14R)'17[L-WVDPN.+42N68)94^L\5%QQ0'"L\/4=+XMV"-7U\*X
MC[<]O['C$G5,PM<(4U'8L> 5I4&D<, L,,Q32QM,R23H&]!&PGOHSAP[ /(6
MG["6, 9+,[L@)QQIC,R;$/?[,?9,C?@Z<5W "N A]ZGI5MIXE7?MA-^= ?5.
M!<*0!>1C!T@$&R?:B[_#9!([6WR!4PK;/L"W8#B=[KFP9IQ62QZ%Y?!&4MB'
M(A"(YH(&*;MADT1/$)#: #_(B#KOMIJN2_,8$H-?N6'J09;4:$D,-0?<@I^Q
MW:6OP[XS(=I$@ _[U;YM,P\X.N+7^#CQGC/ X/S #T,'@R@3IL9O\=.Y\5Y:
M?#74&,,;SG2T*$DC%-V;87Z8?J!1_^M,5\RX/^#9&MPTI9P YXJY3L_W;3I#
MHN,M=9E.>(=1#UP/F=[SZ3T!M7'EI\<;RNE2JUMJ7,OG8%H]AUU3CTC8/?*O
M;*WKPUPE(#U\?P NFH>9$F+LS0WT$!W1EKKI#:=2$2<#G(Q^8 ^XY@:[>27G
MV$Q:2>,1P]E+<T[T?9.-,G6R^\PVN(0Q<F&R/-J/= F1($O /4B<D>:W?S+J
M;+FD#K5*:\UAA5^0]43'BWB S0Y1R/"^<](YI^0=E%PD)T6:SQSDH'97#&*6
M%:F@$=>#!2BFL0T/2VPH.8\9!!S*5A+W4U1M1M,FRFIS(ZNM]$DMWQ67KPV7
M?TJ8%?OMAZ+?-@I@XHL,5R'K\&_(J!?)]=DXC>>ZH01E=,M)77Y3USD5LZ#G
M1O7&3)85>-@QI:\)VPI==8RCX85;&+?[H&RG&UL9XR*Q+>#</]:XH.@!O].3
M-^W)Q> -,Z\H$Q"FZ.#5#K6[EEOE7[,@<^+3R$,2*]W<2!$2_FS_)P$SW*6)
M.KBY7 VXR)\$*VUN7 I>XOF:+<E-N]+60&8Z2)CI3#*3<IG752QCZBVAI*!(
M28YJ-K%X7*1,ERB3Q$""Y$(8*0%XQ0A_H;$0[T.=L$?FP.;&.*>1*UE\AQ]W
MR7S6#I)G7Q<+1ND-[^@LXI^4=P2".&*4GW@^P-L52GPX";JFY_PV10MY+CHO
M0"78-^:0/T6-@K<T ==#4T7!31O##:V,DX9*RF9HT9 IDTC)I^T2NGM*5J[G
M:6IB_&E,%9/AFC%WR<Z/0&N"D@]'F!_8]]P,VB8\]?;DUF5#G:P& 1#%/ L^
M0'P3M)W:P$W2!D_^3IFW&<U/KNO]',B-<@J"D5OM<.,B06W@H0+1.IW<Z]38
MP.,B[R@3M!FZF<1ITB2<_LCM9C;LDKG>)#^=9S]A1M(U9201^@.<+JKR0+-0
MAF% C#C*OUV?0W&!KAQP_],4"HK%3!HJ[^;(X5?&#AQ;2H_'%3)'F@"537@:
M3XAZ](I'\J&F+.Z>%I%WND+./O*$!*L)9>F/7HE@\85?DC6JM<;]Q<.S3WW!
MDST"LO+982S11I%/#K"OD?/K9K)I1MRZ![L.K([8BKQ3R!LXX57&=,TZZ?ZD
MZ  P =>W$^4OOBWD/;6%'NXC,E[P#CE%<<?:<4<&&4T<_8QG$XF2,]+&MF_%
M?6Z222&1"?=XR>V#O)YQ.%J.B.@Q"?'IQ^&H4YE,)<N!_'Z#)>%!7@)K63&!
M+D[TH;R1^%@V%)Z9^6@,C$+J\ HS$,D .!-^UWGMP'["I'Z">4((IO"<E(<B
MZY!N36$:KF.. 1I/;E&P!&ON;:FR55T3H):B2KV?;^I]4:7>O^S4^[P)@[7U
MMRC^+;6@3&'9W#AUX?V@G,[@<YM?WX "D9%R+0V4J]CW.@4FQJ\DVXQY6%K'
M88"E;2'A1\D\2?ZJ]9G)LZJG96K)B$8V.L<_=-IQ)(#7)U[>,4S"H0MXP6Z4
MDY6)TX79Z[=,LIB>S@]_25-.<+3$]G*'/*='OI[N7"W9-85$G@J@J "*"J!,
M+M&_X9/+>$MPQ$(??&%W/ UG%WR93N:.]$1F&M[T*#D.?9&0,9G--<F[$6F9
MO(9('NZ,TP*>B@ QMT>OY+OX<GP?4[&;M>"L?:^;:"-)V5L1HTDY V]38I=8
MH^,$?>HH)114%M!^ BOIV5RO%$F;%Z>-Q8)44&=MV&9/Q#A&9<(5&TZ+TFC8
M+:"+MWQ.*-MX46:2:?54).,9F[@"9AHS(\A8E942G!M"8 Y,C+X3%F;>M0-_
M(DTWHH7H\FV2%=QC[N!!4UC<33]L"VNCIC!EDOIHLH9)'CM!.1+2=R;B][@C
M0 5Z= 9$_N$U07VS@"(BF/9A,XZNC-HX\F_,P,Y:T#2%K"1./05>BI':V@,7
M"<<;9 E[.TP>A8FP1!'P?/L9U< ]HC_K"9#,#WERNBGI-M&\R$1F:75T2X\#
M.S+!<1*ULI3J1.*+:?%C)A#+D^&I7MG,AJ-Y60GEYP!SZ[P@X=-HVDV2FYC!
M8^<Q:SWQDD9]I,F.T',^^R]+NDGN3 Y@W_><R.?Y[LE=Q,R9;7?R6J<F)E#&
M,OR[ZU-#-<I.X>=I3-Y&YA6=USA N2)<[KLB-0/[+HXT3Y+!E)H^YC'SWRFM
M2)8)#?GU1$@-14.>6:PR9'*Y&H2:Y5U0,2GF;EKMB4JK?0:2Z02/.-;TF%ZF
M$8G9]A.S@MLK%'+T_&QCW,>E1?&D4[P?I3H!WN&+\'#QCM*6C4E(FU-Z*3U
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MGGL"U%0)M?B]EIF=-:Z <Q^R%0KUCCZEC<O][(\I\#8V^2?+04E# Z\U<B9
MEL7(RV(\OK(]NL,;<*"D4<F@"#DGB70GUWPA9,5HLR+A6I-PDDI05)RO:;",
MD^BX%"@E^0I6V&)-KJ?FG.?%<BUM&8OS/-;+2YJP^W-E45/K!:SSOW_UHF@0
M_KN]?7-SLQ4R:ZOK7V\W ZN'?9:WF=TU@VW;C,QMHU*HE!NU[4*A8!2*1JUF
M%$L%_%]QF]V62F^Q\35=NT8L\K&7 %WTF5L_!]W$V7H+ [P%!@I,"[:&<4GW
MUW^:HH,\WO6<,=&YNHD<+FX'4F^&3!1S7I+Q.3+)HH]H_>U'M?LK%) EM?LK
MVWUCN[*--YM*D3_,IT7%I^NHR,M91>YW> 4-ZMU9%/EN^BBJ[;WD8=Z1]C3
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M,+[-Q<#_!U!+ 0(4 Q0    ( +> "U<!(=,I_PH  !=>   1
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M4$L! A0#%     @ MX +5UK\XK:.!   8!,   H              ( !)K$
M &5X,S(M,2YH=&U02P$"% ,4    " "W@ M7^$72K<3]  ![# X #
M        @ '<M0  9F]R;3$P+7$N:'1M4$L%!@     )  D +0(  ,JS 0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
